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Abstract 
 
Colorectal cancer (CRC) is the third most common cancer in Western societies and 
approximately 15% are mismatch repair deficient (MMRd). MMRd CRCs have a distinct 
prognosis, respond to immunotherapy, and occur at a high rate in patients with Lynch 
syndrome or constitutional mismatch repair deficiency (CMMRD). Detection of MMR 
deficiency, therefore, guides treatment and identification of associated cancer-
predisposition syndromes. However, there is a need for novel biomarkers to detect MMRd 
CRC, and innovative assays to improve Lynch syndrome and CMMRD diagnosis. 
 I assessed autoantibodies generated against MMRd CRCs as a liquid-biopsy 
biomarker for cancer detection, by analysing the sera of 464 Lynch syndrome gene carriers 
using a recently published, multiplex method. Although autoantibodies correlated with a 
history of CRC, a lack of signal from patients who developed CRC shortly after sampling 
suggests the method has poor sensitivity. Microsatellite instability (MSI) is an established 
biomarker of MMR deficiency. I used single molecule molecular inversion probes to develop 
a sequencing-based MSI assay with an automated results analysis, suitable as a companion 
diagnostic for immunotherapy, and for streamlined Lynch syndrome screening. The assay 
achieved 100% accuracy in 197 CRCs, and was robust to sample variables, including quantity, 
quality, and tumour cell content. Subsequently, I adapted the MSI assay to detect low-level 
MSI in non-neoplastic tissues of CMMRD patients. The assay separated all 32 CMMRD 
patients from 94 controls. For both CRC and CMMRD diagnostics, the MSI assay is cheaper 
and faster than current methods, and is scalable to large cohorts. 
These results suggest that the humoral immune response to MMRd CRCs cannot 
readily be used as a biomarker to detect disease, and that alternatives should be sought. 
However, the MSI assay could be deployed into clinical practice to meet the high demand for 
MMR deficiency testing of CRCs and to improve CMMRD diagnostics. 
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1 
Chapter 1. Introduction 
1.1. Maintaining Genomic Stability through Mismatch Repair 
Genomic instability describes an abnormally high rate of change in the genome of an 
organism or cell, including large structural aberrations and alterations in the DNA base 
sequence (Negrini et al, 2010). Genomic instability can enable tumour growth through 
cellular mutation and acquisition of cancer hallmarks, including uncontrolled proliferation, 
evasion of cell death, angiogenesis and tissue invasion (Hanahan and Weinberg, 2011). 
Complex organisms have therefore evolved robust mechanisms to avoid and repair DNA 
damage to maintain genomic stability. One such mechanism, within the network of the DNA 
damage response (DDR), is the mismatch repair (MMR) system (Jackson and Bartek, 2009). 
MMR is a multistep process that repairs base-base mismatches and insertion-
deletion loops (IDLs), which are frequently generated by polymerase error during DNA 
replication. Lack of repair of these lesions produces substitution and insertion-deletion 
mutations (indels), respectively (Jiricny, 2006). MMR is conserved throughout evolution and 
was first characterised in Escherichia coli and Saccharomyces cerevisiae. In prokaryotes, the 
mismatch or IDL is recognised by MutS, a homodimer that binds to the damaged site and 
recruits a similar homodimeric “DNA-clamp” MutL. The complex of MutS and MutL 
coordinates repair through accessory enzymes, involving exonuclease excision of the nascent 
DNA strand, synthesis of an undamaged replacement by DNA polymerase III and nick-sealing 
by DNA ligase (Kunkel and Erie, 2005; Jiricny, 2006). The key MMR proteins in mammals are 
MutS-Homologs 2, 3 and 6 (MSH2, MSH3, MSH6), MutL-Homolog 1 (MLH1), and Post-
Meiotic Segregation 2 (PMS2). These form heterodimers equivalent to bacterial MutS and 
MutL, specifically MutSα (MSH2-MSH6), MutSβ (MSH2-MSH3) and MutLα (MLH1-PMS2) 
(Kunkel and Erie, 2005; Jiricny, 2006). MutSα and MutSβ recognise and initiate repair of 
lesions of different sizes. MutSα is required for the repair of base-base mismatches and 
single nucleotide IDLs: both tumours and cell lines deficient in MSH6 have a high frequency 
of substitutions and single, but not multiple, nucleotide indels, repair of which can be 
restored by extracts containing MutSα (Drummond et al, 1995; Verma et al, 1999; Wu et al, 
1999). In contrast, MutSβ efficiently repairs a range of larger IDLs, but not the mismatches 
and single-bp IDLs repaired by MutSα (Figure 1.1) (Genschel et al, 1998). Whilst active 
throughout the cell cycle, MMR proteins accumulate and show highest activity during S- 
 
 
2 
 
 
 
Figure 1.1. Simple schematic of the mismatch repair system. Insertion-deletion loops (IDLs) and 
mismatches are generated by polymerase error during DNA replication, distorting the DNA structure. 
These lesions are bound by the MutS heterodimer (MutSα or MutSβ, depending on size of lesion), 
which clamps onto the DNA. The MutLα heterodimer is recruited by MutS and associates with the 
DNA to form a “sliding clamp”. The MutLα sliding clamp dissociates from MutS and diffuses along the 
replicating DNA duplex. It is theorised that association of MutLα with DNA replication machinery 
recruits additional repair proteins and coordinates exonuclease excision of the daughter strand. 
Subsequent to excision, DNA polymerase complex is recruited and synthesises a new daughter strand 
and in doing so corrects the IDL or mismatch (Jiricny, 2006). 
 
 
phase to increase the fidelity of DNA replication (Edelbrock et al, 2009) and signal to the 
wider DDR to coordinate the cellular response to damage, for example through p53 to arrest 
the cell cycle at the G2/M checkpoint and promote apoptosis when damage persists 
(Aquilina et al, 1999; Hickman and Sansom, 1999). MutLα and other MutS and MutL 
homologs also play roles in recombination and mammalian meiosis (Lipkin et al, 2002). 
Microsatellites are tandem repeats of short DNA sequences (1-6bp) that occur at 
hundreds of thousands of loci throughout the human genome. Microsatellites can be 
subdivided into mono-, di-, tri-, tetra-, penta- and hexanucleotide repeats depending on the 
length of the repeat unit (Subramanian et al, 2003; Ellergren, 2004). They are highly mutable 
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with three proposed mutational mechanisms: (1) polymerase slippage during DNA 
replication creating IDLs that are stabilised by the repetitive sequence (Kornberg et al, 1964), 
(2) homology-driven incorporation of retrotransposons (Nadir et al, 1996), and (3) unequal 
crossing over in meiosis (Huang et al, 2002). The degree of mutability depends on several 
factors including genomic locus and the structure of the microsatellite, such as the unit 
sequence and the number of repeats (Bacolla et al, 2008; Kelkar et al, 2008). Taking these 
factors into account, in vivo (Strand et al, 1993), in vitro (Schlötterer and Tautz, 1992) and in 
silico (Dieringer and Schlötterer, 2003) analyses have all shown that polymerase slippage is 
the best model for microsatellite mutation rate and, hence, it is accepted as the 
predominant mechanism (Fan and Chu, 2007). “Microsatellite instability” (MSI) is the term 
used to define this mutability, and is measurable by the rate at which indels are acquired in 
microsatellites. MMR reduces MSI by three orders of magnitude through repair of IDLs 
generated by polymerase slippage, ensuring accurate replication of microsatellites (Strand et 
al, 1993; Koi et al, 1994; Umar et al, 1997; Herman et al, 1998; Deng et al, 1999). Increased 
MSI is a well-established biomarker of MMR deficiency in human disease. 
 
1.2. Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Cancer and 
Implications for Prognosis and Response to Chemotherapy 
Colorectal cancer (CRC) is the third most common cancer in Western society and is the 
second highest cause of cancer-related mortality (Siegel et al, 2017). In the early 1990s it 
was discovered that approximately 15% of CRCs had indels in an exceptionally large number 
of microsatellite loci, indicative of a particularly high rate of MSI – a phenotype denoted as 
MSI-high (Thibodeau et al, 1998). These cancers also had a diploid karyotype and therefore 
lacked the chromosomal instability (CIN) seen in the majority of CRCs. MSI-high CRCs were 
characterised by a better prognosis, an increase in tumour infiltrating lymphocytes (TILs), a 
higher frequency of proximal (right-sided) location and poorer cellular differentiation 
relative to microsatellite stable (MSS) CRCs, suggesting that they belonged to a distinct 
pathway of tumorigenesis (Ionov et al, 1993; Lothe et al, 1993; Thibodeau et al, 1993).  
The MSI-high phenotype occurs in both hereditary non-polyposis CRC (HNPCC) and 
sporadic CRC (Aaltonen et al, 1993). To understand the origins of this phenotype, loss of 
function mutations were introduced into the MMR genes MLH1, MSH2 and PMS1 in yeast 
and were shown to increase the frequency of indels at microsatellite loci (Strand et al, 1993). 
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An association between MMR deficiency and increased MSI in CRC was also established 
when human MSH2 was mapped to chr2p22.1, a locus known to segregate with MSI-high 
HNPCC (Fishel et al, 1993). Subsequently, pathogenic mutations of other MMR genes were 
also discovered in MSI-high HNPCC germline and tumour DNA, including MLH1 (Bronner et 
al, 1994), PMS2 (Nicolaides et al, 1994) and MSH6 (Miyaki et al, 1997). Sporadic MSI-high 
CRCs were shown to have methylation silencing of the MLH1 promoter with resulting loss of 
MLH1 expression (Herman et al, 1998; Deng et al, 1999). The causative link between MMR 
deficiency and MSI in cancer has been further demonstrated in several human CRC cell lines. 
In cell lines containing MLH1 hypermethylation, inhibition of methyl transferases and 
demethylation of the MLH1 promoter restores MLH1 expression and microsatellite stability 
(Herman et al, 1998; Deng et al, 1999). MSI in the HCT116 CRC cell line, which has a 
hemizygous nonsense MLH1 mutation (Papadopoulos et al, 1994), can be reduced by 
transfection with human chromosome 3 from normal fibroblasts, which contains the MLH1 
locus (Koi et al, 1994). The same result was achieved when transfecting HEC59 and HCT15 
cell lines, which have biallelic mutation of MSH2 and MSH6 respectively, with normal 
chromosome 2, which contains the MSH2 and MSH6 genes (Umar et al, 1997). 
MSI is not a feature specific to MMR deficient (MMRd) CRC as MMR proficient 
(MMRp) CRCs can have indel mutations in a minority of microsatellites (Thibodeau et al, 
1998). Therefore, at the National Cancer Institute (NCI) workshop in December 1997, it was 
agreed to designate cancers as MSS if there was no evidence of MSI, MSI-low if <30% of 
markers analysed were mutated, or MSI-high if ≥30% of markers analysed were mutated 
(Boland et al, 1998; Thibodeau et al, 1998). It was unknown if MSI-low tumours represented 
another pathway of tumorigenesis as there is evidence that they have slightly worse 
prognosis than MSS tumours; for example, the cancer-specific survival hazard ratio (HR) of 
MSI-low tumours relative to MSS tumours was 2.0 (95% CI: 1.1-3.6) in a study of 209 MMRp 
CRCs (Wright et al, 2005). However, analyses of large panels of microsatellites (up to 377 
markers) showed that up to 79% of MMRp CRCs could be classed as MSI-low and that MSI-
low samples had no unique clinical or molecular features relative to MSS samples 
irrespective of classification thresholds (Halford et al, 2002; Laiho et al, 2002). The 
conclusion of these studies is that MSS and MSI-low tumours originate from the same 
tumorigenesis pathways, with variation caused by the evolutionary history of the cancer and 
chance mutation; hence only MSI-high is a recognised biomarker of MMR deficiency. 
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 The improved survival of MMRd CRC patients was evident in many early studies 
(Aaltonen et al, 1993; Ionov et al, 1993; Lothe et al, 1993; Thibodeau et al, 1993). In light of 
this, a meta-analysis by Popat et al defined an overall survival HR of 0.65 for a diagnosis of 
MSI-high (95% CI: 0.59-0.71) (Popat et al, 2005), and MMR deficiency has been confirmed as 
an independent prognostic indicator that enhances multivariate models of prognosis, which 
include established clinico-pathological features such as TNM staging (Dienstmann et al, 
2017). A possible cause for the better prognosis is the increased immune cell infiltrate and 
reduced rate of metastasis of MMRd tumours, which are proposed consequences of a high 
mutational burden and generation of tumour associated antigens (Buckowitz et al, 2005). 
Furthermore, there is evidence that MMRd CRCs are resistant to the frontline, adjuvant 
chemotherapy 5-fluorouracil (5-FU), as shown by randomised trials (Ribic et al, 2003; Jover 
et al, 2006), and the poorer overall survival of patients treated with 5-FU observed in stage II 
disease (HR = 2.95; 95% CI = 1.02-8.54; p = .04) (Sargent et al, 2010). This is supported by a 
mechanism defined in cell lines, by which the MMR system is required to induce G2 cell cycle 
arrest and apoptosis through c-Abl/p73α/GADD45α following detection of 5-FU 
(incorporated into the DNA) mispairing with guanine (Li et al, 2009). However, no predictive 
value to MMR status for 5-FU response has been observed in other studies (Bertagnolli et al, 
2009) and combination therapies containing 5-FU, such as irinotecan-5-FU-leucovorin, have 
contrarily been associated with improved disease free survival in MMRd CRCs (Bertagnolli et 
al, 2009). More recent trials of 5-FU combination therapies, covering up to 10 years follow 
up, also failed to identify MMR status as a significant indicator. However, it is not known if 
the better prognosis of MMRd cancers, their relatively low numbers in such studies, or the 
effect of the combined drugs, confounds the predictive value of MMR status for 5-FU 
therapy (André et al, 2015). 
 Promotion of apoptosis by the MMR system in response to DNA damage (Aquilina et 
al, 1999; Hickman and Sansom, 1999) also has therapeutic implications for the use of 
thiopurines and alkylating agents. Whilst these drugs are not used in the treatment of CRC, 
they are used in other cancers associated with MMRd cancer-predisposition syndromes 
(Wimmer et al, 2014; Section 1.6.2). Acute lymphoblastic leukaemia (ALL), for example, is 
typically treated with thiopurines (Vora et al, 2006), which both inhibit nucleoside 
metabolism to slow malignant cell growth, and are incorporated into DNA where the 
thiopurine lesion is recognised by MutSα to promote apoptosis (Karran and Attard, 2008). A 
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study of changes in gene expression associated with ALL relapse found that MSH6 expression 
was inversely associated with sensitivity to mercaptopurine (a thiopurine) (Yang et al, 2008), 
suggesting that resistance to thiopurines can be acquired in ALL through evolution of MMR 
deficiency. Alkylating agents, such as N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) and 
temozolomide, covalently link alkyl groups to DNA bases. These alkyl-DNA adducts are 
mutagenic, through base-mispairing or blockage of replication, and are repaired by a variety 
of mechanisms, including direct reversion of alkylation, base excision repair, nucleotide 
excision repair, and MMR (Fu et al, 2012). Loss of direct repair mechanisms sensitises cells to 
alkylating agents; depletion of the methylguanine methyltransferase (MGMT) enzyme, for 
example, increases temozolomide toxicity (Zhang et al, 2012). MMR is necessary to induce 
apoptosis in response to some alkyl-DNA adducts. In brain tumours, for example, resistance 
to temozolomide in the absence of MGMT is acquired by additional loss of MMR. Normally, 
the MMR system detects mispairing between O6-methylgunaine (the product of MNNG DNA 
methylation) and thymine, and initiates a futile repair cycle where thymine is repeatedly 
paired with O6-methylguanine, leading to promotion of apoptosis via the tumour suppressor 
p53 (Hickman and Sansom, 1999). Without MMR the base mispairing is not recognised and is 
tolerated (Thomas et al, 2017). MMR deficiency, therefore, is associated with resistance to 
numerous therapies for cancer, including 5-FU, thiopurines, and alkylating agents. 
 
1.3. Microsatellite Instability generates Frameshift Mutations that drive Tumorigenesis 
Genomic instability is a hallmark of cancer (Hanahan and Weinberg, 2011), but there has 
been contention regarding its functional relevance. There are two main arguments. First is 
that genomic instability is not a driver of tumorigenesis but is, instead, a passenger caused 
by oncogene-induced replicative stress, whereby an increased rate of cell division reduces 
the fidelity of DNA replication. In opposition is the idea that genomic instability is caused by 
an early event or mutation that leads to additional, functional mutations and, therefore, is a 
critical driver of tumorigenesis (Negrini et al, 2010). Mathematical models that test the 
likelihood that such mutator phenotypes contribute to tumorigenesis have shown that, 
assuming cancer progression to be a multi-step process requiring 4 or more events, mutator 
phenotypes facilitate carcinogenesis within biologically relevant timescales (Beckman and 
Loeb, 2006). Hence it would be expected that driver mutations in a tumour will reflect the 
mutational mechanism of its type of genomic instability. 
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The classical pathway of genetic changes in colorectal tumorigenesis was first 
described by Fearon and Vogelstein, including mutations in oncogenes such as KRAS and 
tumour suppressor genes (TSGs) such as APC and p53 (Fearon and Vogelstein, 1990; Figure 
1.2). These tumours are MMRp and their driver mutations are a combination of point 
mutations and frequent somatic copy number alterations (CNAs) caused by large deletions, 
duplications and other chromosomal rearrangements, which are characteristic of CIN.  
 
 
Figure 1.2. The classical pathway of genetic changes in colorectal tumorigenesis. Fearon and 
Vogelstein described the classical model of genetic changes that occur during colorectal 
tumorigenesis and their associations with each stage. In normal colorectal epithelium, stem cells in 
the base of the crypts reproduce to replenish the epithelium, with daughter cells moving up the walls 
of the crypt to the epithelium surface where they will eventually be shed and replaced. Activation of 
Wnt signalling by loss of function mutations in APC causes stem cells to over-proliferate, forming an 
early adenoma. Gain of function mutations in proto-oncogenes, such as KRAS, drive uncontrolled 
proliferation of epithelial cells, propagating adenoma growth. Loss of function mutations in tumour 
suppressor genes, such as TP53, and other genetic changes progress the adenoma into an invasive 
adenocarcinoma (Fearon and Vogelstein, 1990). 
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MMRd CRCs, however, lack CIN and have a diploid karyotype with a low number of CNAs. 
Instead, they have the MSI-high phenotype and many other small indels and point 
mutations, generally termed “hypermutation” (Muzny et al, 2012). Furthermore, the genes 
mutated in MMRd CRCs are different to those mutated in CRCs with the CIN phenotype, 
evident in significantly lower rates of APC mutation (51% versus 81%, p = 0.0023) and p53 
mutation (20% versus 60%, p < 0.0001), a higher rate of BRAF V600E mutation, and 
mutations in genes such as ACVR2A and TGFBR2 that are rarely seen in MMRp CRCs (Muzny 
et al, 2012). Furthermore, the type of mutations are different in MMRd versus MMRp CRCs, 
with a 50-fold increase in indels in coding mononucleotide repeats (cMNRs), which cause 
pathogenic frameshift mutations in the affected genes by introduction of early stop codons 
(Muzny et al, 2012). Also, where genes associated with the classical pathway of colorectal 
tumorigenesis are mutated in MMRd CRCs, there is a prevalence of cMNR frameshift 
mutations. For example, APC has a much higher incidence of cMNR frameshift mutations in 
MMRd versus MMRp CRCs (p < 0.0002), (Huang et al, 1996) and this observation extends to 
precancerous tumours with 14/26 MMRd versus 3/52 MMRp adenomas containing such 
frameshifts in APC (Sekine et al, 2017). cMNR frameshift mutations can also confer drug-
resistance when MMRd but not MMRp CRC cell lines are exposed to selection by 6-
thioguanine (Bhattacharyya et al, 1994). 
The inherent mutability of microsatellites is proposed to explain their reduced 
density in coding relative to non-coding regions of the genome (Subramanian et al, 2003). 
Furthermore, there has been debate around the functional impact of cMNR frameshift 
mutations in the non-classical genes of colorectal tumorigenesis; are they drivers of 
tumorigenesis or passengers caused by this inherent mutability? Transforming growth 
factor-β receptor 2 (TGFβR2) has multiple regulatory roles in cellular homeostasis and 
growth, and has been linked with both progression and suppression in multiple types of 
cancer (Padua and Massagué, 2009). TGFβR2 was shown to be absent in approximately 81% 
of MMRd CRCs but only 11% of MMRp CRCs, and the causative mutations in the MMRd 
samples were found to be frameshifts due to 1-2bp deletions in a 10bp poly-adenine (A10) 
tract  of the TGFβR2 gene, leading to an early stop codon and protein truncation (Markowitz 
et al, 1995) (Figure 1.3). To confirm functional impact, cell line HCT116, which lacks TGFβR2 
expression due to frameshift mutation in the A10 repeat, was transfected with a wild type 
(WT) copy of the gene; rescue of TGFβR2 expression decreased clonogenicity in culture and 
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Figure 1.3. Frameshift mutations identified in TGFβR2. -1 and -2bp deletions in an A10 repeat within 
the coding sequence of TGFβR2 produce frameshift mutations that introduce early stop codons and 
cause protein truncation. Note that the frameshift also produces a novel sequence of amino acids in 
the C-terminus of the truncated protein. 
 
 
decreased tumorigenicity in athymic mice (Wang et al, 1995). Similarly, the pro-apoptotic 
BAX gene had frameshift mutations in its 8bp poly-guanine (G8) tract in approximately 50% 
of MMRd CRCs, often in both alleles (Rampino et al, 1997), and presence of these BAX 
mutations affected survival of CRC clones inoculated into immune-deficient mice (Ionov et 
al, 2000). The data from TGFβR2 and BAX support functional roles for cMNR frameshift 
mutations in colorectal tumorigenesis. Other cMNR frameshift mutations with similar 
functional evidence for being drivers of tumorigenesis have since been identified, including 
frameshift mutation of an A8 repeat in ACVR2 (Deacu et al, 2004) and an A10 repeat in AIM2 
(Lee et al, 2012). Whole-genome and whole-exome sequencing, comparing the spectrum of 
mutations in colorectal versus endometrial cancers (ECs), has also shown that TGFβR2, 
ACVR2A, AIM2, SLC22A9 and SMAP1 all contain frameshift mutations in 50-70% of MMRd 
CRCs but <25% of MMRd ECs. MMRd ECs likewise have their own set of frequently 
frameshift-mutated genes which are not observed in CRCs, suggesting that cMNR 
frameshifts are subject to selection during tumorigenesis in the context of different tumour 
types (Kim et al, 2013). 
Duval and Hamelin proposed that the biological relevance of cMNR frameshift 
mutations could be determined from their observed frequencies by assuming that all 
microsatellites, coding or non-coding, have a constant mutation rate dependent on length 
and, therefore, genes with cMNRs of a given length that have an over or under 
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representation of frameshift mutations in cancers are likely to be selected for or against 
respectively (Duval and Hamelin, 2002). Adapting this concept into a statistical model, 
Woerner et al have created SelTarbase, a database of genes that are likely targets of 
selection during MSI-driven tumorigenesis (www.seltarbase.org; Woerner et al, 2003; 
Woerner et al, 2005; Woener et al, 2010). Of the 1793 MNRs analysed, 4.0% are predicted to 
be positively or negatively selected in CRC (Woerner et al, 2010). From these predictions and 
the previously described weight of evidence, it is clear that MMR deficiency and MSI 
constitute a mutator phenotype that drives colorectal tumorigenesis. 
 
1.4. Frameshift Mutations stimulate an Anti-Tumour Immune Response 
MMR deficiency was defined as a distinct molecular subtype of CRC by multiple clustering 
algorithms using transcriptomic data (Muzny et al, 2012; De Sousa E Melo et al, 2013; 
Sadanandam et al, 2013; Roepman et al, 2014). These methods were combined into one 
classification algorithm to define the four consensus molecular subtypes (CMS) of CRC. MSI 
and hypermutation were genetic hallmarks of CMS1. CMS1 CRCs also had an increased 
expression of gene signatures related to T helper 1 cells and cytotoxic T lymphocytes (CTLs), 
which are associated with an anti-tumour immune response, and, in opposition to this, 
activation of immune evasion mechanisms (Guinney et al, 2015). Characteristics of CMS1 
agree with the strong association between hypermutation and MMR deficiency in genomic 
analyses of more than 100,000 cancers (Alexandrov et al, 2013; Chalmers et al, 2017) and 
the early observations of increased TILs in MSI-high CRCs indicating that these tumours are 
particularly immunogenic (Ionov et al, 1993; Lothe et al, 1993; Thibodeau et al, 1993). 
Cells throughout the body present intracellular protein antigens to T cells by binding 
of peptide fragments to major histocompatibility complex (MHC) class I receptors on the cell 
surface, facilitating immune responses against cellular infection and dysfunction 
(Matsumura et al, 1992). Tumour associated antigens (TAAs) originate through several 
mechanisms including aberrant gene expression, infection by oncoviruses and abnormal 
post-transcriptional modification (Ilyas and Yang, 2015). Of particular interest is the 
generation of TAAs by mutation of proteins also expressed in normal cells, producing amino 
acid sequences that are recognised as “foreign” by the immune system. An early example is 
antigen LB33-B, presented on MHC class I receptors of melanoma cell line LB33-MEL.A. LB33-
B was tracked back to a point mutation in an exon-intron junction of the MUM1 gene, 
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producing a novel peptide by translation of the intronic sequence, expression of which 
stimulated cell lysis by CTLs (Coulie et al, 1995). Therefore, mutations can generate TAAs 
that stimulate an immune response, and it follows that there is a positive correlation 
between tumour mutational burden and the response rate of cancers to immunotherapy (r = 
0.74, p < 0.001) (Yarchoan et al, 2017). 
There is strong evidence of TAAs being generated as a consequence of the frameshift 
mutations at cMNRs that drive tumorigenesis of MMRd CRCs. It was initially theorised that 
the affected genes could be translated to produce truncated proteins containing 
immunogenic frameshift peptides (FSPs) at their C termini due to the change in reading 
frame downstream of the mutation (Figure 1.3). To test this, Linnebacher et al selected FSP 
antigens from common frameshift mutations in MMRd CRCs that were also predicted in 
silico to bind to MHC class I receptors for antigen presentation to immune cells. CTLs specific 
to these antigens were generated using synthetic FSPs presented on CD40-activated B cells. 
They found that three of the anti-FSP CTL lines were able to lyse cells loaded with the 
respective peptide. Most importantly, CTLs targeting TGFβR2-derived FSPs could lyse 
HCT116, an MMRd CRC cell line which contains the associated frameshift mutation in 
TGFβR2 (Linnebacher et al, 2001). CTLs expanded from the TIL population of MSI-high CRCs 
were similarly able to lyse MSI-high, but not MSS, CRC cell lines, and T cells isolated from the 
peripheral circulation from MSI-high, but not MSS, CRC patients were activated by FSP-
loaded autologous B cells, suggesting that activation of T cells by FSPs also occurs in vivo 
(Saeterdal et al, 2001; Schwitalle et al, 2008). The FSPs required to stimulate peripheral CTLs 
were shown to match the cMNR frameshift mutations present in the tumour, and the 
number of frameshift mutations correlated with the density of TILs and their CTL component 
(Tougeron et al, 2009; Maby et al, 2015). Finally, enzyme-linked immunosorbent assay 
(ELISA) has been use to identified anti-FSP antibodies in the serum of MSI-high CRC patients 
(Reuschenbach et al, 2010), which suggests that both cytotoxic and humoral immune 
responses can be generated against the intrinsic FSP antigens of MMRd CRCs. 
 
1.5. Mismatch Repair Deficient Cancers respond to Immunotherapy  
The immunoediting model of tumour evolution proposes that interaction between tumours 
and the immune system shapes tumour evolution by Darwinian selection (Greaves and 
Maley, 2012). There are three stages to immunoediting. Foremost is “elimination” by which 
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immunosurveillance destroys early tumour cells. “Equilibrium” is reached when clones 
surviving initial elimination continue to propagate but remain asymptomatic under the 
continuing selection pressure of immune destruction, driving tumour evolution toward the 
final stage of “escape”. During escape, mechanisms that allow the tumour to evade immune 
destruction are evolved and disease progresses (Dunn et al, 2002; Mittal et al, 2014). 
Tumour escape of the immune system can be achieved by several mechanisms. These 
include loss of antigen presentation through beta2-microglobulin (β2M) mutation or human 
leukocyte antigen (HLA) copy number variation (Paschen et al, 2003; McGranahan et al, 
2017), disruption of antigen processing through loss of tapasin (Sokol et al, 2015), loss of 
APLNR function, which regulates interferon-γ stimulation of immune cells via JAK1 signalling 
(Patel et al, 2017), inhibition of natural killer cells by intra-tumoral Fusobacterium nucleatum 
(Gur et al, 2015), and tumour or stromal expression of immune checkpoint proteins, such as 
programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4), which inhibit T cell anti-tumour activity (Pardoll et al, 2012). Both loss of 
MHC class I and class II antigen presentation has been observed in MMRd CRC (Kloor et al, 
2007; Surmann et al, 2015), and MMR deficiency is associated with increased PD-L1 
expression in numerous cancer types (p = 0.01) (Kim et al, 2017). Two years ago, the 
immunology of MMRd cancers was thoroughly reviewed (Kloor and von Knebel Doeberitz, 
2016). 
Immune checkpoint proteins can be found on the surface of both immune and non-
immune cells. CTLA-4 is expressed by T cells and auto-regulates activity by increasing its 
concentration on the T cell surface in proportion to the strength of T cell receptor activation, 
where it antagonises further stimulation by competitive binding with the stimulatory 
receptors of antigen presenting cells. Programmed cell death protein 1 (PD-1) is expressed 
on the surface of activated T cells and binding to PD-L1 expressed on tumour or stromal cells 
promotes T cell exhaustion (Pardoll et al, 2012). In cancers where TAA-reactive T cells have 
been exhausted by immune checkpoints, blocking of the checkpoint signal using small 
molecule or antibody inhibitors has proven to be an effective and durable therapy by 
releasing exhaustion and allowing proliferation of the suppressed T cells (Gubin et al, 2014). 
Immune checkpoint blockade by pembrolizumab, an antibody that binds PD-1, had a disease 
control rate (which includes stable disease, partial response or complete response) of 90% in 
MMRd CRCs and 71% in MMRd non-colorectal cancers, whereas MMRp CRCs only had an 
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11% disease control rate (Le et al, 2015). Expansion of pembrolizumab treatment to 12 
different cancer types found complete response in 21% of MMRd cancers and a disease 
control rate of 77%. Overall survival at 2 years was 64% in MMRd cancers despite the 
advanced stage of disease (Le et al, 2017). Analysis of pembrolizumab’s mechanism of action 
revealed expansion of T cell clones that were specifically reactive to FSP antigens related to 
cMNR mutations found in the respective tumours (Figure 1.4), confirming the association of 
response with MMR deficiency (Le et al, 2017). Whilst these initial results are very 
promising, the efficacy of pembrolizumab is still to be confirmed by randomised clinical trials 
(Cummings and Garon, 2017). Hence, the US Food and Drugs Administration (FDA) have 
approved pembrolizumab as a second line treatment in all MSI-high cancers refractory to 
primary treatment (MERCK & Co. Inc, 2017). 
 
 
 
 
Figure 1.4. The mechanism of action of immune checkpoint blockade by pembrolizumab in 
mismatch repair deficient cancers. Mismatch repair deficient cancers frequently contain frameshift 
mutations in coding mononucleotide repeats. Expression of the mutated gene produces frameshift 
peptide antigens that are recognised as “foreign” by the patient’s immune system, stimulating an 
anti-tumour immune response. (A) To escape immune-mediated cytotoxicity, cancer cells express 
programmed cell death ligand 1 (PD-L1), which binds to programmed cell death protein 1 (PD-1) 
expressed on active T cells. The binding of PD-L1 with PD-1 sends inhibitory, or immune checkpoint, 
signals to the T cell to prevent clonal expansion and cytotoxic activity. This inactive state is referred 
to as T cell exhaustion. (B) Blockade of the PD-L1 to PD-1 immune checkpoint by pembrolizumab 
binding to PD-1 releases T cell suppression and exhausted T cells become active, expanding and 
renewing cytotoxicity. 
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1.6. Cancer-predisposition Syndromes associated with Mismatch Repair Deficiency 
Familial adenomatous polyposis (FAP) was recognised in the early 20th century as a high 
penetrance, but surgically curable, cause of CRC, characterised by tens to thousands of 
macroscopically visible polyps of the colorectal epithelium (Gardner, 1951; Dukes, 1952). It 
was later recognised that the majority of hereditary CRC lacked this polyposis phenotype, 
but it was not until Henry Lynch and colleagues retraced Warthin’s family G, which was 
originally reported in 1913, and identified others that the clinical condition of HNPCC 
became accepted (Lynch and Krush, 1971; Lynch et al, 1998; Douglas et al, 2005). While the 
FAP gene was being sought (Groden et al, 1991), an international consortium similarly began 
collecting families with HNPCC with a view to identification of the underlying genes (Section 
1.2). For example, Dunstone and Knaggs (1972) described a family in North East England, 
similar to Warthin’s family G, with 45 cancers in 104 individuals, later shown to have an 
MLH1 mutation (John Burn, personal communication). Initially, Lynch described two types of 
HNPCC depending on the presence of other cancers, typically of the endometrium, but the 
discovery of the MMR genes as the underlying cause made it clear that the clinical 
phenotypes, and the condition known as Muir Torre syndrome which includes types of skin 
cancer, were all variants of the same condition (Lynch et al, 1985). Given the wider range of 
cancers, it was decided to use the diagnostic label of Lynch syndrome instead of HNPCC 
(Lynch et al, 2009). Currently, HNPCC is considered an umbrella term shared by multiple 
distinct cancer syndromes that can be separated by testing the MSI status of tumours and by 
their distinct genetic aetiologies (Figure 1.5). 
The majority of MSI-high HNPCC is attributable to Lynch syndrome, which accounts 
for 2.4-3.7% of all CRC cases (Hampel et al, 2005a; Hampel et al, 2008; Canard et al, 2012; 
Moreira et al, 2012; Pérez-Carbonell et al, 2012; van Lier et al, 2012) and, by extension, 16-
25% of all MMRd CRC. Lynch syndrome is caused by pathogenic germline mutation affecting 
one of four MMR genes, MLH1, MSH2, MSH6 and PMS2, and is a significant burden to 
healthcare services (Lynch et al, 2009). Where a genetic diagnosis of Lynch syndrome is not 
made, MSI-high HNPCC is termed Lynch-like syndrome. Lynch-like syndrome has a CRC risk 
intermediate between Lynch syndrome and the general population (Rodríguez-Soler et al, 
2012) and may be linked to non-MMR germline variants, such as in MUTYH or POLE, that 
result in somatic MMR mutation (Castillejo et al, 2014; Morak et al, 2014), or may be 
attributable to a heterogeneous population of Lynch syndrome cases with un-characterised  
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Figure 1.5. The colorectal cancer syndromes within hereditary non-polyposis colorectal cancer 
(HNPCC). MSI testing can separate HNPCC into distinct cancer syndromes, with MSI-high HNPCC 
being associated with Lynch and Lynch-like syndromes, and MSI-low or MSS HNPCC being associated 
with familial colorectal cancer type X (FCCTX) and polymerase proof reading polyposis. Adapted from 
Carethers and Stoffel, 2015. 
 
 
MMR mutations (Clendenning et al, 2011; Borràs et al, 2013; Rhees et al, 2014; Liu et al, 
2016) mixed with double somatic MMR mutations that appear more like Lynch syndrome 
CRCs than the majority of sporadic MMRd CRCs (Geurts-Giele et al, 2014; Haraldsdottir et al, 
2014; Mensenkamp et al, 2014) (Figure 1.5). MSS HNPCC is a poorly characterised 
phenotype of a heterogeneous population, and is given the name familial CRC type X (FCCTX) 
(Lindor et al, 2005) (Figure 1.5). Efforts to identify causative germline variants have found 
that known cancer predisposition genes are rarely implicated in FCCTX, and the majority of 
candidate genes identified have not been validated (Lorans et al, 2018). It has also been 
suggested that polygenic, rather than monogenic, inheritance may account for a large 
proportion of FCCTX (Ku et al, 2012). Constitutional MMR deficiency (CMMRD), also known 
as biallelic MMR deficiency (Durno et al, 2012), is a very rare childhood cancer syndrome 
caused by germline, biallelic mutation in the same MMR gene (Wimmer et al, 2014). 
 
1.6.1. Lynch syndrome biology and clinical management 
An analysis of 1112 CRC patients genetically tested on suspicion of Lynch syndrome in 2012-
2013 identified 114 (10.3%) patients were germline heterozygous for pathogenic MMR gene 
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(path_MMR) mutations. Of these mutations, 27% were path_MLH1, 35% were path_MSH2, 
3% were EPCAM 3’ deletions, which leads to silencing of downstream MSH2 (Ligtenberg et 
al, 2009), 23% were path_MSH6, and 12% were path_PMS2 (Yurgelun et al, 2015). Lynch 
syndrome gene carriers (meaning individuals carrying an MMR mutation but not necessarily 
presenting with disease) have an increased risk of multiple cancers, in particular CRC and EC, 
with disease penetrance depending on which MMR gene is affected, as estimated by 
prospective data (Figure 1.6). Whilst path_PMS2 mutations are known to cause Lynch 
syndrome (Nicolaides et al, 1994), there is currently insufficient prospective data to 
accurately estimate cancer risks in these patients, although these are significantly lower than 
other path_MMR mutations (Møller et al, 2017b). Therefore, whilst PMS2 mutations 
account for a minority of Lynch syndrome cases (Yurgelun et al, 2015), path_PMS2 variants 
may occur at a higher frequency in the population than variants in any other MMR gene. 
 
 
Figure 1.6. The cumulative cancer risks in Lynch syndrome gene carriers by age 75 years. Significant 
increases in risk relative to the general population are marked with *, using results from the 
Prospective Lynch Syndrome Database (Møller et al, 2017b). GI: gastrointestinal.  
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The increased cancer risk in path_MMR carriers follows the two-hit hypothesis for 
loss of tumour suppressor gene function (Knudson, 2001) as 90-100% of Lynch syndrome  
CRCs contain a “second hit” in the germline-affected MMR gene causing MMR deficiency in 
the tumour (Leach et al, 1996; Liu et al, 1996; Thibodeau et al, 1996; Hampel et al, 2008). 
Initially, it was believed that MMR deficiency was a secondary event in pre-established 
adenomas due to the similar adenoma incidence and histology in Lynch syndrome families 
and age-matched autopsy populations, which suggested a similar initiation and progression 
of colorectal tumours. Combined with the observed increase in high grade dysplasia, size, 
and only slightly earlier onset of adenomas in Lynch syndrome gene carriers, and a lack of a 
polyposis phenotype, it was therefore suggested that loss of MMR is an accelerator rather 
than initiator of tumour progression (Jass and Stewart, 1992; Jass et al, 1994). However, 
subsequent studies on larger populations have shown that there is a 2-3-fold increase in the 
adenoma burden in Lynch syndrome gene carriers relative to age-matched controls, with an 
increased incidence (p = 0.0001) of villous or tubulovillous histology (de Jong et al, 2004a). 
Furthermore, the discovery of MMRd crypt foci (MMR-DCF) in the normal colorectal 
epithelium of Lynch syndrome gene carriers revealed that MMR deficiency can occur in 
phenotypically normal cells (Kloor et al, 2012). MMR-DCF can cover multiple crypts, can have 
aberrant histology and can have cMNR frameshift mutations in genes such as AIM2 and BAX 
(Staffa et al, 2015). This raises the possibility that MMR deficiency could be the initiating 
event of colorectal tumorigenesis in Lynch syndrome. This has recently been supported by 
the discovery of MMRd adenomas outgrowing from MMR-DCF (Figure 1.7), and by the high 
frequency of cMNR frameshift and MMR deficiency related substitution mutations in APC, 
loss of which initiates adenoma formation (Sekine et al, 2017; Ahadova et al, 2018). 
Most significantly, the Lynch syndrome pathway of colorectal tumorigenesis is 
distinct from the pathway associated with sporadic MMRd CRC. MMR deficiency in sporadic 
CRC is associated with the CpG island methylator phenotype (CIMP), whereby widespread 
hypermethylation of CG dinucleotides in the tumour DNA leads to promoter-methylation 
and aberrant silencing of many genes, often including MLH1 (Young et al, 2001). 
Weisenberger et al (2006), in a study of 195 CpG methylation sites in 295 CRCs, showed that 
CIMP characterises a distinct tumour subtype and accounts for nearly all CRCs with BRAF 
V600E mutations (odds ratio (OR) = 203). CIMP has also been associated with the serrated 
pathway of tumorigenesis in which cancers arise from adenomas with a serrated histology 
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(Yamane et al, 2014) rather than the traditional adenomas characteristic of Lynch syndrome 
and most MMRp tumours (Figure 1.8). It follows, therefore, that Lynch syndrome CRCs can 
be distinguished from sporadic MMRd CRCs by key molecular changes as they make up a 
large proportion of those that do not have CIMP or BRAF V600E mutation (Kambara et al, 
2004). 
 
 
 
Figure 1.7. Mismatch repair deficient adenoma associated with mismatch repair deficient (MMRd) 
colorectal crypt focus. A 3µm section of FFPE adenoma tissue resected from a Lynch syndrome 
patient with a germline path_MSH2 mutation was stained by immunohistochemistry (IHC) for MSH2 
expression. (A) Histologically normal and MMR proficient colorectal crypts, showing MSH2 positive 
staining in the nuclei of dividing cells at the base of the crypts. (B) MMRd colorectal crypts, showing 
loss of MSH2 expression but otherwise normal histology. (C) Dysplastic and MMRd tissue of the 
adenoma directly adjacent to the MMRd colorectal crypts. Adapted from Ahadova et al, 2018*. 
* I am joint first author on this publication, however this work is not described in this thesis. Please 
see Appendix L for more details. 
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Figure 1.8. Comparative histology of colorectal adenomas. Haematoxylin and eosin staining of 
colorectal tissues to show differences in histology. (A) Normal colorectal muscosa showing mucus-
producing epithelial cells lining uniformly-structured crypts. (B) Serrated adenoma with the 
eponymous serrated or saw-tooth edge to the crypts. These grow as sessile and flat lesions that do 
not obviously protrude from the colorectal wall (Bartley et al, 2010). (C) Traditional adenomas, with 
villous, tubular or tubulovillous histology, are typically polypous and extend from the colorectal wall 
into the lumen (Buchanan et al, 2011). (D) Close up of tubular histology in a colorectal adenoma, 
showing degradation of crypt architecture and lack of serration.  
 
 
A diagnosis of Lynch syndrome has implications for the clinical management of the 
patient and their family to mitigate their increased risk for colorectal, endometrial and other 
cancers. Management guidelines include surveillance, prophylaxis and genetic counselling 
(Vasen et al, 2013). Numerous studies have assessed the efficacy of surveillance for the two 
most common Lynch syndrome cancers, CRC and EC. Colonoscopy with polypectomy every 
1-2 years is highly effective at reducing CRC risk and mortality in Lynch syndrome families. 
For example, Järvinen et al (2000) observed a 62% reduction in CRC incidence in patients 
under endoscopic surveillance, and 0 versus 9 CRC-related deaths in surveillance and control 
groups respectively. In agreement, there was a statistically significant decrease in the 
standardised mortality ratio associated with colonoscopic surveillance (de Jong et al, 2006). 
However, no benefit has been observed for endometrial surveillance (de Jong et al, 2006). 
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This is perhaps due to the low mortality rates of EC due to symptomatic stage 1 disease that 
is curable by surgical resection (Boks et al, 2002). From these observations, colonoscopic 
surveillance is recommended in 1-2 yearly intervals starting at age 20-25 years (Vasen et al, 
2013), although the optimal time interval is still being debated. Recent comparisons of CRC 
incidence in path_MLH1 carriers shows no difference in the rate of interval cancers between 
1-3 year intervals, reasoning for less frequent surveillance (Seppälä et al, 2017). Surveillance 
may also be tailored by MMR gene in the future, with proposals that path_PMS2 carriers 
should start colonoscopic surveillance at 35-40 years of age, due to lower disease 
penetrance in these patients (Ten Broeke et al, 2018). Prophylactic surgery to remove at risk 
organs is another option for disease management in Lynch syndrome gene carriers, in 
particular partial or sub-total colectomy, and hysterectomy after completion of child-bearing 
(Vasen et al, 2013). Due to the high risk of metachronous CRC (Aarnio et al, 1995), known 
Lynch syndrome patients can choose partial or total colectomy at surgical resection of the 
first tumour, based on evidence that more extensive surgery reduces the risk of 
metachronous CRC by 31% (95% CI: 12-46%, p = 0.002) for every 10cm of colorectum 
removed (Parry et al, 2011). Parry et al (2011) also found no metachronous CRCs were 
diagnosed in study patients opting for a full colectomy (incident rate ratio (IRR): 0.0, 95% CI: 
0.0-7.2 per 1000 person years). Chemoprevention of CRC and other Lynch-spectrum cancers 
is also effective. For example, Lynch syndrome gene carriers with a daily intake of 600mg of 
aspirin were shown to have an IRR for CRC of 0·37 (95% CI: 0·18-0·78, p = 0·008) relative to 
those randomised to placebo, after a median 55.7 months of follow up in the CAPP2 clinical 
trial (Burn et al, 2011). Lifestyle has also been associated with CRC risk in Lynch syndrome, 
including increased risk (HR = 2.34; 95% CIs = 1.17-4.67; p = 0.02) in obese patients 
(Movahedi et al, 2015), and decreased risk (HR: 0.71, 95% CI: 0.53-0.96, p = 0.02) in those 
exercising regularly (Dashti et al, 2018). Therefore, a diagnosis of Lynch syndrome allows 
optimised clinical management and patients to modify their lifestyle to reduce their cancer 
burden. Finally, immunotherapies are applicable to Lynch syndrome cancers due to the high 
rate of MMR deficiency and associated immune response in these tumours (Westdorp et al, 
2016). For example, immune checkpoint blockade by pembrolizumab showed high response 
rates and overall survival at 2 years in MMRd cancers from both Lynch syndrome and 
sporadic patients (Le et al, 2017). 
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1.6.2. Constitutional mismatch repair deficiency biology and clinical management 
Turcot’s syndrome is a familial condition that includes cancer and polyposis of the 
colorectum and tumours of the central nervous system (CNS), but its genetic aetiology was 
unknown for several decades (Turcot et al, 1959). Patients from 14 families fulfilling clinical 
criteria for Turcot’s syndrome were shown to harbour germline mutations in either APC or 
MMR genes MLH1 and PMS2. Families lacking a genetic diagnosis had MSI-high tumours 
characteristic of Lynch syndrome, suggesting that they too had a causative MMR defect 
(Hamilton et al, 1995). Furthermore, these families could be segregated based on the type of 
CNS tumour, with medulloblastomas versus glioblastomas predominating in APC-associated 
and MMR-associated Turcot’s syndrome respectively (Hamilton et al, 1995). Subsequently, 
multiple case studies of Turcot’s syndrome, or of offspring of consanguineous marriages in 
HNPCC kindreds, found biallelic MMR gene mutation in the affected patients, including 
MLH1 (Wang et al, 1999; Ricciardone et al, 1999; Gallinger et al, 2004), MSH2 (Whiteside et 
al, 2002; Toledano et al, 2009), PMS2 (De Rosa et al, 2000; De Vos et al, 2006; Krüger et al, 
2008) and MSH6 (Menko et al, 2004; Ripperger et al, 2010), covering all MMR genes 
involved in Lynch syndrome. The spectrum of cancers in these patients was diverse, 
including brain, haematological and gastrointestinal (GI), and are typically diagnosed in 
childhood to adolescence. Due to their cancer burden, mortality in these case studies was 
high and often at a young age. Pre-malignant or benign phenotypes prevalent in these 
patients included colorectal polyps despite their young age, and features of 
neurofibromatosis type 1 (NF-1), including benign neurological tumours (such as 
neurofibromas), and skin markings (such as café-au-lait maculae, freckling, and 
hypopigmentation). It was proposed that this rare childhood cancer syndrome be called 
CMMRD in reference to its underlying aetiology (Wimmer et al, 2008). 
 Lynch syndrome and CMMRD have a common cause in pathogenic variants in MMR 
genes, but the representation of gene variants in the two syndromes differs. A collation of 
146 genetically confirmed CMMRD cases showed that 58% are caused by PMS2 mutations, 
20% by MSH6 mutations and only 22% by MLH1 or MSH2 mutations (Wimmer et al, 2014). 
This is in contrast to the 6-12% of Lynch syndrome CRCs associated with PMS2 mutation 
(Borràs et al, 2013; Yurgelun et al, 2015). Diagnosing CMMRD caused by PMS2 mutation can 
be complicated by PMS2 pseudogenes on chromosome 7 (Nicolaides et al, 1995). These 
contain paralogous copies of all PMS2 exons and make accurate sequencing and variant 
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calling difficult (Nakagawa et al, 2004). Cases of CMMRD may be misdiagnosed as Lynch 
syndrome or otherwise, due to failure to detect a pathogenic variant. For example, when 
genotyping young CRC patients that lacked PMS2 expression in the tumour, path_PMS2 
nonsense mutations affecting the second allele were initially missed and only recognised 
after repeat sequencing using alternative methods (De Vos et al, 2004). Furthermore, 8% of 
supposed monoallelic path_PMS2 carriers had CRC diagnosed below 30 years of age and all 
on the left-side of the colorectum, a feature more common to CMMRD than Lynch syndrome 
(Goodenberger et al, 2016). Given that only 9% of MMR variants listed in the InSiGHT 
database of CRC-related gene variants affect PMS2, additional knowledge of PMS2 variants is 
needed to reduce the uncertainty in its diagnosis (Blount and Prakash, 2017). 
Clinical details of 197 CMMRD patients were used to define the neoplastic and 
benign features of CMMRD, one of the largest collections of CMMRD data due to this 
syndrome’s rarity (Wimmer et al, 2017). Based on 321 tumours across 34 tumour types, 
haematological malignancies were diagnosed in 38.6%, brain and CNS tumours in 54.8%, and 
Lynch-spectrum cancers in 51.8% of patients. Within the haematological malignancies, non-
Hodgkin’s lymphoma and lymphoid leukaemia were the most common, being diagnosed in 
19.8% and 7.6% of all patients, respectively. The vast majority of CNS tumours are high grade 
glioblastomas, found in 40.6% of all patients, and CRC is the predominant Lynch-spectrum 
cancer being diagnosed in 38.1%. The distribution in age of diagnosis depends on tumour 
type, but haematological malignancies have been diagnosed in patients younger than 1 year 
of age and CNS tumours in patients as young as 2 years (Figure 1.9). 
The Lynch-spectrum cancers of CMMRD patients, the adenomatous histology of their 
colorectal adenomas, and the presence of the MSI-high phenotype in their CRCs, suggests 
that CMMRD cancers develop by tumorigenesis pathways similar to Lynch syndrome, albeit 
accelerated due to the younger age of onset (Aronson et al, 2016). However, the presence of 
a polyposis-like phenotype with histology reminiscent of juvenile polyposis suggests 
alternative progression also occurs in CMMRD (Levi et al, 2015; Aronson et al, 2016). 
CMMRD haematological malignancies are frequently MSI-high but, interestingly, CNS 
tumours rarely are (Bakry et al, 2014). The lack of MSI despite MMR deficiency is particularly 
associated with glioblastomas (Bougeard et al, 2003; Leenen et al, 2011) even when other 
tumours in the same patient are MSI-high (Merlo et al, 1996), suggesting glioblastomas 
progress by a pathway that is not driven by MSI. Indeed, Shlien et al analysed the mutation  
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Figure 1.9. The ages of 197 constitutional mismatch repair deficiency patients at cancer diagnosis. 
Including Lynch-spectrum cancers, brain or central nervous system tumours, and haematological 
malignancies, and the most common cancer types within these groups (Wimmer et al, 2017). 
 
 
spectrum of CMMRD-associated glioblastomas and found them to be ultra-hypermutated 
with an anticipated 600 mutations acquired per cell division, in particular substitution 
mutations, leading to rapid progression of a polyclonal tumour, and insufficient time or 
clonal homogeneity to develop a detectable MSI signal. Concurrent mutation in polymerase 
ɛ and polymerase ɖ, and complete loss of replication-associated repair, was proposed to 
cause this aggressive phenotype (Shlien et al, 2015). 
 CMMRD can also be recognised by its non-neoplastic features, such as the high 
frequency of skin cafe-au-lait maculae or hyperpigmentation that occurs in over 60% of 
patients (Wimmer et al, 2014). These overlap with the NF1 phenotype. Functional 
association between MMR deficiency and NF1 gene mutation has been found, with 40% of 
MMRd cell lines and primary MMRd tumours shown to contain NF1 mutations (Wang et al, 
2003). However, only one patient has been identified with mutated NF1 in blood (Alotaibi et 
al, 2008) despite this being explored in several studies (e.g. Menko et al, 2004; Østergaard et 
al, 2005). Therefore, the cause of the NF1-like phenotype of CMMRD is still to be 
determined. Additional non-neoplastic features are highly varied and include agenesis of the 
corpus callosum and grey matter hypertopia (Baas et al, 2013) and impaired immunoglobulin 
class switch recombination (Peron et al, 2008). A distinct molecular feature of CMMRD 
patients is the lack of MMR in all tissues. This can be observed by immunohistochemistry 
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(IHC) where mutation leads to loss of protein expression (Bakry et al, 2014). A review of MSI 
testing of tumour and normal tissues by Wimmer et al in 2008 found that somatic indels in 
microsatellites were detectable in the normal tissue of CMMRD patients when using highly 
sensitive small pool PCR (Parsons et al, 1995), but not MSI detection techniques normally 
applied to cancer diagnostics such as PCR fragment length analysis (Bacher et al, 2004). 
 The case study of a 43 years old female with biallelic PMS2 mutation describes a 
clinical history in which the severe cancer risk of CMMRD patients can be combated by 
intense surveillance and extensive surgery. In her lifetime, the patient had been diagnosed 
with 9 different cancers from age 10 years and had multiple GI and gynaecological surgeries. 
Surveillance included upper and lower endoscopy, computed tomography (CT) and magnetic 
resonance imaging (MRI) (Sjursen et al, 2009). Prophylactic surgery and endoscopic GI 
surveillance are proven to be effective in Lynch syndrome (Järvinien et al, 2000; Parry et al, 
2011) and other CMMRD case studies have reported early detection of CRC and a lack of 
mortality due to GI malignancy in patients under endoscopic surveillance (Durno et al, 2012; 
Aronson et al, 2016). Brain CT or MRI is routinely used in the diagnosis of brain tumours in 
children (Perkins et al, 2011) and can be used in surveillance for early and asymptomatic CNS 
tumours in CMMRD (Durno et al, 2012). Haematological malignancies can be detected by 
ultrasound of the abdomen, to assess the liver and spleen (Siniluoto et al, 1991), and blood 
counts (Juliusson and Liliemark, 1993). These observations were used by the European Care 
for CMMRD (C4CMMRD) consortium to compile surveillance and management guidelines for 
CMMRD (Table 1.1) (Vasen et al, 2014). 
 The use of aspirin as a chemopreventive has also been debated given its efficacy in 
Lynch syndrome (Burn et al, 2011), with current recommendations from European experts 
that prescription to daily aspirin be considered from first diagnosis of CMMRD, whilst 
clinicians should be cognizant of its risks, in particular cranial bleeds given the frequency of 
brain tumours (Leenders et al, 2018). Immunotherapy has also been considered in CMMRD 
patients but studies are needed to confirm safety and efficacy (Westdorp et al, 2017). 
Indeed, immune checkpoint blockade therapy had durable response in two siblings with 
CMMRD and ultra-hypermutated glioblastomas (Bouffet et al, 2016), so this is a promising 
avenue of research in CMMRD cancer therapy. Therefore, identification of patients with 
germline MMR gene defects, whether causative of Lynch syndrome or CMMRD, is critical to 
provide these patients with personalised clinical management. 
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Cancer Start age Procedure, interval 
NHL/other 
lymphoma 
1 year Clinical examination, 1 per 6months  
Abdominal ultrasound (optional), 1 per 6months 
Leukaemia 1 year Blood count, 1 per 6months 
Brain tumours 2 years Brain MRI, 1 per 6-12months  
CRC 8 years Ileocolonoscopy, 1 per year 
Small bowel cancer 10 years Video capsule/upper GI endoscopy, 1 per year 
Other Lynch-
spectrum* cancer 
20 years Gynaecological examination/transvaginal 
ultrasound/pipelle curettage, 1 per year 
Urine cytology, 1 per year 
*Colorectal, endometrial, small bowel, ureter, renal pelvis, biliary tract, stomach, bladder 
carcinoma. 
Table 1.1. Surveillance recommendations for constitutional mismatch repair deficiency. 
Recommendations agreed by the C4CMMRD consortium. Adapted from Vasen et al, 2014. 
 
 
1.7. The Utility of Biomarkers in Colorectal Cancer and Cancer-predisposition Syndromes 
A biomarker is defined as “A characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention” (Biomarkers Definitions Working Group, 2001). Testing for 
biomarkers can therefore inform healthcare practice. There are two considerations when 
adopting a biomarker test into clinical practice: its analytical validity and its clinical utility 
(Hayes, 2018). Analytical validity defines the ability of the test to detect the biomarker and 
can be summarised by several quantifiable parameters (Ray et al, 2010; Henry and Hayes, 
2012). These include, but not exclusively: 
• sensitivity: the proportion of biomarker-positive cases correctly identified 
• specificity: the proportion of biomarker-negative cases correctly identified 
• accuracy: the proportion of all cases correctly identified 
• concordance: the proportion of results in agreement from repeat testing of the same 
samples 
• robustness: the ability of the test to cope with relevant sample variables, which can 
be measured by multiple parameters 
• validation: where an assay is developed using one cohort of samples, analytical 
validity (e.g. by the above criteria) must be shown in an independent set of samples  
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Furthermore, the standards for reporting diagnostic accuracy (STARD) compiled a list of 25 
items to guide assessment of the analytical validity of a new biomarker test, which includes 
clear statement of the study aim, description of participant selection, number and 
demographic, sample processing, defining the comparator “gold standard” assay used, 
technical aspects of the biomarker test and the method of statistical analysis (Bossuyt et al, 
2003). Clinical utility of a biomarker test is determined by the association between the test 
result and disease outcomes, and the feasibility of its deployment (Ray et al, 2010; Henry 
and Hayes, 2012). Key points to consider include: 
• whether or not the results of the biomarker test influence clinical decisions 
• the incidence or rate of side effects or adverse events in patients subject to the 
biomarker test 
• the cost effectiveness of the biomarker test and interventions informed by the test 
result, which is frequently measured as the economic cost per patient life-year 
gained 
• improvement in measurable clinical outcomes resulting from biomarker testing 
By quantifying the analytical validity and clinical utility of a biomarker test it can be 
compared to alternative methods and strategies to select the most appropriate diagnostic 
tool. 
Biomarker tests are available to assess various aspects of CRC management, from risk 
estimation to disease monitoring (Table 1.2). Early detection of cancer is viewed as the “holy 
grail” of cancer diagnostics due to superior prognosis and more favourable treatment 
options available for early stage disease (Etzioni et al, 2003). For example, 1 year survival 
rates in CRC are 98% in stage 1, 93% in stage 2, 89% in stage 3, but only 44% in stage 4, or 
metastatic, disease, based on the UK population in 2014-2015 (Broggio and Bannister, 2016). 
Biomarkers capable of early detection of CRC in cancer-predisposition syndromes are of 
particular interest. In Lynch syndrome and CMMRD, clinical guidelines state that gene 
carriers should have 1-2 yearly colonoscopies to screen for CRC and to prevent disease by 
polypectomy of precancerous adenomas (Vasen et al, 2013; Vasen et al, 2014). However, 
colonoscopy has its risks, such as perforation of the bowel in 0.5% patients, post-endoscopy 
bleeding in 0.26% patients and mortality in 0.003% patients (Reumkens et al, 2016), and is 
considered to be a highly invasive procedure (Fisher et al, 2011). In a prospective study of 
CRC incidence and mortality in Lynch syndrome patients, only 42.2% of patients were 
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Example Biomarker  Clinical Use Reference 
Germline APC mutation Cancer-risk estimation Groden et al, 1991 
Faecal immunohistochemical testing Early detection/screening Lee et al, 2014 
Tumour Dukes’ or TNM staging and 
grading 
Determine prognosis Labianca et al, 
2010 
Tumour KRAS mutation (anti-EGFR 
antibody) 
Predict therapeutic 
response 
Allegra et al, 2009 
Serum CEA Monitor disease 
progression 
Locker et al, 2006 
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; KRAS, Kirsten 
rat sarcoma viral oncogene homolog; MMR, mismatch repair. 
 
Table 1.2. The utility of biomarkers in colorectal cancer (CRC)-related healthcare. CRC biomarkers 
are useful in the assessment of multiple aspects of disease. This is not an exhaustive list. 
 
 
compliant with colonoscopic screening at the recommended 1-2 year intervals (Stuckless et 
al, 2012). Furthermore, although colonoscopic surveillance increases the median age at first 
CRC diagnosis in Lynch syndrome patients, it does not prevent all CRCs: it has been shown 
that 20% of males and 7% of females develop an interval CRC within 2 years of the previous 
colonoscopy (Stuckless et al, 2012). Comparison of surveillance protocols found no 
difference in CRC incidence or time to diagnosis since last colonoscopy between Lynch 
syndrome patients following longer (3 yearly) and shorter (1-2 yearly) intervals between 
colonoscopies (Møller et al, 2017a; Seppälä et al, 2017). This suggests that the rate of 
tumorigenesis is independent of the surveillance interval and therefore unaffected by an 
increase frequency of prophylactic polypectomy. The quality of colonoscopy is another 
factor to consider, as pre-cancerous lesions may be missed if the full extent of the 
colorectum is not visualised especially when there is a high rate of proximal (right-sided) 
CRCs in Lynch syndrome (Lynch et al, 2009). However, in a study of colonoscopy quality in 
Lynch syndrome, only 9% of interval cancers were detected in sections of the colorectum un-
visualised in the previous colonoscopy, and only 21% of cancers were in the same location as 
an adenoma removed in the previous colonoscopy (suggesting incomplete polypectomy), 
leaving the origin of approximately 70% of interval cancers unexplained (Haanstra et al, 
2013). Ahadova et al showed that 17.4% (95% CI: 7.8-31.4%) of Lynch syndrome CRCs have 
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mutations in CTNNB1 that encodes β-catenin, a component of the Wnt signalling pathway. 
The majority of these CRCs (62.5%) lacked any evidence of polypous growth. Instead, they 
appeared to invade directly into the colorectal wall and so may be undetectable by 
colonoscopy and, therefore, are a plausible explanation for interval cancers in Lynch 
syndrome patients under colonoscopic surveillance (Ahadova et al, 2016). In addition, the 
thousands of MMR-DCF in the colorectum of healthy Lynch syndrome gene carriers (Kloor et 
al, 2012) have been associated with cMNR frameshift mutations (Staffa et al, 2015) and 
evolution into MMRd tumours (Ahadova et al, 2018), suggesting that these may also 
contribute to the undetectable and pre-cancerous lesions during colonoscopy. Therefore, 
less invasive methods, such as biomarker tests, for the early detection of MMRd CRC would 
greatly benefit both Lynch syndrome gene carriers and, most likely, CMMRD patients. 
To screen patients with germline MMR gene defects for biomarkers of MMRd CRC, 
the relevant patients must first be identified. Currently Lynch syndrome is severely 
underdiagnosed, with an estimated 1.2% of Lynch syndrome gene carriers known to medical 
services in 2011 (Hampel and de la Chapelle, 2011). As will be discussed in more detail later, 
testing any and all CRCs for biomarkers of MMR deficiency can be used to detect potential 
cases of Lynch syndrome (Newland et al, 2017), given that Lynch syndrome accounts for 
approximately 23% of all MMRd CRCs (Hampel et al, 2008). MMR deficiency testing of 
cancers also informs the use of immunotherapy, with MMRd cancers of any type responding 
to immune checkpoint blockade (Le et al, 2017). Finally, the lack of MMR in all tissues of 
CMMRD patients can also be detected to complement genetic diagnosis (Bodo et al, 2015). 
Thus, there are several distinct clinical needs for biomarker tests of MMR deficiency. 
 
1.8. Biomarkers for the Early Detection of Colorectal Cancer 
Current methods (using biomarkers or otherwise) for early detection of CRC include analysis 
of tumour-derived nucleic acids in blood, detection of specific proteins (or proteomic 
signatures) in liquid biopsies such as blood or urine, and clinical examination to name just a 
few. However, each of these biomarkers have their limitations for screening and early 
detection, due to either a lack of analytical validity or clinical utility. Here I will discuss a few 
examples. 
 Circulating tumour DNA (ctDNA) constitutes a fraction of cell free DNA (cfDNA), 
which consist of 180bp fragments of genomic DNA released into circulation by apoptotic 
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cells, with fragments defined by the DNA structure around histone bodies (Jahr et al, 2001). 
ctDNA has conventionally been used for longitudinal monitoring of cancer progression and 
relapse (Taly et al, 2013 ; Schøler et al, 2017), and evolution of therapeutic resistance, for 
example mutation of KRAS to confer resistance to anti-EGFR therapy in CRC (Diaz et al, 2012; 
Siravegna et al, 2015). It was suggested ctDNA could be used for early detection in CRC when 
it was shown that 47% of stage 1 cancer patients had detectable ctDNA across multiple 
cancer types, including CRC (Bettegowda et al, 2014). However, due to its low abundance in 
a background of cfDNA from non-neoplastic cells, detection of ctDNA requires very sensitive 
techniques. Picodroplet digital PCR is one such technique that has been effective in CRC 
diagnostics (Taly et al, 2013; Bettegowda et al, 2014), and more recently next generation 
sequencing (NGS)-based methods using very high read depths have been employed (Shu et 
al, 2017). Unfortunately, these techniques are costly and time-consuming. Furthermore, 
ctDNA is usually quantified by the fraction of cfDNA which contains mutations present in the 
cancer (Bettegowda et al, 2014), and prior knowledge of the tumour is incompatible with 
screening for early diagnosis. Instead, extensive gene panels of frequently mutated genes 
can be assessed, such as the 382 gene panel used by Shu et al (2017), but this will further 
increase cost. Additional challenges include distinguishing between mutations that occur 
during natural aging from those associated with malignancy, and defining cancer location 
(Aravanis et al, 2017). Circulating micro RNAs have also been shown to detect advanced 
colorectal adenomas with 73.0% sensitivity and 79.7% specificity (Huang et al, 2010) and 
aberrant methylation of APC, MGMT and other genes in ctDNA has 86.5% sensitivity and 
92.1% specificity for stage 1 and 2 CRC (Lee et al, 2009), highlighting that there are several 
avenues of research into use of circulating nucleic acids for the early detection of CRC. 
Single protein biomarkers from liquid biopsy often have poor sensitivity, particularly 
for early stage disease (Borrebaeck et al, 2017). For example, carcinoembryonic antigen 
(CEA) is a clinically accepted serum biomarker for multiple cancers, but its sensitivity is only 
21% for stage 1 CRC and 37% overall, irrespective of CRC stage (Su et al, 2012). Combinations 
of protein biomarker can improve detection; Zhang et al reported sensitivity of 94% and 
specificity of 98% for CRC using a panel of 4 serum peptides CA199, CA242, CA125, and 
CA153 (Zhang et al, 2016). However, meta-analyses have highlighted that studies conducted 
in a clinical setting such as that of Zhang et al where patients have consulted a clinician due 
to related symptoms or disease, rather than screening in average-risk individuals, can bias 
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results, with receiver operating characteristic (ROC) area under curve (AUC) values being 
higher in clinic- versus screening-based studies (AUC range 0.68-0.996 versus 0.62–0.78 
respectively) (Bhardwaj et al, 2017). New approaches harnessing proteomics are in 
development in numerous cancer types, with a view to analysing protein biomarker 
signatures, using methods such as multiplexed ELISA and bead-based arrays (Borrebaeck et 
al, 2017). Non-blood based approaches for CRC screening include faecal immunochemical 
testing (FIT), which quantifies the micrograms of haemoglobin per gram of stool as a 
biomarker of colorectal bleeding. As a screening tool for early detection of cancer in average 
risk populations, FIT has a sensitivity of 79% (95% CI: 69-86%), and specificity of 94% (95% CI: 92-
95%) using thresholds of >20µg/g, based on a meta-analysis of nineteen studies (Lee et al, 
2014). However, FIT sensitivity for right-sided (proximal) CRC is as low as 20% (95% CI: 11-
31%) (Haug et al, 2011). Therefore, like circulating nucleic acids, protein biomarkers of CRC 
can have very low sensitivity for early stage or pre-malignant tumours, and research is 
ongoing to identify novel markers and develop multi-marker panels to increase sensitivity 
(Borrebaeck et al, 2017). 
 
1.9. Early Detection of Mismatch Repair Deficient Colorectal Cancer using Autoantibodies 
The immune response against MMRd CRC may provide a novel source of biomarkers for 
early detection of CRC (Reuschenbach et al, 2010). Immune cells and signals, such as 
inflammatory cytokines, circulate throughout the body. For example, T cells reactive to FSP 
TAAs have been isolated from the peripheral circulation as well as the TIL population 
(Saeterdal et al, 2001; Schwitalle et al, 2008). It may be feasible to detect immunological 
biomarkers from liquid biopsy for early detection of MMRd CRC, which would be a less 
invasive surveillance method than the currently recommended colonoscopy. 
The humoral immune response and the generation of autoantibodies (antibodies 
targeting antigens derived from self-molecules) against TAAs has been explored in numerous 
cancer types. For example, TP53 mutations frequently lead to over expression of p53 protein 
in tumour cells and so it was hypothesised that p53 autoantibodies would be detectable in 
CRC patients. Angelopoulou et al (1997) found that 53/229 (23%) of CRC patients, but no 
controls, had p53 autoantibodies in their serum. Hammel et al (1997) found similar results 
with p53 autoantibodies in sera from 14/54 (26%) CRC patients, but not from controls. In 
addition, they showed over-expression of p53 in tumours from 22 patients, 10 of whom had 
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p53 autoantibodies, suggesting that p53 over-expression can, but is not necessary to, 
stimulate autoantibody production (Hammel et al, 1997). In three autoantibody-positive 
patients, antibody titre correlated with CEA concentration over 10-16 months of clinical 
follow up (Angelopoulou et al, 1997), and in 11/13 patients p53 autoantibodies decreased 
following surgical resection of the tumour (Hammel et al, 1997). Agreement with these 
results has been found in other cancer types.  For example, in a study of breast cancer, 9% of 
patients had p53 autoantibodies, but analysis of p53 accumulation in tumour tissues showed 
only a weak association between over-expression of p53 and detectable autoantibodies (p = 
0.05) (Angelopoulou et al, 2000). A meta-analysis of >130 publications has concluded that 
p53 autoantibodies have 30% sensitivity and 96% specificity in cancers tested, and that the 
signal is associated with p53 accumulation in the tumour and missense mutations (Soussi et 
al, 2000). 
The low sensitivity of a single antibody assay can be improved by panel testing, for 
example using microarrays (Robinson et al, 2002). A 22-TAA panel for autoantibody 
detection in sera was 81.6% sensitive and 88.2% specific for prostate cancer, with a higher 
ROC AUC than prostate serum antigen (0.93 versus 0.80) (Wang et al, 2005) and analysis of 
autoantibodies against a panel of 3 TAAs had 55% sensitivity and 95% specificity for 
preclinical lung cancer (Pereira-Faca et al, 2007). These and other studies suggest that 
autoantibodies can be used to monitor disease and may be applicable to early detection 
(Desmetz et al, 2011). As proof of principle, antibody titres against TAAs have previously 
been used to predict cancer incidence: increased serum titres of p53 autoantibodies were 
significantly associated with lung cancer incidence in a high risk group, with an average lead 
time to diagnosis of 3.5 years (Li et al, 2005). 
Currently, tests for autoantibodies, which include ELISA and microarrays, lack the 
analytical validity required of biomarkers for early detection due to generally low sensitivity 
and inadequate specificity – such screening tests need to have exceptionally high specificity 
to avoid over-diagnosis, with a recommended ROC AUC >0.95 (Hartwell et al, 2006). 
However, autoantibodies are still attractive candidate biomarkers for several reasons. For 
instance, the immune response to TAAs amplifies the signal from transient antigens that 
would be near impossible to detect otherwise. Also, handling and storage of samples is 
simplified by the stability of antibodies in serum, due to resistance to proteolysis that affects 
other peptides, and antibodies are particularly stable in serum in vivo with half-lives >7 days, 
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meaning that the timing of sample collection is not critical (Anderson and LaBaer, 2005). 
Finally, autoantibodies may be more sensitive and specific in immunogenic cancer types. 
Autoantibodies against FSPs (αFSP-Abs) associated with MMRd cancer have been 
detected. Ishikawa et al (2003) generated a λ phage-display library from cDNA of three 
MMRd CRC cell lines and screened for TAAs using sera from an MMRd CRC patient. Serum 
antibodies were present against 64 antigens, 49 of which were shown to be specific to 
MMRd CRC by exposure of these antigens to sera from controls and other cancer patients. 
Significantly, one antigen was associated with a frameshift mutation in a G7 tract of CDX2, 
which would lead to a novel 30 amino acid sequence at the C terminus of the CDX2 protein. 
This frameshift mutation was also found in the tumour of the patient with serum antibodies 
against this FSP. Using ELISA, Reuschenbach et al (2010) exposed 6 FSPs associated with 
common cMNR frameshift mutations in MMRd CRCs to sera from 69 MMRd CRC patients, 
and autoantibodies against FSPs derived from TAF1B and TGFβR2 were observed in 8 
(11.6%) and 7 (10.1%) patients, but only 3 (5.8%) and 1 (1.9%) controls respectively. Whilst 
these anti-FSP antibodies (αFSP-Abs) individually had very low sensitivity, a multiplexed, 
bead-based method, which assesses 32 αFSP-Abs simultaneously, has been developed that 
may be able to address the low sensitivity of single autoantibody biomarkers. As an initial 
test of this method, it was shown to be able to detect ASTE1-FSP and TAF1B-FSP 
autoantibodies in patients vaccinated with the respective synthetic peptide, but the number 
of sera tested was limited (Reuschenbach et al, 2014). 
Autoantibody tests for early detection of MMRd CRC is an intriguing prospect. Due to 
the frequent frameshift mutations in multiple cMNRs that are intrinsic to tumour 
progression (Woerner et al, 2010), it is possible to build a panel of synthetic FSPs with 
confidence that some of the corresponding mutations will exist in preclinical tumours, such 
as in the 32 FSP panel designed by Reuschenbach et al (2014). Once detected, αFSP-Abs may 
also be able to monitor disease, as has been observed with p53 autoantibodies 
(Angelopoulou et al, 1997; Hammel et al, 1997) and observed by loss of the anti-CDX2 FSP 
antibody from one patient’s serum 7 years after CRC-resection (Ishikawa et al, 2003). 
Another potential advantage of analysing αFSP-Abs is that they are proof of an immune 
response against the cancer, and may provide information on prognosis and therapeutic 
response. For example, the immunoscore method of characterising TILs is a better predictor 
of patient prognosis in CRC than MMR deficiency (Mlecnik et al, 2016). This is particularly 
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significant as not all MMRd cancers respond to immune checkpoint blockade and, whilst 
some may be explained by evolution of alternative immune evasion mechanisms (Sade-
Feldman et al, 2017), this may be due to an inadequate anti-tumour immune response. 
Quantification of the immune response by αFSP-Abs as a mechanism-driven biomarker of 
therapeutic response would, therefore, be superior to qualifying mutational load by MMR 
deficiency testing alone and assuming immunogenicity (Topalian et al, 2016). This is 
particularly significant as immune checkpoint blockade produces numerous side effects 
similar to auto-immune disease, some of which can be severe (Postow et al, 2018), meaning 
it is critical to target suitable patients. However, the analytical validity and clinical utility of 
αFSP-Abs needs to be explored. 
 
1.10. Mismatch Repair Deficiency testing to identify Cancer-predisposition Syndromes 
Biomarkers of MMR deficiency can be used in the diagnosis of Lynch syndrome and CMMRD. 
 
1.10.1. Diagnosing Lynch syndrome 
Lynch syndrome accounts for a large proportion of hereditary CRC and the availability of 
disease-preventing and, ultimately, life-saving options make the identification of Lynch 
syndrome gene carriers an important task for healthcare providers (Vasen et al, 2013). 
However, in 2011 it was estimated that only 1.2% of all Lynch syndrome gene carriers were 
known (Hampel and de la Chapelle, 2011) despite frequency-estimates of one carrier per 
370-1000 of the population, based on Finnish and American statistics (Aaltonen et al, 1998; 
Hampel and de la Chapelle, 2011). This is equivalent to one million carriers in Europe (Vasen 
et al, 2010). In the Icelandic population, which has experienced a genetic bottleneck, the 
frequency is as high as one carrier per 226 (Haraldsdottir et al, 2017).  
Historically, Lynch syndrome was diagnosed following clinical indicators defined in 
the Amsterdam criteria, including a family history of Lynch-spectrum cancers and early onset 
of disease (Vasen et al, 1991; Vasen et al, 1999). The Bethesda guidelines, defined at the NCI 
meeting in 1996, used less stringent familial criteria but included assessment of other 
disease features, such as adenoma incidence (Table 1.3). Amsterdam and Bethesda criteria 
performance has been tested in registered Lynch syndrome families, revealing sensitivities 
of 23% and 70% respectively (Terdiman et al, 2001). However, testing in families previously 
identified by family history and age of disease onset creates an ascertainment bias and 
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confounds results, an issue recognised during revision of the Bethesda guidelines in 2002 
(Umar et al, 2004). Alternative screening strategies were encouraged (Umar et al, 2004), and 
it was concurrently suggested that tumours should be tested for MMR deficiency to select 
patients for MMR gene testing to identify pathogenic germline variants (Rodriguez-Bigas et 
al, 1997). Aaltonen et al (1998) showed that fragment length analysis of PCR-amplified 
microsatellites (MSI FLA) of an unselected cohort of 509 CRCs detected 63 (12%) MMRd 
tumours and, by germline genetic testing of this selected population, identified 10 Lynch 
syndrome cases with mutations in MLH1 or MSH2. A direct comparison of molecular and 
clinical screening strategies for the detection of path_MLH1 or path_MSH2, carriers in a 
cohort of 1222 CRC patients from the EPICOLON I study, found sensitivities and specificities 
of 90.9% and 93.9% for MSI FLA, 81.8% and 94.2% for immunohistochemistry to detect loss 
of MMR protein expression (MMR IHC), and 90.9% and 77.1% for Bethesda criteria (Piñol et 
al, 2005). This showed that testing for biomarkers of MMR deficiency in CRC is 
 
Guidelines Criteria 
Amsterdam II At least 3 relatives with a Lynch-associated cancer (CRC, cancer of the 
endometrium, small bowel, ureter, or renal pelvis). All of the following 
criteria should be met: 
• One should be the first-degree relative of the other 2 
• At least 2 successive generations should be affected 
• At least 1 CRC should be diagnosed before age 50 yr Familial 
adenomatous polyposis should be excluded 
Bethesda Individuals with cancer in families that fulfil the Amsterdam criteria 
Individuals with 2 Lynch-related cancers, including synchronous or 
metachronous CRCs or associated extracolonic cancers 
Individuals with CRC and a first-degree relative with CRC and/or 
Lynch-related extracolonic cancer and/or colorectal adenoma; 1 of 
the cancers diagnosed at age <45 yr and the adenoma diagnosed at 
<40 yr 
Individuals with CRC or endometrial cancer diagnosed at <45 yr 
Individuals with right-sided CRC with an undifferentiated pattern 
(solid/cribriform) on histopathology diagnosed at <45 yr 
Individuals with signet ring cell–type CRC diagnosed at <45 yr 
Individuals with adenomas diagnosed at <40 yr 
 
Table 1.3. Clinical criteria for Lynch syndrome screening. The Amsterdam II and Bethesda criteria for 
the identification of Lynch syndrome families, as summarised by Terdiman et al, 2001. 
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superior to clinical criteria for identification of Lynch syndrome. A more recent comparison 
of screening strategies has confirmed the superiority of MSI FLA or MMR IHC over Bethesda 
criteria using a cohort of 2093 CRC patients, with molecular screening of CRCs having 100% 
sensitivity and 92% specificity, whilst Bethesda criteria only had 86% sensitivity and 78% 
specificity for Lynch syndrome (Pérez-Carbonell et al, 2012). 
 The lower sensitivity and specificity of clinical screening using family history and age 
of onset of disease is likely due to the criteria being based on patient characteristics 
influenced by ascertainment bias. Early data suggested the median age of CRC diagnosis in 
Lynch syndrome gene carriers was <50 years, but this was largely based on probands. In 
contrast, the median age of diagnosis is 61.2 years for CRC and 62.0 years for EC in mutation 
positive members of Lynch families when probands are excluded (Hampel et al, 2005b). This 
older age of disease onset was confirmed when molecular screening of 1117 CRCs diagnosed 
<70 years of age showed that 70% of Lynch syndrome CRCs were diagnosed in patients over 
50 years (van Lier et al, 2012). Also, the lower penetrance of path_MSH6 and path_PMS2 
mutations mean that family histories are less obvious than in path_MLH1 and path_MSH2 
families (Kariola, 2004; Sjursen et al, 2010), and familial criteria do not exclude the broader 
HNPCC phenotype, which includes patients associated with FCCTX (Figure 1.5; Lindor et al, 
2005). Furthermore, the presence of BRAF mutation and CIMP in sporadic MMRd, but not 
Lynch CRCs, can be used to improve the specificity of molecular screening for Lynch 
syndrome (Parsons et al, 2012). BRAF V600E testing, for example, allows identification and 
removal of approximately 40% of sporadic MMRd CRCs from Lynch syndrome screening 
pipelines (Domingo et al, 2004). Similarly, MLH1 methylation testing of MMRd CRCs removes 
up to 78% of sporadic cases (Pérez-Carbonell et al, 2010). However, despite its greater 
specificity for Lynch syndrome over BRAF V600E testing, MLH1 methylation testing reduces 
sensitivity by exclusion of Lynch syndrome tumours with MLH1 methylation as the second 
hit, which occurs in 53% of CRCs arising in path_MLH1 gene carriers (Kaz et al, 2007), and 
Lynch syndrome tumours associated with germline MLH1 epimutation (Suter et al, 2004). 
The cost-effectiveness of molecular screening is agreed across multiple studies, 
accounting for the cost of screening and cascade testing of family members of genetically 
confirmed probands against the benefits of surveillance and prophylaxis (Mvundura et al, 
2010; Ladabaum et al, 2011). A comprehensive economic evaluation of multiple screening 
strategies (Snowsill et al, 2014) concluded that MSI FLA or MMR IHC, followed by BRAF 
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V600E or MLH1 methylation testing, in CRCs diagnosed <70 years of age is a cost effective 
medical intervention, with incremental cost-effectiveness ratios as low as £5,491 per Quality 
Adjusted Life Year (QALY)-gained, which is below the £20,000 threshold set by UK National 
Institute of Health and Care Excellence (NICE). The UK Royal College of Pathologists included 
MMR deficiency testing of all CRCs diagnosed <50 years of age in their 2014 Dataset for 
colorectal cancer histopathology reports (Loughrey et al, 2014) and, subsequently, NICE 
published its Diagnostic Guidance 27 (DG27) stating that all CRCs should be tested for MMR 
deficiency, by MSI FLA or MMR IHC, followed by BRAF V600E or MLH1 methylation, to select 
patients for germline MMR gene testing (Newland et al, 2017). Similar guidelines can be 
found from the American Society for Clinical Pathology, and the European Society for 
Medical Oncology (Balmana et al, 2013; Stoffel et al, 2015). Despite these guidelines and the 
severe under-diagnosis of Lynch syndrome gene carriers (Hampel and de la Chapelle, 2011), 
only 28.2% of 152,993 CRCs diagnosed in the US were tested for MMR deficiency during 
2010-2012 (Shaikh et al, 2018). Whilst rates were increasing, from 22.3% in 2010 to 33.1% in 
2012, these statistics are of concern given that there is over a decade of literature and 
guidelines supporting MMR deficiency testing to screen for Lynch syndrome (Hamilton, 
2018). These rates are also low in comparison to germline genetic testing for BRCA1/2 in 
young (aged ≤45 years) breast cancer patients, for whom testing is recommended by US 
guidelines, with 65.3% of patients aged 41-45 years being tested in 2012, and 72.9% of those 
aged ≤40 years (Kehl et al, 2016). 
 
1.10.2. Diagnosing constitutional mismatch repair deficiency 
CMMRD is a less significant healthcare burden compared to Lynch syndrome due to its 
rarity. However, the near certainty of cancer diagnosis in these patients, and the availability 
of surveillance guidelines makes identification critical for their clinical management (Vasen 
et al, 2014). Currently, clinical criteria can be used to select patients for CMMRD genetic 
testing based on their malignant, pre-malignant, and non-neoplastic features, as defined by 
the C4CMMRD consortium in 2014 (Table 1.4). Unfortunately, the pleiotropic phenotype of 
CMMRD requires many criteria to be considered, and this is further complicated by overlap 
with other syndromes, in particular NF1. Also, the families of biallelic PMS2 patients only 
have a low incidence, or even lack, of Lynch-spectrum cancers (De Vos et al, 2006; Urganci et 
al, 2015), which can be explained by the much lower penetrance of Lynch syndrome in 
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path_PMS2 heterozygotes compared to other MMR genes (Møller et al, 2017b). Family 
history and patient phenotype, as in Lynch syndrome screening, is not always a useful 
criterion for CMMRD diagnosis. Therefore, germline genetic testing by diagnostic sequencing 
of all MMR genes is required to confirm diagnosis, and is a viable frontline test, given the 
rarity of the disease. However, PMS2 mutations account for nearly 60% of CMMRD (Wimmer  
 
Criteria Points 
Indication for CMMRD testing in a cancer patient, add points from 
malignancies/pre-malignancies and additional features listed below 
≥3 
Carcinoma from the Lynch-spectrum* at age <25 years 3 
Multiple bowel adenomas at age <25 years and absence of 
APC/MUTYH mutation(s) or a single high-grade dysplasia adenoma at 
age <25 years 
3 
WHO grade III or IV glioma at age <25 years 2 
NHL of T-cell lineage or sPNET at age <18 years 2 
Any malignancy at age <18 years 1 
Clinical sign of NF1 and/or ≥2 hyperpigmented and/or hypopigmented 
skin alterations Ø>1 cm in the patient 
2 
Diagnosis of Lynch syndrome in a first- or second-degree relative  2 
Carcinoma from Lynch-spectrum* before the age of 60 in first-degree, 
second-degree, and third-degree relative 
1 
A sibling with carcinoma from the Lynch-spectrum*, high-grade 
glioma, sPNET or NHL 
2 
A sibling with any type of childhood malignancy 1 
Multiple pilomatricomas in the patient 2 
One pilomatricoma in the patient 1 
Agenesis of the corpus callosum or non-therapy-induced cavernoma in 
the patient 
1 
Consanguineous parents 1 
Deficiency/reduced levels of IgG2/4 and/or IgA 1 
*Colorectal, endometrial, small bowel, ureter, renal pelvis, biliary tract, stomach, bladder 
carcinoma. sPNET, supratentorial primitive neuroectodermal tumours. 
 
Table 1.4. Clinical criteria for constitutional mismatch repair deficiency (CMMRD) screening. 
Germline testing of MMR genes for biallelic mutation is considered when patients present with one 
of the listed malignancies or pre-malignancies and have points ≥3, by addition of points from 
multiple features. These consensus criteria were agreed by the C4CMMRD consortium. Adapted from 
Wimmer et al, 2014. 
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et al, 2014) and is a known dead zone of diagnostic sequencing (Mandelker et al, 2016). The 
difficulty in sequencing and interpreting PMS2 variants can cause uncertain genetic diagnosis 
(Nakagawa et al, 2004), as can any other MMR variant of unknown significance. Assays are 
needed to segregate CMMRD from phenotypically-similar syndromes and confirm genetic 
diagnoses by proof of functional impact of any variants detected. 
IHC to show a loss of MMR in non-neoplastic tissues has frequently been used to 
clarify CMMRD diagnosis. Alternatively, the detection of MSI in non-neoplastic tissues is 
another functional assessment of CMMRD, but MSI cannot be detected by standard FLA 
techniques due to the very weak signal. Small pool PCR of microsatellite markers allows FLA 
of products from single or low copy number templates to achieve sufficient sensitivity, but 
the protocol is laborious as it requires analysis of hundreds of PCR products per sample 
(Parsons et al, 1995). To improve biomarker tests of MMR deficiency in non-neoplastic 
tissues of CMMRD patients, Ingham et al developed the germline MSI (gMSI) assay to detect 
MMR deficiency in peripheral leukocytes from blood. The assay uses multiplexed PCR to 
amplify and fluorescently label three dinucleotide repeats (DNRs), and capillary 
electrophoresis traces of amplicons are analysed by comparing heights of the major peak 
(which varies from patient to patient due to polymorphisms of marker length) with the 
+1repeat/+2bp peak (defined relative to the major peak). Individual markers achieved up to 
100% sensitivity and 98.9% specificity in 8 CMMRD patients with biallelic PMS2 or MSH2 
mutations and 90 controls (Ingham et al, 2013). Ex vivo MSI (evMSI) is an alternative assay 
that detects MSI in primary lymphoblastoid cell lines (LCLs) derived from patient leukocytes, 
using a similar fluorescently-labelled FLA method as gMSI. However, three MNR rather than 
DNR markers are used, including two markers found in the Promega MSI Analysis System. In 
a cohort of 14 genetically confirmed CMMRD patients, including biallelic MLH1, MSH6 and 
PMS2 mutations, together with 23 controls (including 12 Lynch syndrome gene carriers), 
evMSI was 100% sensitive and specific (Bodo et al, 2015).  A technique explored in parallel 
by Bodo et al was methylation tolerance of LCLs, based on the logic that MMR is required to 
initiate cell cycle arrest and apoptosis in response to methylation damage to the DNA 
(Karran and Stephenson, 1990). Quantifying LCL tolerance of the methylating agent MNNG 
by cell survival assays had equal sensitivity and specificity to evMSI (Bodo et al, 2015). 
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1.11. The Inadequacies of Current Biomarker Tests for Mismatch Repair Deficiency 
Immune checkpoint blockade has proven to be a highly effective therapy in MMRd cancers 
(Le et al, 2015; Le et al, 2017), and MMR deficiency is associated with cancer-predisposition 
syndromes Lynch syndrome and CMMRD, both of which have extensive guidelines for 
disease management (Vasen et al, 2013; Vasen et al, 2014). MMR deficiency testing is 
therefore applicable to three scenarios; 1, selection of patients eligible for immune 
checkpoint blockade therapies such as pembrolizumab, which has been approved by the FDA 
as a second line therapy in any MSI-high cancer (MERCK & Co. Inc, 2017), 2, screening of all 
CRCs to identify Lynch syndrome, which is currently severely underdiagnosed, as per NICE 
DG27 (Newland et al, 2017), and 3, assessment of non-neoplastic tissue to clarify CMMRD 
diagnosis, which is otherwise complicated by a pleiotropic phenotype and sometimes 
difficult genetic diagnosis (Wimmer et al, 2014). 
MMR deficiency tests used in routine clinical practice include MSI FLA and MMR IHC. 
MSI FLA initially used PCR amplification of a variety of microsatellite markers, including 
MNRs, DNRs and others, and PCR amplicons were analysed by Southern blotting. Instability 
at a marker was observed by the presence of amplicons of a novel length relative to the 
lengths observed in tissue from matched normal (i.e. non-neoplastic) DNA. Matched normal 
DNA was important to account for length polymorphisms in the germline, which are 
common to microsatellites, and to help resolve the “stutter bands” produced by PCR error 
(Figure 1.10) (Aaltonen et al, 1993). However, different laboratories favoured different 
markers and so an optimal panel of microsatellite markers to unify MSI diagnostics was 
defined by the NCI, including two MNRs (BAT25, BAT26) and three DNRs (D5S346, D2S123, 
D17S250) (Boland et al, 1998). These markers were chosen from panels of approximately 30 
markers based on sensitivity for MMR deficiency and ease of interpretation (Bocker et al, 
1997; Dietmaier et al, 1997). Diagnostic thresholds were specified as follows: tumours with 
≥30% of markers showing instability were to be classified as MSI-high, tumours showing 
instability in <30% of markers as MSI-low, and tumours showing no markers with instability 
as MSS (Thibodeau et al, 1998). However, using the NCI panel of two MNRs and three DNRs, 
MSH6 deficient tumours were frequently misclassified as MSI-low or MSS (Wu et al, 1999) 
due to MSH6 being critical to maintaining MNR stability but not microsatellites with longer 
repeat units due to redundant repair by MutSβ (Verma et al, 1999). Adoption of panels 
exclusively composed of MNRs correctly classifies 97.7-100% of MSH6 deficient tumours as 
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MSI-high (You et al, 2010). Furthermore, the quasi-monomorphism of the MNRs used 
reduces the need for matched normal DNA (Suraweera et al, 2002), and MNRs produce less 
PCR stutter relative to DNRs (Buhard et al 2004); hence MNRs can be used to re-classify MSI-
low tumours as MSS due to removal of ambiguous results from DNRs (Murphy et al, 2006). A 
multiplexed, fluorescently-labelled FLA of 5 MNRs by capillary electrophoresis achieved near 
100% accuracy for MMR deficiency diagnosis (Bacher et al, 2004), and has been developed 
into the widely used MSI Analysis System (Promega) (Figure 1.10). A recent meta-analysis 
using nine high quality studies, for example by excluding those that measure diagnostic 
accuracy in case-control populations as this can inflate results (Rutjes et al, 2005), found that 
the sensitivity of MSI FLA testing CRCs for the detection of Lynch syndrome ranged from 67% 
to 100% (Coelho et al, 2017). This wide variability could be due to rates of MSI-high in Lynch 
syndrome CRCs, however, all of the studies in this meta-analysis used out-dated MSI marker 
panels, such as mixtures of mono-, di- and tetra-nucleotide repeats, or the NCI marker panel 
of two MNRs and three DNRs (Boland et al, 1998), which is the likely explanation for lower 
estimates of sensitivity, highlighting the importance of using appropriate markers. 
MMR IHC is used to detect loss of MMR protein expression resulting from loss of 
function mutations (Leach et al, 1996; Thibodeau et al, 1996), and has been accepted as an 
alternative to MSI FLA (Boland et al, 1998). Comparisons of IHC and FLA found 91-98% 
concordance of results, with lower sensitivity using IHC (90.6-95.2%) (Thibodeau et al, 1998; 
Chapusot et al, 2002; Chapusot et al, 2004). However, in these early studies only MLH1, 
MSH2 and, variably, MSH6 proteins were analysed, reducing sensitivity. Also, a meta-analysis 
of IHC performance observed only 74% sensitivity for loss of MLH1 function (Shia, 2008). This 
low sensitivity of IHC for MLH1 deficiency was often caused by loss of function missense 
mutations that retained protein antigenicity (Salahshor et al, 2001; Wahlberg et al, 2002). 
Staining for the full complement of MMR proteins increases the sensitivity and specificity of 
IHC for MMR deficiency to near 100%, equivalent to MSI FLA (Hampel et al, 2005a; Southey 
et al, 2005). This is partly due to negative PMS2 staining identifying those cases where MLH1 
mutations produce non-functional but antigenic MLH1 protein, due to degradation of PMS2 
that fails to complex with the non-functional MLH1 to form the MutLα heterodimer (de Jong 
et al, 2004b; Mangold et al, 2005). 
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Figure 1.10. Microsatellite instability (MSI) detection by fragment length analysis (FLA). (A) PCR and 
FLA by Southern blot of a dinucleotide repeat shows that some tumours (T) have amplicons of 
lengths not detected in matched normal DNA from the same patient (N), as indicated by arrows. 
These length changes are a signal of indel mutations in the microsatellite, and a high burden of these 
(in ≥ 30% of markers) is referred to as MSI-high, a biomarker of mismatch repair (MMR) deficiency. 
Note the stutter bands from both matched normal and tumour DNAs due to PCR error. Taken from 
Aaltonen et al, 1993. (B) PCR of the MSI Analysis System (Promega) panel of five mononucleotide 
repeats and FLA of fluorescently-labelled amplicons using capillary electrophoresis, of DNA from a 
MMR deficient endometrial cancer and matched normal DNA. Again, amplicons from the tumour 
DNA of lengths not detected from the matched normal DNA are indicated by arrows and are a signal 
of indel mutations in the microsatellites. Penta-C and Penta-D are pentanucleotide repeats used in 
genetic fingerprinting and confirm identity of tumour and matched normal DNA. Stutter peaks are 
caused by PCR error. Taken from Tafe et al, 2014. 
  
 
MMR deficiency testing, by MSI FLA or MMR IHC, has established analytical validity 
over many years of use in clinical practice. Both tests have high diagnostic accuracy for MMR 
deficiency, irrespective of which MMR gene is affected, when appropriate methods are used, 
as described above. With respect to reproducibility, MMR IHC can give variable results due 
to subjective interpretation of staining patterns, which can be difficult with poor tissue 
quality, and to differences in protocols and antibodies used between laboratories (Shia, 
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2008). In contrast, MSI FLA is considered highly reproducible, with >95% concordance of 
results generated by independent pathology laboratories (Boyle et al, 2014b). Both 
techniques are considered robust, being applicable to fresh, high quality material, and to 
formalin fixed paraffin embedded (FFPE), low quality material (Chapusot et al, 2002; Bacher 
et al, 2004). Another sample variable that can affect diagnostic test results is sample purity 
and whether or not the analyte of interest is at a high enough representation in the sample 
to be detected by the assay being used, often referred to as the lower limit of detection 
(LLoD) of the assay (Armbruster and Pry, 2008). In the case of MMR deficiency testing of 
CRCs, this is equivalent to the MMRd tumour cell content of the tissue being analysed or 
from which DNA was extracted. MSI FLA can detect 10% MMRd tumour cell content (Berg et 
al, 2000) and focal absence of MMR staining is detectable by IHC (Chapusot et al, 2002), 
therefore both tests have a LLoD that is lower than the typical >20% tumour cell content 
used for diagnostic sequencing (Smits et al, 2014). 
The clinical utility of MSI FLA and MMR IHC is evident in the impact a diagnosis of 
MMR deficiency in CRC has on clinical decisions, the benefit to patients, and the cost-
effectiveness of MMR deficiency testing to screen for Lynch syndrome, as summarised in the 
economic evaluation of Snowsill et al (2014). However, the demands of cancer diagnostics 
have changed with the release of NICE diagnostic guidance, which recommend MMR 
deficiency testing of all 41,000 CRCs detected per annum in the UK (Cancer Research UK 
Statistics, 2015; Newland et al, 2017), and with the FDA approval of MMR deficiency testing 
as a companion diagnostic for immune checkpoint blockade in all cancers (MERCK & Co. Inc, 
2017). As discussed earlier, clinical uptake of testing has been poor (Shaikh et al, 2018), 
which suggests current methods of MMR deficiency testing are inadequate. Methods that 
are not only accurate, reproducible, robust and cost-effective, but also applicable to high 
throughput testing, are now needed. In this context the key disadvantage of both MSI FLA 
and MMR IHC is the reliance on expert interpretation of results on a case-by-case basis, 
which is feasible for low numbers of samples, but time consuming and costly otherwise 
(Shia, 2008; Zhang, 2008). In particular, the stutter bands/peaks and quasi-monomorphism 
of the markers used in MSI FLA ideally require matched normal DNA and multiple 
interpreters to ensure correct classification (Lindor et al, 2006; Zhang, 2008), while IHC 
requires trained and skilled pathologists to both process samples and analyse tumour 
 
 
43 
 
histology and variable staining patterns (Shia et al, 2008). Novel biomarker tests of MMR 
deficiency are therefore needed to meet new clinical demand. 
With respect to CMMRD diagnostics, IHC is insensitive to variants that produce 
antigenic but non-functional proteins (Sjursen et al, 2009; Mork et al, 2016), and ideally 
requires internal positive control staining of TILs or other stromal cells (Shia et al, 2008), 
which is clearly not possible in CMMRD. Also, IHC relies on solid tissue biopsies, which are 
difficult to acquire for normal tissue. MSI FLA fails to detect CMMRD in non-neoplastic 
tissues unless small pool PCR is used (Wimmer et al, 2008), which is a laborious technique 
that requires careful dilution of template DNA and hundreds of PCRs per sample (Parsons et 
al, 1995). A significant advantage of the gMSI assay presented by Ingham et al is the simple 
laboratory workflow and automatable analysis. However, due to the use of DNRs, gMSI 
cannot detect patients with biallelic MSH6 mutations (Ingham et al, 2013). evMSI uses MNRs 
and can detect biallelic MSH6 mutations, but is an expensive and time consuming technique, 
requiring approximately 120 days of cell culture post immortalisation of LCLs to develop the 
MSI signal (Bodo et al, 2015). Similarly, time and cost of LCL culture hinders clinical utility of 
MNNG tolerance assays (Bodo et al, 2015). Ideally, an assay of MSI in normal tissue would 
combine the simple workflow and analysis of gMSI with the sensitivity and specificity of LCL 
evMSI or MNNG tolerance, which is capable of detecting deficiency of all MMR genes. 
 
1.12. Detection of Microsatellite Instability using Next Generation Sequencing 
Informative biomarkers can be found in the cancer genome. As an example from CRC, gain of 
function mutations in the KRAS oncogene predict resistance to anti-epidermal growth factor 
therapies such as cetuximab (Allegra et al, 2009). Frampton et al (2013), for example, 
showed the power of NGS to test for these genetic biomarkers by detection of base 
substitutions, indels, CNAs and gene fusions across 287 cancer-associated genes. 83 cell 
lines, with thoroughly characterised mutations, were used for analytical validation of the 
pipeline, showing 95-99% sensitivity and >99% specificity across mutation types. When the 
same NGS gene panel and analysis pipeline was applied to 2,221 cancers from routine 
clinical services, actionable mutations were identified in 76% of cancers, which was 
approximately a 3-fold higher yield than established, non-NGS-based biomarker tests. 
Significantly, NGS can be deployed for high throughput cancer diagnostics due to simple 
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laboratory protocols for library preparation, and automated analysis of potentially 
thousands of samples in parallel (Frampton et al, 2013). 
 Several software packages have been developed to classify MSI status based on NGS 
data. Lu et al (2013) identified 505,657 microsatellites from Ref-seq transcriptomic data 
(O’Leary et al, 2016) that could be assessed in RNA-seq of tumours. The ratio of indels at 
microsatellites versus indels detected at non-microsatellite loci was used to determine MMR 
status with 100% accuracy relative to MSI FLA in a cohort of 14 MMRd and 14 MMRp CRCs 
(Lu et al, 2013). Another package, MSIsensor (Niu et al, 2014), applicable to whole genome, 
whole exome or gene panel sequencing data, computes the sequencing read count 
distribution across different microsatellite lengths detected at each locus in the tumour, and 
compares these to read count distributions from matched normal DNA. Chi-squared tests for 
significant differences in these distributions determines if a locus is unstable or stable, and 
the proportion of unstable loci is used to classify MMR status. When implemented in exome 
sequencing data from 242 ECs, MSIsensor had 98.6% sensitivity and 97.6% specificity relative 
to MSI FLA with a threshold of 3.5% unstable loci. mSINGS (Salipante et al, 2014) similarly 
analyses the proportion of reads of different microsatellite lengths at multiple loci and, using 
exome data from three different panels covering from 15 to 2957 microsatellite loci, 
achieved 96.4-100% sensitivity and 97.2-100% specificity relative to MSI FLA. A comparison 
of MSI-classification software, including MSIsensor, mSINGS and MSI-ColonCore (which uses 
a similar analysis), using sequencing data from the ColonCare gene panel in 54 MMRd and 37 
MMRp CRCs, showed equivalent performance, with accuracy ranging from 96.7-98.9% (Zhu 
et al, 2018). This testifies that, despite subtle differences in analysis pipelines and input data, 
analysing the distribution of sequencing reads associated with microsatellite length is an 
accurate method of detecting MSI-high tumours. 
 Software to classify MSI status have been used on NGS gene panels that (non-
exclusively) sequence MMR genes including MLH1, MSH2, MSH6 and PMS2, EPCAM (to 
detect 3’ deletions that silence MSH2), and BRAF, as a high throughput method for Lynch 
syndrome screening (Gray et al, 2018; Hampel et al, 2018). This approach reduces the Lynch 
syndrome screening pipeline to just two steps; tumour-sequencing followed by genetic 
testing to confirm any MMR mutations in the germline. Additional, clinically actionable 
genetic markers can also be included within the gene panel, such as RAS gene mutations that 
confer resistance to anti-EGFR therapy, and mutation of DYPD that is associated with 5-FU 
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toxicity (Hampel et al, 2018). Parallel sequencing of tumour and germline DNA, whilst 
doubling the initial cost, further reduces Lynch syndrome screening to one step, and 
determination of somatic origin of MMR mutations is feasible in one analysis pipeline (Gray 
et al, 2018); identifying Lynch-like tumours with double somatic MMR mutations avoids the 
unnecessary management of these patients as Lynch syndrome cases (Mensenkamp et al, 
2014). However the cost of tumour-sequencing is a barrier to its deployment, with an 
estimated cost in clinical practice of 607±207€ per sample in a recent French, nationwide, 
study (Marino et al, 2018). 
To reduce costs, NGS-based assays that target a small number of clinically actionable 
hotspot loci have also been developed. MSIplus (Hempelmann et al, 2015) is a PCR-based 
assay that amplifies 11 MNR loci, RAS gene mutation hotspots and the BRAF V600E locus for 
amplicon sequencing using Illumina platforms. mSINGS is used to analyse MSI status from 
the 11 MNRs. In 78 tumours, the assay achieved 97% sensitivity and 100% specificity relative 
to MSI FLA (Hempelmann et al, 2015). However, MSIplus is only partially multiplexed, and 
uses long (up to 28bp) MNRs that are known to be both prone to PCR and sequencing error 
(Fazekas et al, 2010), and are more likely to be polymorphic (Ananda et al, 2013). 
Furthermore, the robustness of MSIplus to sample variables has not been tested, and 5% of 
samples failed to give interpretable scores. These uninterpretable samples were excluded 
from accuracy calculations and remained unresolved (Hempelmann et al, 2015). Recently, 
our research group has developed a PCR and NGS-based MSI test using a novel marker panel 
of short (7-12bp) MNRs, and a novel analysis pipeline that uses both the proportion of reads 
containing deletion mutations in the microsatellite markers, and the allelic bias of these 
deletions, to classify MSI status. In an analysis of 209 CRCs, the assay gave 98% sensitivity 
and 98% specificity relative to the MSI Analysis System (Redford et al, 2018). As is the case 
for many NGS-based MSI tests, the analytical validity of this assay needs to be proven by 
assessment of assay reproducibility and robustness (Jennings et al, 2017). Also, the current 
assay requires two rounds of PCR and isn’t fully multiplexed. Continued development of the 
protocol toward high throughput cancer diagnostics is needed to optimise clinical utility.  
 Another advantage of NGS is its ability to detect somatic variants at very low 
frequencies within template DNA. This is of particular interest for diagnosis of CMMRD 
through detection of low level MSI in non-neoplastic tissues, which normally requires highly 
sensitive but laborious techniques like small pool PCR (Parsons et al, 1995), or time-
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consuming primary cell culture to develop an MSI signal (Bodo et al, 2015). For instance, 
using a read depth >1000x, Spencer et al (2014) showed that they could detect variant allele 
fractions (VAFs) ranging from 25% down to 2.5% using mixtures of HapMap DNAs. However, 
reliable calling of VAFs lower than this, likely to be required for NGS-based CMMRD 
detection, is difficult due to the 1-1.5% error rate of NGS platforms (Shendure and Ji, 2008). 
Several techniques have been developed that allow accurate detection of VAFs of 
<1% by molecular barcoding of the DNA molecules to be sequenced (Marx, 2016). To use 
molecular barcoding, the sample DNA must be sequenced to a redundant read depth such 
that the total number of reads is greater than the number of original DNA molecules 
captured for sequencing. Sequencing errors can then be discriminated from true mutations 
by assessing the concordance of variants from multiple reads that are all derived from one 
original DNA molecule – those variants found in the majority of, or all, redundant reads are 
likely to be true variants present in the original DNA molecule, whereas variants found only 
in single, or minority of, redundant read(s) are likely to be errors. The molecular barcode 
facilitates the grouping of redundant reads (Figure 1.11). For example, Safe-SeqS shears 
template DNA and ligates short oligonucleotides containing a section of 12-14 random 
nucleotides onto each end of the DNA fragments before amplification and sequencing. The 
12-14 random nucleotides constitute the molecular barcode, with approximately 17-268 
million possible sequences per barcode. Amplification of these fragments incorporates the 
molecular barcode into each and every amplicon. Amplicon sequencing covers both region 
of interest and molecular barcode such that reads with the same barcode from the same 
locus can be grouped in downstream analyses for variant versus error discrimination (Kinde 
et al, 2011). More recent methods of molecular barcoding of sample DNA fragments use 
double stranded molecular barcodes so that reads from complementary strands from the 
same DNA duplex can be grouped to discriminate against strand specific lesions, allowing 
detection of VAFs as low as 2.4×10-7. These include Duplex Sequencing (Schmitt et al, 2012; 
Kennedy et al, 2014) and CypherSeq (Gregory et al, 2016). In the development of NGS-based 
MSI tests it is, therefore, feasible to incorporate molecular barcodes into reads to increase 
sensitivity for low-level MSI, which may be able to detect MSI in the non-neoplastic tissues 
of CMMRD patients. 
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Figure 1.11. Utilising molecular barcodes (MBs) in next generation sequencing (NGS) to 
discriminate true variants from PCR and sequencing errors. DNA fragments containing the sequence 
of interest are tagged with MBs (different colours represent unique barcode sequences) and primer 
annealing sites. PCR amplifies the DNA fragments with their associated MBs and the amplicons are 
sequenced. Each read has a MB that traces it back to the original DNA fragment and reads of the 
same locus and same MB can be grouped. Therefore PCR and sequencing errors that occur randomly 
within the minority of reads in a group can be discriminated from true variants that will be present in 
the majority to all of the reads in a group.  
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1.13. Summary and Aims 
MMR deficiency defines a distinct molecular subtype of CRC that can be identified by its MSI-
high phenotype (Guinney et al, 2015). These CRCs respond well to immunotherapy (Le et al, 
2015) and are associated with cancer-predisposition syndromes: Lynch syndrome and 
CMMRD (Lynch et al, 2009; Wimmer et al, 2014). 
Accurate biomarker tests for the early detection of MMRd CRCs are yet to be realised 
and CRC screening in Lynch syndrome and CMMRD currently relies on colonoscopy (Vasen et 
al, 2013; Vasen et al, 2014), which is invasive, leading to lack of compliance to surveillance 
protocols (Stuckless et al, 2012), and is insensitive to a significant proportion of CRCs in 
Lynch syndrome (Seppälä et al, 2017). αFSP-Abs have been detected in the peripheral 
circulation of MMRd CRC patients (Reuschenbach et al, 2010) and a multiplexed, but 
unproven, method to quantify αFSP-Abs in serum has recently been developed 
(Reuschenbach et al, 2014), suggesting it may be used as a novel, non-invasive biomarker 
test for the early detection of MMRd CRC. 
For such surveillance and other preventative measures to be applied, Lynch 
syndrome gene carriers and CMMRD patients must first be identified. NICE DG 27 states that 
all CRCs should be tested for MMR deficiency, followed by BRAF V600E or MLH1 methylation 
testing (Newland et al, 2017), to select patients for germline genetic testing for Lynch 
syndrome. However, current MMR deficiency tests are not scalable for high throughput 
cancer diagnostics, evident from the poor uptake of testing (Shaikh et al, 2018), and novel 
approaches are required. NGS is amenable to automated and scalable MSI testing (Zhu et al, 
2018) and our research group has developed a cheap, PCR and NGS-based assay with high 
sensitivity and specificity for MSI-high CRCs that requires optimisation and further analytical 
validation (Redford et al, 2018). 
CMMRD diagnosis is complicated by a pleiotropic phenotype that overlaps with 
otherwise unrelated syndromes, variable family history and sometimes difficult genetic 
diagnosis due to the presence of pseudogenes that interfere with PMS2 sequencing 
(Wimmer et al, 2014). Assaying MMR deficiency in the non-neoplastic tissues of suspected 
CMMRD patients would clarify diagnosis, but current molecular techniques are either 
insensitive for specific mutations or laborious and expensive (Ingham et al, 2013; Bodo et al, 
2015). NGS-based MSI tests can use high read depths and molecular barcoding to detect rare 
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somatic variants (Marx et al, 2016), which may be applicable to the low-level MSI in the non-
neoplastic tissues of CMMRD patients. 
The aims of the work outlined in this thesis were to: 
1. Quantify the αFSP-Abs titres in the serum of Lynch syndrome gene carriers and test 
the association of αFSP-Abs with MMRd CRC, using the multiplexed, bead-based 
methodology of Reuschenbach et al (2014). 
2. Develop a high throughput and accurate NGS-based MSI test for CRC diagnostics that 
is reproducible and robust to sample variables, with a view to improving the uptake 
of MMR deficiency testing in Lynch syndrome screening and providing a companion 
diagnostic for immune checkpoint blockade therapy. 
3. Adapt this NGS-based MSI test for the detection of low-level MSI in the non-
neoplastic tissues of CMMRD patients as a functional, molecular assay to clarify 
uncertain diagnoses. 
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Chapter 2. Materials and Methods 
 
2.1. Ethical Approval for Research Conducted 
Human sera were obtained from the CaPP3 clinical trial biobank with patient consent for the 
use of collected material in research at Newcastle University. The CaPP3 trial is an ongoing 
study analysing the optimal dose of aspirin for chemoprevention of cancer in a cohort of 
Lynch syndrome gene carriers (ISRCTN16261285). 
Human CRC tissue samples were obtained, either as formalin fixed paraffin embedded (FFPE) 
tissues, or as DNA extracted from FFPE tissues, following ethical review (REC reference 
13/LO/1514), which was extended until January 2019. 
Samples received from Division of Human Genetics, Medical University of Innsbruck, Austria, 
were collected and used with consent of the patient and following local ethical review. 
 
2.2. Human Tissue and DNA Samples 
2.2.1. Samples for the assessment of immunological biomarkers 
494 serum samples collected from the first 500 recruits to the CaPP3 clinical trial were 
assessed for reactivity against FSPs as a measure of αFSP-antibody titres. The serum samples 
were all collected during patient consultation at trial entry and randomisation (year 0), 
according to the CaPP3 Study Protocol (ISRCTN16261285). 
 
2.2.2. Samples for development of a smMIP-based MSI assay for cancer diagnostics 
19 anonymised CRC DNAs, originally extracted from FFPE tissue, were provided by the 
Department of Molecular Pathology, University of Edinburgh, UK. 73 anonymised CRC DNAs, 
originally extracted from FFPE tissue, were provided by the Genetics Service of the Complejo 
Hospitalario de Navarra and Hereditary Cancer Group, Biomedical Research Institute of 
Navarra, Spain. These 92 samples were residual stocks from the work described by Redford 
et al (2018) and were used in the MSI classifier training cohort.  
105 anonymised CRC samples, either as DNA extracted from FFPE tissue or 10µm-thick FFPE 
tissue sections, were provided by the Northern Genetics Service, Newcastle Hospitals NHS 
Foundation Trust, UK. 6 of these CRC samples were used with samples from Edinburgh and 
Spain in the MSI classifier training cohort, and the remaining 99 were used to validate the 
MSI assay and classifier. All samples are listed in Appendix A. 
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All samples were independently tested for MSI status using MSI Analysis System v1.2 
(Promega) by the contributing pathology laboratory. BRAF V600E status was also tested in 
46 of the MSI-high samples from the Northern Genetics Service, Newcastle, by high 
resolution melt curve analysis (HRM) on a LightCycler 480 (Roche) according to Nikiforov et 
al (2009). 
DNA extracted from fresh tissues of an MMRd CRC and a biopsy of normal colorectal 
mucosa, taken 10cm from the tumour margin in the same patient, were used as MSI-high 
and MSS controls, and were originally provided by the Northern Genetics Service, Newcastle 
Hospitals NHS Foundation Trust, UK. These were taken from residual stocks of work 
previously conducted by our research group (Alhilal PhD Thesis, 2016). 
 
2.2.3. Samples for development of a smMIP-based MSI assay for constitutional mismatch 
repair deficiency 
94 germline DNA samples, extracted from peripheral blood leukocytes (PBLs), of 94 
anonymised control patients were provided by Dr Katharina Wimmer, Division of Human 
Genetics, Medical University of Innsbruck, Austria. These control samples were selected 
from patients consulted for non-cancer related reasons, and consenting to use of residual 
DNA samples in assay development. 
36 germline DNA samples, extracted from peripheral blood leukocytes (PBLs), of 32 
genetically confirmed CMMRD patients were provided by Dr Katharina Wimmer, Division of 
Human Genetics, Medical University of Innsbruck, Austria. Samples were collected by Dr 
Wimmer from several clinicians; sample data, including source, can be found in Appendix B. 
All patients were consented for use of samples in assay development. 
40 germline DNA samples, extracted from PBLs, of 40 genetically confirmed Lynch syndrome 
gene carriers, with pathogenic germline variants in MLH1 (n =9), MSH2 (n = 21), MSH6 (n = 
8), and PMS2 (n =1) (1 patient had not disclosed their MMR variant), were provided by the 
CaPP3 clinical trial biobank (ISRCTN16261285). 
 
2.3. Cell Line Samples and Cell Culture Protocols 
Genomic DNA from embryonic stem cell H9 (Thomson et al, 1998) was a gift from L. Lako 
(Institute of Genetic Medicine, Newcastle University, UK) and was used as MSS control DNA 
during smMIP-based MSI assay development. 
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Both HCT116 and K562 cell lines were gifted by J. Irving (Northern Institute for Cancer 
Research, Newcastle University, UK). HCT116 is an MMRd CRC cell line, containing a 
hemizygous MLH1 truncation S252X (Papadopoulos et al, 1994; Boyer et al, 1995), and 
provided MSI-high control genomic DNA during smMIP-based MSI assay development. K562 
is an MMRp chronic myeloid leukaemia cell line (Klein et al, 1976) and provided MSS control 
genomic DNA during smMIP-based MSI assay development. HCT116 and K562 cells were 
both grown in RPMI growth medium containing 2mM L-glutamine (Gibco), 10% fetal bovine 
serum (Gibco) and 60µg/ml penicillin and 100µg/ml streptomycin (Gibco), at 37°C and 5% 
CO2. HCT116 cells grow as a monolayer and were passaged and/or harvested at 80-90% 
confluence by decanting expired growth medium, washing the monolayer in 5ml PBS 
(Gibco), detaching the cells using 0.05% Trypsin-EDTA in PBS (Gibco) for 2-5min, before re-
suspending the cell pellet in fresh growth medium for passaging. K562 cells grow in 
suspension and were passaged and/or harvested at a density of 1x106cells/ml. To harvest 
HCT116 or K562 cells, cell suspension was centrifuged at 1500g for 5min and the 
supernatant discarded, the pellet washed in 5ml PBS, and again centrifuged at 1500g for 
5min and the supernatant discarded. The cell pellet was used for DNA extraction 
immediately, or stored at -80°C until ready for DNA extraction. 
 
2.4. DNA Extraction 
Genomic DNA extraction from FFPE CRC tissue used GeneRead DNA FFPE Kit (QIAGEN), 
following the manufacturer’s protocol. 
Genomic DNA extraction from cell lines used Wizard Genomic DNA Purification Kit 
(Promega), following the manufacturer’s protocol. 
 
2.5. DNA Quantification and Dilution 
Sample template DNAs and amplicons were quantified using QuBit 2.0 Fluorometer and 
QuBit dsDNA BR or QuBit dsDNA HS Kits (Invitrogen), following the manufacturer’s protocol. 
DNA ng/μl was converted to nanomolar concentration (nM) using the following equation, 
where 660g/mol/bp is the average molar mass of one base pair of DNA and N bp is the 
number of base pairs in the DNA molecule of interest: concentration  =  density × 106660 g mol/bp ×  N bp⁄  
Dilutions of template DNAs and amplicons used 10mM Tris-Cl at pH8.5. 
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2.6. Generation of Samples containing Known Proportions of MSI-high DNA 
To assess the lower limit of detection of the smMIP-based MSI assay for cancer diagnostics, 
DNA samples containing different proportions of MSI-high DNA were generated. Pure MSI-
high DNA extracted from HCT116 (see section 2.3) was diluted to 25ng/µl. 19 MSS DNAs, 
originally extracted from control patient PBLs (see Section 2.2.3) and confirmed to be free of 
length polymorphisms in any of the microsatellites analysed during the course of this work 
(see Section 5.4), were mixed in equal quantity to provide sufficient stock of pure MSS DNA, 
which was also diluted to 25ng/µl. In triplicate, the series of samples containing varying MSI-
high content were generated by serial dilution as described in Table 2.1. These sample series 
were used to assess the lower limit of detection of the smMIP-based MSI assay. 
 
MSI-high Content Mixture 
50.00% 10µl of MSI-high DNA + 10µl of MSS DNA 
25.00% 10µl of 50.00% mixture + 10µl of MSS DNA 
12.50% 10µl of 25.00% mixture + 10µl of MSS DNA 
6.25% 10µl of 12.50% mixture + 10µl of MSS DNA 
3.13% 10µl of 6.25% mixture + 10µl of MSS DNA 
1.56% 10µl of 3.13% mixture + 10µl of MSS DNA 
0.78% 10µl of 1.56% mixture + 10µl of MSS DNA 
Table 2.1: Generation of samples with varying MSI-high DNA content. 
 
 
2.7. Detection of Frameshift Peptide Serum Reactivity 
2.7.1. Generation of median fluorescence intensity data for frameshift peptides  
28 FSPs and a control FLAG peptide were analysed per serum sample. FSPs are listed in 
Appendix C. All laboratory work was conducted by Jonathan Dörre and Dr Miriam 
Reuschenbach at the Department of Applied Tumour Biology, Heidelberg University Hospital, 
Germany, and the raw data was provided in *.xlsx format by Dr Reuschenbach and Dr Kloor 
(Heidelberg University) for processing and analysis by me in Newcastle. The following 
laboratory protocol is adapted directly from Reuschenbach et al (2014), with additions from 
personal communication and my own experience with the protocol. 
The amino acid sequences of FSPs were predicted in silico from cMNR frameshift mutations 
identified in >60% of MMRd CRCs (Woerner et al, 2010). Each FSP was synthesised with an 
N-terminal biotin tag (connected by a 6-aminohexanoic acid linker) and a C-terminal FLAG 
octapeptide. A FLAG-only control peptide was also synthesised, containing the N-terminal 
 
 
55 
 
biotin tag (and linker) covalently bound directly to the FLAG octapeptide, with no 
intermediate FSP sequence. All peptides were HPLC-purified to >95% purity (Genaxxon 
Bioscience), and were dissolved in DMSO and stored at 5mg/ml at -80°C. 
Polystyrene beads containing fluorescent dyes and coated with avidin were purchased at 
2.5million beads/ml in phosphate buffer saline (PBS) containing BSA, Tween-20, and sodium 
azide (LumAvidin, Luminex Corp). Prior to use, beads were spun down at 13,000rpm for 
2min, and washed in PBS containing 0.1 % casein. Peptides were diluted in PBS and 0.1% 
casein from DMSO stocks to 400nM. The FSPs and FLAG-only control peptide were bound to 
the surface of the beads through biotin-avidin conjugation: the washed bead pellet was 
sonicated and resuspended in the peptide dilution, and incubated for 30min on a shaker 
protected from light. Importantly, the beads contained different fluorescent dyes, and each 
FSP was bound to beads of a specific fluorescence. Beads were spun down at 13,000rpm, 
and washed three times in PBS plus 0.1 % casein, and incubated for 30 min in PBS, 0.1 % 
casein and 1µM biotin (Sigma-Aldrich) to block free avidin. After an additional washing step, 
peptide-coated beads were resuspended in PBS containing 0.1 % casein and 0.05 % sodium 
azide, and stored at 4°C in the dark to protect the fluorophores. 
Patient sera were preincubated at a dilution of 1:50 in 0.5 % casein-PBS blocking buffer 
containing 0.5 % polyvinylalcohol, 0.8 % polyvinylpyrrolidone, and 2.5 % CBS-K (MERCK) to 
suppress non-specific binding of sera to the beads. Each serum was then diluted two fold, to 
a final concentration of 1:100, in a filter plate containing a multiplex of FSP- and FLAG 
control-bead conjugates, with each peptide represented by 3,000 beads. The mix of beads 
and sera were incubated for 30min on a shaker protected from light. The filter plate was 
washed three times in PBS containing 1% Tween-20. Beads were incubated in PBS, 0.1 % 
casein and 1µM biotin (Sigma-Aldrich) to block free avidin, for 30min on a shaker protected 
from light. The filter plate was washed once in PBS containing 1% Tween-20. Beads were 
incubated in PBS, 0.1 % casein and 1:2000 dilution of anti-human IgG conjugated to a 
phycoerythrin (PE) fluorophore to label each bead with a fluorophore for quantification of 
primary antibody binding, for 30min on a shaker protected from light. The filter plate was 
washed three times in PBS containing 1% Tween-20. Beads were resuspended in PBS and 
0.1% casein and the plate was loaded into the Luminex-100. 
Using the Luminex-100, each reaction was analysed by passing the beads through a channel, 
one bead at a time, with two measurements taken per bead: the fluorescence of the bead 
 
 
56 
 
dye was used to determine the FSP being measured, and the fluorescence of the PE 
fluorophore was used to quantify the bound antibodies; the raw data output for a serum 
sample is the median fluorescence intensity (MFI) of PE detected for each FSP. 
 
2.7.2. Analysis of serum reactivity against frameshift peptides 
Anonymised patient data was available from the CaPP3 database extract taken on 
17.02.2016. Normalisation of MFI data (see Section 3.5) gave a measure of “serum 
reactivity” for each FSP. Analyses of serum reactivity and patient variables used custom R 
scripts and R packages quantreg for quantile regression and pvclust for FSP clustering. 
 
2.8. Design of Single Molecule Molecular Inversion Probes 
2.8.1. Selection of marker loci for the smMIP-based MSI assay  
A total of 27 short mononucleotide repeats (7-12bp in length) with neighbouring SNP, 
previously identified by our lab (Redford et al, 2018; Section 4.1), were selected to assess 
MSI status as a biomarker of MMR deficiency (Appendix D). The SNPs allow analysis of allelic 
bias of deletions in the microsatellite markers in heterozygous patients. 17 of these markers 
were previously confirmed as highly sensitive and specific for MSI (Redford et al, 2018) and 
10 additional markers were selected to provide more options for panel optimisation. 
BRAF V600E locus (Appendix D) was included so that the assay can diagnose MMR deficiency 
and screen for Lynch syndrome in one test. Sporadic MMRd CRCs frequently have BRAF 
V600E whilst Lynch syndrome CRCs do not, and so BRAF V600E positive CRCs can be 
excluded from germline genetic testing (Domingo et al, 2004). 
The KRAS codons 12 and 13 mutation hotspot locus (Appendix D) was included as a proof of 
principle of the modularity of a smMIP-based assay and the ease with which it could be 
expanded to include other clinically actionable genetic markers. RAS gene mutations are of 
clinical relevance as they confer resistance to anti-EGFR therapeutics, such as cetuximab (De 
Roock et al, 2010a), and RAS gene testing is required before application of anti-EGFR 
therapies (Cooper et al, 2017). 
 
2.8.2. Design of smMIPs using MIPgen 
MIPgen (Boyle et al, 2014a) was used to generate smMIPs for each marker using the inputs: 
hg19 as a .fasta file and indexed by SAMtools v1.3 and BWA v0.7.12, and a .bed file of 
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marker loci, and parameters: tag size 6,0, minimum capture size 120 and maximum capture 
size 150. These parameters, respectively, determine the lengths (N nucleotides) of the 
molecular barcode tags neighbouring the extension arm and ligation arm of the smMIP, and 
the size of the region of interest to captured (which includes sequence within the extension 
and ligation arms of the smMIP). Molecular barcodes of length N6 provided 4096 possible 
barcode sequences, which would be sufficient to represent unique template DNA molecules, 
given target read depths ~5000 reads per marker and the redundant coverage of template 
molecules in amplicon sequencing (i.e. generation of multiple reads per molecular barcode; 
Casbon et al, 2011).  
Final smMIP sequences (Appendix E) were selected by the following in silico criteria: 
successful capture of marker and associated SNP (for microsatellite loci), no SNPs in the 
smMIP extension or ligation arms and logistic score >0.8. 
All smMIPs and smMIP protocol-associated primers (Appendix E) were synthesised by and 
purchased from Metabion GmbH (Planegg, Germany). 
 
2.8.3. Validation of smMIP designs and amplicons 
smMIPs designs were validated in the laboratory by successful generation of smMIP 
amplicons of the expected size (240-270bp) and confirmation that these amplicons 
contained the correct sequence by PCR amplification of a region internal to the amplicon. 
Primers were designed and paired such that a forward primer targeting the “backbone” 
sequence of the smMIP amplicon (i.e. the sequence common to all smMIP amplicons) could 
be paired with a reverse primer targeting the “internal” sequence specific to the marker 
locus, and vice versa, to ensure the primers were specific to the amplicon and would not 
amplify any contaminating genomic DNA (Figure 2.1). 
Primers for validation of smMIP amplicons (Appendix E) were designed using Primer3 
(Untergasser et al, 2012; http://primer3.ut.ee/). 
PCR amplification to validate smMIP amplicons used 1x Herculase II Reaction Buffer 
(Agilent), 1.25U Herculase II Fusion DNA Polymerase (Agilent), 6.25nmol dNTPs (Agilent), 
6.25pmol forward primer, 6.25pmol reverse primer, and 1µl of a 1 in 1000 dilution of 
purified smMIP amplicon in a 25µl reaction volume. Reactions were incubated at 98°C for 30 
seconds, followed by 30 cycles of 98°C for 10 seconds, 57°C for 30 seconds, and 72°C for 30 
seconds, followed by 72°C for 2 minutes. 
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Figure 2.1: Design of PCR primers to verify sequence content of smMIP amplicons. MIP_bbFP: MIP 
backbone forward primer. MIP_bbFP: MIP backbone reverse primer. Marker_intFP: marker-specific 
forward primer. Marker_intRP: marker-specific reverse primer. For full details of smMIP amplicon 
structure see Figure 4.1 
 
 
2.9. Single Molecule Molecular Inversion Probe Amplification Protocol 
2.9.1. Probe phosphorylation 
smMIPs were individually phosphorylated using 10U of T4 Polynucleotide Kinase (NEB), 1X 
T4 DNA Ligase buffer (NEB) and 1μM of unphosphorylated smMIP in a 100µl reaction 
volume, and incubated at 37°C for 45 minutes and 80°C for 20 minutes. Phosphorylated 
smMIPs were diluted 1:10,000 using TE buffer (Sigma) in a multiplex pool, such that each 
smMIP was at 0.1nM (0.1fmol/µl). 
 
2.9.2. Target capture and amplification 
Markers were amplified in singleplex or multiplex following the smMIP-based protocol of 
Hiatt et al (2013) using a SensoQuest thermocycler (SensoQuest GmbH). smMIPs were 
annealed to template DNA using 1x AmpLigase Reaction Buffer (Lucigen), 0.125fmol of each 
smMIP and 50-200ng of template DNA (unless stated otherwise) in a 10µl reaction volume, 
incubated at 98°C for 3 minutes, 85°C for 30 minutes, 60°C for 60 minutes, and 56°C for 120 
minutes. Gap-fill and ligation captured target sequence in circularised smMIPs using 1x 
AmpLigase Reaction Buffer (Lucigen), 5U AmpLigase DNA Ligase (Lucigen), 3.2U Herculase II 
Fusion DNA Polymerase (Agilent), 300pmol dNTPs (Agilent) in 10µl added to each reaction 
for a total 20µl reaction volume, incubated at 56°C for 60 minutes and 72°C for 20 minutes. 
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Non-circularised smMIPs and template DNA were digested using 1x AmpLigase Reaction 
Buffer (Lucigen), 20U Exonuclease I (NEB) and 100U Exonuclease III (NEB) in 3µl added to 
each reaction for a total 23µl reaction volume, incubated at 37°C for 60 minutes and 95°C for 
2 minutes. Following digestion of linear DNAs, 10µl of this target capture reaction was mixed 
with 1x Herculase II Reaction Buffer (Agilent), 1.25U Herculase II Fusion DNA Polymerase 
(Agilent), 6.25nmol dNTPs (Agilent), 6.25pmol MIP amplification forward primer and 
6.25pmol MIP amplification reverse primer in a 25µl reaction volume, incubated at 98°C for 
2 minutes, followed by 30 cycles of 98°C for 15 seconds, 60°C for 30 seconds and 72°C for 30 
seconds, followed by 72°C for 2 minutes. smMIP amplification reverse primers contain 
unique sample index sequences (Appendix E); different samples in the same sequencing run 
used different smMIP amplification reverse primers for sequencing read de-multiplexing. 
Remaining target capture reaction was stored at -20°C. 
smMIP reaction products (smMIP amplicons at 240-270bp) were analysed using 3% Agarose 
gel electrophoresis at 80mV for 60 minutes or QIAxcel (QIAGEN) using method AL420. 
 
2.10. Library Preparation for Amplicon Sequencing 
Each sequencing run was planned according to the desired mean number of reads per 
marker per amplicon, the number of markers amplified per sample by smMIP protocol and 
the number of samples, using the following equation: 
reads/marker/sample  = 0.75 × 
sequencing kit read capacity
N markers × N samples
 
The 0.75 factor accounts for generation of non-specific reads, based on the findings of 
Niedzicka et al (2016) and confirmed by our own data (see Section 4.4). Sequencing kit read 
capacity is the expected number of reads generated from a MiSeq v3 or v2 kit. 
4nM sequencing libraries were prepared by purification of smMIP amplicons using 
Agencourt AMPure XP Beads (Beckman Coulter) following manufacturer’s protocols, diluting 
purified amplicons to 4nM in 10mM Tris pH 8.5 and pooling 4nM amplicons in equal volumes 
to create the final 4nM DNA library. 
 
2.11. smMIP Amplicon Sequencing on the Illumina MiSeq 
4nM libraries of smMIP amplicons were sequenced using the MiSeq platform (Illumina) 
following the manufacturer’s protocol and using the GenerateFastq workflow, paired end 
sequencing and smMIP custom sequencing primers (Appendix E), as specified in the MiSeq 
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Sample Sheet (Appendix F), according to the protocol of Hiatt et al (2013). Sequencing run 
metrics, such as the % of base calls with quality >Q30, were acquired from 
basepace.illumina.com. 
 
2.12. Sequencing Read Analysis 
2.12.1. Generation of Marker Result tables 
Unprocessed reads contained in fastq files generated by the MiSeq were aligned to 
reference genome hg19 using BWA v0.6.2 (Li and Durbin, 2010). Marker loci were analysed 
from .sam files and, for each marker, microsatellite lengths and SNPs observed in both 
orientations, i.e. concordant in both forward and reverse reads, were counted and 
summarised in Marker Result tables using custom R scripts written by Dr Mauro Santibanez-
Koref (Institute of Genetic Medicine, Newcastle University; Figure 2.2). 
For BRAF and KRAS, the same Marker Result tables were generated with columns 
representing the base detected at the mutation hotspot. As there was no microsatellite 
associated with these mutation hotspots, microsatellite length was determined from an 
arbitrary locus and Marker Result table rows were not used in analyses. 
Optionally, molecular barcodes could be analysed from the sequencing reads and Marker 
Result tables could contain marker data generated from single molecule sequences 
(smSequences) rather than all reads (see Section 5.4). Analysis of molecular barcodes and 
generation of smSequence Marker Result tables used custom R scripts written by Dr 
Santibanez-Koref. 
The microsatellite lengths and SNP alleles summarised in these Marker Result tables were 
used for multiple downstream analyses, including sample classification. 
 
 
Figure 2.2: Example Marker Result table. The Marker result table contains a count of reads at a 
specific marker, with reads distributed to table cells according to the SNP identified (columns) and 
the length of the microsatellite relative to the reference genome hg19 (rows).  
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2.12.2. MSI classification using a naïve Bayes approach 
Sample classification was performed as described by Redford et al (2018). In summary, 
sequencing reads from 24 short MNRs were analysed for both microsatellite deletions, and 
the allelic bias of these deletions, to estimate ratio of the posterior probabilities that the 
data were generated by an MSI-high or MSS phenotype (a Bayes factor). This could be 
presented as a sample score by the following equation: 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 𝑙𝑙𝑠𝑠𝑙𝑙10 𝑃𝑃(𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀|𝑂𝑂)𝑃𝑃(𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀|𝑂𝑂)  
Samples with scores > 0 are considered MSI-high and with scores < 0 as MSS. The classifier 
parameters were determined from a training cohort of 98 CRCs of known MSI status (see 
Sections 2.2.2 and 4.5). The MSI classifier was then validated in a second, independent 
cohort of 99 CRCs. Training and execution of the MSI classifier used custom R scripts written 
by Dr Santibanez-Koref and the Marker Result tables as input. For classifier training, MSI-low 
samples were considered equivalent to MSS samples as described in the literature (Halford 
et al, 2002; Laiho et al, 2002). 
 
2.12.3. Read and variant counting 
During development of the smMIP-based assay for cancer diagnostics and CMMRD 
detection, counts of total reads for each marker and the number of reads containing variant 
or wild type (WT) microsatellite length, or number of reads containing different SNPs, were 
used. Read and variant counting used custom R scripts and the Marker Result tables as 
input. 
 
2.12.4. Hotspot mutation calling 
The relative frequency of BRAF and KRAS variants could be analysed to determine mutation 
status. Hotspot mutation calling used custom R scripts and Marker Result tables as input. 
 
2.12.5. CMMRD classification 
A method to detect CMMRD by microsatellite length variants in germline DNA extracted 
from PBLs was developed. In summary, 40 germline DNAs from anonymised controls were 
used to define the distribution of microsatellite lengths detected in a non-CMMRD 
population. Samples are then scored by the probability that the observed lengths of 
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microsatellites belong to these control distributions, with high scores indicating a high 
probability the sample is not from a control population (see Section 5.5). 
CMMRD classification used custom R scripts, ExtDist and metap packages, and the Marker 
Result tables as input. 
 
2.13. Germline Confirmation of MSH6 c.3557-1G>C Mutation 
MMR gene mutation was confirmed using Sanger sequencing. Primer sequences (Appendix 
G) were provided by Dr Katharina Wimmer (Division of Human Genetics, Medical University 
of Innsbruck, Austria) and primers were synthesised by and purchased from Metabion. 
MMR gene mutation loci were amplified using a SensoQuest thermocycler (SensoQuest 
GmbH). Each reaction contained 1x Herculase II Reaction Buffer (Agilent), 1.25U Herculase II 
Fusion DNA Polymerase (Agilent), 6.25nmol dNTPs (Agilent), 6.25pmol forward primer and 
6.25pmol reverse primer in a 25µl reaction volume, and was incubated at 98°C for 2 
minutes, followed by 30 cycles of 98°C for 15 seconds, 54°C for 20 seconds and 72°C for 30 
seconds, followed by 72°C for 3 minutes. To digest dNTPs and single stranded DNAs, 10U 
Exonuclease I (NEB) and 1U Shrimp Alkaline Phosphatase (NEB) were added to 5μl of PCR 
product and incubated at 37°C for 15 minutes and 80°C for 15 minutes. Fluorescence-
labelled termination fragments were generated from the exonuclease and phosphatase 
treated PCR product using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems), following manufacturer’s protocols, and were analysed using a SeqStudio 
Genetic Analyser (Applied Biosystems), following manufacturer’s protocols. 
 
2.14. Statistical Analyses and Graphics 
Unless stated otherwise, all statistical analyses used base R, version 3.3.1.  
Proportions and frequencies were modelled using the binomial distribution to determine 
confidence intervals, calculated in R, using the Hmisc package. 
Graphs were plotted in R using the ggplot2, grid and gridExtra packages. 
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Chapter 3. The Utility of Anti-Frameshift Peptide Antibodies in the Serum to 
detect Mismatch Repair Deficient Colorectal Cancer 
 
3.1. Introduction 
Circulating αFSP-Abs are generated in patients with MMRd CRC in response to novel 
peptides expressed from genes containing cMNR frameshift mutations (Ishikawa et al, 2003; 
Reuschenbach et al, 2010). The possibility of using αFSP-Abs as a liquid-biopsy biomarker for 
the early detection of MMRd CRC is appealing for Lynch syndrome surveillance, which 
currently relies on the invasive and frequently insensitive technique of colonoscopy 
(Stuckless et al, 2012; Møller et al, 2017a; Seppälä et al, 2017). Multiplexed methods of 
detecting αFSP-Abs in the serum is particularly appealing as MMRd cancers are susceptible 
to multiple cMNR frameshift mutations, meaning that multiple αFSP-Abs may be generated 
against any one cancer, and singleplex detection of cancer-associated autoantibodies 
generally has low sensitivity for disease (Robinson et al, 2002). Previously, Reuschenbach et 
al (2014) used a novel multiplex method to analyse antibody titres against a panel of 32 
synthetic FSPs (selected by frequency of cMNR frameshift mutation), using sera from 20 
MSI-high CRC patients prior to surgical resection of their tumours, and serum from one MSI-
high CRC patient post-surgical resection of their tumour. This latter patient had also been 
enrolled on the Micoryx clinical trial (NCT01461148), designed to test the hypothesis that 
vaccination by FSPs may prevent cancer relapse, meaning they had been vaccinated with 2 
of the 32 FSPs analysed. They found that an antibody signal was evident in many of the MSI-
high CRC patients, and relatively strong signals were generated in the Micoryx trial patient 
for the two FSPs with which they had been vaccinated (Figure 3.1). To assess reproducibility 
of the method, Reuschenbach et al, repeat tested the 20 sera and showed that the 
regression R2 of original versus repeat results was >0.98 in all FSPs and all sera. 
 Whilst these results are promising, the study was a presentation of method and not 
designed to answer a biological question. With the small number of patients analysed and 
the lack of cancer-free controls, the observed antibody signal may be background noise 
rather than a quantification of αFSP-Ab titre in the serum. Also, the antibody signals in the 
MSI-high cancer patients were approximately 10-fold weaker than antibody signals from the 
two vaccine FSPs in the Micoryx trial patient, which remained unexplained (Figure 3.1). To 
better understand the association between MSI-high CRC and αFSP-Ab titre a larger cohort 
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of patients would be needed. Also, αFSP-Abs have previously been detected in the serum of 
cancer-free Lynch syndrome gene carriers using the alternative technique of ELISA 
(Reuschenbach et al, 2010), suggesting that background antibody signal may differ in Lynch 
syndrome patients compared to the general population. Therefore, for the early detection of 
MMRd CRC in the context of Lynch syndrome surveillance, this method would need to be 
tested in a cohort of Lynch syndrome gene carriers. 
 
 
Figure 3.1: Detection of antibody signal against a panel of 32 frameshift peptides (FSPs). FSPs are 
named by “Gene(frameshift deletion size)”. 20 MSI-high colorectal cancer patients (filled dots) and 
one patient from the Micoryx trial (open circles), vaccinated with ASTE(-1) and TAF1B(-1) FSPs, were 
tested by the multiplex method of Reuschenbach et al and the antibody signal against each FSP 
quantified. The Micoryx trial patient has minimal antibody signal against all FSPs except for ASTE(-1) 
and TAF1B(-1). The 20 MSI-high CRC patients have comparatively weaker antibody signals against 
multiple other FSPs. Figure taken from Reuschenbach et al, 2014. 
  
 
CaPP3 is an ongoing clinical trial that is recruiting Lynch syndrome gene carriers to 
analyse the optimal dose of aspirin for chemoprevention of cancer, by double-blind 
randomisation of patients to 100, 300 or 600mg of daily aspirin (ISRCTN16261285). It is run 
from Newcastle University under the guidance of its Chief Investigator, Prof Sir John Burn, 
and Programme Manager, Dr Gill Borthwick, and is building a biobank of material from its 
patients, including FFPE cancer tissues, germline DNAs, and, most significantly, sera. Serum 
samples are taken from patients at trial entry (year 0), at year 2, and at year 5, with a view to 
analysing the longitudinal effect of aspirin on circulating cytokines and other biomarkers, 
including αFSP-Abs. Therefore the hundreds of patients recruited and the detailed collection 
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of patient data and patient follow up, make the CaPP3 trial a useful resource for the 
exploration of αFSP-Ab titres for the early detection of MMRd CRC. 
 
3.2. Aims 
To analyse the association between MMRd CRC diagnosis and αFSP-Ab titres, with a view to 
αFSP-Ab titres being used in Lynch syndrome surveillance, I aimed to: 
1. Quantify αFSP-Ab titres in the serum of the first 500 Lynch syndrome gene carriers 
recruited to the CaPP3 clinical trial using the multiplex method Reuschenbach et al. 
2. Correlate αFSP-Ab titres with patient variables, in particular incidence of CRC. 
 
3.3. Cohort Description and Justification of Method 
For this work, I was given access to the CaPP3 clinical trial biobank and anonymised patient 
data. From the first 500 patients recruited, sera from 494 patients were available for 
analysis. Of these 494 samples, 464 were collected within trial protocol (0-4 days from blood 
draw to long term storage at -80°C), ensuring serum quality based on preliminary analyses 
by Dr Miriam Reuschenbach and Dr Matthias Kloor (personal communication). Patient 
details and variables of interest are shown in Table 3.1. A history (i.e. before blood draw) or 
on-trial (i.e. after blood draw) diagnosis of CRC or Lynch spectrum cancers (see Table 3.1 
legend), were of interest due to the high frequency of MMR deficiency and associated cMNR 
frameshift mutations that lead to expression of antigenic FSPs. Measures of cancer 
prophylaxis taken by the patient, either by surgery or daily aspirin intake, were also of 
interest as these may indirectly impact αFSP-Ab titres by suppression of latent MMRd 
lesions, whether benign or malignant. 
The 28 FSPs analysed in this study contained some of the 32 FSPs used by 
Reuschenbach et al in their 2014 publication, as well as additional FSPs. These FSPs were 
selected by two criteria: 1. The cMNR frameshift mutation was present in >60% of MMRd 
CRCs using frequencies reported in the SelTarBase database (Woerner et al, 2010), and 2. 
The FSP produced an antibody signal from sera of MSI-high CRC patients in preliminary 
analyses (Reuschenbach and Kloor, personal communication). Due to the different spectra of 
cMNR frameshift mutations in different cancer types (Kim et al, 2013), the low incidence of 
on trial CRCs at the time of analysis (Table 3.1), and the long half-life of antibody production 
due to immunological memory (Dörner and Radbruch, 2007), an analysis of the association 
of αFSP-Ab titres with a history of CRC diagnosis was the primary focus of this study. 
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Variable Patients (n = 464) 
MMR gene mutation (n) MLH1: 
MSH2: 
MSH6: 
PMS2: 
EPCAM 3’ del: 
Not Disclosed: 
 
136 
181 
83 
29 
5 
30 
Age at blood draw (years) Median: 
Range: 
 
47 
19-77 
Sex (n) Male:  
Female: 
Not Disclosed: 
 
193 
262 
9 
History of cancer (n) 
 
Time from diagnosis to blood draw 
(months) 
CRC: 
Median: 
Range: 
 
Lynch spectrum: 
Median: 
Range: 
112 
78 
5-440 
 
147 
71 
5-440 
 
On trial cancer (n) 
 
Time from blood draw to diagnosis 
(months) 
CRC: 
Median: 
Range: 
 
Lynch spectrum*: 
Median: 
Range: 
3 
12 
2-19 
 
10 
4.5 
1-19 
 
Surgical removal of at-risk tissues (n) Colorectal: 
Colorectal or gynaecological: 
None: 
 
99 
187 
277 
 
Pre-trial chemoprophylaxis (n) Daily aspirin (ever) 
Daily aspirin (≥2years) 
Never daily aspirin 
114 
31 
350 
 
 
Table 3.1: Patient details of the Lynch syndrome gene carrier cohort. The patient variables 
presented include age, sex, and cancer incidence, as well as other variables that may affect anti-
frameshift peptide antibody titres in the serum.   
*Note: Lynch spectrum cancers include: colorectal cancer (CRC), endometrial cancer, ovarian cancer, 
gastric cancer, small intestinal cancer, uroepithelial cancer, glioblastoma, sebaceous gland 
carcinoma, keratocanthomas (Lynch et al, 2009). 
 
 
For each patient sample, the 28 FSPs and a FLAG-only control were analysed by the 
multiplex method of Resuchenbach et al (2014; Figure 3.2; Section 2.7.1). Laboratory work 
was conducted by Jonathan Dörre and Dr Miriam Reuschenbach at the Department of 
Applied Tumour Biology, Heidelberg University Hospital. The multiplex protocol mixes  
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Figure 3.2: A multiplex method of detecting anti-frameshift peptide antibodies (αFSP-Abs) in serum 
(Reuschenbach et al, 2014). (A) Synthetic FSP and C-terminal FLAG with biotin and linker, and FLAG-
only control with biotin and linker, are (B) bound to fluorescent beads coated with avidin. Bead 
preparations are pooled and incubated with patient serum to bind αFSP-Abs. (C) Subsequently, anti-
human IgG secondary antibodies with phycoerythrin (PE) fluorophores are bound to the αFSP-Abs. 
The FLAG-only control accounts for non-specific binding. (D) Beads are analysed by a Luminex-100. 
Beads are passed, one by one, through a channel where fluorescence is measured to identify the FSP 
by the bead dye and quantify the bound antibodies. 
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patient sera with synthetic FSPs that are conjugated to beads containing fluorescent dyes, 
with each FSP represented by a specific fluorescence. αFSP-Abs from the patient sera bind to 
the FSP-bead conjugates and are detectable by secondary binding of anti-human IgG 
antibodies with covalently bound phycoerythrin (PE) fluorophores. The raw data output for a 
sample is the median fluorescence intensity (MFI) of PE for each FSP. MFI data was provided 
by Dr Reuschenbach and Dr Kloor for analysis. 
In addition to the data from the 464 samples from the Lynch syndrome gene carriers, 
Dr Reuschenbach and Dr Kloor provided MFI data for 11 positive control samples, all taken 
at different time points from two MMRd CRC patients that had been vaccinated with FSPs 
ASTE1(-1) and TAF1B(-1) as part of the Micoryx clinical trial. However, the study cohort had 
its limitations, most notably was a lack of any other controls. Given that Lynch syndrome 
gene carriers may have αFSP-Abs irrespective of MMRd cancer incidence (Reuschenbach et 
al, 2014) and may have a different background compared to the general population, control 
samples from cancer-free and MMR mutation-negative patients would have been valuable. 
Furthermore, the positive controls were only vaccinated with two of the 28 FSPs analysed, 
hence positive controls were lacking for the other FSPs, which would be needed for an 
accurate definition of αFSP-Ab concentration. Despite this lack of controls, analysis of sera 
from the 464 Lynch syndrome gene carriers could still be used to answer the question of 
whether or not αFSP-Ab titres are associated with a history of MMRd CRC.  
 
3.4. Subtraction-based Normalisation does not equalise Baseline FSP Serum Reactivity 
As is common for assays of substrate binding, MFI data needed to be normalised relative to 
a control to account for non-specific binding and background fluorescence. Therefore, 
before analysing the data with respect to patient variables, I wanted to assess its structure 
and the validity of the normalisation method. Data normalisation by Reushenbach et al 
(2014) subtracted the MFI of the FLAG-only control from the MFI of each FSP, and each 
resulting MFI was defined as an “antibody signal”. However, during my analysis I opted to 
use the term “serum reactivity” for normalised data as the detected signal may not solely be 
due to αFSP-Ab binding to the FSP-bead conjugates. Furthermore, the data normalisation 
method of Reuschenbach et al assumes the FLAG-only control MFI is equally representative 
of the non-specific binding and fluorescence for each FSP, and that signal from αFSP-Ab 
binding is additive to this background fluorescence. However, there are several reasons why 
this assumption might not be valid. Each FSP is conjugated to a bead containing a different 
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fluorescent dye, which may interfere with absorbance and fluorescence of the PE 
fluorophore used to quantify binding. Also, the structures of the FSPs in the multiplex are 
very different, and each FSP may have a unique level of non-specific binding relative to the 
FLAG-only control. Finally, the assumption that fluorescence from any αFSP-Ab is additive to 
the background may not be true, and a multiplicative model may be more appropriate. To 
test these assumptions, FSP MFI was plotted against FLAG-only control MFI. There was clear 
evidence of heteroscedasticity in the relationship between FSP and control MFI as the 
variance in FSP MFI increased with increasing control MFI (Figure 3.3A; Appendix H). This 
heteroscedasticity shows that an additive model is not an appropriate basis for the 
normalisation method as subtraction is not equivalent for higher control MFI due to 
increased variance. Positive skew was also observed in the MFI data for all peptides (Figure 
3.3B); to better fit the MFI data to a normal distribution, a transformation by the natural 
logarithm was used (Figure 3.3C). A comparison of ln(MFI) for each FSP and the control 
ln(MFI) showed a reduction in heteroscedasticity (Figure 3.3D; Appendix H). Normalisation 
could then be achieved by subtracting the control ln(MFI) from each FSP ln(MFI) for a patient 
– due to the log transformation this is equivalent to normalisation by division, suggesting 
that a multiplicative model of control versus FSP MFI is suitable. 
 Before analysing the data I wanted to validate the method of normalisation. Criteria 
for this validation were required, based on clear assumptions and clear expectations of the 
range of serum reactivity that should be generated. Normalisation of the data should allow 
fair comparison within patients between FSPs, and within FSPs between patients. Therefore, 
it would be expected that normalisation produces equivalent base-line serum reactivity for 
each patient or FSP. A critical assumption of the data is that, for any FSP, the majority of 
patients will not have serum reactivity due to specific binding of αFSP-Abs. This assumption 
is based upon the observation that only a minority of Lynch syndrome gene carriers and MSI-
high CRC patients generated αFSP-Ab signals using an independent technique, ELISA 
(Reuschenbach et al, 2010). Translated to a criterion for data normalisation, I expected that 
the median serum reactivity for any FSP or patient should be approximately 0, with the 
majority of data falling within a short range either side of this. To test the validity of 
subtraction of the FLAG-only control ln(MFI) from FSP ln(MFI) as a method of data 
normalisation, I analysed the distribution of serum reactivity across FSPs and across patients. 
It was clear that the median serum reactivity varied widely between FSPs as for 13/28 
FSPs >75% of the data fell entirely above or below 0 (Figure 3.4A). The median serum 
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Figure 3.3: Data structure for median fluorescence intensity (MFI). (A) Comparison of frameshift 
peptide (FSP) MFI and the FLAG-only control MFI in example frameshift peptides (FSPs) BANP(-1) and 
AIM2(-1), with each data point representing one patient. (B) The distribution of MFI for BANP(-1) and 
for the FLAG-only control. (C) The distribution of log transformed MFI (ln(MFI)) for BANP(-1) and for 
the FLAG-only control. (D) Comparison of FSP ln(MFI) and the FLAG-only control ln(MFI) in example 
FSPs BANP(-1) and AIM2(-1), with each data point representing one patient. 
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reactivity for patients was also highly variable, and when compared with the control ln(MFI), 
there was a significant correlation between the two (β = -0.179, p < 10-16, R2 = 0.15); which 
can be interpreted as a decrease in median serum reactivity as the non-specific fluorescence 
increases for a sample (Figure 3.4B). The differences in median serum reactivity between 
FSPs and between patients, and the correlation of serum reactivity with the control MFI do 
not fulfil the criteria specified for a valid method of data normalisation. 
Figure 3.4: Distribution of serum reactivity between frameshift peptides (FSP) and between 
patients. FSP ln(MFI) was normalised by subtraction of FLAG-only control ln(MFI). (A) Distribution of 
serum reactivity is shown for each FSP. (B) Median serum reactivity for each patient relative to their 
FLAG-only control ln(MFI); blue line = linear regression line, grey area = 95% CI for linear regression. 
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3.5. Regression-based Normalisation equalises Baseline FSP Serum Reactivity 
For normalisation by division to be valid, it would be expected that for each FSP the ln(MFI) 
should increase one-to-one in relation to the FLAG-only control ln(MFI) when no αFSP-Abs 
are present. Based on the assumption that the majority of patients do not have αFSP-Abs, 
median regression can be used to test the relationship between FSP and FLAG-only ln(MFI) 
across all patients. Median regression was used as the median will not be affected by any 
extreme values from (the assumed minority of) individuals with αFSP-Abs against the FSP. 
Knowing that data normalisation by division was not appropriate, I expected to see the 
coefficient of the quantile regression deviating from 1. Indeed, median quantile regression of 
ln(MFI) for each FSP against ln(MFI) of the FLAG-only control showed a significant deviation 
of the regression coefficient from 1 in 22/28 of the FSPs (Table 3.2), confirming that the 
control MFI does not represent background fluorescence equally for each of the FSPs. 
The median quantile regression statistics for each FSP also provided an alternative 
method of normalisation. For a patient (𝑃𝑃) and FSP (𝐹𝐹), the serum reactivity can be 
calculated using the following equation, where 𝑚𝑚𝐹𝐹 is the coefficient derived from median 
quantile regression of the FSP ln(MFI) versus the control ln(MFI): 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚 𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐹𝐹.𝑃𝑃 = ln(𝑀𝑀𝐹𝐹𝑀𝑀)𝐹𝐹.𝑃𝑃 − 𝑚𝑚𝐹𝐹 . (ln(𝑀𝑀𝐹𝐹𝑀𝑀)𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶.𝑃𝑃) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Median regression of each frameshift peptide (FSP) compared to the FLAG-only control. 
For each FSP the ln(MFI) was compared to ln(MFI) of the FLAG-only control by median regression and 
the regression coefficient (β) determined with 95% confidence intervals (95% CIs). 
 
FSP β 95% CIs  FSP β 95% CIs 
ACVR2(-1) 0.94 0.90-0.98  MYH11(-1)A 0.92 0.90-0.96 
ACVR2(-2) 0.91 0.88-0.94  MYH11(-1)B 0.92 0.90-0.95 
AIM2(-1) 0.84 0.82-0.88  MYH11(-1)C 0.71 0.63-0.74 
AIM2(-2) 1.11 1.09-1.14  MYH11(-2) 0.92 0.90-0.94 
ASTE1(-1) 0.73 0.69-0.78  POLD3(-1) 0.96 0.95-0.98 
ASTE1(-2) 1.03 0.98-1.07  PTHLH(-1) 0.90 0.87-0.93 
BANP(-1) 1.01 0.97-1.05  Q96PS6(-1) 1.08 1.03-1.11 
C14orf106(-1) 0.63 0.53-0.69  Q96PS6(-2) 1.06 1.03-1.10 
C14orf106(-2) 1.00 0.99-1.03  SLC22A9(-1)A 0.64 0.57-0.68 
C1orf34(-2)B 0.77 0.72-0.81  SLC22A9(-2) 1.01 0.98-1.03 
CASP5(-1) 0.47 0.42-0.53  TAF1B(-1) 0.41 0.35-0.46 
LMAN1(-1) 0.64 0.60-0.69  TGFBR2(-1) 0.62 0.60-0.65 
LMAN1(-2) 0.90 0.87-0.92  TMEM60(-2) 0.99 0.96-1.01 
MARCKS(-2) 1.03 0.98-1.08  UPF3A(-1) 0.67 0.61-0.70 
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Using normalisation by regression, each FSP had a median serum reactivity of approximately 
0 and no correlation was observed between the median serum reactivity for a patient and 
the ln(MFI) of the FLAG-only control (Figure 3.5). However, the variation in median serum 
reactivity for each patient remained high. For instance, the range of median serum reactivity 
 
 
Figure 3.5: Distribution of serum reactivity between frameshift peptides (FSP) and between 
patients. FSP ln(MFI) was normalised by the described method of quantile regression. (A) 
Distribution of serum reactivity is shown for each FSP, and (B) the median serum reactivity for each 
patient is shown in comparison to their FLAG-only control ln(MFI). 
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values is from -0.7 to approximately 0.9, yet the interquartile range for serum reactivity 
values for each FSP were between -0.5 and 0.5. Furthermore, patients with median serum 
reactivity >0 had increased serum reactivity values across all FSPs compared to patients with 
median serum reactivity <0 (Mann-Whitney U test, p < 10-15). This is unexpected based, 
again, on the assumption that only a minority of Lynch syndrome gene carriers should have 
serum αFSP-Abs against a minority of FSPs (Reuschenbach et al, 2010). Due to the limitations 
of the cohort analysed, specifically a lack of suitable controls as discussed in Section 3.3, the 
source of this could not be explored with confidence, and it was assumed to be a technical 
artefact caused by variation between sample reactions. Therefore, a “per patient” correction 
factor was needed to resolve the broad range of median serum reactivity values observed 
between patients. Following the regression-based normalisation, the median serum 
reactivity for each patient was subtracting from the serum reactivity of each FSP for that 
patient, therefore normalising serum reactivity between patients such that their median 
serum reactivity was equal to 0. I checked that this additional step in normalisation did not 
negatively affect the distribution of serum reactivity values for each FSP, and found that the 
median serum reactivity for each FSP remained close to 0 (Figure 3.6). 
 
 
Figure 3.6: Distribution of serum reactivity between frameshift peptides (FSPs). FSP ln(MFI) was 
normalised by the described method of quantile regression, followed by per patient correction. The 
distribution of serum reactivity is shown for each FSP.  
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As a final check of the method, I normalised the ln(MFI) data from 11 positive control 
samples from two patients vaccinated with ASTE1(-1) and TAF1B(-1) either by subtraction or 
by regression and per patient correction. A comparison of serum reactivity from the two 
methods shows that FSPs for which the patients were not vaccinated cluster closer to 0 
using the novel method, and the serum reactivity of the two FSPs the patients were 
vaccinated with is increased using the novel method (Figure 3.7). Ideally the method would 
also be validated in cancer-free and MMR mutation-negative controls and across repeats, 
but given the limitations of the cohort and the resources available it was not feasible to run 
this validation. However, as there was an improvement of normalisation by regression and 
per patient correction compared to normalisation by subtraction of control ln(MFI), I 
decided to use this novel method of normalisation in all subsequent analyses.  
 
 
 
Figure 3.7: Distribution of serum reactivity between frameshift peptides (FSPs) in positive control 
samples. FSP ln(MFI) was normalised by two methods, subtraction (equivalent to division; left-hand 
panel) and the novel method of quantile regression, followed by per patient correction (right-hand 
panel). The distribution of serum reactivity is shown for each FSP, and the two FSPs with which the 
patients were vaccinated, ASTE1(-1) and TAF1B(-1), are highlighted by an asterisk (*).  
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3.6. Frameshift Peptides cluster by Serum Reactivity 
The generation of αFSP-Abs would require a complex interaction between mutations in the 
DNA, expression of the FSP, presentation of the FSP antigen to the immune system, and 
stimulation of a humoral immune response. At each stage multiple factors could influence 
the ultimate generation of αFSP-Abs. Given these potential influences on αFSP-Ab titres, it 
was of interest to see if any associations existed between the serum reactivity of the FSPs. 
This was tested by un-supervised clustering of FSPs by the serum reactivity detected for 
each, and four statistically significant cluster groups were identified (Figure 3.8). 
 
 
 
Figure 3.8: Frameshift peptide (FSP) clustering by serum reactivity. FSP serum reactivity was 
clustered using Ward’s method and bootstrapping used to define statistically significant cluster 
groups (p > 95%), with p values shown at each branch point in red. Red boxes highlight four 
significant cluster groups. 
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The presence of FSP clustering is an interesting finding, and biological explanations are 
discussed in Section 3.8. However, it is potentially a technical artefact of the method, but the 
resources and controls to explore this further were lacking. Irrespective of its source, the 
association between FSPs was informative for results interpretation. 
 
3.7. A History of Colorectal Cancer is associated with Frameshift Peptide Serum Reactivity 
In addition to cancer incidence, it was assumed that several patient variables may affect 
αFSP-Ab titres (see Section 3.3). To inform results interpretation, I looked for correlations 
between these patient variables before any analyses of association with FSP serum 
reactivity. No correlations were particularly striking or unexpected (Figure 3.9). Patient age 
was associated with a history of cancer, which is consistent with the increasing cumulative 
cancer risk for Lynch syndrome gene carriers as they age (Møller et al, 2017b). Patient age 
was also associated with surgical removal of colorectal or gynaecological tissues or whole 
organs, which is consistent with guidelines for extensive surgery in Lynch syndrome gene 
carriers for therapeutic or prophylactic reasons (Vasen et al, 2013). Patient age was 
associated with daily intake of aspirin, which is consistent with use of aspirin in 
cardiovascular disease (Calonge et al, 2009). Female sex was negatively correlated with a 
history of CRC and colorectal surgery, in agreement with an increased CRC rate in males with 
path_MLH1 mutations relative to females and the presence of path_MLH1 variants in 
approximately 30% of the patient cohort (Møller et al, 2017b), but positively correlated with 
colorectal or gynaecological surgery, consistent with prophylactic surgery to reduce risk of 
gynaecological cancers (Vasen et al, 2013). CRCs made up the majority of Lynch syndrome 
cancers diagnosed prior to blood draw and hence there was a strong, positive correlation 
between a history of CRC and Lynch spectrum cancers. A history of cancer was also 
associated with surgery, likely to be therapeutic according to guidelines (Vasen et al, 2013). 
Due to the multiple covariates of interest that may affect FSP serum reactivity, a 
Multivariate Analysis of Covariance (MANCOVA) was used to analyse the data, with the 
patient variables as the independent variables and the serum reactivity of all 28 FSPs as the 
dependent variables. As this was an exploratory analysis, variables to be analysed further 
were identified by a p value < 0.05, with no correction for multiple testing. The MANCOVA 
found age (p = 0.04) and a history of CRC (p = 0.02) to be significantly associated with FSP 
serum reactivity (Table 3.3). 
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Figure 3.9: Correlation of patient variables. Pair-wise Pearson correlation was used to test 
associations between patient variables. The correlation r statistic (colour) and significant p values (*) 
are indicated. 
  
 
Patient variable  p value     
 Age   0.040 * 
 Sex   0.195  
 Colorectal surgery   0.743  
 Colorectal or gynaecological surgery   0.073  
 Daily aspirin intake (>2years)   0.560  
 Daily aspirin intake (ever)      0.740  
 History of colorectal cancer    0.020 * 
 History of Lynch spectrum cancer      0.596  
 On trial colorectal cancer diagnosis    0.958  
 On trial Lynch spectrum cancer diagnosis   0.069  
 Global model 0.077  
 
Table 3.3: Multivariate analysis of frameshift peptide (FSP) serum reactivity and patient variables. 
Patient variables with a statistically significant association with FSP serum reactivity are indicated by 
an asterisk (*). 
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The association of FSP serum reactivity with patient age and history of CRC was 
followed up by univariate analyses. In univariate analysis, patient age was not significantly 
associated with FSP serum reactivity (multiple linear regression, p = 0.0542), and none of the 
regression coefficients of individual FSPs, derived from the multiple regression model, were 
significant using a Bonferroni corrected threshold for multiple testing (p > 0.0018).In 
univariate analysis, patient history of CRC was again significantly associated with FSP serum 
reactivity (multiple logistic regression, p = 0.0089). Furthermore, two of the regression 
coefficients for individual FSP serum reactivity were significant using a Bonferroni corrected 
threshold for multiple testing (p < 0.0018, Table 3.4). The distributions of serum reactivity for 
these two FSPs, LMAN1(-2) and TAF1B(-1), were subsequently analysed with respect to a 
history of CRC. In LMAN1(-2), the significant difference in serum reactivity between patients 
with and without a history of CRC diagnosis was confirmed (Mann-Whitney U test, p = 0.003; 
Figure 3.10A). However, this was not so for TAF1B(-1) (Mann-Whitney U test, p = 0.153; 
Figure 3.10B), although a trend toward higher serum reactivity was evident in the patient 
group with a history of CRC. In the multiple regression that identified LMAN1(-2) and 
TAF1B(-1), the significance of each regression coefficient accounts for variance attributable 
to other variables. Interestingly, LMAN1(-2) is not part of a significant cluster group (Figure 
3.8) and, therefore, will have less shared variance in serum reactivity with other FSPs than 
TAF1B(-1), leading to similar p values when analysed as a single variable or as part of a 
multiple regression. TAF1B(-1), however, is part of a significant cluster group (cluster 2; 
Figure 3.8), and therefore its shared variance with other FSPs in the same cluster will not 
contribute to calculations of significance in the multiple regression, producing a significant 
result which is not observed when analysed as a single variable. 
Previously, Reuschenbach et al compared the highest optical density (a measure of 
antibody binding from ELISA, equivalent to serum reactivity) detected in MSI-high CRC 
patients and controls, and found a significant increase in the MSI-high CRC patients (p = 
0.036) (Reuschenbach et al, 2010). A similar observation was made in our cohort of Lynch 
syndrome gene carriers, those patients with a history of CRC had a significant increase in 
their highest serum reactivity compared to those patients without a history of CRC (Mann-
Whitney U test, p = 0.012). The time from CRC diagnosis to blood draw may also affect FSP 
serum reactivity as long term antibody production decreases with time (Dörner and 
Radbruch, 2007). Multiple regression against the serum reactivity of all FSPs showed that 
there was a trend associating serum reactivity with time since CRC diagnosis (p = 0.072), but 
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FSP β p value FSP β p value 
 TAF1B(-1) 2.9167 0.0003 *  BANP(-1) 0.0153 0.9857 
 LMAN1(-1) 1.2530 0.1815  TGFBR2(-1) -0.0815 0.8950 
 ASTE1(-1) 1.1966 0.0511  MYH11(-1)B -0.1393 0.6729 
 SLC22A9(-2) 1.1528 0.2619  PTHLH(-1) -0.1484 0.8643 
 POLD3(-1) 1.1229 0.3892  C1orf34(-2)B -0.3996 0.5785 
 Q96PS6(-1) 1.0784 0.2231  C14orf106(-1) -0.4733 0.4565 
 MYH11(-1)C 0.6382 0.2960  SLC22A9(-1)A -0.5405 0.4737 
 ASTE1(-2) 0.4763 0.6378  MYH11(-1)A -0.7110 0.4074 
 ACVR2(-2) 0.4568 0.6211  CASP5(-1) -0.8659 0.1826 
 C14orf106(-2) 0.3867 0.5656  Q96PS6(-2) -0.9560 0.2720 
 MYH11(-2) 0.3791 0.5546  AIM2(-1) -1.1139 0.0687 
 ACVR2(-1) 0.3772 0.4611  AIM2(-2) -1.2687 0.2657 
 TMEM60(-2) 0.2305 0.8152  UPF3A(-1) -1.4690 0.1369 
 MARCKS(-2) 0.0905 0.8921  LMAN1(-2) -4.2851 0.0009 *
Table 3.4: Regression coefficients (β) from multiple logistic regression of patient colorectal cancer 
(CRC) history and frameshift peptide (FSP) serum reactivity. FSPs with serum reactivity that are 
significantly associated with a history of CRC (p < 0.0018) are indicated by an asterisk (*). 
Figure 3.10: Distribution of serum reactivity in patients with or without a history of colorectal 
cancer (CRC). Shown for two FSPs that had significant associations between serum reactivity and a 
history of CRC by multiple regression, (A) LMAN1(-2), (B) TAF1B(-1). 
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the regression coefficients for individual FSPs were not significant, following Bonferroni 
correction for multiple testing (p > 0.0018). Finally, the three patients that were diagnosed 
with CRC on-trial (i.e. following blood draw, Table 3.1) were analysed. Serum reactivity for all 
FSPs was <0.4 for these three patients, giving no indication of serum reactivity beyond that 
observed in the majority of other Lynch syndrome gene carriers. 
 
3.8. Discussion 
The overall aim of this study was to assess the applicability of αFSP-Ab monitoring as a 
potential surveillance tool in Lynch syndrome gene carriers for early detection of CRC. To 
achieve this, a novel multiplex method based on antibody binding to beads coated with 
synthetic FSPs was used. The method had previously been explored in a relatively small 
cohort of 20 MSI-high CRC patients, with no selection by germline MMR gene mutation 
status (Reuschenbach et al, 2014). Therefore, a larger cohort of Lynch syndrome gene 
carriers was needed to address this aim. Sera taken at trial entry from patients participating 
in the CaPP3 clinical trial provided a cohort of 464 samples. However, due to its novelty, the 
technical aspects of the bead-based multiplex also needed to be assessed to optimise the 
method of normalisation. 
 Normalisation is required to account for technical or sample variables that may affect 
binding kinetics or quantification of fluorescence. In this method, such variables are 
accounted for by a FLAG-only control, and it was originally assumed that fluorescence from 
binding would follow an additive model. However, I found that a multiplicative model better 
represented the relationship between FSP MFI and control MFI, evident in the 
heteroscedasticity in variance for the raw data, which was removed by log transformation. 
Modelling the MFI signal versus control MFI by a multiplicative model fits with common 
assumptions of binding kinetics. Modelling serum protein 𝑃𝑃 (specific and non-specific 
antibodies, and other molecules that contribute to PE fluorescence) and ligand 𝐿𝐿 (FSP-bead 
conjugate) binding as a second order reaction: 
𝑃𝑃 + 𝐿𝐿 ↔𝑃𝑃𝐿𝐿 
the concentration of protein-ligand [𝑃𝑃𝐿𝐿], which is equivalent in this case to the 
concentration of the fluorescent antibody-FSP-bead conjugate, can be calculated by: [𝑃𝑃𝐿𝐿] = 𝐾𝐾𝐴𝐴[𝑃𝑃][𝐿𝐿] 
where 𝐾𝐾𝐴𝐴 represents the association constant of binding (Pollard, 2010). The sample 
variables that affect binding (specific and non-specific), such as the concentration of 
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peptides in the serum, or the concentration of salts, etc, will affect one of 𝐾𝐾𝐴𝐴 or [𝑃𝑃]. 
Likewise, technical variables, such as batch temperature, or the concentration of FSP-bead 
conjugates, etc, will affect one of 𝐾𝐾𝐴𝐴 or [𝐿𝐿]. These are multiplicative terms, and therefore 
this second order model of binding, for background and true signal, is consistent with the 
observation that an additive model was not appropriate for the relationship between FSP 
and control MFI. 
 When testing the method of normalisation, a regression-based and per patient 
correction was superior to normalisation by division (subtraction of log transformed data), 
giving an equivalent base-line serum reactivity between patients and between FSPs. 
Regression-based normalisation is a common tool. For example, it is frequently used to 
analyse microarray data in gene expression analyses to account for intensity variations from 
the quantity of input RNA, differences in detection or labelling efficiencies of different dyes, 
and spatial differences on the microarray surface (Quackenbush, 2002). However, as 
discussed within the results section, the validity of the regression and per patient 
normalisation needs to be confirmed and it is likely a superior normalisation method could 
be developed with additional experimentation. For example, whilst it was assumed for this 
study that the majority of Lynch syndrome gene carriers will not have αFSP-Abs based on the 
evidence of Reuschenbach et al (2010), it is feasible that their frequent history of MMRd CRC 
(Møller et al, 2017b), and increased rate of MMRd precancerous lesions, such as colorectal 
adenomas (de Jong et al, 2004a) and MMR-DCF (Kloor et al, 2012), produces a background 
of αFSP-Abs obscuring the normalisation procedure. Comorbidities and other disease could 
also have an effect on the immunological background of the patient, but this data was not 
available. These unaccounted variables could be a biological explanation for the large range 
in the median serum reactivity between different patients observed before per patient 
normalisation. However, here it was assumed that this variation was a technical artefact 
given there was no means to explore biological explanations, and because any signal would 
need to be detectable above such background for this method to be clinically useful for 
surveillance in Lynch syndrome gene carriers. Hence, samples from cancer-free and MMR 
mutation negative controls would be desirable to accurately describe the relationship 
between FSP and control MFI and further improve the normalisation method. Furthermore, 
the regression method assumes a linear model is appropriate, but additional data 
transformation may be needed for this to apply (Quackenbush, 2002). Again, negative 
controls would clarify this. Despite these caveats and limitations of the study cohort, the 
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regression and per patient normalisation showed a clear improvement from the previous 
method of normalisation, and therefore was used to generate serum reactivity data for all 
analyses. 
 The clustering of FSPs by serum reactivity was an interesting finding. Explanations 
could be biological or technical. Technical reasons could include similarities in preparation of 
FSP-bead conjugates, or non-specific features of FSP structure such as length, 
hydrophobicity, or formation of secondary structure. As was the case for optimisation of 
normalisation, such technical variables would ideally need a cohort of negative controls and 
a series of experiments to be tested. However, such additional work was beyond the 
resources of this study. The biological explanations for FSP clustering by serum reactivity 
come back to the influences of the different stages through which mutations in an MMRd 
tumour stimulate a humoral immune response. For example, cMNR mutations are likely 
drivers of MMRd tumorigenesis and would therefore be subject to strong selection 
pressures (Duval and Hamelin, 2002) and, hence, it is feasible that patterns of cMNR 
mutations arise depending on the other mutations within the tumour, the tumour 
microenvironment, and so on. Similarly, the HLA type of the patient will determine the 
affinity of MHC receptors for any FSPs expressed, leading to variation in the pattern of FSP 
antigen presentation to the immune system from patient to patient (Saeterdal et al, 2001). 
However, much of this is speculation and there is no evidence, to my knowledge, to support 
or refute these possibilities. Given time and resources, the method of Reuschenbach et al 
(2014) could be used to answer these hypotheses. 
 αFSP-Abs generated in response to MMRd CRCs could be used for surveillance of 
Lynch syndrome gene carriers as an alternative to the invasive procedure of colonoscopy, 
which cannot detect some precancerous lesions, evident in the frequent diagnosis of CRC 
during surveillance intervals (Seppälä et al, 2017), and has low rates of compliance (Stuckless 
et al, 2012). An association between FSP serum reactivity and a history of CRC was found in 
the cohort of Lynch syndrome gene carriers analysed. In addition, Lynch-spectrum cancers 
were not associated with FSP serum reactivity, consistent with selection of FSPs based on 
the frequency of the associated cMNR frameshift mutation in MMRd CRCs (Woerner et al, 
2010) and the different frequencies of cMNR mutations in different cancer types (Kim et al, 
2013). A history of CRC, rather than diagnosis of CRC after blood draw, was used due to the 
low number of on-trial cancers and based on the assumption that the production of 
antibodies will continue for a long time after disease. Previously, it has been shown that 
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long-lived plasma cells and memory B cells are responsible for antibody secretion over many 
years, potentially decades, following viral infection (Dörner and Radbruch, 2007), which is 
likely applicable to tumours. For example, B cell follicles (centres of antibody production and 
B cell activation and differentiation) form within the tumour microenvironment (Bindea et 
al, 2013), and both T and B cell populations develop anti-tumour immunological memory 
(Nielsen et al, 2012; Sarvaria et al, 2017; Amsen et al, 2018). In support of this, I found no 
association between FSP serum reactivity and the length of time from CRC diagnosis to blood 
draw despite the association between CRC history and FSP serum reactivity.  
Other observations from this study include a weak association between age and FSP 
serum reactivity. This may be due to the association of age with a history of CRC (Pearson’s 
correlation r = 0.277, p < 10-9), and could also reflect humoral responses against a history of 
MMRd lesions that do not progress to cancer, such as MMRd colorectal adenomas or MMR-
DCF, which have both been shown to contain cMNR frameshift mutation also found in CRC 
(Iino et al, 2000; Staffa et al, 2015). Also, when the association between a history of CRC and 
serum reactivity was analysed by multiple regression, it was found that regression 
coefficients of two FSPs were statistically significant. TAF1B(-1) showed the expected 
positive correlation between CRC history and serum reactivity, explicable by a humoral 
immune response against cancers containing cMNR frameshift mutations in the respective 
gene. However, LMAN1(-2) serum reactivity was negatively correlated with CRC history, 
which is difficult to explain biologically; could LMAN1min2 serum reactivity represent a 
shadow of immunological prevention of cancer? 26/28 FSPs analysed showed no significant 
association of serum reactivity with a history of CRC, which does not hold promise for these 
markers being used as early detection biomarkers of disease. 
αFSP-Abs were hypothesised to be a good candidate biomarker for the early 
detection of MMRd CRC due to the high immunogenicity of FSPs (Kloor and von Knebel 
Döberitz, 2016). However, the individual insensitivity of an FSP to detect αFSP-Abs in the 
MMRd CRC patient sera could be explained by a lack of any of several required conditions 
within the patient tumour immune response. These include a lack of the frameshift mutation 
in the tumour, an incompatible HLA type of the patient, or the evolution of immune evasion 
by the tumour (Kloor and von Knebel Döberitz, 2016). The method used in this study was, 
therefore, chosen as it could multiplex many FSPs to improve the sensitivity of autoantibody 
detection (Robinson et al, 2002). Diagnostic accuracy of early detection using this method 
could not be assessed due to a lack of controls to validate the analysis method and the low 
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number of on-trial CRC diagnoses. However, FSP serum reactivity values observed in the 
three patients who developed on-trial CRCs did not appear distinct from background noise, 
with all values falling below a serum reactivity of 0.4, despite the high likelihood of latent 
malignancy at the time of blood draw (diagnosis was within 2-19 months of trial entry). 
Therefore, detection of αFSP-Abs by the described method is not a sensitive assay despite its 
multiplex analysis, and it is unlikely to have clinical utility for the surveillance of Lynch 
syndrome gene carriers. This lack of sensitivity could be due to technical or biological 
reasons. Technical reasons are less likely given the detection of αFSP-Abs against ASTE1(-1) 
and TAF1B(-1) in the positive control sera of patients vaccinated with these same FSPs. With 
respect to possible biological explanations, there is sufficient evidence to show that cMNR 
mutations lead to specific immune responses against the associated FSP antigen (Saeterdal 
et al, 2001; Schwitalle et al, 2008; Tougeron et al, 2009; Maby et al, 2015; Le et al, 2017), but 
these studies assessed cellular rather than humoral immunity, for example by stimulating 
peripheral and tumour infiltrating lymphocytes with FSPs, or T cell killing of MMRd cell lines. 
The publication of Reuschenbach et al in 2010 is the only study I am aware of, other than 
Resuchenbach et al, 2014, that has analysed humoral immunity against MMRd cancer using 
multiple sera and multiple FSPs. Reuschenbach et al (2010) used ELISA, a well-established 
technique for detection of serum antibodies, and showed serum reactivity in 20/69 (29%) 
MMRd CRC patients against at least one FSP in a panel of 8 derived from 6 cMNR frameshift 
mutations common to MMRd CRC. However, 9/31 (29%) healthy, Lynch syndrome gene 
carriers and 8/52 (15.4%) controls, respectively, also had serum reactivity against one FSP or 
more. This suggests that αFSP-Abs are only infrequently generated against MMRd CRCs and 
that non-specific binding to FSPs may account for the majority of signal observed. Although 
Reuschenbach et al (2010) used a much smaller panel of FSPs, their results are consistent 
with the observations of this study, suggesting that αFSP-Ab titres are likely to be poor 
biomarkers for the early detection of MMRd CRC. 
3.9. Conclusions and Future Work 
By using the multiplex method of Reuschenbach et al (2014), I showed that there is an 
association in Lynch syndrome gene carriers between a diagnosis of CRC and serum 
reactivity to FSPs, likely due to αFSP-Abs in the peripheral circulation. However, detection of 
αFSP-Abs by the described method is unlikely to be a useful biomarker test for early 
detection of MMRd CRC as the majority of patients with a CRC diagnosis (pre- or post-blood 
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draw) have serum reactivity values equivalent to patients without a CRC diagnosis. 
Furthermore, all but two of the FSPs analysed show no correlation with CRC incidence. It is 
feasible that optimisation of the method, particularly data normalisation, may improve its 
sensitivity for αFSP-Abs, but this would require significant investment to analyse cancer-free 
and MMR mutation-negative controls to validate normalisation and test technical variables. 
If the protocol can be optimised and shown to be robust to technical variables, additional 
data and samples collected as the CaPP3 clinical trial progresses will be available to, for 
example, re-assess the FSP serum reactivity of additional patients with on-trial CRC 
diagnoses, which would be a more direct evaluation of the analytical validity of the method 
for early detection of CRC in Lynch syndrome gene carriers. The longitudinal design of the 
CaPP3 study would also allow monitoring of patient FSP serum reactivity over time, which 
could be more informative than using a cross sectional study of a Lynch syndrome gene 
carrier population. Again, more detailed technical validation of the method would be the 
priority before any additional studies were carries out.  
 Whilst this study failed to develop a novel biomarker test for Lynch syndrome 
surveillance, extensive guidelines exist for alternative surveillance methods (Vasen et al, 
2013). Colonoscopy, for example, remains an effective surveillance technique (Järvinen et al, 
2000) even if it does not detect all colorectal lesions in Lynch syndrome gene carriers 
(Seppälä et al, 2017). Therefore, irrespective of these result, the identification of Lynch 
syndrome gene carriers is required for optimal patient management, and novel biomarker 
tests for MMR deficiency in CRC are needed to meet the demand for high throughput 
screening of all CRCs (Newland et al, 2017). 
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Chapter 4. Development of a Short Mononucleotide Repeat Sequencing Assay 
to Detect Microsatellite Instability in Colorectal Cancer 
 
4.1. Introduction 
High throughput MMR deficiency testing is needed to meet two clinical needs: testing of all 
CRCs to screen for Lynch syndrome, and testing of any solid cancer to predict response to 
immune checkpoint blockade therapy. I aimed to develop an NGS-based MSI assay that 
facilitates automated and cheap MSI analysis, continuing the work of Redford et al (2018). In 
their study, Redford et al defined 120 informative microsatellite markers from whole 
genome sequence data from MSI-high and MSS CRCs, and matched normal tissue in The 
Cancer Genome Atlas. MNRs, rather than DNRs for example, were selected for their superior 
sensitivity and specificity for MSI status (Bacher et al, 2004), including sensitivity for MSH6 
deficiency (You et al, 2010). The lengths of these MNRs ranged from 7-12bp, making them 
“short” relative to the longer markers employed by other assays. The MSI Analysis System 
(Promega), for example, uses 21-28bp MNRs (Bacher et al, 2004). Short MNRs are less likely 
to be polymorphic (Ananda et al, 2013), meaning that matched normal DNA was not needed 
for results interpretation. Furthermore they can be accurately sequenced due to low PCR 
and sequencing error (Fazekas et al, 2010). Finally, each selected marker had an associated 
SNP with a minor allele frequency >20%, within 30bp of the microsatellite, allowing the 
allelic origin of microsatellite length variants to be determined in heterozygotes. 
A panel of 17 of these markers was selected based on sensitivity and specificity for 
MSI status from sequencing a discovery cohort of 6 MSI-high CRCs and 6 MSS CRCs. The 
method amplified the 17 marker panel in singleplex from each sample, and amplicons from 
each sample were pooled, purified and subject to a second PCR in which sample index 
sequences and sequencing adapters (for compatibility with Illumina sequencing platforms) 
were added. Sample-indexed amplicons were pooled into a sequencing library, sequenced in 
forward and reverse orientations on the MiSeq platform (Illumina), and fastq files were 
processed, as described in Section 2.12.1. A naïve Bayes approach (Section 2.12.2) was 
followed to develop an MSI classifier that would classify samples as MSI-high or MSS using 
the proportion of reads containing deletions and their allelic distribution. It was trained 
using a cohort of 67 MSI-high and 72 MSS CRCs, which had previously been typed by the MSI 
Analysis System (Promega). An independent cohort of 70 CRCs (36 MSI-high, 34 MSS, again 
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typed by MSI Analysis System) was used for validation and, across both cohorts, the assay 
achieved 98% sensitivity and 98% specificity (Redford et al, 2018), equivalent to FLA, IHC and 
NGS-based methods (Zhu et al, 2018). Deletions, rather than any variant in microsatellite 
length, were used as deletions are more frequent than insertions in MSI-high CRCs and cell 
lines, suggesting that any insertions detected are likely PCR or sequencing error (Sia et al, 
1997; Lu et al, 2013). Increased discrimination of MSI status was achieved by analysing the 
allelic bias of reads containing deletions, as single deletion events will stochastically affect 
one allele and not the other. MSI-low samples were considered equivalent to MSS samples 
(Section 2.12.2; Halford et al, 2002; Laiho et al, 2002). 
 The turnaround time (TAT) of the assay was estimated to be 11 days and the cost was 
£26.20 per sample, assuming 96 samples being analysed per batch. Both TAT and cost are 
therefore inferior to the dominant MSI Analysis System (Promega), and this was largely due 
to the singleplex amplification of the 17 markers (Alhilal PhD Thesis, 2016). Protocol 
optimisation by multiplexing of the markers was needed. There is a plethora of programs 
available to design PCR primers suitable for multiplexing, but interactions between primers 
limit the number of markers in the multiplex, which is often difficult to predict, and 
differential amplification efficiency of different primer pairs produces unequal 
representation of each amplicon, which is not trivial to balance (Sint et al, 2012). Molecular 
inversion probes (MIPs) are an attractive technique for target enrichment due to robust 
multiplexing, with several thousand loci being amplified in one reaction (O’Roak et al, 2012), 
and a simple, automatable protocol (Hiatt et al, 2013; Neveling et al, 2017; Figure 4.1). To 
balance the number of sequencing reads detected from each locus the concentration of 
each MIP can be modified with ease (Niedzicka et al, 2016). Many of the 120 markers 
defined by Redford et al were untested and, therefore, potentially superior to those selected 
and so could be added into the multiplexed assay. Furthermore, detection of BRAF V600E 
mutations in MMRd CRCs indicates the tumour is of sporadic origin and is not Lynch 
syndrome (Domingo et al, 2004), hence simultaneous testing of BRAF reduces the Lynch 
syndrome screening pipeline to one step prior to germline genetic testing rather than the 
current practice of MMR deficiency testing followed by BRAF testing (Newland et al, 2017). 
RAS gene mutations predict CRC response to anti-EGFR therapy (De Roock et al, 2010a) and 
substitutions at KRAS G12 and G13 account for approximately 93% of all RAS gene mutations 
in CRC. Therefore, inclusion of other, relevant biomarkers in the multiplex, such as BRAF and 
KRAS mutation hotspots, would make the assay competitive with gene panel sequencing. 
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Figure 4.1: Protocol for multiplex loci capture, molecular barcode (MB) tagging, and amplification 
by single molecule molecular inversion probes (smMIPs). The protocol uses four steps. 1: The two 
targeting arms of each probe anneal to marker loci in the template DNA. Each MIP molecule contains 
an MB as a unique identifier. 2: probes circularise by polymerase extension from the 3’ arm of the 
probe to gap-fill between the targeting arms, and nick sealing by ligation of the 3’ end of the 
extension to the 5’ targeting arm. 3: exonuclease treatment removes linear DNAs, including template 
DNA and un-circularised probes. 4: PCR amplification using universal primers adds sample index 
sequences and sequencing adapters to create sequencing-ready amplicons. 
 
In addition to optimising the assay protocol, it was important to show the analytical 
validity of the assay with a view to its acceptance into clinical practice (Hayes, 2018). A 
collaboration between the Association for Molecular Pathology and the College of American 
Pathologists has defined guidelines for the validation of NGS-based oncology assays, 
covering the parameters that must be tested to support analytical validity and define assay 
limits (Jennings et al, 2017). These guidelines extensively cover the quality controls (QCs) for 
samples and sequencing to ensure reliable assay performance. Many of these QCs are 
independent of the assay. For example, it is recommended that, during sample preparation, 
equipment is thoroughly cleaned or new disposable consumables be used for each sample to 
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prevent contamination. For sequencing, it is recommended that cluster density, or total 
reads generated, be monitored to ensure they are within the expected range, as 
exceptionally densities or read depths suggest error in library preparation, or execution of 
sequencing. Some QCs, however, are dependent on the assay. For example, the lower limit 
of detection (LLoD) of an assay will determine the minimum tumour cell content required in 
a sample to generate reliable results. 
The MSI classification method of Redford et al (2018) uses the probability that the 
observed proportion of reads containing microsatellite deletions and the observed 
distribution to deletions to different alleles belong to an MSI-high or MSS CRC. Sample 
variables that will affect results include: 
1. sample composition, as a lower MSI-high content will reduce the signal to noise ratio 
2. sample quality, as poor quality may introduce changes in the microsatellite sequence 
3. sample quantity, as low library complexity (i.e. a low number of sample molecules 
sequenced) may skew representation of template DNA in sequencing reads 
Sequencing variables that will affect results include: 
1. read depth, as lower read counts will increase the confidence intervals of an 
observed proportion of reads (assuming read counting follows a binomial 
distribution) 
2. base-call quality, as erroneous base-calls may change the detected length of a 
microsatellite 
Therefore, each of these variables should be assessed during assay development to define 
assay QCs. For such assessments, the guidelines of Jennings et al recognise that it is 
infeasible to control for every sample variable. Therefore, based on calculations of non-
parametric tolerance intervals, they recommend that a minimum of 59 independent 
samples, representative of the sample population the assay is intended for, should be used 
to test any of these parameters. 
 
4.2. Aims 
To optimise the MSI assay of Redford et al (2018), and to test its analytical validity, I aimed 
to: 
1. Multiplex the 17 short MNRs, previously proven to be highly accurate for MSI status, 
together with additional microsatellite markers defined by Redford et al (2018) using 
smMIPs. 
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2. Determine the diagnostic accuracy (i.e. sensitivity and specificity) of the smMIP-
based MSI assay, by re-training of the MSI classifier described by Redford et al (2018) 
and validation in an independent cohort of CRCs. 
3. Include additional, clinically actionable biomarker loci, specifically BRAF V600 and 
KRAS G12 and G13 mutation hotspots, in the smMIP-based MSI assay. 
4. Determine the limits of the smMIP-based MSI assay with respect to sample and 
sequencing variables, and define assay-specific QCs. 
 
4.3. Multiplex Amplification of Microsatellites using Molecular Inversion Probes 
Amplification and sequencing errors in microsatellite length can be reduced by use of high 
fidelity, Phusion polymerases, and the highest fidelity of these was found to be Herculase ii 
polymerase (Agilent; Fazekas et al, 2010). For this reason, Herculase ii polymerase was used 
in the work of Redford et al (2018). To show that the smMIP protocol could use Herculase ii 
polymerase instead of the Taq polymerase used in the original protocol, a positive control 
smMIP sequence was obtained from the study of Hiatt et al (2013) and shown to be 
amplifiable with Herculase ii polymerase in our laboratory (Figure 4.2A). Subsequently, 
smMIPs for the 17 short MNR loci analysed by Redford et al (2018) were designed using 
MIPgen (Section 2.8.2; Boyle et al, 2014a). These smMIPs were tested in singleplex (Figure 
4.2B) and 15/17 produced visible amplicons. The two markers that failed to amplify (IM66 
and LR20) were not taken forward. To verify the content of each smMIP amplicon, primers 
targeting the sequence internal to the smMIP targeting arms were designed, compatible 
with primers specific to the universal sequence of smMIP amplicons (Section 2.8.2). PCR 
amplification, using these primers and purified smMIP amplicon as template, produced 
secondary amplicons of the expected size, confirming that the smMIP amplicons contained 
the correct sequence (Figure 4.2C). The 15 MIPs were then pooled together, the markers 
were amplified in a 15plex reaction (Figure 4.2D), and the expected products were again 
verified by amplification of sequence internal to the amplicons (Figure 4.2E). 
 
4.4. Amplicon Sequencing identifies Variants in Control Samples 
The smMIP protocol produces amplicons containing sequencing adapters and sample index 
sequences (for read demultiplexing) for use with Illumina sequencing, a ubiquitous platform 
in healthcare services globally (Levy and Myers, 2016) and, hence, appropriate for high 
throughput assays. Four control samples were selected for sequencing, including DNAs  
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Figure 4.2: Amplification of marker loci using single molecule molecular inversion probes (smMIPs). 
(A) A positive control smMIP (PosC) (Hiatt et al, 2013) was used in a singleplex reaction to capture 
and amplify template DNA from K562 (+), alongside a template negative reaction (-). The expected 
smMIP amplicon size was 272bp. (B) Singleplex smMIPs were used to capture and amplify 17 
microsatellite markers (Redford et al, 2018; three examples shown), with expected amplicon size of 
240-270bp. (C) PCR verification of amplicons from B, showing examples from 2 markers using internal 
primers in both forward and reverse orientations (FP and RP). (D) 15 microsatellite markers were 
captured and amplified in one multiplexed-smMIP reaction. (E) PCR verification of amplicons from D, 
showing examples from 5 markers.  
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extracted from K562 (an MMRp chronic myeloid leukaemia cell line), HCT116 (an MMRd CRC 
cell line), and an MMRd CRC with a matched normal colorectal mucosa biopsy. Each sample 
was amplified using the 15plex smMIP reaction. The target read depth of sequencing was 
≥5000 reads/marker/sample, requiring a minimum of 400,000 total reads (Section 2.10), 
assuming that the proportion of total reads generated would equal 0.75 x total read output, 
based on observations from Niedzicka et al (2016). Therefore, a MiSeq v2 Nano Kit (capacity 
of 1,000,000 reads, and the smallest kit available) was chosen. Amplicons from each sample 
were purified, quantified and diluted to 4nM, before pooling in equal volumes to give a final 
4nM sequencing library. There was a 6-week delay between library preparation and MiSeq 
loading and the number of reads passing the MiSeq quality filter was only 301,367 (Table 
4.1), much lower than anticipated, perhaps due to degradation of the library during the 6-
week delay. Reads were aligned to reference genome hg19 and summarised in Marker 
Result tables that count the reads according to microsatellite length and SNP detected 
(Section 2.12.1). The proportion of reads passing filter aligned to the marker loci was 0.84, in 
agreement with the assumed 0.75 used in target read depth calculations. Reads were 
detected for each of the 15 markers, ranging from 706 to 12,553 (Table 4.2). 
To expand the microsatellites analysed, in a separate analysis, smMIPs were designed 
for 9 additional markers from the original list of 120 (Redford et al, 2018), and redesigns for 
LR20 and IM66 were attempted. smMIPs for the BRAF V600 and KRAS G12 and G13 
mutation-hotspots were also designed. Loci coordinates were compiled by Dr Harsh Sheth, I 
ran MIPgen, and subsequently Dr Sheth tested the smMIPs in singleplex and then multiplex 
based on protocols optimised in the first 17 markers. The smMIP for IM66 again failed to 
produce a visible amplicon, but smMIPs for LR20, the 9 additional microsatellites, and BRAF 
and KRAS were all successfully amplified in singleplex and multiplex. The same four samples, 
K562, HCT116, and the MMRd CRC with matched normal colorectal mucosa, were 
sequenced using the 12plex of additional markers, a 10pM loading concentration and a 
MiSeq v2 Nano Kit. In this sequencing run, a total of 1,444,882 reads were generated (Table 
4.1), which was much higher than the previous run and kit capacity. At such high numbers of 
reads the 10pM loading concentration risked run failure due to over clustering of the MiSeq 
flow cell. Therefore, it was decided that DNA libraries should be prepared as near to MiSeq 
loading as possible to ensure library quality and sufficient read depth, and that 8pM should 
be loaded in future to avoid over clustering. In the 12plex sequencing run, all markers were 
covered, with read depth ranging from 6,388 to 49,795 reads/marker/amplicon (Table 4.2). 
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Parameters 15plex Library 12plex Library 
Loading Concentration 8pM* 10pM 
Reads passing filter 301,367 (95.0%) 1,444,882 (89.2%) 
Reads aligned  253,692 1,272,430 
Reads aligned/passing filter 0.84 0.88 
Reads/marker/sample (mean±SD) 4,228 ±3,817 23,692 ±12,437 
Base calls ≥Q30 78.00% 69.80% 
*library was ~6 weeks old
Table 4.1: Statistics from the two sequencing runs. 
Marker Marker Details Reads Detected Library 
AP0035322 Microsatellite A(9) 1,538 15plex 
BRAF Hotspot p.V600 49,795 12plex 
DEPDC2 Microsatellite G(8) 2,184 15plex 
GM01 Microsatellite A(10) 35,515 12plex 
GM07 Microsatellite A(11) 3,816 15plex 
GM09 Microsatellite A(8) 3,557 15plex 
GM11 Microsatellite A(9) 4,081 15plex 
GM14 Microsatellite A(11) 6,684 15plex 
GM17 Microsatellite A(9) 8,537 15plex 
GM22 Microsatellite A(10) 46,054 12plex 
GM26 Microsatellite A(10) 13,365 12plex 
GM29 Microsatellite A(10) 22,352 12plex 
IM16 Microsatellite A(9) 4,630 15plex 
IM49 Microsatellite A(12) 706 15plex 
KRAS Hotspot p.G12,G13 31,391 12plex 
LR10 Microsatellite A(10) 18,042 12plex 
LR11 Microsatellite A(11) 3,795 15plex 
LR17 Microsatellite A(10) 21,684 12plex 
LR20 Microsatellite A(8) 6,388 12plex 
LR24 Microsatellite A(9) 1,684 15plex 
LR36 Microsatellite A(12) 4,170 15plex 
LR40 Microsatellite A(9) 12,908 12plex 
LR44 Microsatellite A(12) 1,359 15plex 
LR46 Microsatellite A(8) 37,161 12plex 
LR48 Microsatellite A(11) 12,553 15plex 
LR49 Microsatellite A(7) 4,131 15plex 
LR52 Microsatellite A(12) 23,455 12plex 
Table 4.2: Mean reads detected per marker per sample from the two sequencing runs. 
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Marker Results tables from both sequencing runs were used to analyse the 
distribution of reads to different lengths of microsatellite in each marker. It was anticipated 
that the two MMRp samples (K562 and the matched normal colorectal mucosa) would show 
fewer variants in microsatellite length compared to the two MMRd samples (HCT116 and 
the MMRd CRC). The matched normal colorectal mucosa showed only low frequencies of 
length variants, likely due to the expected PCR and sequencing error (Figure 4.3). Similar 
observations were made for K562 except for -1 deletions in approximately one third of reads 
in markers GM07 and LR48 (Figure 4.3). This suggests that one allele of these markers had 
been mutated given that K562 is triploid (Klein et al, 1976). Mutation in 2 of 25 
microsatellites is consistent with the MSI-low phenotype of some MMRp cancers (Halford et 
al, 2002; Laiho et al, 2002). HCT116 contained increased frequency of length variants in 
roughly 21-23/25 microsatellites compared to the MMRp samples, consistent with an MSI-
high phenotype (Figure 4.3). For the majority of these markers, approximately one half of 
reads contained one length of microsatellite and the other half of reads contained another 
length, suggesting differential mutation in the two alleles of a clonal population. Markers 
that showed only slight increases in frequency of length variants could represent subclonal 
mutations. The MMRd CRC had increased frequency of length variants in 15/25 
microsatellites, consistent with an MSI-high phenotype. However, reads were not evenly 
distributed between two different lengths as was seen in HCT116, which is consistent with 
the sample containing a mix of MMRd tumour cells and MMRp stromal cells (Figure 4.3 – 
spans 2 pages). For both MMRd samples, increases in length variants were due to deletions, 
as expected (Sia et al, 1997; Lu et al, 2013), which supports the use of deletion and not 
insertion frequency in the MSI classifier developed by Redford et al (2018). 
Detection of allelic bias of microsatellite deletions requires a sample to be 
heterozygous at the associated SNP. Where >80% of reads were associated with the same 
SNP allele the sample was considered homozygous for the marker-associated SNP and 
therefore allelic bias of deletions could not be assessed, for example K562 at LR44_SNP1 
(Figure 4.4). Where the multiple alleles were detected at the SNP locus and ≥20% of reads 
were associated with the minor allele the sample was considered heterozygous for the 
marker-associated SNP, and allelic bias of deletions could be assessed. For example, the 
matched normal sample showed a similar proportion of reads assigned to C and T alleles at 
both WT (0) and deletion (-1) lengths of microsatellite in marker LR44, suggesting no allelic 
bias (Figure 4.4). However, for the MMRd CRC there is a greater proportion of reads  
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containing a -2 deletion assigned to the C allele than there are reads containing a -2 deletion 
assigned to the T allele, evidence of allelic bias of this deletion (Figure 4.4). The statistical 
significance of read count distribution to the different alleles was calculated by constructing 
a two-by-two table for the count of reads containing deletions versus the count of reads 
containing WT microsatellite length, as distributed between alleles, and using Fisher’s Exact 
test. In the MMRd samples, the majority of markers (where the sample was heterozygous at 
the SNP locus) showed a significant difference in the deletion frequency between alleles, 
which was not the case for the MMRp samples (Table 4.3). 
Figure 4.4: Distribution of reads by microsatellite length and allele. Examples are shown for two 
markers with associated SNPs, LR44_SNP1 and LR10_SNP1, in four samples: K562, a mismatch repair 
proficient (MMRp) cell line; HCT116, a mismatch repair deficient (MMRd) cell line; matched normal, a 
biopsy of MMRp colorectal mucosa from the same patient as the MMRd CRC; and a MMRd CRC. 
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Marker_SNP K562 HCT116 Matched Normal MMRd CRC 
AP0035_SNP1 NA NA 0.755 0.495 
DEPDC2_SNP1 0.763 0.000 NA NA 
GM01_SNP1 0.373 NA 0.404 0.060 
GM07_SNP1 NA 0.000 NA NA 
GM09_SNP1 NA 0.075 NA NA 
GM11_SNP1 NA 0.000 NA NA 
GM11_SNP2 NA NA NA NA 
GM14_SNP1 NA NA NA NA 
GM17_SNP1 NA NA NA NA 
GM22_SNP1 NA NA 0.636 0.018 
GM26_SNP1 NA 0.000 0.229 0.316 
GM29_SNP1 NA 0.000 0.449 0.000 
IM16_SNP1 0.013 NA NA NA 
IM16_SNP2 NA NA NA NA 
IM16_SNP3 NA NA NA NA 
IM49_SNP1 NA NA NA NA 
LR10_SNP1 NA 0.001 0.042 0.000 
LR10_SNP2 NA 0.001 NA NA 
LR11_SNP1 NA 0.095 NA NA 
LR11_SNP2 NA 0.062 NA NA 
LR17_SNP1 NA NA NA NA 
LR17_SNP2 NA NA NA NA 
LR17_SNP3 NA NA NA NA 
LR17_SNP4 NA NA NA NA 
LR20_SNP1 0.387 NA 0.737 0.670 
LR24_SNP1 1.000 1.000* NA NA 
LR36_SNP1 0.764 NA NA NA 
LR40_SNP1 NA NA 0.452 0.000 
LR44_SNP1 NA 1.000* 0.539 0.000 
LR44_SNP2 NA 1.000* 0.133 0.000 
LR46_SNP1 NA NA 0.828 0.000 
LR48_SNP1 NA NA 0.264 0.550 
LR49_SNP1 0.774 NA NA NA 
LR52_SNP1 0.012 NA 0.000 0.000 
Sample 
Summary 
Homozygous: 26 
Heterozygous: 8 
p < 0.05: 2 
Homozygous: 21 
Heterozygous: 13 
p < 0.05: 7 
Homozygous: 21 
Heterozygous: 13 
p < 0.05: 2 
Homozygous: 21 
Heterozygous: 13 
p < 0.05: 9 
Table 4.3: Detection of allelic bias of deletions in the microsatellite markers. Markers where the 
associated SNP is homozygous are denoted by NA. Markers where the associated SNP is 
heterozygous were assessed for statistical significance of the allelic bias of deletions in the 
microsatellite, using Fisher’s Exact test: p values are presented in the table and the data is 
summarised for each sample. 
*Note: for HCT116 markers LR24 and LR44 there are very few or no WT reads (see Figure 4.3 for LR44
as an example) resulting in non-significant tests for allelic bias.
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Marker Result tables were also used to detect substitution mutations at the BRAF 
and KRAS mutation-hotspots. For each locus, the bases detected across the four samples 
were determined and then, for each sample, the proportion of reads containing each base 
was plotted (Figure 4.5). For BRAF, the matched normal colorectal mucosa, K562, and 
HCT116 all contained the WT adenine in nearly 100% of reads, with any variants likely due to 
error (present in <1% of reads). However, the MMRd CRC had 11% of reads assigned to 
thymine (Figure 4.5A). The observed A>T substitution represents the BRAF V600E mutation, 
suggesting that this MMRd CRC is of sporadic origin. For KRAS, there were four loci 
sequenced that are associated with substitution mutations in the G12 and G13 codons. At 
these loci, all samples contain the WT base in near to 100% of reads, except for HCT116 at 
chr12 25398281, where 52% of reads are assigned to thymine rather than the WT cytosine 
(Figure 4.5B). This C>T substitution is associated with KRAS G13D, a known mutation in 
HCT116 (Yun et al, 2009). 
 
 
Figure 4.5: Detection of RAS/RAF mutations. The proportion of reads containing different bases at 
mutation hotspots (chromosomes and coordinates using reference genome hg 19) are shown for (A) 
BRAF and (B) KRAS. The A>T substitution at chr7 140453136 in the MMR deficient CRC represents 
BRAF V600E. The C>T substitution at chr12 25398281 in HCT116 represents KRAS G13D.  
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4.5. Training the MSI Classifier 
The MSI classifier requires training in a cohort of samples to determine the probability that 
observations of microsatellite deletion frequencies and the allelic bias of deletions belong to 
either an MSI-high or MSS CRC population. Residual DNA samples from the work of Redford 
et al (2018) were compiled into a training cohort of 51 MSI-high and 47 MSS CRCs (a priori 
classification by MSI Analysis System, Promega). HCT116 and H9, an embryonic stem cell 
line, were included as MSI-high and MSS controls, giving a total of 100 samples. The training 
cohort was amplified using a multiplex of the 27 smMIPs, comprising the 25 short MNR 
markers, and BRAF and KRAS mutation hotspots. Amplicons were sequenced to a mean read 
depth (±SD) of 3,719 ±3,149 reads/marker/sample with 75.3% of base-calls ≥Q30. Read 
depth was lower than the target >5,000reads/marker/sample. Previously, MiSeq v2 kits were 
used and so it was assumed that v3 kits may need a higher DNA library loading 
concentration; subsequent sequencing used 8pM for v2 kits and 12pM for v3 kits and 
achieved target read depths. Unfortunately, no reads were detected for marker AP0035 in 
87/98 samples. AP0035 was one of the less accurate markers in the work of Redford et al 
(2018) and, with the addition of 9 new markers not analysed by Redford et al, its inclusion 
was not necessary. Therefore, AP0035 was excluded from all further analyses. 
The relative frequency of deletions in the microsatellite was determined for each 
marker across the 47 MSS CRCs and, from this empirical distribution, a threshold was set at 
the 95th percentile for each marker individually, as different markers have different, intrinsic 
error rates. Therefore, assuming the empirical distributions to be representative of the MSS 
CRC population, there would be 95% probability of an MSS CRC having a deletion frequency 
below the threshold, and 5% probability of an MSS CRC having a deletion frequency above 
the threshold. The probability of an MSI-high CRC having a deletion frequency above or 
below these thresholds could then be determined, again assuming the empirical 
distributions from the 51 MSI-high CRCs sequenced in the training cohort to be 
representative of the MSI-high CRC population. Considering two example markers, GM11 
and IM49, the proportions of MSI-high samples falling above the threshold were 44/51 and 
45/51, respectively. Therefore, for these two markers, the probabilities of observing a 
deletion frequency above the threshold in an MSI-high CRC would be 86.3% and 88.2% for 
GM11 and IM49, respectively. Conversely the probabilities of observing a deletion frequency 
below the threshold in an MSI-high CRC would be 13.7% and 11.8% for GM11 and IM49, 
respectively (Figure 4.6). 
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Figure 4.6: Distribution of training cohort samples by the relative frequency of microsatellite 
deletions. The proportion of reads containing a deletion in microsatellite length (deletion frequency) 
was determined for both MSI-high and MSS CRCs in the training cohort; the 0.95 quantile of deletion 
frequencies detected in the MSS samples was used as a threshold (dotted lines) to dichotomise the 
distributions. The proportion of MSI-high CRCs above and below the threshold can be used to 
calculate probabilities that an observed deletion frequency belongs to a MSI-high CRC population. 
 
 
It is also possible to assess deletion frequency in different alleles when the sample is 
heterozygous at the neighbouring SNP. If allelic bias of deletion is present, it gives additional 
confidence that it is a true mutation rather than the result of error, which should affect both 
alleles equally. Assessment of allelic bias was possible in >30% of samples in all of the 24 
microsatellite markers (Table 4.4). To establish the significance of allelic bias, two-by-two 
contingency tables were constructed, distributing reads according to length of microsatellite 
detected (deletion versus WT) and according to the allele detected, and Fisher’s Exact tests 
were performed. A threshold was set at p = 0.05, and for each marker the probability of an 
observation from an MSI-high or MSS sample falling above or below this threshold was 
determined from the empirical distributions of p values from the 47 MSS and the 51 MSI-
high CRCs of the training cohort. Again using GM11 and IM49 as example markers, for the 
MSI-high samples 23/28 and 19/26 samples fall below the threshold, and for MSS samples 
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Marker_SNP Relative Frequency  
DEPDC2_SNP1 0.316 
GM01_SNP1 0.398 
GM07_SNP1 0.541 
GM09_SNP1 0.439 
GM11_SNP1 0.510 
GM11_SNP2 0.122 
GM14_SNP1 0.449 
GM17_SNP1 0.490 
GM22_SNP1 0.367 
GM26_SNP1 0.459 
GM29_SNP1 0.378 
IM16_SNP1 0.469 
IM16_SNP2 0.245 
IM16_SNP3 0.000 
IM49_SNP1 0.490 
LR10_SNP1 0.429 
LR10_SNP2 0.418 
LR11_SNP1 0.418 
LR11_SNP2 0.408 
LR17_SNP1 0.000 
LR17_SNP2 0.000 
LR17_SNP3 0.490 
LR17_SNP4 0.490 
LR20_SNP1 0.520 
LR24_SNP1 0.469 
LR36_SNP1 0.469 
LR40_SNP1 0.194 
LR44_SNP1 0.439 
LR44_SNP2 0.439 
LR46_SNP1 0.480 
LR48_SNP1 0.327 
LR49_SNP1 0.439 
LR52_SNP1 0.510 
 
Table 4.4: The proportion of samples in which allelic bias can be assessed for each marker. A total 
of 98 samples were analysed in the training cohort. If a sample was heterozygous for a marker-
associated SNP the allelic bias of microsatellite deletions could be assessed. The table shows the 
proportion of the 98 samples that were heterozygous for each SNP associated with each of the 
markers. 
Note: AP0035 has been excluded due to a lack of reads in Marker Result tables for 87/98 samples. 
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4/22 and 3/22 samples fall below the threshold, respectively (Figure 4.7). Therefore, for 
GM11, the probabilities of observing a p value for allelic bias below the 0.05 threshold would 
be 82.1% and 18.2% for an MSI-high and an MSS sample, respectively. Conversely, the 
probabilities of observing a p value for allelic bias above the 0.05 threshold in GM11 would 
be 17.9% and 81.8% for an MSI-high and an MSS sample, respectively. For IM49, the 
probabilities of observing a p value for allelic bias below the 0.05 threshold would be 73.1% 
and 13.6% for an MSI-high and an MSS sample, respectively. Conversely, the probabilities of 
observing a p value for allelic bias above the 0.05 threshold in IM49 would be 26.9% and 
86.4% for an MSI-high and an MSS sample, respectively. 
 
 
 
 
Figure 4.7: Distribution of samples relative to classifier thresholds. (A) The proportion of reads 
containing a deletion in microsatellite length (deletion frequency) was determined for both MSI-high 
and MSS CRCs in the training cohort; the 0.95 quantile of deletion frequencies detected in the MSS 
samples was used as a threshold (dotted lines). (B) The significance of allelic bias of deletions was 
represented by the p value from Fisher’s Exact tests for the count of reads distributed to different 
microsatellite lengths across alleles, with a threshold set at p = 0.05. MSI status (MSI-high or MSS) 
was determined a priori by MSI Analysis System (Promega).  
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Having trained the MSI classifier, for any marker an observed deletion frequency or 
observed p value of allelic bias could be converted into two probabilities: one probability of 
the observation 𝑂𝑂𝑂𝑂 belonging to a MSI-high population 𝑝𝑝(𝑂𝑂𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀), and a second probability 
of the observation 𝑂𝑂𝑂𝑂 belonging to a MSS population 𝑝𝑝(𝑂𝑂𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀). Where allelic bias could 
not be computed (e.g. the sample was homozygous at the associated SNP) the probabilities 
associated with allelic bias for that marker were set to 1. Also, where the deletion frequency 
was below the threshold for a marker, indicating no evidence for deletion at the 
microsatellite, the probabilities associated with allelic bias for that marker were set to 1. 
Relative probabilities from each marker could be condensed into one term by multiplication: 
𝑝𝑝(𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀)
𝑝𝑝(𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀) = � 𝑝𝑝(𝑂𝑂𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀)𝑝𝑝(𝑂𝑂𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀)𝑁𝑁𝑖𝑖=1  
A sample score (S) could then be calculated: 
𝑀𝑀 =  log10  𝑝𝑝(𝑀𝑀𝑀𝑀𝑀𝑀)𝑝𝑝(𝑀𝑀𝑀𝑀𝑀𝑀) . 𝑝𝑝(𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀)𝑝𝑝(𝑂𝑂|𝑀𝑀𝑀𝑀𝑀𝑀) 
where 𝑝𝑝(𝑀𝑀𝑀𝑀𝑀𝑀) and 𝑝𝑝(𝑀𝑀𝑀𝑀𝑀𝑀) are set to 0.15 and 0.85 as the a priori probability of sample 
being MSI-high or MSS, respectively. Samples with S > 0 are classified as MSI-high, indicating 
MMR deficiency (Redford et al, 2018). 
The trained MSI classifier subsequently typed the training cohort with 100% 
sensitivity (95% CIs: 93.0-100.0%) and 100% specificity (95% CIs: 92.5-100.0%) (Figure 4.8: 
left-hand panel). In addition, control samples, HCT116 and H9, were correctly classified, with 
scores of 38.04 and -20.6, respectively. To determine if there was redundancy in the panel of 
microsatellites, the most discriminatory markers were defined by backward stepwise 
selection (performed by Dr Mauro Santibanez-Koref). Reducing the number of markers 
analysed would reduce assay costs (see Section 4.10) by increasing the number of samples 
that could be tested per sequencing run. In brief, the full panel of 24 markers was reduced 
by removing the least discriminatory marker at each step, until the classifier was no longer 
100% accurate. Loss of accuracy occurred from 6 to 5 markers. From this 5 marker panel, 
each of the 19 markers that had been removed in previous steps was added individually to 
see which 6 marker panel gave the best separation between MSI-high and MSS samples. The 
most discriminatory panel comprised: GM07, GM11, GM14, LR36, LR44, and LR52. Naturally, 
classification by the 6 marker panel also achieved 100% accuracy (Figure 4.8: right-hand 
panel). Equivalent accuracy from one quarter of the markers shows redundancy in the 
microsatellites analysed.  
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Figure 4.8: Self-classification of the training cohort. 98 CRCs with known MSI status were used to 
train an MSI classifier that analyses the relative frequency and allelic bias of deletions in a panel of 
short mononucleotide repeats (MNRs), according to the method described by Redford et al (2018). 
Classifier score (S) > 0 is MSI-high, and S < 0 is MSS. Self-classification of the training cohort achieved 
100% sensitivity and 100% specificity, relative to typing by the Promega MSI Analysis System (colour), 
using either 24 markers (left-hand panel) or 6 of the most discriminatory markers (right-hand panel). 
 
 
4.6. MSI Classification is Accurate and Reproducible 
To balance the reads from each smMIP, the mean number of reads detected for each marker 
in the training cohort was calculated relative to the overall mean read depth per marker per 
sample, and a new multiplex pool of 26 smMIPs was made with the concentration of each 
smMIP inversely proportional to the relative number of reads detected for that marker 
(Appendix I). Using this read-balanced smMIP multiplex, 50 MSI-high CRCs and 49 MSS CRCs 
were then amplified as an independent validation cohort, with the assistance of Christine 
Hayes, and sequenced to a mean read depth (±SD) of 7,320 ±4,192 reads/marker/sample 
with 57.2% of base-calls ≥Q30. Sequencing using the read-balanced smMIP multiplex had a 
much lower coefficient of variation in read depth between markers (35%) compared to the 
training cohort (68%). In the validation cohort, the MSI classifier again achieved 100% 
sensitivity (95% CIs: 92.9-100.0%) and 100% specificity (95% CIs: 92.8-100.0%) relative to 
typing by MSI Analysis System (Promega), using all 24 short MNRs (Figure 4.9: left-hand 
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panel). Furthermore, classification using the 6 most discriminatory short MNRs, as identified 
from the training cohort, was also 100% accurate (Figure 4.9: right-hand panel). 
To assess reproducibility of the assay and classifier, 16 MSI-high and 16 MSS CRCs 
from the validation cohort were amplified a second time using a freshly prepared, read-
balanced smMIP pool, again targeting the 24 short MNRs, and BRAF and KRAS mutation 
hotspots. These amplicons were sequenced to a mean read depth (±SD) of 5,408 ±2,160 
reads/marker/sample with 85.4% of base-calls ≥Q30. Classification was 100% concordant 
with previous results and classifier scores were strongly correlated between sample repeats 
(β = 0.97, p < 10-16, R2 = 0.97). 
 
 
 
Figure 4.9: MSI classifier validation. 99 CRCs, independent from the training cohort, with known MSI 
status were used to validate the MSI classifier. Classifier score (S) > 0 is MSI-high, and S < 0 is MSS.  
Classification of the validation cohort achieved 100% sensitivity and 100% specificity, relative to 
typing by the Promega MSI Analysis System (colour), using either 24 markers (left-hand panel) or 6 of 
the most discriminatory markers (right-hand panel).  
 
 
4.7. MSI Classification is Robust to Low MSI-high Content 
To assess the lower limit of detection (LLoD), defined here as the lowest proportion of MSI-
high DNA within total template DNA at which a sample is classified as MSI-high, a DNA-
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mixture series of 0.78-100% MSI-high DNA content (two-fold increments) was created in 
triplicate, by mixing HCT116 MSI-high DNA into control MSS DNA extracted from peripheral 
blood leukocytes (PBLs, Section 2.6). This triplicate series and control MSS DNAs were 
amplified using a read-balanced, 24 MNR smMIP pool. Amplicons were sequenced to a mean 
read depth (±SD) of 4,763 ±1,288 reads/marker/sample with 84.7% of base-calls ≥Q30. 
Increasing the MSI-high DNA content of the template DNA increased the proportion 
of reads containing insertion-deletion mutations in the microsatellite (Figure 4.10A). To 
confirm that the mixture series was accurate, I compared the observed proportion of reads 
containing variants in microsatellite length with the expected result. The expected 
proportion could be calculated by the following equation: propMUTreads|P𝑀𝑀𝑀𝑀𝑀𝑀 = propMUTreads𝑀𝑀𝑀𝑀𝑀𝑀 +  P𝑀𝑀𝑀𝑀𝑀𝑀*(propMUTreads𝑀𝑀𝑀𝑀𝑀𝑀 – propMUTreads𝑀𝑀𝑀𝑀𝑀𝑀) 
where P𝑀𝑀𝑀𝑀𝑀𝑀 is the proportion of MSI-high DNA content within the sample mixture, propMUTreads𝑀𝑀𝑀𝑀𝑀𝑀 is the proportion of mutant reads observed in sequencing pure MSS 
DNA, and propMUTreads𝑀𝑀𝑀𝑀𝑀𝑀 is the proportion of mutant reads observed in sequencing pure 
MSI-high DNA. The observed and the expected proportions were strongly correlated (β = 
1.009, p = 2x10-16, R2 = 0.996, Figure 4.10B), giving confidence in the accuracy of DNA mixing. 
MSI classification of the DNA-mixture series was accurate from 3.13% or more MSI-
high content in each replicate sample series (Figure 4.10C), approximating the LLoD to 3%. 
According to Jennings et al (2017), to specify a LLoD with confidence, 59 samples of the 
variant allele frequency (VAF) of interest (which, in this case, would be the MSI-high content 
of the sample DNA) should be tested. However, they recognise the difficulty in collecting 59 
independent samples of equal VAF and suggested artificial samples could be used. To 
simulate additional samples a method of randomly mixing reads from two samples was 
designed by Dr Santibanez-Koref, creating in silico samples. 27 simulated sample series, 
again ranging from 0.78% to 100% MSI-high content (two-fold increments), were generated 
using reads from pure MSI-high and pure MSS samples, with reads/marker equal to the 
reads/marker of the MSI-high sample, and each sample was scored. Simulated sample scores 
were closely associated with the corresponding score from the mixing of template DNAs 
(Figure 4.10C), suggesting that in silico read mixing is a valid method for simulating 
additional samples. To simulate a large number of independent samples to analyse the 
robustness of the MSI classifier to low MSI-high content, reads from 50 of the MSI-high and 
48 of the MSS CRCs from the validation cohort were mixed, generating 2400 simulated 
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sample series. These were scored and the proportion of samples classified as MSI-high 
calculated. Approximately 95% of simulated samples were correctly classified as MSI-high 
using 25% reads from an MSI-high CRC or more (Figure 4.10D). Due to the heterogeneous 
mixture of stromal and tumour cells in MSI-high CRCs, this cannot be used to estimate a 
LLoD, but supports the conclusion that the MSI classifier is robust to low MSI-high content. 
 
 
Figure 4.10: The robustness of the MSI classifier to low MSI-high content. (A) As the MSI-high 
content of a sample increases so does the frequency of reads containing variants in microsatellite 
length, which correlates closely with expected results (B). (C) Scoring of samples of varying MSI-high 
content by mixing reads or template DNA from MSI-high and MSS controls generates comparable 
results. By both methods, the assay lower limit of detection can be approximated to 3% MSI-high 
content. (D) Samples simulated from read mixing of MSI-high and MSS CRCs shows the MSI classifier 
is robust (95% of samples correctly classified as MSI-high) down to 25% MSI-high CRC read content.  
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To directly compare the assay LLoD with that of FLA, replicates ranging from 1.56-12.5% 
MSI-high DNA content were independently classified using the MSI Analysis System 
(Promega), with the observer blinded to both sample content and experimental purpose. 
FLA reliably detected 6.25% MSI-high DNA content (Table 4.5). 
 
MSI-high content (%) Diagnosis Unstable Markers Uncertain Markers 
 1.56  MSS  0/5  0/5 
 1.56  MSS  0/5  0/5 
 1.56  MSS  0/5  0/5 
 3.13  MSI-high  3/5  5/5 
 3.13  MSI-high  2/5  5/5 
 3.13  MSI-high  2/5  5/5 
 6.25  MSI-high  5/5  2/5 
 6.25  MSI-high  5/5  0/5 
 6.25  MSI-high  5/5  0/5 
 12.5  MSI-high  5/5  0/5 
 12.5  MSI-high  5/5  0/5 
 12.5  MSI-high  5/5  0/5 
 
Table 4.5: Microsatellite instability classification by fragment length analysis of DNA-mixtures of 
varying MSI-high DNA content. A series of samples with varying MSI-high DNA content tested by the 
smMIP-based MSI assay were also analysed using the MSI Analysis System (Promega). Fragment 
length analysis classified samples as MSI-high which contained ≥3.13% MSI-high DNA. However, the 
pathologist was uncertain of the status of all 5 markers. Therefore, confident classification as MSI-
high was only achieved in samples with ≥6.25% MSI-high DNA content. 
 
 
4.8. MSI Classification is Reliable from sequencing 75 Molecules per Marker 
To establish the lowest quantity of template DNA required for accurate smMIP-based 
classification, 2-fold dilution series of 9 DNA samples, comprising 3 cell lines (HCT116, K562 
and H9), 3 MMRd CRCs and 3 MMRp CRCs, were generated. CRC samples were selected 
based on availability of residual DNA. 0.78-100ng of each sample was amplified using a read-
balanced 24 MNR smMIP pool. Production of smMIP amplicons of the expected 240-270bp 
was visually inspected using 3% agarose gel electrophoresis. smMIP amplicons were deemed 
visible between 3.13-100ng of template DNA across all samples (Figure 4.11) and so these 
reactions were sequenced to a mean read depth (±SD) of 243,073 ±64,485 reads/sample 
with 82.8% of base-calls ≥Q30. I have quoted read depth in units of reads/sample rather 
than reads/marker/sample as the proportion of reads aligned to the marker loci was 
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correlated with the input quantity of template DNA, with an increase in aligned reads as 
input quantity increased (Figure 4.12A). Due to the low quantity of amplicons from some of 
these samples, a template negative was also sequenced. For the template negative sample 
127,756 total read pairs were detected, but only 152 reads (0.12%) were aligned to a 
marker, consistent with low frequency index mis-assignment observed on Illumina platforms 
(Illumina Inc., 2017). 
 
 
Figure 4.11: Visualisation of smMIP amplicons. Serial 2-fold dilutions of 9 samples were created, 
including 3 fresh sources (HCT116, H9, and K562) and 6 FFPE tissues (MMRd CRCs 207950, 244881 
and 246847, and MMRp CRCs 213428, 215770 and 231954). Equal input volumes of the dilution 
series, such that template DNA ranged from 0.78-100ng for each sample, were amplified using the 
smMIP-based MSI assay. Primer dimers are visible at approximately 80bp. 
 
112 
 
To test the accuracy of the dilution series, the number of template molecules 
sequenced, as measured by the number of molecular barcodes (MBs) detected, was 
compared to the input quantity of template DNA for the 9 samples. The number of 
molecules sequenced and input quantity were closely correlated in each of the 9 samples (β 
= 0.84-0.96, p < 10-3, R2 = 0.986-0.997, Figure 4.12B), giving confidence in the dilution series. 
The effect of decreasing the quantity of template DNA on the detection of variants in 
microsatellite length was roughly assessed by looking at the absolute change in the 
frequency of reads containing length variants in samples where 3.13-50ng of template DNA 
was used, with change measured relative to results from 100ng of template DNA (Figure 
4.12C). Notably the median, interquartile range, and total range of absolute change, all 
increased across the MSI-high samples as the quantity of template DNA decreased. 
However, no such effect was evident for the MSS samples and the absolute change in these 
samples remained small. As the MSI classifier uses the relative frequency of microsatellite 
deletions to classify samples, these observations suggested there would be increased error 
in classification when using low sample quantity, particularly for MSI-high samples. 
To assess the effect of low quantities of template DNA on classification, each sample 
was scored for each input quantity sequenced. I noted that two of the MMRd CRC samples 
derived from FFPE tissue (207950 and 244881), had consistently much lower numbers of 
MBs detected (equivalent to template molecules sequenced) compared to the other samples 
(Figure 4.12B), suggesting that these samples were of a lower quality. Therefore, sample 
scores were compared to the mean template molecules sequenced per marker, to assess the 
effect of both template quantity and quality. This showed that, in these 9 samples, a 
minimum of 75 MB/marker is sufficient for reliable classification (Figure 4.12D). In summary, 
recommended QCs should include a minimum input of 25ng of sample DNA and a minimum 
of 75 MB/marker. 
 
4.9. BRAF and KRAS Mutations are Reproducibly Detected 
Within the validation cohort, 46 of the 50 MSI-high CRCs had been independently tested for 
BRAF V600E using high resolution melt curve analysis (HRM; Nikiforov et al, 2009). All of the 
14 CRCs that tested positive for BRAF V600E by HRM had ≥5% variant alleles associated with 
BRAF V600E mutation. Of the 32 CRCs that tested negative for BRAF V600E by HRM, 30 
samples had BRAF V600E detected in ≤0.6% of reads and 2 samples had BRAF V600E 
detected in 1.67% and 1.72% of reads. The error rate of NGS platforms is estimated to be 1- 
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Figure 4.12: Sequencing results and classification of low quantity samples. (A)* Proportion of all 
sequencing reads aligning to markers at varying input quantities of template DNA of 9 samples. (B) 
Number of molecular barcodes (MBs) detected per sample at varying input quantities of template 
DNA of 9 samples. (C) The absolute change in microsatellite deletion frequency detected when 
varying input quantities of template DNA, as shown for MSI-high and MSS samples collectively. (D) 
MSI classifier scores from varying input quantities of template DNA of 9 samples, as measured by the 
mean number of MBs detected per marker. A 75 MBs minimum is shown by the vertical dotted line. 
*Note: 4 additional markers were included in this sequencing run, part of another piece of work not 
described in this thesis. The proportions of aligned reads shown are only for the 24 shortMNRs versus 
the total read output from the MiSeq, hence proportions are lower than the 0.75 used when 
calculating target read depth (Niedzicka et al, 2017; Table 4.1). 
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1.5% (Shendure and Ji, 2008), suggesting these 2 samples may contain true mutations at 
very low VAFs not detectable by HRM. 
Unfortunately, no samples were independently tested for KRAS mutations to 
determine the accuracy of KRAS genotyping by the smMIP-based assay. However, NGS is 
generally accepted to be as accurate as the long established technique of Sanger sequencing 
for variant detection (Beck et al, 2016). To compare our results to the literature, the 
frequencies of BRAF and KRAS mutations were analysed. Given the error rate of NGS 
platforms (Shendure and Ji, 2008), a ≥1.5% VAF threshold was used for mutation calling. The 
observed frequencies of BRAF and KRAS mutations was in line with the literature (Table 4.6), 
and the expected association between BRAF V600E and an MSI-high phenotype (Muzny et 
al, 2012) was observed (OR: 5.56, 95% CIs: 2.56-12.5, p < 10-5). Only one sample had both 
BRAF V600E and a KRAS G12 or G13 mutation, with VAFs of 1.67% for BRAF V600E and 
11.6% for KRAS G13D. I also observed an over representation of KRAS G13D in MSI-high 
tumours relative to other KRAS mutations (OR: 7.69, 95% CIs: 2.27-25.0, p < 10-3). 
When assessing the reproducibility of the MSI classifier, BRAF and KRAS mutation 
hotspots were also sequenced (Section 4.6). Using the same 1.5% VAF threshold for 
mutation calling, results from the repeat testing of these 32 CRCs had 100% concordance for 
both BRAF V600E and KRAS G12 and G13 variants. For the BRAF V600 locus, there was a 
strong correlation between VAF in the validation cohort and repeat testing (Figure 4.13A; β = 
0.93, p < 10-16, R2 = 0.99), and a similarly strong correlation was found for KRAS (Figure 
4.13B; β = 1.06, p < 10-16, R2 = 0.97), suggesting hotspot mutation detection is reproducible. 
 
Mutation 
Observed Literature 
MSI-high (n=99) MSS (n=98) MSI-high MSS 
BRAF V600E 36.4% (27.6-46.2%) 
9.2% 
(4.9-16.5%) 31% 7% 
KRAS G12, G13 variants* 21.2% (14.3-30.3%) 
38.8% 
(29.7-48.7%) 43%* 59%* 
 
Table 4.6: Frequency of BRAF and KRAS mutations in colorectal cancers (CRCs). CRC samples from 
training and validation cohorts were combined and the frequency of mutations determined, with 
95% confidence intervals. Frequencies observed in the literature are taken from Rajagopalan et al 
(2002). 
*Note: Rajagopalan et al (2002) analysed KRAS codons 59 and 61 in addition to codons 12 and 13. 
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Figure 4.13: Variant allele frequency compared between repeat testing of 32 CRCs… (A) at the BRAF 
V600 mutation hotspot, and (B) at the KRAS G12, G13 mutation hotspot. 1.5% thresholds used for 
mutation calling are shown by dotted lines. 
 
 
4.10. Assay Cost and Turnaround Time are Superior to Established Methods 
The cost and TAT of an assay are significant determinants of its aptness for high throughput 
diagnostics. The cost of reagents per sample for the smMIP-based MSI assay, including 
charges for use of the MiSeq instrument, and the TAT were calculated and compared to 
Promega MSI Analysis System v1.2 (Table 4.7). A full breakdown of reagent costs is available 
in Appendix J. This comparison shows the smMIP-based MSI assay is superior in cost to 
Promega MSI Analysis System v1.2, especially at the highest throughput using a panel of 10 
markers. With respect to TAT, the Promega MSI Analysis System v1.2 is faster per batch, but 
a reliance on marker by marker, sample by sample, results interpretation limits the number 
of samples per batch. Therefore, at scale the smMIP-based MSI assay is superior in TAT. 
Additionally, for Lynch syndrome screening, the smMIP-based MSI assay includes BRAF 
V600E testing for no additional cost or time, reducing the recommended two test screening 
pipeline (Newland et al, 2017) to one test, further improving its cost and TAT in relation to 
current methods. A potential disadvantage of the smMIP protocol is the multiple steps 
required. However, for each step the hands on time is brief and is fully automatable 
(Neveling et al, 2017). 
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  smMIP-based MSI assay MSI Analysis System v1.2, Promega 
Cost 25 markers 
  
£8.19-12.70/sample Tumour, normal 
 
£16.06/sample*  
 10 markers 
 
£5.94-7.75/sample 
 
Tumour only 
 
£8.03/sample* 
Batch 96+ samples 
 
24 samples 
 
TAT 4-5 days/batch 
 
2-3 days/batch 
 
 
Table 4.7: Summary of cost analysis and turnaround time (TAT). Costs for the smMIP-based MSI 
assay assumes a read depth of 2000 reads/marker/sample, and the range covers sequencing on a 
MiSeq v2 Micro, v2, or v3 kit (Appendix J). 25 markers includes 24 short MNRs and the BRAF V600 
mutation hotspot. *Costs for MSI Analysis System v1.2 are calculated from Promega list price for 
product MD1641, which includes 100 reactions, and does not include costs of capillary 
electrophoresis. TAT for both assays includes DNA extraction and sample preparation, through to 
result. Details of batch size and TAT for the MSI Analysis System v1.2 were provided by the Northern 
Genetics Service, Newcastle Hospitals NHS Foundation Trust. 
 
 
4.11. Discussion 
I aimed to continue the development of a sequencing-based MSI assay applicable to high 
throughput cancer diagnostics, as a screening tool for Lynch syndrome and to inform use 
immunotherapy. To do so, smMIP technology was used to multiplex and expand the marker 
panel of a singleplex, 17 marker, MSI assay previously developed by our research group 
(Redford et al, 2018). Only one marker, IM66, failed to be amplified using singleplex smMIPs, 
despite multiple designs, suggesting that MIPgen (Boyle et al, 2014a) is a reliable tool for 
creating MIP-based assays. Furthermore, MIPs are known to be robust to multiplexing 
(O’Roak et al, 2012), and in this project I found that pooling several smMIPs and adjusting 
their concentrations (to balance reads from each marker) was simple and effective. The 
marker panel was also expanded to include an additional 9 short MNRs, and BRAF and KRAS 
mutation hotspots relevant to CRC diagnostics. The modularity of a smMIP-based diagnostic 
assay is appealing for the ease with which it could be adapted to other cancer types, for 
example by inclusion or exclusion of clinically actionable biomarkers as appropriate. The 
success of the use of smMIPs is evident in the cost reduction and TAT of the assay, whilst 
maintaining high sensitivity and specificity. Previously, the singleplex assay was estimated to 
cost £26.20/sample, with a TAT of 11 days (Alhilal PhD Thesis, 2016), whereas the assay now 
costs £5.94-12.70/sample with a TAT of 4-5days for batches of 96 or more samples. 
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The smMIP-based MSI assay uses monomorphic and short (7-12bp) MNRs that have 
significantly lower PCR and sequencing error rates compared to longer markers (Fazekas et 
al, 2010). This low error rate allowed thresholds in the frequency of microsatellite deletions 
to be defined and used for MSI classification. Each marker is also associated with a SNP of 
minor allele frequency >20%, allowing the allelic bias of deletions to be assessed, giving 
further discriminatory power. An algorithm using these thresholds and the  relative 
frequency and allelic bias of deletions in the 24 microsatellite markers, has been trained to 
calculate the relative probability that a sample belonged to an MSI-high or MSS phenotype, 
summarising the result in one score (Redford et al, 2018). Scoring is an automated process 
and hence the assay does not require expert, case-by-case, marker-by-marker result 
interpretation. The monomorphism of the markers also removes the need for matched 
normal DNA. When applied to both training and validation cohorts, the assay classified 197 
CRCs with 100% sensitivity and 100% specificity, relative to FLA using the Promega MSI 
Analysis System. Classifier performance was therefore found to be equivalent using either 
the singleplex MSI assay or smMIP-based MSI assay. The 197 samples used were all DNA 
from FFPE tissues derived from pathology services, representing the spectrum of samples 
the assay is designed for, and in excess of the minimum 59 independent samples 
recommended for analytical validation of NGS-based assays (Jennings et al, 2017). 
The smMIP-based MSI assay fulfils other requirements of an ideal diagnostic test. For 
example, Jennings et al (2017) suggest repeat testing of three samples using new batches of 
all reagents to show that the assay is reproducible. Here, I used a freshly prepared smMIP 
multiplex pool, new reagents and a distinct sequencing run, and showed 100% classification 
concordance in repeat testing of 32 CRC samples. The linear correlation between original 
and repeat scores was very strong, with low variation (linear regression R2 = 0.97). Despite 
the reproducibility of the assay in my hands, ideally it should also be run by an independent 
operator in a different laboratory to confirm this. 
Diagnostic tests must also be robust to sample variables. The most critical variables 
with respect to tumour samples are tumour cell content, and the quantity and quality of 
DNA. For the smMIP-based MSI assay, I simulated variation in the MMRd cell content of a 
sample by mixing different quantities of MSI-high DNA, from MMRd CRC cell line HCT116, 
and MSS DNA, from MMRp PBLs. The assay correctly classified the samples generated down 
to 3.13% MSI-high content, suggesting a LLoD of approximately 3%. This was superior to FLA 
by the MSI Analysis System, which correctly classified the same DNA mixtures at ≥6.25% 
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MSI-high content. At 3.13%, classification by FLA was uncertain in every marker. Jennings et 
al (2017) recommend testing 59, independent sample containing the VAF of interest to 
reliably define the LLoD, but recognise this is not feasible and that artificial substitutes may 
be used. In this study, with the help of Dr Santibanez-Koref, I opted for an in silico method of 
sequencing-read mixing, which was shown to give comparable results to DNA mixing in 27 
simulated series. To further test the robustness to MSI-high content, read mixture series 
were created between the MSI-high and MSS CRCs from the validation cohort, generating 
2400 simulated series. 95% of these simulated samples were classified as MSI-high when 
only 25% of reads originated from an MSI-high CRC. Given that the MSI-high CRCs will not 
consist of purely MMR tumour cells and are therefore already diluted, this 25% actually 
represents a much lower MSI-high content, potentially as low as 1.25% in some samples 
assuming a minimum of 5% tumour cell content in these samples. Whilst this in silico 
method of mixing reads from MSI-high CRCs and MSS CRCs cannot help define a LLoD due to 
the “impurity” of the MSI-high CRC read samples, it supports that the smMIP-based MSI 
assay is robust to low MSI-high content. 
The CRC DNA samples used were extracted from FFPE tissues, meaning they would 
have a poorer quality than the control DNAs extracted from fresh cell lines. However, the 
assay amplified these FFPE-derived DNAs and MSI classification was 100% accurate. smMIPs 
incorporate MBs into reads allowing the number of sample DNA molecules sequenced to be 
quantified. As discussed by Jennings et al (2017), the number of template molecules 
sequenced, or library complexity, is a critical QC metric for any NGS-based diagnostic test. By 
diluting 9 samples, including low quality FFPE-derived DNAS and cell line controls, I showed 
that classification was reliable when more than a mean 75 MB/marker was detected. 
Additional sequencing metrics that should be accounted for by a diagnostic assay 
include read depth and the percentage of base-calls above or equal to a quality score of Q30 
(Jennings et al, 2017). Target read depths were calculated to be >5000reads/marker/sample, 
which was not achieved in all runs. Notably, the training cohort read depth was only 
3,719reads/marker/sample as the capacity of the MiSeq flow cell was not used. Early 
experiments used MiSeq v2 kits and defined 8pM as the optimal DNA library loading 
concentration. However, due to the number of samples and need for a higher capacity kit, 
v3 kits were used for subsequent experiments, including sequencing of the training cohort. 
The lower read depth of the training cohort may be due to the loading of an 8pM library on a 
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MiSeq v3 flow cell – subsequently 12pM libraries were loaded for v3 kits, which gave 
expected read depths, and an 8pM loading concentration continued to be used for v2 kits. 
Another consequence of reduced quantity of template DNA was reduced read depth, 
as fewer reads aligned to marker loci. Whilst the reason for this has not been confirmed, I 
speculate that non-specific amplicons and primer dimers carried through purification 
constitute a greater proportion of reaction product as template DNA decreases (see Figure 
4.11). This is supported by the 127,756 sequencing reads generated from a template 
negative reaction, of which only 52 reads (0.12%) were aligned to markers. Those few reads 
that were aligned to a marker are possibly due to sample index mis-assignment (Illumina 
Inc., 2017). The consequence of this observation is that target read depth calculations should 
consider the quantity of template DNA being used in reactions. For example, the 0.75 
adjustment factor for off-target reads should be decreased if using less than 100ng of 
sample. An alternative is to optimise purification to remove non-specific products, in 
particular primer dimers. However, this was not pursued during this work due to time 
constraints. 
For the majority of sequencing runs, more than 75% of base-calls were ≥Q30, which 
is within the expected range of Illumina sequencing platforms. However, the validation 
cohort sequencing run only had 57.2% of base-calls ≥Q30, but classification was 100% 
accurate. Therefore, whilst it is desirable for sequencing to have >75% of base-calls ≥Q30, it 
appears that the smMIP-based MSI assay and classifier can tolerate lower. To formally test 
this would require excessive investment due to the cost of each sequencing run. 
It is recommended that BRAF V600E or MLH1 promoter methylation testing are 
carried out following MMR deficiency testing in all MMRd CRCs to improve screening 
specificity by identification and exclusion of sporadic cases. The inclusion of BRAF V600E 
testing in the smMIP-based MSI assay streamlines the LS screening pipeline, requiring only 
one tumour test prior to germline testing of MMR genes, equivalent to tumour-sequencing 
(Hampel et al, 2018). The assay was able to detect low VAF in BRAF down to 1.7%, with 
improved sensitivity compared to HRM analysis, which has an estimated LLoD of 10% 
(Nikiforov et al, 2009). The alternative test for MLH1 promoter methylation has a higher 
specificity than BRAF V600E when screening for Lynch syndrome (Pérez-Carbonell et al, 
2010). However, testing both markers is redundant due to their association (Pérez-Carbonell 
et al, 2010). Arguably, BRAF V600E is also the superior marker as MLH1 methylation occurs 
as a second hit in the CRCs of approximately 55% of MLH1 mutation carriers (Young et al, 
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2001; Kaz et al, 2007), and therefore MLH1 methylation testing has a lower sensitivity for 
Lynch syndrome screening than BRAF V600E testing (sensitivity 84.2% versus 100%, 
respectively) (Moreira et al, 2015). In addition, germline epimutations in MLH1 cause Lynch 
syndrome, and these too would be excluded by MLH1 methylation testing (Suter et al, 
2004). This lower sensitivity of MLH1 methylation testing of Lynch syndrome screening was 
also observed by Hampel et al (2018), relative to tumour-sequencing that analysed BRAF 
V600 only. 
One smMIP targeting KRAS G12 and G13 mutation hotspots was also included in the 
assay multiplex, as a proof of principle that the assay can be expanded to other, clinically 
actionable, biomarkers beyond MSI and BRAF V600. Using a ≥1.5% mutant read threshold, 
the frequencies of BRAF and KRAS mutations detected were similar to frequencies previously 
observed (Rajagopalan et al, 2002). However, the 95% CIs quoted show that significantly 
fewer KRAS mutations were detected in both MSI-high and MSS CRCs. This can be explained 
by the slightly higher frequency of BRAF mutations, which are considered mutually exclusive 
with KRAS mutation (De Roock et al, 2010a), and the inclusion of mutations in KRAS codons 
59 and 61 in the reference study (Rajagopalan et al, 2002). Therefore, for our smMIP-based 
assay to comprehensively cover RAS gene mutations, additional smMIPs would be needed. 
The smMIP-based assay detected only one sample with both BRAF and KRAS mutations, 
which could be an extremely rare, sub-clonal co-occurrence (Sahin et al, 2013), or perhaps 
sequencing error as the BRAF VAF in this sample was only 1.67% given estimates of 
sequencing error of 1.0-1.5% on NGS platforms (Shendure and Ji, 2008). A significant 
predominance of KRAS G13D mutations was found in the MSI-high versus MSS CRCs, 
consistent with the findings of others (Oliveira et al, 2004; Phipps et al, 2013). Whilst 
selection pressures between the different functions of G12 and G13 mutations may be the 
cause of this (De Roock et al, 2010b), it is interesting that the specific C>T substitution 
responsible for the G13D mutation is prevalent in mutational signature 6 (the pattern of 
random mutations throughout a tumour genome), which is associated with MMRd CRCs 
(Alexandrov et al, 2013). This suggests that loss of MMR may influence the specific driver 
mutations that are acquired during tumorigenesis (Ahadova et al, 2018). 
The cost of a diagnostic assay is a significant factor in its clinical uptake. Tumour-
sequencing for example, has an estimated cost of 607±207€ per sample (Marino et al, 2018), 
which may inhibit its uptake. Whilst the cost estimates of Marino et al (2018) include 
overheads, personnel costs, etc, the reagent and consumables costs for target enrichment 
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and sequencing were estimated to be 291€ per sample, significantly more than a targeted 
assay such as our smMIP-based MSI assay. Indeed, we found that our assay has an 
equivalent reagent cost to FLA when using 24 microsatellite plus BRAF markers, ranging from 
£8.19-£12.70 depending on the capacity of the MiSeq kit used. However, 6 microsatellites 
were sufficient for accurate MSI classification so these costs can be reduced by decreasing 
the number of markers to increase the number of samples per sequencing run. Furthermore, 
amplicons were purified per sample in the protocol of this study, but it is feasible to pool 
amplicons prior to purification, saving additional cost and time. The smMIP protocol is also 
fully automatable (Neveling et al, 2017), which would again reduce cost and handling. 
Finally, BRAF V600E detection is included within the assay, avoiding expenditure on 
additional tests for Lynch syndrome screening. The modularity of smMIPs means it would be 
trivial to incorporate other clinically actionable markers for negligible extra cost. These 
advantages make the described MSI assay particularly suited to high throughput diagnostics, 
for example in large testing laboratories where hundreds to several thousand CRCs may be 
assessed each year, but does not preclude use of IHC or FLA in smaller scale laboratories 
given the long established efficacy of these methods. However, given the clinical guidelines 
for MMR deficiency testing of CRCs (Newland et al, 2017), and the strong likelihood that 
these will be expanded to other cancer types due to the pan-cancer efficacy of immune 
checkpoint blockade therapy (Le et al, 2017), it is likely that clinical service will become more 
reliant on centralised diagnostic services to meet demand. 
 
4.12. Conclusions and Future Work 
The smMIP-based MSI assay developed here, which has built upon the work of Redford et al 
(2018), is highly sensitive and specific for MSI status in CRCs, simultaneously detects BRAF 
V600E, is reproducible, and is robust to sample variables given the specified QCs (Table 4.8). 
The automation of laboratory workflow and results interpretation removes the need for 
expert personnel and provides a cheap, scalable assay. Combined, these factors suggest that 
a high throughput smMIP-based MSI assay is a suitable companion diagnostic for immune 
checkpoint blockade therapy and is applicable to two-step Lynch syndrome screening 
strategies. 
From here, our research group intends to commercialise the assay, which may 
require further protocol optimisation, most notably removing redundant markers from the 
panel and selection of an optimal set to further reduce cost. We will also deploy the assay 
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into the Northern Genetics Service, who have been our collaborators throughout this study, 
for clinical validation (whereby the assay will be ran in parallel with standard diagnostic 
procedures on clinical samples in real time) and formal testing of assay reproducibility. 
Finally, we have been working with a commercial partner, NimaGen, to transfer the assay 
into pre-aliquoted plates, to further reduce sample and reagent handling. NimaGen currently 
market smMIP assays for BRCA gene sequencing (Neveling et al, 2017).  
 Having developed the MSI assay for CRC diagnostics, it was of interest to explore its 
application to the detection of low-level MSI in normal tissues as a biomarker of CMMRD. 
 
 
Variable or Parameter Quality Control Critera 
DNA sample tumour cell content 
 
≥3% 
 input quantity 
 
≥25ng 
Sequencing base-call quality 
 
75% ≥Q30 
 molecules sequenced ≥75 MB/marker 
 
 
Table 4.8: Quality controls for the smMIP-based MSI assay for reliable classification. 
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Chapter 5. Accurate Detection of Constitutional Mismatch Repair Deficiency 
by a Sequencing-based Microsatellite Instability Assay 
 
5.1. Introduction 
CMMRD is a highly penetrant cancer-predisposition syndrome that manifests in childhood to 
early adolescence, caused by germline mutation in both alleles of an MMR gene (Wimmer et 
al, 2017). Guidelines for the management of this condition recommend surveillance and 
altered treatment (Vasen et al, 2014). Identification of CMMRD uses clinical features, such as 
diagnosis of malignancy, family history and non-neoplastic features, according to published 
guidelines (Wimmer et al, 2014). However, many of the clinical features of CMMRD overlap 
with other syndromes, and hence genetic diagnosis by germline sequencing of MMR genes is 
required (Wimmer et al, 2014). Genetic diagnosis can be confounded by variants of 
unknown significance (VUS) in MMR genes and the multiple pseudogenes of PMS2 (De Vos 
et al, 2004), which accounts for approximately 60% of CMMRD (Wimmer et al, 2017). 
Low-level MSI occurs in the non-neoplastic tissues of CMMRD patients and is 
detectable by highly sensitive MSI assays (Ingham et al, 2013; Bodo et al, 2015). Such 
diagnostic tests can be used to clarify uncertain genetic diagnoses. However, current assays 
are limited by insensitivity for biallelic, germline mutation of MSH6 by analysis of DNRs 
(Ingham et al, 2013), or require laborious and expensive methodology (Bodo et al, 2015), 
which restrict clinical utility. In chapter 4, I presented a smMIP and sequencing-based MSI 
assay, applicable to high throughput cancer diagnostics. The smMIPs utilise molecular 
barcodes to count the number of template DNA molecules sequenced as an assay QC, based 
on the assumption that each molecular barcode corresponds to a single template molecule 
of DNA. However, an alternative use of molecular barcodes is to group reads that share the 
same barcode to summarise the sequence content of the majority of reads within the group 
in a single molecule sequence (smSequence), representing the sequence of the original 
template molecule. Analysing smSequences rather than all reads equalises representation of 
template DNA molecules and reduces PCR and sequencing errors, which will only be present 
in the minority of reads within a molecular barcode group. By reducing noise, smSequences 
therefore facilitate detection of low frequency variants (Casbon et al, 2011). Hence, whilst 
use of smSequences was not necessary to assess MSI in CRCs, it was of interest to see if our 
assay would be sensitive to the low-level MSI in non-neoplastic tissues of CMMRD patients 
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by adoption of an alternative, smSequence-based analysis of microsatellite length. The 
analysis of MNRs suggested it would also be sensitive for constitutional MSH6 deficiency 
(Bodo et al, 2015). 
As well as being suitable for routine confirmation of genetic diagnosis in suspected 
CMMRD patients, the simplicity and low cost of the smMIP and sequencing-based MSI assay 
would make it ideal for screening larger cohorts of patients. For example, there are currently 
no estimates of the frequency of CMMRD in paediatric haematological malignancy. Whilst it 
is recognised that germline genetic testing for causative mutations is required in this 
population, diagnosis is challenging due to the number of genes to screen and frequent lack 
of family history or other distinguishing clinical features (Furutani and Shimamura, 2017). A 
CMMRD screening tool to streamline these diagnostic pathways could be an invaluable 
addition to the clinical management of haematological malignancies, and similarly for other 
childhood malignancies. Furthermore, the full phenotypic spectrum and prevalence of 
CMMRD are not known (Durno et al, 2017); cheap diagnostic assays would facilitate research 
efforts to identify CMMRD in populations with related conditions. 
 
5.2. Aims 
To apply the smMIP and sequencing-based MSI assay, developed in Chapter 4, to CMMRD 
diagnostics, I aimed to: 
1. Assess the use of molecular barcodes to reduce PCR and sequencing error in the 24 
short MNRs analysed by our MSI assay. 
2. Develop an automatable method to detect low frequency variants in microsatellite 
length, and determine the ability of the assay to detect CMMRD. 
 
5.3. Study Samples and Method 
To address the study aims, the study was split into two parts; here I will summarise the 
division of samples for clarity. 
A pilot cohort of 40 control, germline DNA samples extracted from the PBLs of 
anonymised patients, and 5 CMMRD, germline DNA samples extracted from PBLs of 
genetically confirmed CMMRD patients, was sequenced using the smMIP-based MSI assay 
across three sequencing runs, to exclude batch effects. The 40 pilot control samples were 
used to determine the reduction in PCR and sequencing error by use of molecular barcodes. 
The pilot CMMRD samples were then analysed to see if they could be distinguished from the 
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controls. A blinded cohort of 31 CMMRD and 54 control samples was analysed across three 
more sequencing runs. The spread of these samples across multiple runs was due to the 
incremental collection of samples for analysis, as explained in Section 5.6. All CMMRD 
patient samples, from pilot and blinded cohorts, are summarised in Appendix B. 
 
5.4. Single Molecule Reads reduce Error in Microsatellite Length Variant Detection 
A pilot cohort of 5 CMMRD samples and 40 anonymised control DNAs extracted from 
peripheral blood leukocytes (PBLs) were amplified and sequenced across three sequencing 
runs, using the same smMIP-based method developed in Chapter 4 and described in Section 
2.9, to a mean (±SD) read depth of 2,735 ±1,120 reads/marker/sample, with a mean 83.4% 
of base calls of quality >Q30. The reads were processed according to Section 2.12.1, utilising 
molecular barcodes. The frequency distribution of molecular barcode groups, according to 
the number of reads they contain, showed that the vast majority of reads share a molecular 
barcode with at least one other read and therefore, whilst groups containing only one read 
are the most frequent, the majority of molecular barcode groups contain ≥2 reads. The 
assignment of multiple reads to the majority of barcode groups showed that error correction 
by use of smSequences would be testable. As an illustrative example, a distribution is shown 
for marker GM07 in one of the control samples (Sample ID: 40) (Figure 5.1). 
 
Figure 5.1: The frequency distribution of molecular barcode groups by the number of reads within 
each group. Sequencing reads from microsatellite marker GM07 in a control sample (Sample ID: 40) 
were grouped according to molecular barcode. Each group was classed by the number of reads 
within it, and the frequency of groups containing different numbers of reads was determined. 
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There are two considerations to define criteria for smSequence generation. First, a 
minimum of two reads per group are needed to allow correction of PCR and sequencing 
errors as correction relies on comparison of sequences between reads (Figure 5.2). 
Increasing the minimum number of reads required per group could lead to large numbers of 
reads being discarded, potentially counteracting any benefit from error correction. Second, 
length variants can originate from true mutations, or PCR and sequencing errors. By 
grouping reads by molecular barcode, erroneous microsatellite lengths that do not represent 
the original template molecule can be identified as they will only occur in the minority of 
reads in a group. Where there is only one read in a group or different lengths are equally 
represented, PCR and sequencing errors cannot be identified. Therefore, the length of the 
microsatellite in the smSequence must be found in the majority of reads in the group to be 
confident that it is the true length in the original, template DNA molecule (Figure 5.2). 
 
 
Figure 5.2: Definition of single molecule sequences (smSequences). There are three steps to define  
smSequences. One, reads are generated with molecular barcodes (MB, unique sequences identified 
by colour). Two, reads are grouped by molecular barcode, assuming that all reads in a group 
represent the same template DNA molecule. Three, molecular barcode groups are discarded if one 
length of microsatellite cannot be found in the majority of reads within the group, and where there is 
only one read in the group. 
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I aimed to use smSequences to reduce the noise in detection of variants in 
microsatellite length so that low frequency, true variants would be detectable. Based on the 
assumption that template DNA from MMRp PBLs should not be affected by MSI, variants in 
microsatellite length from control samples were classed as errors of PCR or sequencing. To 
determine whether or not use of smSequences was able to reduce error rate, the relative 
frequency of variants in microsatellite length in the 40 controls was, therefore, used as a 
quantitative measure of assay error rate in each marker. Again using marker GM07 in one of 
the control samples (Sample ID: 40) as an illustrative example, the relative frequency of 
variants detected reduces from 7.07% (98/1387) for all reads to 0.87% (2/230) for 
smSequences, which is equivalent to an 8-fold reduction in error rate (Figure 5.3A). 
However, by modelling read counts as a binomial distribution, changes in the relative 
frequency of variants may be a result of reduced count number; statistical analysis was 
needed to confirm that any change in error rate was significant. Two-by-two tables were 
constructed that included the counts containing WT or variant microsatellite lengths for all 
reads and for smSequences (Figure 5.3B), and Fisher’s exact test was used to compare count 
distribution. In the example, the reduction in error rate is significant (p < 0.05). 
 
Figure 5.3: Count of reads with different microsatellite lengths, using either all reads irrespective of 
molecular barcode, or single molecule sequences (smSequences). Sequencing reads from 
microsatellite marker GM07 in an anonymised control sample (Sample ID: 40) were counted, using 
either reads irrespective of molecular barcode, or reads grouped by molecular barcode and 
summarised in one smSequence. Counts include wild type (WT) and variant microsatellite length, and 
are shown as (A) a graph or as (B) a two-by-two contingency table suitable for Fisher’s exact test. 
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The results of error rate analysis in all 24 microsatellites in the 40 control samples are 
shown in Figure 5.4. To prevent germline variants from affecting analyses, observations 
where variants in microsatellite length had a relative frequency > 0.4 (indicating the sample 
is heterozygous or homozygous for a novel length of microsatellite) were excluded from 
further analyses. Across the 960 observations (24 microsatellite markers in 40 controls) only 
6 germline variants were detected and excluded. Using all reads, it was evident that different 
markers had different, base error rates (Figure 5.4, top panel). To quantify the change in 
error rate when smSequences were used rather than all reads, I used the equation: 
𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓. 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  𝑎𝑎𝑒𝑒𝑒𝑒𝑓𝑓𝑒𝑒 𝑒𝑒𝑎𝑎𝑟𝑟𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑎𝑎𝑒𝑒𝑒𝑒𝑓𝑓𝑒𝑒 𝑒𝑒𝑎𝑎𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑟𝑟𝑠𝑠𝑎𝑎𝑟𝑟𝑠𝑠  
Fold-change above 1 means smSequences have increased error rate of microsatellite length 
detection, and fold-change below 1 means smSequences have decreased error rate of 
microsatellite length detection, relative to analysis of all reads irrespective of molecular 
barcode. All markers show a reduction in error rate in all samples when smSequences are 
used except for GM09 in four samples, with the vast majority showing a two-fold or greater 
reduction in error (fold-change in error rate < 0.5) (Figure 5.4, middle panel). The four 
samples that showed an increase in error rate for GM09 had very low counts of 
smSequences (15-25) detected at GM09, despite counts of smSequences for other markers 
(166-596) and read depth in GM09 (1999-3010) equivalent to other samples. Indeed very 
low counts of smSequences in GM09 were observed for several other samples, but it was 
uncertain what the cause of this was (see Section 5.8), so I chose to keep GM09 in the 
marker panel. In some observations, use of smSequences removed all error in microsatellite 
length detection such that all smSequences contained a wild type (WT) microsatellite length, 
giving an infinite-fold reduction in error (fold-change in error rate = 0) (Figure 5.4, middle 
panel); this was more frequent in less error prone markers where the base error rate from 
all reads was already very low (Figure 5.4, compare middle and top panels). Excluding those 
samples where fold-change = 0, the magnitude of fold-change is correlated with the base 
error rate of the marker (rs = -0.29, p < 10-10), showing that smSequences facilitate a greater 
reduction of error in more error-prone markers. For 15/24 markers, this fold-change was 
significant (p < 0.05) in the majority of the control samples analysed (Figure 5.4, bottom 
panel). In summary, using smSequences significantly reduced the error in detection of 
variants in microsatellite length, and for some markers the majority of samples contained no 
false variants in smSequences. smSequences would, therefore, improve detection of true,  
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Figure 5.4: Using single molecule sequences (smSequences) reduces the error in detection of 
variants in microsatellite length. Top panel: microsatellites are listed from left to right in order of 
increasing error rate, as measured by the relative frequency of microsatellite length variants from all 
reads, averaged (mean) across the 40 control samples analysed (Sample IDs: 1-40). Middle panel: 
when smSequences were analysed compared to when all reads were analysed irrespective of 
molecular barcode, the change in error rate was determined (fold-change <1 represents a reduction 
in error rate). Bottom panel: the proportion of fold-changes in error rate that are statistically 
significant was determined for each marker using Fisher’s exact test.  
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low frequency variants and it was decided that smSequences should be used in the analysis 
of CMMRD samples. In addition, 6 germline variants were detected among the 40 samples. 
Hence, any automated method of CMMRD classification using the smMIP and sequencing-
based MSI assay would need to identify and exclude rare germline variants so that they 
cannot influence result interpretation. 
 
5.5. CMMRD Samples are identifiable by Deviation in Microsatellite Lengths from Controls 
As a preliminary assessment of whether or not the assay could detect low frequency variants 
in microsatellite length associated with CMMRD,  5 CMMRD samples (Sample ID: A-E) had 
been included in the pilot cohort. These included samples from two patients with 
homozygous PMS2 mutation, one patient with homozygous MSH6 mutation, one patient 
with compound heterozygous MSH6 mutation, and one patient with compound 
heterozygous MLH1 mutation. Again, sequencing of the pilot cohort was spread across three 
different runs to prevent batch effects from obscuring analyses. Read data was summarised 
as the relative frequency of smSequences that contained a wild type length of microsatellite 
(prWT). I hypothesised that there would be a decrease in prWT in the 24 markers in CMMRD 
samples due to presence of low frequency variants in microsatellite length. Indeed, prWT 
was significantly lower in 22/24 markers (p < 0.05) from the 5 CMMRD patients. 
Having observed this difference in prWT in the majority of markers, I aimed to 
develop a simple method of sample classification based on the prWT. When analysing CRCs, 
the distribution of microsatellite deletion frequency was modelled in both MSI-high and MSS 
cancers to define marker specific thresholds, therefore allowing the MSI classifier to 
determine the relative probability a sample was either MSI-high or MSS (Chapter 4). Due to 
the rarity of CMMRD, with approximately 200 known cases globally (Wimmer et al, 2017), 
using such a classifier is not feasible as samples are not readily available to model 
distributions in CMMRD or validate thresholds. Therefore, for CMMRD classification a 
scoring method was devised that would quantify deviation of a sample from a control 
distribution. For each marker, the Beta distribution was used to model the prWT in a control, 
non-CMMRD population using the smSequences from the 40 control samples (Figure 5.5; 
Appendix K), with exclusion of germline length variants (prWT < 0.6). Using these 
distributions, the probability of an observed prWT being smaller than expected of a control 
population was determined, and for each sample a single score (Table 5.1) was calculated by  
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Figure 5.5: Modelling the distribution of the proportion of smSequences containing wild type (WT) 
length of microsatellite (prWT). The prWT was determined in each marker across 40 control samples 
(Sample IDs: 1-40), and for each marker the prWT were modelled by a Beta distribution, excluding 
samples with germline length variants (prWT < 0.6). A comparison of Beta (black line) and empirical 
(red line) distributions is shown for 9 markers. Graphs for all markers are shown in Appendix K. 
 
 
combining the probabilities from the 24 markers, again excluding germline variants (prWT < 
0.6), using Fisher’s method and the following equation: 
𝑠𝑠𝑐𝑐𝑓𝑓𝑒𝑒𝑎𝑎 =  − log10(𝑐𝑐𝑓𝑓𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑎𝑎𝑓𝑓 𝑝𝑝𝑒𝑒𝑓𝑓𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑓𝑓𝑐𝑐𝑟𝑟𝑝𝑝) 
The 40 control sample scores ranged from 0.00 to 1.47 and the 5 CMMRD sample scores 
ranged from 10.02 to 27.34, showing that these CMMRD samples have a minimal probability 
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of belonging to a control, non-CMMRD population based on the observed prWT in the 24 
microsatellite markers. 
 
 
 Sample ID: 16 (control) Sample ID: C (CMMRD) 
Marker prWT probability prWT probability 
DEPDC2 1.000 1.000 0.994 0.055 
GM01 0.997 0.155 0.997 0.168 
GM07 0.992 0.711 0.936 0.000 
GM09 0.996 0.205 0.999 0.259 
GM11 0.997 0.166 0.997 0.143 
GM14 1.000 1.000 0.966 0.001 
GM17 1.000 1.000 0.997 0.160 
GM22 0.997 0.044 0.998 0.122 
GM26 1.000 1.000 0.989 0.000 
GM29 1.000 1.000 0.991 0.025 
IM16 0.997 0.286 0.989 0.014 
IM49 0.986 0.182 0.973 0.008 
LR10 0.996 0.276 0.981 0.002 
LR11 0.996 0.302 0.987 0.015 
LR17 0.995 0.458 0.966 0.000 
LR20 1.000 1.000 0.997 0.027 
LR24 0.529 NA 0.996 0.030 
LR36 1.000 1.000 0.989 0.036 
LR40 0.997 0.189 0.990 0.003 
LR44 0.989 0.590 0.951 0.001 
LR46 0.996 0.048 0.995 0.030 
LR48 0.989 0.100 0.977 0.007 
LR49 1.000 1.000 1.000 1.000 
LR52 0.962 0.086 0.897 0.000 
 
combined p: 0.32  
score: 0.49 
combined p: 4.57 x10-28 
score: 27.34 
 
Table 5.1: Conversion of observed proportion of smSequences containing a wild type microsatellite 
length (prWT) to a probability and per sample score. Using the Beta distribution of prWT for each 
marker in 40 controls (Sample IDs: 1-40), observed prWT can be converted to a probability. This 
probability therefore represents the probability that an observation is less than would be expected in 
a control, non-CMMRD population. Observed prWT and the associated probabilities are shown for 
one control and one CMMRD sample (Sample IDs: 16 and C, respectively). Note the presence of a 
germline length variant in sample 16, marker LR24; such germline length variants were excluded 
from scoring. Probabilities were combined by Fisher’s method and sample score is equal to –
log10(combined probability); the higher the score the greater the deviation of the sample from a 
control, non-CMMRD population. 
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5.6. CMMRD Samples are Identifiable with High Accuracy 
A blinded cohort of 56 samples was amplified and sequenced using the smMIP-based MSI 
assay to a mean (±SD) read depth of 4,539 ±1,320 reads/marker/sample, with a mean 84.5% 
of base calls of quality >Q30. The blinded cohort included 16 samples from 15 genetically 
confirmed CMMRD patients, covering biallelic mutation of each of the four MMR genes 
implicated in CMMRD, and 40 control samples. All samples were independent from those 
analysed in the pilot cohort. Each sample was scored according to its observed prWT from 
the 24 markers and using the method described in Section 5.5. Again, all samples, clinical 
details and scores are summarised in Appendix B. 
The 16 CMMRD samples scored from 1.59 to 53.72, and the 40 control samples 
scored from 0.00 to 1.08. This establishes that the method can fully separate CMMRD 
samples from the controls with high accuracy. One CMMRD sample (Patient ID: 8, Sample ID: 
99, score = 1.59) scored low relative to the other CMMRD samples (scores = 5.71-53.72) and 
much lower than an affected sibling (Patient ID: 9, Sample ID: 82, score = 19.09) who shares 
the same compound heterozygous mutation of MSH6. This score of 1.59 is equivalent to a 
2.6% probability the sample comes from a control population, and therefore raised suspicion 
that the sample was DNA from another individual. Sanger sequencing was used to confirm 
sample identity by detection of the c.3557-1G>C splice site mutation at the 5’ end of exon 7 
that affects one allele of MSH6 in this patient. Their second allele contains an intragenic 
deletion covering exons 3-7, hence it was expected that Sanger sequencing would detect 
only the substitution at the affected locus. In parallel with sample 99, sample 82 (from the 
affected sibling) was sequenced as a positive control, and sample 95 was sequenced as a 
negative control. Sanger sequencing confirmed the identity of sample 99 (Figure 5.6). 
Interestingly, patient 8 was aplastic at the time of blood draw for sample 99 due to 
chemotherapy for T cell lymphoma, and it is feasible that the low leukocyte count or therapy 
might have influenced the frequency of microsatellite length variants in PBLs, and hence 
sample score. 
To see if the low score from patient 8 was reproducible, 2 additional samples (one 
from an independent blood draw taken at a time similar to sample 99, and the other blood 
draw taken 8 weeks later once the patient had recovered from aplasia) were collected. This 
was also an opportunity to assess additional CMMRD samples, including samples from 
patients homozygous for a hypomorphic mutation in PMS2. These patients have residual 
MMR activity and an attenuated phenotype, with much later onset of malignancy than is 
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Figure 5.6: Confirmation of the identity of sample 99. The patient that sample 99 was extracted 
from has a causative splice site mutation in MSH6, specifically c.3557-1G>C, and an intragenic 
deletion in the second allele of MSH6, spanning the same locus. Sanger sequencing of the MSH6 
splice site confirmed presence of the hemizygous c.3557-1G>C mutation in sample 99 and a positive 
control sample (Sample ID: 82) from an affected sibling. Sample 95, a negative control, did not 
contain the mutation. Note the sequence shown is that of the reverse strand. 
 
 
typical of CMMRD (Li et al, 2015) and, therefore, it was expected that their PBLs would have 
lower frequencies of variants in microsatellite length than other CMMRD samples. A second, 
blinded cohort was assembled, including 10 samples from 9 genetically confirmed CMMRD 
patients, 14 control samples, the two new samples from patient 8, and the 3 samples from 
the 3 patients homozygous for the hypomorphic PMS2 mutation. The cohort was amplified 
and sequenced using the smMIP-based MSI assay to a mean (±SD) read depth of 3,288 
±1,898 reads/marker/sample, with a mean 84.7% of base calls of quality >Q30. Each sample 
was scored by the described method. Scores from the 10 CMMRD samples ranged from 3.54 
to 54.55, and the 14 control samples scored from 0.00 to 1.14, again showing that CMMRD 
samples are separable from controls. The two samples from patient 8 again scored relatively 
low, including scores of 2.08 and 4.62, but remained distinguishable from controls. The 
samples from patients homozygous for the hypomorphic PMS2 mutation scored 2.76, 4.28, 
and 5.90, showing that they were also separable from controls but had lower scores than the 
majority of CMMRD patients, consistent with their residual MMR activity (Li et al, 2015). 
135 
 
 Finally, to ensure the method of CMMRD identification would not pick up Lynch 
syndrome, DNAs extracted from the PBLs of Lynch syndrome gene carriers participating in 
the CaPP3 clinical trial (n = 40, see Section 2.2.3) was analysed. These samples covered 9 
MLH1, 21 MSH2, 8 MSH6, and 1 PMS2 mutation carriers. One patient did not disclose which 
MMR gene was affected. Samples were sequenced by the smMIP-based MSI assay to a mean 
(±SD) read depth of 2,681 ±985 reads/marker/sample, with a mean 83.2% of base calls of 
quality >Q30, and scored. Scores ranged from 0.00 to 0.92, meaning that Lynch syndrome 
gene carriers are indistinguishable from non-CMMRD controls.  
A collective analysis of all 36 CMMRD samples, covering 32 patients, and 94 control 
samples, excluding any repeats of the same sample (see Section 5.7), showed that the assay 
was capable of separating all of the analysed CMMRD samples from the controls (Figure 5.7; 
Table 5.3). As well as having genetic confirmation of mutations in both alleles of one of the 
MMR genes in the CMMRD patients, all samples were analysed with the gMSI assay (Ingham 
et al, 2013) by Barbara Mühlegger at the Division of Human Genetics, Medical University of 
Innsbruck. gMSI accurately detected CMMRD, with no false positives, expect for 15 CMMRD 
samples from patients with biallelic germline mutation of MSH6 (Table 5.2). 
 
 
Figure 5.7: Score distribution of constitutional mismatch repair deficiency (CMMRD) and control 
samples. DNA samples from peripheral blood leukocytes of 32 CMMRD and 94 control patients were 
scored, and can be separated by an a posteriori threshold (score >1.53, dotted line). * scores for 
patient 8. † scores for patients homozygous for hypomorphic PMS2 mutation. 
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Patient ID Genotype Sample ID Score gMSI A gMSI B gMSI C 
25 MSH2 hom 132 54.55 0.155 0.146 0.396 
17 MSH6 comp het 43 53.72 -0.062 -0.007 -0.053 
7 PMS2 hom 54 53.59 0.037 0.233 0.294 
24 MSH2 hom 116 43.10 0.065 0.038 0.197 
12 MLH1 hom 49 42.98 0.055 0.11 -0.009 
23 MSH2 hom 104 42.52 0.048 0.082 0.259 
15 PMS2 hom 98 36.97 0.067 0.085 0.482 
20 MSH2 hom 87 27.67 0.047 0.079 0.232 
1 PMS2 hom C 27.34 0.300 0.067 0.061 
10 PMS2 hom 56 25.52 0.179 0.082 0.328 
3 MSH6 hom D 24.88 -0.038 -0.022 -0.048 
7 PMS2 hom 93 23.20 -0.025 0.182 0.27 
2 PMS2 hom A 23.03 0.093 0.287 0.394 
9 MSH6 comp het 82 19.09 -0.065 -0.049 -0.079 
14 MSH6 hom 76 18.07 -0.052 -0.026 -0.053 
21 MSH6 hom 101 17.61 -0.036 -0.058 -0.061 
19 MSH2 hom 58 14.85 0.068 0.06 0.259 
18 PMS2 hom 71 14.49 -0.016 0.096 0.29 
5 MLH1 comp het E 14.43 0.022 0.051 0.062 
16 MSH6 comp het 83 13.70 -0.074 -0.05 -0.07 
26 PMS2 comp het 113 13.08 -0.045 0.056 0.216 
28 PMS2 hom 130 12.82 0.24 0.138 0.323 
6 MSH6 hom 65 12.47 -0.066 -0.059 -0.054 
4 MSH6 comp het B 10.02 -0.050 -0.040 -0.024 
11 MSH6 hom 91 9.85 -0.066 -0.059 -0.064 
27 PMS2 comp het 124 9.83 0.175 0.152 0.249 
22 MSH6 hom 109 7.39 -0.04 -0.06 -0.111 
31 † PMS2 hom 115 5.90 0.049 0.064 0.065 
13 PMS2 hom 51 5.71 -0.009 0.151 0.294 
32 MSH6 hom  128 4.78 0.012 -0.035 -0.044 
8 * MSH6 comp het 102 4.62 -0.066 -0.055 -0.062 
30 † PMS2 hom 120 4.28 -0.039 0.061 0.145 
22 MSH6 hom 107 3.54 -0.04 -0.061 -0.105 
29 † PMS2 hom 125 2.76 0.028 -0.03 0.053 
8 * MSH6 comp het 105 2.08 -0.067 -0.053 -0.065 
8 * MSH6 comp het 99 1.59 -0.07 -0.047 -0.083 
 
Table 5.2: Genotype, sample scores and gMSI results of the 32 patients with constitutional 
mismatch repair deficiency. Each sample was scored by the described method. gMSI ratios for three 
markers (A, D2S123; B, D17S250; C D17S791) were calculated with the Peak Heights software 
(Ingham et al, 2013). Marker ratios presented here are the observed ratio minus the marker-specific 
threshold; positive values represent ratios above the threshold. If two or more of the gMSI markers 
are above the threshold the sample is classified as CMMRD. Thresholds were calculated as per 
Ingham et al (2013), using the same 40 controls as were used for the control distributions for score 
calculation (see Section 5.5). * patient 8, blood drawn whilst aplastic or recently recovered from 
aplasia. † patients homozygous for hypomorphic PMS2 mutation. 
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5.7. Identification of Contamination in a Control Sample 
Three control samples (selected by availability of DNA, Sample IDs: 6, 7, and 9) were 
included as repeats in sequencing runs 1, 2, 3, and 5 (unfortunately I neglected to include 
them on sequencing run 4 and 6). The repeats were scored as described before, and all but 
one fell within the range expected of controls (score = 0.00-0.87); sample 7 on sequencing 
run 5 (second, blinded cohort) scored 6.00 (Table 5.3). Whilst this repeat did have the lowest 
read depth, it is not exceptionally lower than other repeats, and the minimum marker depth 
was 746 reads. Furthermore, the observed prWT of each marker and the probability it was 
from a control population was compared between sequencing run 1 and sequencing run 5, 
and showed that multiple markers contribute to the unexpected high score in sample 7 
(Table 5.4). This confirmed this wasn’t an erroneous case due to low coverage of one or two 
markers. 
To clarify the reason for this discordant result I wanted to confirm sample identity. 
The only genetic data available for sample 7 were the microsatellite markers and associated 
SNPs sequenced. Polymorphisms in our microsatellites are rare, and sample 7 contained 
none. However, the 33 SNPs of MAF >20% are suitable for sample identification due to the 
high likelihood that any two samples will have different alleles. The different bases detected 
 
Sample ID Sequencing Run Read depth (per marker) Score 
6 1 3422 0.87 
 2 2712 0.49 
 3 1240 0.01 
 5 1300 0.01 
7 1 3043 0.04 
 2 3610 0.18 
 3 1650 0.52 
 5 1102 6.00 
9 1 4030 0.21 
 2 4203 0.00 
 3 1954 0.00 
 5 1381 0.03 
    
Table 5.3: Repeat testing of three control samples as a quality control. Three control samples were 
sequenced on four of the sequencing runs and scored as a rough indication of whether or not score 
may be affected by batch. Read depth is the mean number of reads detected per marker. 
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 Sample ID: 7 (run 1) Sample ID: 7 (run 5) 
Marker prWT probability prWT probability 
DEPDC2 0.998 0.292 1.000 1.000 
GM01 1.000 1.000 0.995 0.036 
GM07 0.983 0.189 0.956 0.000 
GM09 1.000 1.000 1.000 1.000 
GM11 0.998 0.198 1.000 1.000 
GM14 0.991 0.097 1.000 1.000 
GM17 1.000 1.000 1.000 1.000 
GM22 1.000 1.000 0.993 0.006 
GM26 1.000 1.000 1.000 1.000 
GM29 1.000 1.000 1.000 1.000 
IM16 0.995 0.119 1.000 1.000 
IM49 0.979 0.039 1.000 1.000 
LR10 1.000 1.000 0.990 0.030 
LR11 1.000 1.000 0.990 0.036 
LR17 0.990 0.139 0.972 0.001 
LR20 1.000 1.000 1.000 1.000 
LR24 1.000 1.000 0.996 0.018 
LR36 1.000 1.000 0.986 0.018 
LR40 0.998 0.266 1.000 1.000 
LR44 0.984 0.313 0.987 0.510 
LR46 1.000 1.000 1.000 1.000 
LR48 0.996 0.478 0.967 0.001 
LR49 1.000 1.000 0.992 0.003 
LR52 0.981 0.702 0.964 0.108 
 score: 0.04 score: 6.00 
 
Table 5.4: Summary of read data from sample 7 in two sequencing runs. The observed proportion 
of smSequences containing a WT length of microsatellite (prWT) and the probability the observation 
belongs to a control population in each microsatellite marker for sample 7 in two sequencing runs. 
 
 
across the four sequencing runs for each of the SNP loci were summarised, and 
subsequently, the proportion of reads assigned to each base was determined for each run. 
Read proportions by allele were plotted and analysed to see if sample 7 had a distinct profile 
in sequencing run 5 compared to the previous runs. Indeed, it was evident that reads were 
assigned to the same bases in all runs except for sample 7 in sequencing run 5, which had a 
minority of reads assigned to novel alleles or significantly different proportions of reads 
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assigned to the same allele (Figure 5.8). This suggested the reaction was contaminated with 
another DNA. There were two possible points of contamination, either in the template DNA 
or in the sample indexing reverse primer, as all other samples gave scores as expected and 
template negative reactions were blank, suggesting common reagents were not the source 
of contamination. However, determining the exact source of contamination is not relevant 
to the work described in this thesis. Given that the scores from the other repeats and 
controls fell within the expected range of controls, equivalent to 13-100% probability the 
samples belong to a control population, and given that the one exceptional score is 
explained by contamination, this data suggests that the assay is stable. Due to the limited 
availability of CMMRD samples, a statistically robust analysis of assay reproducibility was not 
feasible. 
 
 
Figure 5.8: The proportion of reads assigned to different SNPs in sample 7 repeats. Sample 7 was 
sequenced across 4 different sequencing runs (numbered 1, 2, 3, and 5). In sequencing run 5, the 
second blinded cohort, sample 7 shows significant differences in the proportions of reads assigned to 
different SNPs in several of the microsatellite markers, compared to the runs 1, 2, and 3. Four 
markers are shown as illustrative examples, (A) DEPDC2, (B) LR48, (C) IM16, and (D) IM49. Error bars 
show 99% confidence intervals from the binomial distribution of read counts. 
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5.8. Discussion 
Here, I have presented an MSI assay capable of detecting CMMRD with 100% accuracy by 
detection of low frequency variants in microsatellite length in PBL DNA samples. The assay is 
therefore applicable as a companion to genetic testing for CMMRD in suspected patients, 
such as those identified by the criteria of the C4CMMRD consortium guidelines (Wimmer et 
al, 2014). Also, the assay is a development of the smMIP-based MSI assay for CRC 
diagnostics, and hence has the benefits of simplicity, scalability and low cost, as discussed in 
section 4.11. Therefore, it is an appropriate screening tool in larger cohorts of patients. This 
is particularly pertinent as there are, approximately, only 200 known cases of CMMRD 
(Wimmer et al, 2017), yet it is estimated that up to one per 370-1000 of the population carry 
a heterozygous MMR mutation (Aaltonen et al, 1998; Hampel and de la Chapelle, 2011), 
implying that CMMRD may be more prevalent than the 200 known cases suggests. For 
example, adoption of germline genetic testing is required in childhood haematological 
malignancies as it is likely many are associated with unidentified germline mutations 
(Furutani and Shimamura, 2017). However, sequencing the many potential genes would 
incur a prohibitive cost, and therefore screening tools to guide differential diagnosis, such as 
the assay described here, are desirable. Unselected screening of patients with other 
childhood malignancies related to CMMRD is equally applicable. 
 Our current understanding of the CMMRD phenotype may be skewed by the 
ascertainment bias of current clinical guidelines. For example, the effect of ascertainment 
bias on the estimates of phenotype has been observed in Lynch syndrome, whereby analysis 
of affected family members of probands, rather than the probands themselves, showed a 
much later median age of disease onset (Hampel et al, 2005b). This can have a downstream 
effect on screening strategies, with early guidelines recommending screening in CRC patients 
under 50 years of age despite 70% of Lynch syndrome CRCs being diagnosed in patients over 
50 years of age when screening of CRCs by MMR deficiency testing was applied (van Lier et 
al, 2012). Indeed, alongside guidelines for surveillance and management of CMMRD, the US 
Multi-Society Task Force on Colorectal Cancer raised the gaps in our knowledge that require 
further research, including the prevalence, disease spectrum, and genotype-phenotype 
correlations of CMMRD (Durno et al, 2017). Therefore, despite its rarity, identification of 
additional cases by large scale screening would begin to fill in these gaps. In summary, due to 
its scalability, the assay presented here has broad applicability to both clinical practice and 
research with respect to CMMRD. 
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The error prone amplification and sequencing of microsatellites (Fazekas et al, 2010) 
will obscure accurate detection of low frequency variants, such as those in microsatellite 
length found in the normal tissues of CMMRD patients (Bodo et al, 2015). Therefore, to 
address the difficulty of detecting low frequency variants in microsatellites I used molecular 
barcodes to group reads originating from the same template molecule so that PCR and 
sequencing errors could be identified and a hypothetical smSequence, assumed to represent 
the sequence content of a single template DNA molecule, used in variant detection (Casbon 
et al, 2011). Very recently Waalkes et al (2018) used smMIPs to sequence a panel of 111 long 
(16-40bp) microsatellites for MSI testing in cancer diagnostics. They used molecular 
barcodes in a very similar method, according to Carlson et al (2015), to show a reduction in 
the number of length variants detected in microsatellites, suggesting a reduction in error. 
Here, I have confirmed that use of smSequences significantly reduces the error of detecting 
variants in microsatellite length using 40 control samples which can be assumed should not 
contain detectable microsatellite mutations. In combination with our selective use of short 
(7-12bp) markers known to have lower error rates (Fazekas et al, 2010), the use of 
smSequences frequently removed all PCR and sequencing error. However, marker GM09 
showed an increased error rate in four of the control samples. These samples, and others, 
had very low counts of smSequences in GM09 despite unremarkable counts for total reads in 
GM09 and counts for smSequences in other markers. Therefore, this result is difficult to 
explain. For example, if there was a variable in these samples interfering with target capture 
or amplification of GM09 it would be expected that this would affect other markers as well 
or would be detectable in the read depth of GM09. An alternative is that there was an error 
in probe synthesis or the bioinformatic pipeline that makes detection of molecular barcodes 
for this marker unreliable. However, this is speculation and would require further research. 
Regardless, use of the full marker panel, including GM09, was able to accurately detect 
CMMRD patients. However, GM09 could be excluded in future analyses, and the modified 
panel validated in a set of independent samples. 
By characterising the proportion of smSequences with a WT microsatellite length in 
40 control samples, I generated distributions reflective of the control population, against 
which samples could be scored. This removed the need to characterise the distribution in 
the CMMRD population, which would be limited by the scarcity of CMMRD samples, and 
heterogeneity of germline mutations. To assess assay performance, I analysed samples from 
32 genetically-confirmed CMMRD patients, which is a relatively large cohort given that only 
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~200 patients have been published so far (Wimmer et al, 2017). This cohort covers biallelic 
mutation of each of the four MMR genes to address genetic heterogeneity of this syndrome, 
and the assay was able to separate all CMMRD samples from controls irrespective of 
mutation (Figure 5.7). The probability a sample was not from a control population was 
converted into an easily described score such that higher scores indicated increased MSI and 
increased likelihood of CMMRD. Using a score threshold of >1.53 (>97% probability the 
sample is not from a control population), the assay detected CMMRD with 100% accuracy, 
irrespective of which MMR gene was mutated (Figure 1). Naturally, a score threshold should 
be picked a priori and validated, but the scarcity of CMMRD samples prevented threshold 
validation. Instead, standard thresholds used for statistical probabilities can be applied. For 
example, a score threshold of >1.30, equivalent to >95% probability, would have generated 
two false positives (100% sensitivity, 98% specificity). A more conservative score threshold of 
>2.00, equivalent to >99% probability, would have missed only one CMMRD sample (97% 
sensitivity, 100% specificity, Sample ID: 99). However, this sample was collected during 
exceptional circumstances, discussed below, and hence a score threshold of >2.00 ensures 
high specificity, which is particularly important if used as a screening tool in larger cohorts. 
Included within the cohort was a variety of samples, which allowed a limited analysis 
of variables that may affect score, such as hypomorphic MMR mutation, patient age, and 
clinical history. Samples from patients 29, 30 and 31, homozygous for a hypomorphic PMS2 
variant, all scored relatively low (score = 2.76-5.90; Table 5.2), which may be indicative of 
their residual MMR activity and attenuated phenotype (Li et al, 2015). Therefore, it may be 
worth testing if assay score has any prognostic value, for example by indicating the 
penetrance of germline mutations. 
Three samples from patient 8 (score = 1.59-4.62) scored much lower than the sample 
from an affected sibling, patient 9 (score = 19.09; Table 5.2). At the time of blood draws, 
patient 8 was aplastic, or just recovered from aplasia, due to chemotherapy for T cell 
lymphoma. A decreased frequency of microsatellite length variants in repopulating PBLs in 
CMMRD patients is consistent with the observation in mice that hematopoietic stem cells 
with a higher burden of microsatellite mutation are associated with defective repopulation 
(Reese et al, 2003). Whilst this is speculative, it may be pertinent to avoid using blood 
samples drawn from aplastic patients, or to interpret negative results as inconclusive if such 
samples are unavoidable. In the future, a time course of samples taken during patient 
recovery from aplasia may be informative. 
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We also observed relatively lower scores from patient 22 (score = 3.54-7.39) 
compared to an affected sibling, patient 21 (score = 17.61; Table 5.2), who is 8-9 years older. 
In this case, patient 22 was only 13 and 15 months old at blood draws, and had not 
presented with cancer. An association between age and frequency of microsatellite length 
variants has been observed in the general population (Coolbaugh-Murphy et al, 2005) and 
may be applicable to CMMRD patients. However, formal analysis of the effect of age, and 
other, variables on score would require larger numbers of samples and patients, and is 
beyond the scope of this work. 
Due to the limitation in the number of CMMRD samples and quantity of each sample 
provided for this work, it was not feasible to assess other parameters of assay performance, 
despite the recommendations from the Association for Molecular Pathology and the College 
of American Pathologists for the analytical validation of NGS-based diagnostic tests (Jennings 
et al, 2017). For example, assessment of assay reproducibility would require repeat testing 
of the majority of samples, yet only a handful of the CMMRD samples have sufficient DNA 
remaining to do so. Given more time and access to additional samples these assay 
parameters could be assessed. One issue raised by these guidelines is the sensitivity of NGS-
based diagnostic tests to contamination and the need for quality checks in sample handling. 
In the repeat testing of three control samples, it was found that a repeat of sample 7 gave an 
unexpected high score. In this case, the SNPs associated with the microsatellite markers 
were able to detect contaminating DNA by detection of novel or changed representation of 
bases at the SNP loci in the affected sequencing run compared to previous runs. It is feasible 
that this use of SNPs could be explored further to give an additional assay QC for 
contamination, for both CMMRD and cancer diagnostics. Furthermore, even small quantities 
of contamination, depending on the source, could be critical to detection of CMMRD given 
that assay score is sensitive to very small changes in variant frequency (Table 5.1). Whilst 
assessment of contamination would not be of general utility to clinical diagnostic services, in 
which appropriate controls will be in place to prevent contamination, the analysis of the 
SNPs provides a means to explore unexpected or inconsistent results. 
 
5.9. Conclusions and Future Work 
In conclusion, a smMIP and sequencing-based assay that utilises molecular barcodes can 
detect low frequency variants in microsatellite length in PBLs of CMMRD patients with high 
accuracy, including CMMRD caused by MSH6 mutation. The laboratory workflow is simple 
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and analysis is automated, applicable to rapid turnaround times within clinical decision 
windows. Therefore, the assay could be deployed immediately to compliment genetic 
testing. Being cheap and designed for high throughput diagnostics, the assay could also be 
used for screening in larger cohorts of patients, for example in cases of childhood, 
haematological malignancy. Such unselected screening of relevant childhood malignancies 
will improve our understanding of CMMRD, including its frequency, phenotype and disease 
spectrum. Given additional samples and a more thorough understanding of the distribution 
of scores in the CMMRD population, a more robust classifier could be defined. Finally, it is 
apparent that several factors, including age, mutation pathogenicity, and leukocyte 
repopulation, may affect the frequency of variants in microsatellite length in PBLs, and 
therefore sample score. The assay could be used to explore these biological mechanisms in 
more detail in the context of CMMRD, which may improve score interpretation and provide 
novel insights into disease mechanisms. 
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Chapter 6. General Discussion and Future Work 
 
6.1. The Clinical Utility and Analytical Validity of Mismatch Repair Deficiency Biomarkers 
and Tests in Cancer Diagnostics 
The overall utility of biomarker tests can be assessed by their analytical validity and clinical 
utility (Hayes, 2018). As discussed in Section 1.7, several factors inform analytical validity, 
including accuracy of results, concordance of repeat testing, robustness to sample and 
technical variables, and clinical validation. Clinical utility can be judged by assay influence on 
clinical decisions, its adverse effects to the patient, its cost and practicality, and generation 
of measurable improvement in healthcare practice and patient outcomes (Ray et al, 2010; 
Henry and Hayes, 2012). 
MMR deficiency affects approximately 1 in 6 of all CRCs (Thibodeau et al, 1998) and 
is present in 90-100% of CRCs diagnosed in the context of Lynch syndrome (Leach et al, 
1996; Liu et al, 1996; Thibodeau et al, 1996; Hampel et al, 2008). Furthermore, all tissues of 
CMMRD patients, normal and neoplastic, are MMRd (Wimmer et al, 2008). In the broadest 
sense, detection of MMR deficiency is important to clinicians and patients as it can be used 
to identify associated cancer-predisposition syndromes and informs disease management 
due to the unique properties of MMRd relative to MMRp tumours (Bodo et al, 2015; Le et al, 
2015; Newland et al, 2017). Here, I will summarise the clinical utility and analytical validity of 
each of the biomarkers and assays of MMR deficiency investigated or developed during this 
work. 
 
6.1.1. Anti-frameshift peptide antibodies as a liquid biopsy biomarker of colorectal cancer 
The “holy grail” of cancer diagnostics is considered to be early detection due to the greater 
variety of treatment options available to, and the improved survival of, patients with lower 
stage disease (Etzioni et al, 2003). MMRd CRCs are a distinct molecular subtype (Guinney et 
al, 2015) and the immunogenicity of these tumours provides a potential source of antibody-
based biomarkers for early detection of disease (Reuschenbach et al, 2010). My study of 
αFSP-Abs titres (Chapter 3) was aiming to find a novel biomarker of MMRd CRC using a 
recently published and novel technique. Had initial findings been promising it would have 
been feasible to develop the method into a biomarker assay, applicable to clinical 
surveillance in patients at high risk of MMRd CRC, such as Lynch syndrome gene carriers. 
Given the invasiveness and limitations of colonoscopy in detection and prevention of some 
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Lynch syndrome colorectal tumours (Stuckless et al, 2012; Seppälä et al, 2017), the clinical 
utility of such a surveillance assay could have been high. 
FSP serum reactivity was found to be associated with a history of CRC in the cohort of 
Lynch syndrome gene carriers analysed, suggesting that αFSP-Abs are detectable and in 
agreement with previous studies that have used the alternative technique of ELISA to 
quantify αFSP-Ab titres in MSI-high CRC patients (Ishikawa et al, 2003; Reuschenbach et al, 
2010). However, my results suggest the individual and collective sensitivity of FSP serum 
reactivity for CRC is low as the majority of values from patients with a history of CRC fell 
within the background noise, as was also observed for three samples where CRC was 
diagnosed shortly after blood draw. It is conceivable that the sensitivity could be improved 
by optimising the method, but cancer-free and MMR mutation-negative controls were 
lacking, and to address this was not possible due to financial and logistical constraints. 
However, given the clear signals from positive control samples (patients vaccinated with 
synthetic FSPs) that were not observed in the CRC patients, I believe that αFSP-Abs are 
insensitive biomarkers for early detection of CRC possibly due to the lack, or instability, of a 
humoral immune response to cMNR frameshift mutations. In conclusion, αFSP-Abs are likely 
to have low clinical utility, but additional research is needed to confirm this, starting with 
technical validation of the method (Section 3.9). The analytical validity of the method was 
not formally assessed due to limitations of the cohort analysed, such as the low number of 
on-trial CRC diagnose and lack of controls. Alternative biomarkers for liquid biopsy-based 
surveillance of Lynch syndrome gene carriers should be considered (see Section 6.2.1). 
 
6.1.2. A sequencing-based microsatellite instability assay for colorectal cancer diagnostics 
NICE Diagnostic Guidance 27 states that all CRCs should be tested for MMR deficiency to 
screen for Lynch syndrome, either by loss of MMR protein expression or detection of high 
levels of MSI in the tumour, such that patients and affected family members can benefit 
from altered treatment and surveillance (Newland et al, 2017). These guidelines are based 
on the high accuracy and cost-effectiveness of unselected molecular screening, using the 
established techniques of IHC or FLA (Pérez-Carbonell et al, 2012; Snowsill et al, 2014). MMR 
deficiency also informs use of immune checkpoint blockade, with pembrolizumab recently 
receiving FDA-approval as a second-line therapy in MSI-high solid cancers, irrespective of the 
tissue of origin (MERCK & Co. Inc, 2017). Despite the accepted analytical validity and clinical 
utility of these biomarker assays, they are not suitable for high throughput MMR deficiency 
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testing due to reliance on case-by-case and marker-by-marker results interpretation. 
Furthermore, to fulfil Lynch syndrome screening guidelines separate tests for BRAF V600E or 
MLH1 promoter methylation are needed.  
 I developed a sequencing-based MSI assay from the assay of short MNRs described 
by Redford et al (2018), adopting smMIP technology to multiplex the markers, and 
expanding the panel to include additional short MNRs and the BRAF V600 locus (Chapter 4). 
The assay classifier was trained and validated, achieving 100% accuracy relative to FLA by 
MSI Analysis System (Promega), and giving 100% results concordance on repeat testing. The 
MSI assay was also robust to sample variables, including low quality template DNA from 
FFPE tissue, low MSI-high content, and low quantity template DNA. Accurate classification 
was achieved from as few as 75 molecular barcodes/marker. Following the guidelines of 
Jennings et al (2017) for the analytical validation of NGS-based oncology assays, assay QCs 
were also defined. BRAF V600E testing was included in the test to reduce the Lynch 
syndrome screening pipeline to one screening test, to be followed by germline genetic 
testing of MMR genes. The cost and TAT of the assay is equivalent to, and arguably better 
than, the dominant MSI Analysis System (Promega), and the laboratory workflow and 
analysis are both fully automatable. These results demonstrate the analytical validity and 
clinical utility of the smMIP and sequencing-based MSI assay, and in several aspects the 
assay is superior to those used in current practice, most notably in its scalability. Hence, it is 
suitable for deployment and clinical validation. Alongside clinical validation, additional 
improvements can be made to the assay, such as reduction in the number of markers 
analysed to reduce sequencing costs, and transfer of the assay into a kit to further 
streamline the protocol (Section 4.12). 
 
6.1.3. A sequencing-based microsatellite instability assay to detect constitutional 
mismatch repair deficiency  
Identification of CMMRD is critical for the appropriate clinical management of the patient, 
with patients benefitting from surveillance and altered treatment (Vasen et al, 2014). Due to 
a pleiotropic phenotype, genetic diagnosis by detection of pathogenic mutations affecting 
both alleles of the same MMR gene is the gold standard. However, MMR VUS and PMS2 
pseudogenes can confound genetic diagnosis and so companion diagnostic tools are needed 
(Wimmer et al, 2017). CMMRD can be identified by MSI testing of normal, non-neoplastic 
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tissues using highly sensitive techniques, but current assays are laborious or insensitive to 
MSH6 deficiency (Ingham et al, 2013; Bodo et al, 2015). 
 The smMIP and sequencing-based MSI assay was repurposed, using a novel analysis 
method capable of detecting low level MSI in the PBLs of CMMRD patients (Chapter 5). It 
incorporates molecular barcodes into reads to facilitate reduction of PCR and sequencing 
error in microsatellites for accurate detection of low frequency length variants. Other 
methods to detect low frequency variants have been developed, such as Safe-SeqS (Kinde et 
al, 2011), Duplex Sequencing (Schmitt et al, 2012; Kennedy et al, 2014) and CypherSeq 
(Gregory et al, 2016). However, the original methods are not optimised to target specific loci 
and instead shear the template DNA, ligate molecular barcodes to the non-specific DNA 
fragments, universally amplify the fragments, and then sequence the amplicons. Adapting 
these protocols to targeted sequencing is limited. SafeSeqS, for example, was further 
adapted to target specific loci using an initial two-round PCR with primers to introduce the 
molecular barcodes, followed by universal amplification (Kinde et al, 2011). However, the 
reliance on PCR to initially capture the targets limits multiplexing, and multiplexing was not 
demonstrated by Kinde et al (2011), only discussed. Similar, more recent, PCR-based 
methods for introducing molecular barcodes to amplicons can multiplex tens of markers 
(Ståhlberg et al, 2016), whereas smMIPs can be multiplexed in their thousands (Hiatt et al, 
2013). The concentration of each smMIP in a pool can also be balanced to equalise read 
depth between markers with ease, as shown in this work and by others (Niedzicka et al, 
2016). The smMIP protocol is also simple and has been shown to be fully automatable 
(Neveling et al, 2017). 
The assay uses short MNRs that are sensitive to MSH6 deficiency so that it is 
informative irrespective of the affected MMR gene. The clinical utility of the assay was 
evident in the high accuracy that was achieved, with perfect separation of CMMRD samples 
from controls, making it a suitable complementary test for uncertain genetic diagnoses. In 
addition, its low cost and scalability could facilitate screening of large cohorts of patients, 
such as cases of childhood leukaemia (Furutani and Shimamura, 2017). With respect to 
analytical validity, it was difficult to formally test the assay in the context of CMMRD 
diagnostics given the scarcity of CMMRD samples; the 32 patients analysed are a relatively 
large cohort with respect to the total patient population, accounting for approximately 15% 
of all known cases in the literature (Wimmer et al, 2017). However, the assay is evidently 
highly sensitive and specific, uses high quality and quantity DNA extracted from PBLs, and 
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uses the same robust protocols as used in the MSI assay for cancer diagnostics, suggesting it 
is appropriate for clinical deployment. 
 
6.2. The Future Direction of Biomarker Tests for Mismatch Repair Deficiency 
The work presented in this thesis has an impact on MMR deficiency testing in cancer 
diagnostics beyond the interpretation of clinical utility and analytical validity of the individual 
biomarkers and tests described. 
 
6.2.1. Surveillance for mismatch repair deficient cancers in high risk populations 
αFSP-Abs were insensitive for the early detection of on-trial CRCs in three patients, yet the 
gold standard technique for the early detection of CRC in at-risk populations remains 
colonoscopy, a relatively invasive procedure that fails to detect 7-20% of colorectal tumours 
in Lynch syndrome (Stuckless et al, 2012; Ahadova et al, 2015). αFSP-Abs are derived from 
the frequent cMNR frameshift mutations found in MMRd cancers. Therefore, as generation 
of αFSP-Abs against an MMRd cancer appears to be an infrequent or undetectable event, 
detection of the frameshift mutations in cfDNA, indicative of ctDNA from an MMRd cancer, 
could be a more tractable biomarker for Lynch syndrome surveillance. As discussed in 
Section 1.8, ctDNA can be used to monitor cancer progression and relapse (Diaz et al, 2012; 
Taly et al, 2013; Siravegna et al, 2015; Schøler et al, 2017), and several studies have reported 
fractions of ctDNA within cfDNA ranging between 0.01% and 93% by detection of cancer-
associated variants (Jahr et al, 2001; Diehl et al, 2005). The lowest ctDNA fractions are found 
in early stage disease (0.01-1.7%) (Jahr et al, 2001). Hence, for the early detection of cancer, 
highly sensitive but costly and laborious techniques are needed to detect low frequency 
variants (<1%) from ctDNA in a background of WT cfDNA, such as picodroplet digital PCR 
(Taly et al, 2013; Bettegowda et al, 2014) and high read depth NGS (Shu et al, 2017). 
 Here, I have described the use of smMIPs and molecular barcodes to reduce PCR and 
sequencing error such that CMMRD samples can be separated from controls by detection of 
low frequency microsatellite length variants present in genomic DNA from PBLs. Based on 
this experience, it would be of interest to see if an smMIP-based assay can detect cMNR 
frameshift mutations in cfDNA for potential use as a liquid biopsy-based biomarker of MMRd 
cancer. Sequencing and molecular barcoding of reads has previously been used to detect 
mutations at VAFs as low as 0.1% in cfDNA extracted from blood plasma (Ståhlberg et al, 
2016). Similar sensitivity was achieved when smMIPs and their molecular barcodes were 
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used to analyse 33 mutations across clinically informative cancer genes in cell line and 
tumour samples, although cfDNA was not tested (Hiatt et al, 2013). Typically, cMNRs range 
between 5-13bp (Woerner et al, 2010), which is comparable to the short MNRs analysed for 
CMMRD detection. Hence, despite the high error rate in sequencing of microsatellites 
(Fazekas et al, 2010), it is reasonable to assume that molecular barcodes will also allow error 
reduction and detection of low frequency variants in cMNRs. Furthermore, due to their 
robustness to multiplexing (O’Roak et al, 2012), smMIPs can analyse many cancer-associated 
loci simultaneously providing a relatively cheap screening assay, as was achieved with our 
panel of 24 short MNRs. The high frequency of cMNR frameshift mutations in MMRd CRCs, 
with many occurring in >60% (Woerner et al, 2010), means a reliable panel could be 
constructed for cancer detection without prior knowledge of mutation status. As cMNRs 
frameshifts are driver mutations, it is also more likely that they will be detectable compared 
to the marker of short MNRs used in the MSI test, and, due to the differences in cMNR 
frameshifts between different cancer types (Woerner et al, 2010), they may provide 
information on the type of cancer. However, it is also possible that the current assay of short 
MNRs can detect MSI in cfDNA as a biomarker of MMRd cancer. Finally, as was hypothesised 
of αFSP-Abs, detection of MSI in cfDNA may additionally give a measure of the mutational 
burden of a cancer and therefore its likely response to immunotherapy (Topalian et al, 2016; 
Yarchoan et al, 2017). 
 There are several disadvantages of analysing cfDNA rather than antibody titres. 
Whilst antibodies are relatively stable in serum (Anderson and LaBaer, 2005), serum cfDNA 
can be contaminated by lysis of PBLs and hence rapid processing of the blood sample or use 
of stabilising reagents is required (Norton et al, 2013). However, this can be addressed by 
setting up the appropriate clinical pipeline for sample workup. cfDNA also tends to be low 
quantity and highly fragmented (Jahr et al, 2001). By assessing the robustness of the MSI 
test for cancer diagnostics, I showed that amplicons were visible from as little as 3.13ng of 
template DNA, a quantity of sample that is achievable from the median 184ng of cfDNA 
extracted from 1ml of patient serum (Fong et al, 2009). Also, the size of the smMIP 
annealing site (120-150bp) is less than the average 180-220bp fragment size of cfDNA (Jahr 
et al, 2001). In conclusion, it would be pertinent to assess the applicability of the smMIP, 
sequencing and data analysis methods presented here to the detection of cMNR frameshift 
mutations, or short MNR instability, in cfDNA, with a view to developing an assay for 
surveillance in Lynch syndrome gene carriers. 
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6.2.2. Microsatellite instability testing in cancer diagnostics 
A plethora of methods have been presented in recent years with respect to MMR deficiency 
testing of cancers to screen for Lynch syndrome and, more recently, with a view to 
companion diagnostics for immune checkpoint blockade therapy. Beyond the established 
techniques of IHC and FLA, and the growing application of NGS-based methods, some 
research groups have developed alternative assays. For example, N_LysT is a PCR and high 
resolution melting curve (HRM)-based assay that detects microsatellite length variants by 
differential melting temperatures of amplicons. The key advantage of this approach is the 
rapid TAT as both PCR amplification and HRM analysis of amplicons are conducted in one 
tube using one thermocycler program (Susanti et al, 2018). However, the use of HRM means 
that only one marker can be analysed at a time, and whilst individual markers can show high 
(>95%) sensitivity for the MSI-high phenotype (Findeisen et al, 2005), multiple markers must 
be analysed due to the continuum of the MSI spectrum from MSS and MSI-low phenotypes 
in MMRp cancers to the MSI-high phenotype in MMRd cancers (Boland et al, 1997). 
Parallel analysis of multiple microsatellite markers in many samples requires 
techniques capable of generating large quantities of data, such as NGS. Hence novel NGS-
based methods of assessing MSI have been appearing in the literature for 5 years or more, 
particularly with a focus on software that analyses microsatellites captured in whole 
genome, whole exome, or gene panel sequencing (Lu et al, 2013; Niu et al, 2014; Salipante 
et al, 2014; Gray et al, 2018; Hampel et al, 2018; Zhu et al, 2018). However, the high cost of 
such approaches (Marino et al, 2018) is prohibitive to their use for screening the 41,000 
CRCs diagnosed each year in the UK (Cancer Research UK Statistics, 2015), as recommended 
by NICE and others (Balmana et al, 2013; Stoffel et al, 2015; Newland et al, 2017). Hence 
cheaper MSI assays are required, that can also benefit from the advantages of NGS. Here, I 
have shown that the smMIP and sequencing-based MSI assay has a superior cost per sample 
than gene panel, whole exome, or whole genome sequencing. Like other NGS-based assays, 
it uses the Illumina sequencing platforms that are ubiquitous in research and clinical 
laboratories around the world (Levy and Myers, 2016), and multiplexes multiple 
microsatellites and other clinically actionable biomarkers to optimise clinical testing.  
The low cost and scalability of the smMIP and sequencing-based MSI assay make it a 
competitive option for routine diagnostics. However, an argument against targeted 
sequencing assays is that, if gene panel sequencing is to become routine in cancer health 
care, why not deploy extensive sequencing assays now? For example, it is estimated that 
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9.9% of all CRCs are due to mutations associated with hereditary cancer syndromes, and only 
a third of these are attributable to Lynch syndrome (Yurgelun et al, 2017). Therefore, 
germline gene panel sequencing of CRC patients may be more appropriate than screening 
for Lynch syndrome only. The costs and QALYs-gained from gene panel testing of germline 
DNA in patients with >5% probability of hereditary cancer (based on a predictive, clinical 
algorithm) have recently been modelled, using two approaches, either germline gene panel 
testing, or MMR IHC of the tumour, followed by germline MMR gene testing according to 
Lynch syndrome screening recommendations. When immediate germline gene panel testing 
was applied, 8,076 (29.1%) patients were found to have a hereditary cancer syndrome, with 
an additional 5,984 affected, first degree relatives identified through cascade testing. When 
Lynch syndrome screening was applied, 2,584 (9.3%) patients were found to have Lynch 
syndrome, with an additional 1,915 first degree relatives also testing positive for MMR gene 
mutation. From the appropriate clinical management of identified patients, it was estimated 
that gene panel sequencing had a cost of $1,543 per QALY-gained, whilst Lynch syndrome 
screening had a cost of $1,882 per QALY-gained, suggesting that germline, gene panel 
sequencing of CRC patients suspected of hereditary disease is more cost-effective than 
screening for Lynch syndrome-only in the same patient cohort (Gu et al, 2018). However, 
these analyses were performed in preselected patients, which will reduce costs per QALY-
gained, but will also reduce screening sensitivity. For Lynch syndrome screening, it has 
previously been shown that Bethesda criteria, which rely on age at diagnosis, family history 
of Lynch spectrum cancers, etc, are less sensitive and less specific for identification of Lynch 
syndrome gene carriers than molecular screening for MMR deficiency in CRC patients (Pérez-
Carbonell et al, 2012). Therefore, such analyses of cost-effectiveness can be skewed in 
favour of gene panel sequencing as they do not account for the cases missed by pre-
selection of patients based on clinical criteria. Finally, the more genes that are sequenced 
without guidance as to which genes are likely to contain the causative mutation, the more 
time will be required to interpret VUS. For example, in their study of germline, gene panel 
sequencing of 1112 CRC patients suspected of hereditary disease, Yurgelun et al (2015) 
identified at least one VUS in 479 patients. It is, therefore, perhaps more appropriate to 
consider economic models that use multiple diagnostic pathways for the application of NGS 
to clinical oncology rather than a “one-size-fits-all” approach. In such an economic model of 
the CRC diagnostic pipeline, cheap, high throughput screening tools, such as the smMIP and 
sequencing-based MSI assay presented in this work, would be the first line of reference for 
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the clinician, ensuring rapid identification of those patients with germline, pathogenic 
mutations where clinical guidelines exist for altered treatment. Such rapid screening is not 
mutually exclusive with germline gene panel sequencing of additional cases of interest, for 
example where clinical criteria elicit suspicion of hereditary disease. 
The health technology assessment by Snowsill et al (2014) concluded that unselected 
screening for Lynch syndrome by MSI testing of all CRCs diagnosed under the age of 70 
years, followed by BRAF V600E testing of MSI-high CRCs to remove sporadic cases, and, 
finally, germline MMR gene testing, had an incremental cost-effectiveness ratio of £5,491 
per QALY-gained relative to no testing (diagnosis of Lynch syndrome based on clinical 
criteria), which was well below the NICE cost-effectiveness threshold of £20,000 per QALY-
gained. In their diagnostic guidance, NICE expanded these recommendations to include all 
CRC diagnoses irrespective of age (Newland et al, 2017). However, Lynch syndrome gene 
carriers are also at high risk of multiple, other cancer types, most prominently endometrial, 
ovarian, upper GI, and urinary tract cancers (Møller et al, 2017b), and it appears that the 
majority of these cancer types are affected by MMR deficiency (Gurin et al, 1999; Simpson et 
al, 2001; Hampel et al, 2006; Gylling et al, 2007; Pal et al, 2008; van der Post et al, 2010). The 
most frequent cancer in female Lynch syndrome gene carriers is EC, not CRC (Hampel et al, 
2006). Strategies to identify Lynch syndrome based on EC result in very similar conclusions as 
strategies using CRC diagnoses. Primarily, unselected molecular screening of tumours for 
MMR deficiency followed by germline genetic testing reveal that 1.8% (95% CI: 0.9-3.5%) of 
ECs are due to Lynch syndrome, similar to rates observed in CRC (Hampel et al, 2006), and 
inclusion of MLH1 methylation testing can exclude sporadic cases to improve screening 
specificity (Leenen et al, 2012). Furthermore, 41% of Lynch syndrome patients identified by 
molecular screening had no indicators of Lynch syndrome based on Bethesda criteria or 
other clinical features (Mills et al, 2014), showing MMR deficiency testing to be the superior 
screening strategy in terms of sensitivity and specificity. Finally, cost-effectiveness analyses 
have shown that screening for Lynch syndrome by MMR deficiency testing of ECs diagnosed 
under the age of 70 is cost-effective, with incremental cost-effectiveness ratio of €6,668 per 
life year gained relative to screening by Bethesda guidelines, which had only 43% sensitivity 
in the cohort tested in parallel to cost analyses (Goverde et al, 2016); cost effectiveness is 
therefore equivalent to MMR deficiency testing of CRCs (Snowsill et al, 2014). Whilst clinical 
guidelines do not exist yet for MMR deficiency testing of extracolonic cancers to screen for 
Lynch syndrome, the cheap, automatable and scalable MSI test described in this thesis 
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would be able to meet the increasing demand. Indeed, as the number of samples to be 
analysed increases, the per sample cost of the assay decreases, as higher capacity 
sequencing kits can be used (Appendix J). 
Another application of NGS gene panel, whole exome, or whole genome sequencing 
is the identification of somatic mutations in the tumour that inform therapeutic choice. In 
CRC, gain of function mutations in BRAF, KRAS, NRAS, or PIK3CA are clinically informative as 
they predict response to anti-EGFR therapy (Lièvre et al, 2006; De Roock et al, 2010a). From 
the plethora of evidence in the literature, NICE Technology Appraisal 439 states that 
cetuximab and panitumumab (monoclonal antibodies that block EGFR signalling) should be 
used as first line therapy only in RAS wild type metastatic CRC (Cooper et al, 2017). As 
discussed in Section 4.11, a key advantage of an smMIP-based assay is that it is modular, 
with it being relatively trivial to add smMIPs targeting additional biomarkers into the 
multiplex. This was shown using a smMIP targeting the KRAS G12 and G13 mutation hotspot. 
MSI testing informs use of pembrolizumab, or other immune checkpoint blockade therapies, 
following FDA approval of pembrolizumab as a second line therapy for any MSI-high solid 
cancer irrespective of the tissue of origin (MERCK & Co. Inc, 2017). With ongoing clinical 
trials to confirm the efficacy of immune checkpoint blockade in MMRd cancers (Cummings 
and Garon, 2017), its use as a first line therapy will likely increase in coming years, further 
fuelling the demand for high throughput MSI testing in a broad spectrum of cancer types. 
Finally, the score generated by the assay covers a broad scale that allows quantification of 
the MSI signal, rather than the tripartite classification using FLA. Whilst this was not explored 
here due to a lack of clinical or pathology data on the CRC patients and their tumour, it 
would be possible to correlate classifier score with a variety of disease phenotypes, such as 
patient age, prognosis, tumour stage, genetic background, and so on. Specifically, it would 
be interesting to see if assay score within MSI-high samples correlates with tumour response 
to immune checkpoint blockade, as has been shown for tumour mutational burden 
(Yarchoan et al, 2017). 
Due to its modularity, an smMIP-based MSI test could also be tailored to different 
cancer types to maximise the number of clinically relevant biomarkers analysed for each 
tumour tested, making it competitive with gene panel, whole exome, and whole genome 
sequencing. It is also worth considering that actionable mutations, such as RAS gene 
mutations, occur in hotspots. For example, KRAS G12 and G13 mutations account for more 
than 90% of RAS gene mutations in CRC (Rajagopalan et al, 2002), and therefore select loci 
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could be included with minimal additional smMIPs. By targeting hotspot loci, an smMIP-
based assay would have a much lower price point than more extensive sequencing methods, 
and the 3-5 day TAT would allow rapid profiling of tumours to extract the most relevant 
information within treatment decision windows. Again, it is worth considering that cheap, 
targeted assays are not mutually exclusive with gene panel, whole exome, or whole genome 
sequencing – it is justifiable to reserve more expensive but comprehensive sequencing to 
cases of interest rather than apply these as the front line diagnostic tool. A final argument 
often used in favour of gene panel, whole exome, or whole genome sequencing is the ever 
falling cost of NGS (Horak et al, 2016). However, the MSI assay presented is also an NGS-
based method and hence would benefit from these cost reductions; given that it is already 
cheaper than the dominant MSI Analysis System (Promega), this only argues in favour of 
targeted sequencing. 
Ultimately, the development of this assay was driven by a need to improve the 
uptake of MMR deficiency testing, and the true measure of an assays clinical utility is in the 
improved outcomes for patients (Ray et al, 2010; Henry and Hayes, 2012). Current estimates 
of the rate of clinical uptake of MMR deficiency testing and the number of known Lynch 
syndrome gene carriers are becoming outdated. For example, the most recent estimates of 
clinical uptake are based on data from 2010-2012 (Shaikh et al, 2018), and estimates of what 
percentage of Lynch syndrome gene carriers are known have not been updated since 2011 
to my knowledge (Hampel and de la Chapelle, 2011). Therefore, with deployment of the 
smMIP and sequencing-based MSI assay into local clinical practice, it would be pertinent to 
audit the rate of MMR deficiency testing in recent years to formally assess the effect of both 
the guidelines that recommend MMR deficiency testing, such as NICE DG27 (Newland et al, 
2017), and the advances in available technologies. 
 
6.2.3. Microsatellite instability testing of non-neoplastic tissues 
MMR deficiency affects all tissues of CMMRD patients and the low level MSI in the non-
neoplastic tissues is a biomarker by which CMMRD can be identified. Advantages of a blood-
based assay are that it is minimally invasive and does not rely on the excision of tumour 
tissue, and therefore a diagnosis can be determined prior to surgery and other treatment 
decision. By applying the smMIP and sequencing-based assay to screening large cohorts of 
patients, for example those affected by childhood haematological malignancy (Furutani and 
Shimamura, 2017), the phenotypic spectrum of CMMRD will be better understood (Durno et 
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al, 2017) and the assay refined. One point of assay refinement is the panel of markers used. 
As PMS2 is the predominantly affected gene in CMMRD (Wimmer et al, 2017) and is the 
arguably the most difficult to interpret, due to pseudogenes (Nakagawa et al, 2004) and 
being the poorest annotated of the MMR genes in variant databases (Blount and Prakash, 
2017), it would be appropriate to analyse a wider spectrum of microsatellite markers to find 
those that are most sensitive and specific for PMS2 deficiency. For example, although 
insensitive for MSH6 deficiency, the DNRs used in the gMSI assay of Ingham et al (2013) 
achieve high accuracy for CMMRD detection using a simple PCR-based protocol and analysis. 
Additional, longer MNRs, and di-, tri- and tetra-nucleotide repeats are all candidate markers, 
and a reduction in the error of sequencing these different types of microsatellite, by use of 
molecular barcodes, has been shown in the literature (Carlson et al, 2015; Waalkes et al, 
2018), suggesting they too could be used to detect low-level MSI. Furthermore, the short 
MNRs used in the panel of the smMIP and sequencing-based MSI assay were selected for 
their instability in MSI-high CRCs, and it should not be assumed that markers sensitive to 
MMR deficiency in cancer are the most sensitive to MMR deficiency in normal tissues. 
Differences between cancers and normal tissue are also apparent in the level of MSI 
detected. Comparing the results in Chapters 4 and 5, it is evident that the rate of indel 
mutations in microsatellites is greatly increased in MMRd CRCs compared to MMRd non-
neoplastic PBLs. A likely explanation for this is the mono- or oligo-clonality of cancers, 
whereby the majority of tumour cells originate from one dominant clone and are, therefore, 
genetically homogeneous compared to precursor lesions, as shown by whole exome 
sequencing of CRCs and colorectal adenomas (Cross et al, 2018). In contrast, the PBL 
population is derived from a heterogeneous population of hematopoietic stem cells, 
especially in young individuals, as modelled in silico and in mouse models (Roeder et al, 
2008) and more recently shown by whole exome sequencing of 12,380 patients (Genovese 
et al, 2014). Indeed, clonal (rather than polyclonal) haematopoiesis is seen as an aberration 
of age and is associated with risk of haematological malignancy (Genovese et al, 2014). 
Therefore, variants in microsatellite length may be common to CMMRD PBLs, but they will 
not be represented throughout the PBL population and hence individual variants occur at a 
low frequency and are difficult to detect. Interestingly, ultra-hypermutated glioblastomas 
diagnosed from either a sporadic or CMMRD background are MSS by conventional MSI 
testing, despite MMR deficiency and loss of polymerase proof reading leading to complete 
ablation of replication error correction. This surprising observation was explained by the 
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rapid mutation rate of these tumours (approximately 600 mutations acquired per cell 
division) leading to rapid progression of a highly heterogeneous tumour population, with no 
dominant clone ever becoming established (Shlien et al, 2015). Therefore, the evolutionary 
landscape of a tumour or tissue as well as its MMR deficiency determines the strength of an 
MSI signal. 
 These considerations are also relevant to another application of MSI testing of non-
neoplastic tissues: screening for Lynch syndrome. The presence of MMR-DCF in the normal 
colorectal mucosa of Lynch syndrome gene carriers shows that MMR deficiency can strike in 
their non-neoplastic tissues (Kloor et al, 2012). It follows that MSI may be detectable in the 
non-neoplastic tissues of Lynch syndrome gene carriers as a biomarker of germline, 
heterozygous MMR gene mutation. Indeed, increased frequency of variants in microsatellite 
length have been detected in PBLs and buccal cells of Lynch syndrome gene carriers using 
small pool PCR of three DNRs D2S123, D5S346, and D17S518 (Coolbaugh-Murphy et al, 
2010; Hu et al, 2011), two of which are used by the gMSI assay for CMMRD diagnosis 
(Ingham et al, 2013). Alternatively, bacterial vectors have been used for high fidelity 
replication of single copies of BAT26 (an A26 MNR) initially amplified from patient PBLs to 
show increased microsatellite deletions in Lynch syndrome gene carriers (Alazzouzi et al, 
2005). Both techniques require dilution of template DNA to single copies, to facilitate 
detection of microsatellite length variants, and hundreds of PCRs per sample, but were able 
to separate the Lynch syndrome gene carriers analysed (n = 6, Alazzouzi et al, 2005; n = 7, 
Coolbaugh-Murphy et al, 2010; n = 8, Hu et al, 2011) from controls. Furthermore, 
Coolbaugh-Murphy et al (2010) and Hu et al (2011) found a correlation between Lynch 
syndrome gene carrier age and the frequency of microsatellite length variants, in agreement 
with previous studies using the same method in the general population (Coolbaugh-Murphy 
et al, 2005). 
The limited number of samples analysed in these studies, due to the laborious 
methods used, restrict the conclusions that can be drawn from their results, however it is an 
intriguing possibility that normal tissues could be screened to identify Lynch syndrome gene 
carriers by detection of low-level MSI, as was achieved for CMMRD. In this study, DNAs 
extracted from the PBLs of a small cohort of Lynch syndrome gene carriers (n = 40) was 
analysed using the same method as described for CMMRD detection (Section 5.6). Scores 
ranged from 0.00 to 0.92, meaning that, by this method, Lynch syndrome gene carriers are 
indistinguishable from controls. However, as discussed above, the panel of short MNRs may 
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not be the most sensitive markers for MSI in non-neoplastic tissues, supported by the use of 
a long MNR by Alazzouzi et al (2005), and the use of DNRs by Coolbaugh-Murphy et al (2010) 
and Hu et al (2011). Also, the analysis method, quantifying instability by the proportion of 
smSequences containing a WT length of microsatellite, is relatively simplistic and could be 
developed, for example, to look at the allelic distribution of microsatellite lengths detected 
as was shown to be effective in cancer diagnostics. In addition, protocol optimisation may be 
required, such as use of higher sequencing depth. 
As discussed in Chapter 5, the assay score for CMMRD could be affected by a number 
of factors, including patient age, their clinical history, and their genetic background, 
particularly the penetrance of their MMR variants. However, the rarity of the syndrome may 
make answering these research questions difficult. Alternatively, Lynch syndrome gene 
carriers may be as common as 1 in 300 of the general population (Hampel and de la 
Chapelle, 2011; Win et al, 2017), and should the assay be adapted to detect Lynch syndrome 
gene carriers as suggested, these questions could be answered in the context of monoallelic 
path_MMR gene variants. The different penetrance of MMR variants is particularly 
interesting – it is known that in some cancer-predisposition syndrome that different 
pathogenic variants within the same gene can be associated with greatly different disease 
phenotypes, including age of onset and tumour spectrum; in Li-Fraumeni syndrome, for 
example, dominant negative mutations in TP53 are associated with osteosarcomas, 
adrenocortical carcinomas, CNS tumours, and soft tissue sarcomas diagnosed in childhood, 
whereas non-dominant negative variants are associated with adult age-of-onset and a 
predominance of breast cancer (Bougeard et al, 2015). 
 An smMIP and sequencing-based assay for the detection of Lynch syndrome gene 
carriers from analysis of low level MSI in PBLs would remove the requirement for tumour 
tissue, and therefore bring Lynch syndrome screening and diagnosis forward in the clinical 
management of cancer patients. This is particularly relevant for the first cancer diagnosis in a 
Lynch syndrome patient, where early diagnosis of germline MMR defects is informative for 
patient treatment (Vasen et al, 2013). For example, the high risk for metachronous CRCs in 
Lynch syndrome (Aarnio et al, 1995) dictates that patients should be offered more extensive 
surgery, with the risk of subsequent CRC being reduced by 31% for every additional 10cm of 
colorectum resected (Parry et al, 2011), but this is not possible if diagnosis follows surgical 
resection of the tumour for testing. Another strategy to identify Lynch syndrome gene 
carriers is to screen the general population irrespective of cancer diagnosis, which is feasible 
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given estimates that there may be 3-4 carriers per 1000 in the general population (Hampel 
and de la Chapelle, 2011; Win et al, 2017). Population screening has been modelled 
previously using familial risk criteria to screen those aged 25 years or older in a population 
representative of the USA. Individuals with a ≥5% risk of being from a Lynch syndrome family 
were tested for pathogenic MMR gene mutations, and this general population screening 
model showed that colorectal and endometrial cancer incidence in the Lynch syndrome gene 
carrier population would fall by 12.4% and 8.8%, respectively, at a cost of $26,000 per QALY-
gained relative to no testing (Dinh et al, 2011). Again, it has been shown multiple times that 
familial criteria have a poor sensitivity relative to MMR deficiency testing (Pérez-Carbonell et 
al, 2012) and, with appropriate modifications to the low cost and scalable, smMIP and 
sequencing-based MSI assay presented, molecular screening of the general population could 
be used to detect low level MSI in normal tissues as a biomarker of heterozygous MMR gene 
mutation. General population screening strategies must have an exceptionally high 
specificity to reduce the number of false positives detected (Hartwell et al, 2006) and the 
detection of MSI in the non-neoplastic tissues of Lynch syndrome gene carriers needs to be 
proven with larger numbers of patients; however, the tools developed in this study provide a 
means to explore this idea further. 
 
6.3. Concluding Remarks 
MMR deficiency defines a distinct subtype of CRC (Guinney et al, 2015) and is associated 
with cancer predisposition syndromes, Lynch syndrome and CMMRD (Wimmer et al, 2008; 
Lynch et al, 2009). The unique features of MMR deficiency, for example the immunological 
interactions of affected tumours (Kloor and von Knebel Döberitz, 2016), and the high risks 
for multiple cancers in associated syndromes (Møller et al, 2017b; Wimmer et al, 2017), 
make its identification critical for disease and patient management. The importance of such 
personalised medicine has been recognised for over a decade, particularly with respect to 
therapeutic response (Schilsky, 2010), and will become increasingly available to health care 
services as we further understand the heterogeneity of cancer. In their short review titled 
“Personalised medicine in oncology: questions for the next 20 years”, Blay et al (2012) 
highlight the need to transition knowledge with respect to heterogeneity in genetic and 
clinical characteristics into practice, and the need to address the cost burden of novel tests 
and treatments. Alongside personalised medicine is “precision prevention and early 
detection”, in which at-risk populations are identified by their mechanistic association with 
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disease, such that appropriate interventions can reduce cancer risk and increase detection 
rates (Rebbeck et al, 2018). It is my hope that, by continuing the development of a novel MSI 
test, I have contributed to personalised medicine by providing a cheap and accurate 
biomarker test for MMR deficiency, an appropriate companion diagnostic for immune 
checkpoint blockade therapy. The novel MSI test can also be used for the identification of 
Lynch syndrome gene carriers and CMMRD patients by MSI testing of CRC and non-
neoplastic tissues, respectively, facilitating precision prevention and early detection 
strategies (Vasen et al, 2013; Vasen et al, 2014). Whilst additional research is needed to 
determine whether or not αFSP-Abs are an appropriate biomarker for the early detection of 
MMRd CRC, I believe this study has provided alternative ideas for the pursuit of cancer cares 
holy grail (Etzioni et al, 2003). 
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Chapter 7. Appendices 
7.1. Appendix A: Colorectal Cancer Sample Data and Source 
Sample MSI Status BRAF V600E Source Sample MSI Status BRAF V600E Source 
D206487 MSI-high NA Newcastle L0226 MSI-high NA Pamplona 
D227036 MSI-high NA Newcastle L0247 MSS NA Pamplona 
D248097 MSS NA Newcastle L0255 MSS NA Pamplona 
D250194 MSS NA Newcastle L0261 MSS NA Pamplona 
D250997 MSI-high NA Newcastle L0275 MSI-high NA Pamplona 
D251725 MSS NA Newcastle L0284 MSI-high NA Pamplona 
E08 MSS NA Edinburgh L0287 MSI-high NA Pamplona 
E43 MSI-high NA Edinburgh L0288 MSS NA Pamplona 
E44 MSI-high NA Edinburgh L0290 MSS NA Pamplona 
E49 MSI-high NA Edinburgh L0300 MSS NA Pamplona 
E55 MSI-high NA Edinburgh L0303 MSI-high NA Pamplona 
E57 MSI-high NA Edinburgh L0376 MSI-high NA Pamplona 
E60 MSS NA Edinburgh L0379 MSI-high NA Pamplona 
E65 MSI-high NA Edinburgh L0400 MSI-high NA Pamplona 
E67 MSS NA Edinburgh L0406 MSI-high NA Pamplona 
E74 MSS NA Edinburgh L0408 MSI-high NA Pamplona 
E76 MSS NA Edinburgh L0409 MSI-high NA Pamplona 
E81 MSS NA Edinburgh L0421 MSI-high NA Pamplona 
E83 MSS NA Edinburgh L0444 MSS NA Pamplona 
E85 MSS NA Edinburgh L0455 MSI-high NA Pamplona 
E89 MSI-high NA Edinburgh L0481 MSI-high NA Pamplona 
E90 MSI-high NA Edinburgh L0489 MSI-high NA Pamplona 
E91 MSI-high NA Edinburgh L0497 MSI-high NA Pamplona 
E93 MSS NA Edinburgh L0515 MSI-high NA Pamplona 
E97 MSI-high NA Edinburgh L0525 MSI-high NA Pamplona 
L0006 MSI-high NA Pamplona L0526 MSI-high NA Pamplona 
L0029 MSI-high NA Pamplona L0531 MSS NA Pamplona 
L0054 MSS NA Pamplona L0533 MSS NA Pamplona 
L0080 MSS NA Pamplona L0535 MSS NA Pamplona 
L0086 MSS NA Pamplona L0536 MSS NA Pamplona 
L0091 MSI-high NA Pamplona L0552 MSS NA Pamplona 
L0093 MSS NA Pamplona L0576 MSS NA Pamplona 
L0100 MSS NA Pamplona L0584 MSS NA Pamplona 
L0104 MSI-high NA Pamplona L0650 MSI-high NA Pamplona 
L0106 MSI-high NA Pamplona L0688 MSI-high NA Pamplona 
L0113 MSI-high NA Pamplona L0718 MSI-high NA Pamplona 
L0142 MSS NA Pamplona L0811 MSI-high NA Pamplona 
L0143 MSI-high NA Pamplona L0812 MSI-high NA Pamplona 
L0146 MSS NA Pamplona L0817 MSS NA Pamplona 
L0149 MSI-high NA Pamplona L0819 MSS NA Pamplona 
L0150 MSS NA Pamplona L0863 MSS NA Pamplona 
L0153 MSS NA Pamplona L0897 MSS NA Pamplona 
L0179 MSI-high NA Pamplona L0899 MSS NA Pamplona 
L0203 MSI-high NA Pamplona L0914 MSS NA Pamplona 
L0210 MSI-high NA Pamplona L0924 MSS NA Pamplona 
L0211 MSI-high NA Pamplona L0928 MSS NA Pamplona 
L0213 MSS NA Pamplona L0953 MSS NA Pamplona 
L0214 MSI-high NA Pamplona L0954 MSI-high NA Pamplona 
L0218 MSS NA Pamplona L0956 MSS NA Pamplona 
Table 7.1: CRCs in the classifier training cohort. MSI status assessed by the Promega MSI Analysis 
System v1.2. BRAF V600E assessed by high resolution melt curve analysis (Nikiforov et al, 2009). 
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Sample MSI status BRAF V600E Source Sample MSI status BRAF V600E Source 
155063 MSS NA Newcastle 233715 MSS NA Newcastle 
155087 MSS NA Newcastle 234543 MSI-high pos Newcastle 
155088 MSS NA Newcastle 237260 MSI-high neg Newcastle 
155089 MSS NA Newcastle 237780 MSI-high neg Newcastle 
155090 MSS NA Newcastle 238659 MSI-high pos Newcastle 
155501 MSS NA Newcastle 239222 MSI-high neg Newcastle 
155502 MSS NA Newcastle 239405 MSI-high neg Newcastle 
155694 MSS NA Newcastle 239970 MSI-high pos Newcastle 
155695 MSS NA Newcastle 241981 MSI-high pos Newcastle 
156188 MSS NA Newcastle 242117 MSI-high pos Newcastle 
167234 MSS NA Newcastle 244031 MSI-high neg Newcastle 
168888 MSS NA Newcastle 244881 MSI-high neg Newcastle 
204448 MSI-high neg Newcastle 245457 MSI-high NA Newcastle 
205882 MSI-high neg Newcastle 245836 MSI-high pos Newcastle 
207950 MSI-high neg Newcastle 245838 MSI-high pos Newcastle 
210173 MSS NA Newcastle 246656 MSI-high neg Newcastle 
210177 MSS NA Newcastle 246847 MSI-high pos Newcastle 
210178 MSS NA Newcastle 246849 MSI-high neg Newcastle 
210179 MSS NA Newcastle 247641 MSI-high neg Newcastle 
210180 MSI-high NA Newcastle 249555 MSI-high neg Newcastle 
210386 MSS NA Newcastle 249985 MSI-high neg Newcastle 
210777 MSS NA Newcastle 250505 MSI-high neg Newcastle 
210778 MSS NA Newcastle 250512 MSI-high neg Newcastle 
211727 MSS NA Newcastle 251058 MSI-high pos Newcastle 
212963 MSS NA Newcastle 252045 MSI-high neg Newcastle 
213233 MSI-high neg Newcastle 252048 MSI-high neg Newcastle 
213428 MSS NA Newcastle 252782 MSI-high pos Newcastle 
213520 MSI-high neg Newcastle 253580 MSI-high neg Newcastle 
215118 MSS NA Newcastle 253977 MSI-high neg Newcastle 
215770 MSS NA Newcastle 254175 MSI-high neg Newcastle 
216379 MSS NA Newcastle 254340 MSS NA Newcastle 
220045 MSS NA Newcastle 254574 MSS NA Newcastle 
220926 MSS NA Newcastle 255075 MSS NA Newcastle 
223129 MSS NA Newcastle 255078 MSI-high pos Newcastle 
223962 MSS NA Newcastle 255809 MSI-high neg Newcastle 
225162 MSS NA Newcastle 255810 MSI-high neg Newcastle 
225729 MSS NA Newcastle 255811 MSI-high NA Newcastle 
226491 MSS NA Newcastle 256265 MSS NA Newcastle 
226724 MSS NA Newcastle 256267 MSI-high neg Newcastle 
227175 MSS NA Newcastle 256271 MSI-high NA Newcastle 
228082 MSS NA Newcastle 257349 MSI-high neg Newcastle 
228417 MSS NA Newcastle D222913 MSI-high neg Newcastle 
228418 MSS NA Newcastle D223305 MSI-high neg Newcastle 
229072 MSS NA Newcastle D227036 MSI-high pos Newcastle 
229073 MSS NA Newcastle D229104 MSI-high neg Newcastle 
229291 MSS NA Newcastle D229113 MSI-high pos Newcastle 
229618 MSS NA Newcastle D234036 MSI-high neg Newcastle 
229619 MSS NA Newcastle D238498 MSI-high neg Newcastle 
229995 MSS NA Newcastle D238861 MSI-high pos Newcastle 
231954 MSS NA Newcastle 
Table 7.2: CRCs in the assay validation cohort. MSI status assessed by the Promega MSI Analysis 
System v1.2. BRAF V600E assessed by high resolution melt curve analysis (Nikiforov et al, 2009). 
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7.2. Appendix B: Constitutional Mismatch Repair Deficiency and Control Patient Samples 
Patient 
ID 
Genotype Age First 
Malignancy 
Malignancy Type Referring Physician Sample 
ID 
Age at Blood 
Draw 
Score gMSI A gMSI B gMSI C 
1 PMS2 hom 13years B-cell Burkitt
lymphoma
Iman Ragab C 13years 27.34 0.30 0.07 0.06 
2 PMS2 hom 5years glioblastoma Christian Kratz, 
Tim Ripperger 
A 5years 23.03 0.09 0.29 0.39 
3 MSH6 hom 13years colorectal cancer Iman Ragab D 20years 24.88 -0.04 -0.02 -0.05
4 MSH6 comp het 6years medulloblastoma Amedeo Azizi B 6years 10.02 -0.05 -0.04 -0.02
5 MLH1 comp het 6years T-NHL Michaela Nathrath E 21years 14.43 0.02 0.05 0.06 
6 MSH6 hom 11years glioblastoma Christian Kratz, 
Andreas Beilken 
65 11years 12.47 -0.07 -0.06 -0.05
7 PMS2 hom 9years glioblastoma Claudia Blattmann, 
Hans-Jürgen Pander 
54 
93 
≤9years 
9years 
53.59 
23.20 
0.04 
-0.03
0.23 
0.18 
0.29 
0.27 
8 * (F1) MSH6 comp het 10years T-cell lymphoma Stephan Lobitz 99 12years 1.59 -0.07 -0.05 -0.08
102 12years 4.62 -0.07 -0.06 -0.06
105 12years 2.08 -0.07 -0.05 -0.07
9 (F1) MSH6 comp het No Tumour NA Stephan Lobitz 82 9years 19.09 -0.07 -0.05 -0.08
10 PMS2 hom ND ND Manon Suerink 56 ND 25.52 0.18 0.08 0.33 
11 MSH6 hom 5years Wilms tumour Daniel Rueda 91 ND 9.85 -0.07 -0.06 -0.06
12 MLH1 hom 7months T-cell lymphoma Daniel Rueda 49 7months 42.98 0.06 0.11 -0.01
13 PMS2 hom 2years ALL Daniel Rueda 51 ND 5.71 -0.01 0.15 0.29 
14 MSH6 hom 13months medulloblastoma Julia Täubner 76 ND 18.07 -0.05 -0.03 -0.05
15 PMS2 hom 20years colorectal cancer Hagit Baris 98 26years 36.97 0.07 0.09 0.48 
16 MSH6 comp het 3years B-ALL Danuta 
Lewandowska 
83 8years 13.70 -0.07 -0.05 -0.07
17 MSH6 comp het 4years medulloblastoma Thorsten 
Rosenbaum 
43 4years 53.72 -0.06 -0.01 -0.05
18 PMS2 hom 7years sPNET Benoit Florkin 71 10years 14.49 -0.02 0.10 0.29 
19 (F2) MSH2 hom 9years colorectal cancer Karin Dahan 58 13years 14.85 0.07 0.06 0.26 
20 (F2) MSH2 hom 17years glioblastoma Karin Dahan 87 17years 27.67 0.05 0.08 0.23 
21 (F3) MSH6 hom 9years glioblastoma Imschweiler 101 9years 17.61 -0.04 -0.06 -0.06
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22 (F3) MSH6 hom No Tumour NA Imschweiler 107 13months 3.54 -0.04 -0.06 -0.11
109 15months 7.39 -0.04 -0.06 -0.11
23 (F2) MSH2 hom 9years colorectal cancer Karin Dahan 104 19years 42.52 0.05 0.08 0.26 
24 MSH2 hom 2years,  
4months 
medulloepithelioma Demirsoy 116 2years, 
11months 
43.10 0.07 0.04 0.20 
25 MSH2 hom ND T-cell lymphoma Demirsoy 132 6years 54.55 0.16 0.15 0.40 
26 PMS2 comp het 4years sPNET Aretz 113 14years 13.08 -0.05 0.06 0.22 
27 PMS2 comp het 9years B-cell lymphoma Aretz 124 9years 9.83 0.18 0.15 0.25 
28 PMS2 hom ND T-cell NHL Aretz 130 2years 12.82 0.24 0.14 0.32 
29 † PMS2 hom 24years brain tumor George Chong, 
William Foulkes 
125 24years 2.76 0.03 -0.03 0.05 
30 † PMS2 hom 3years medulloblastoma George Chong, 
William Foulkes 
120 18years 4.28 -0.04 0.06 0.15 
31 † PMS2 hom No Tumour NA George Chong, 
William Foulkes 
115 21years 5.90 0.05 0.06 0.07 
32 MSH6 hom 10years colorectal cancer George Chong, 
William Foulkes 
128 23years 4.78 0.01 -0.04 -0.04
Control01 NA NA NA NA 1 NA 0.002 -0.06 -0.02 -0.06
Control02 NA NA NA NA 2 NA 0.829 -0.05 -0.04 -0.05
Control03 NA NA NA NA 3 NA 0.533 -0.07 -0.05 -0.06
Control04 NA NA NA NA 4 NA 0.424 -0.04 -0.08 -0.08
Control05 NA NA NA NA 5 NA 0.046 -0.06 -0.04 -0.06
Control06 NA NA NA NA 6 NA 0.868 -0.07 -0.05 -0.06
Control07 NA NA NA NA 7 NA 0.042 -0.06 -0.05 -0.05
Control08 NA NA NA NA 8 NA 0.32 -0.08 -0.02 -0.08
Control09 NA NA NA NA 9 NA 0.205 -0.05 -0.04 -0.05
Control10 NA NA NA NA 10 NA 0.145 -0.05 -0.03 -0.07
Control11 NA NA NA NA 11 NA 0.28 -0.04 -0.05 -0.11
Control12 NA NA NA NA 12 NA 0.03 -0.04 -0.02 -0.02
Control13 NA NA NA NA 13 NA 0.10 -0.05 -0.06 -0.04
Control14 NA NA NA NA 14 NA 0.00 0.00 -0.06 -0.04
Control15 NA NA NA NA 15 NA 0.42 -0.08 -0.06 -0.07
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Control16 NA NA NA NA 16 NA 0.49 -0.07 -0.07 -0.04
Control17 NA NA NA NA 17 NA 0.00 -0.06 -0.04 -0.06
Control18 NA NA NA NA 18 NA 0.06 0.00 -0.06 -0.06
Control19 NA NA NA NA 19 NA 0.05 -0.08 -0.05 -0.07
Control20 NA NA NA NA 20 NA 0.03 -0.08 0.00 -0.02
Control21 NA NA NA NA 21 NA 0.01 -0.06 -0.03 0.00 
Control22 NA NA NA NA 22 NA 0.02 -0.07 -0.05 -0.05
Control23 NA NA NA NA 23 NA 0.00 -0.07 -0.07 -0.07
Control24 NA NA NA NA 24 NA 0.06 -0.07 -0.07 -0.08
Control25 NA NA NA NA 25 NA 0.78 -0.03 -0.07 -0.07
Control26 NA NA NA NA 26 NA 0.16 -0.07 -0.02 -0.08
Control27 NA NA NA NA 27 NA 0.00 -0.07 -0.06 -0.08
Control28 NA NA NA NA 28 NA 0.00 -0.04 -0.06 -0.03
Control29 NA NA NA NA 29 NA 0.48 -0.05 -0.06 -0.09
Control30 NA NA NA NA 30 NA 0.00 -0.07 -0.05 -0.07
Control31 NA NA NA NA 31 NA 0.16 -0.08 -0.07 -0.06
Control32 NA NA NA NA 32 NA 1.47 -0.08 -0.06 -0.08
Control33 NA NA NA NA 33 NA 0.02 -0.08 -0.06 -0.08
Control34 NA NA NA NA 34 NA 0.06 -0.08 -0.05 -0.05
Control35 NA NA NA NA 35 NA 1.46 -0.07 -0.07 -0.07
Control36 NA NA NA NA 36 NA 0.00 -0.07 -0.06 -0.07
Control37 NA NA NA NA 37 NA 0.14 -0.05 -0.07 -0.07
Control38 NA NA NA NA 38 NA 0.07 -0.08 -0.04 -0.07
Control39 NA NA NA NA 39 NA 0.57 -0.08 -0.07 -0.08
Control40 NA NA NA NA 40 NA 0.01 -0.06 -0.04 -0.09
Control41 NA NA NA NA 41 NA 0.66 -0.07 -0.06 -0.09
Control42 NA NA NA NA 42 NA 0.28 -0.08 -0.05 -0.08
Control43 NA NA NA NA 44 NA 0.01 -0.08 -0.05 -0.09
Control44 NA NA NA NA 45 NA 0.46 -0.05 -0.06 -0.07
Control45 NA NA NA NA 46 NA 0.21 -0.08 -0.05 -0.08
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Control46 NA NA NA NA 47 NA 0.00 -0.07 -0.05 -0.07
Control47 NA NA NA NA 48 NA 0.03 -0.02 -0.05 -0.04
Control48 NA NA NA NA 50 NA 0.03 -0.05 -0.04 -0.07
Control49 NA NA NA NA 53 NA 0.05 -0.08 -0.05 -0.08
Control50 NA NA NA NA 55 NA 0.20 -0.08 -0.07 -0.09
Control51 NA NA NA NA 59 NA 0.09 -0.08 -0.04 -0.09
Control52 NA NA NA NA 60 NA 0.03 -0.08 -0.06 -0.07
Control53 NA NA NA NA 61 NA 1.02 -0.08 -0.05 -0.08
Control54 NA NA NA NA 62 NA 0.09 -0.08 -0.05 -0.09
Control55 NA NA NA NA 63 NA 0.13 -0.08 -0.06 -0.09
Control56 NA NA NA NA 64 NA 0.13 -0.06 -0.05 -0.09
Control57 NA NA NA NA 66 NA 0.00 -0.07 -0.05 -0.07
Control58 NA NA NA NA 68 NA 0.10 -0.06 -0.06 -0.09
Control59 NA NA NA NA 69 NA 0.60 -0.07 -0.05 -0.08
Control60 NA NA NA NA 70 NA 0.00 -0.08 -0.06 -0.05
Control61 NA NA NA NA 72 NA 0.58 -0.07 -0.04 -0.09
Control62 NA NA NA NA 73 NA 0.22 -0.07 -0.06 -0.10
Control63 NA NA NA NA 74 NA 0.02 -0.08 -0.07 -0.05
Control64 NA NA NA NA 75 NA 0.09 -0.07 -0.06 -0.08
Control65 NA NA NA NA 77 NA 0.11 -0.08 -0.05 -0.08
Control66 NA NA NA NA 78 NA 0.01 -0.06 -0.09 -0.08
Control67 NA NA NA NA 79 NA 0.00 -0.07 -0.07 -0.07
Control68 NA NA NA NA 80 NA 0.10 -0.08 -0.07 -0.07
Control69 NA NA NA NA 81 NA 0.00 -0.06 -0.05 -0.09
Control70 NA NA NA NA 84 NA 0.00 -0.08 -0.06 -0.09
Control71 NA NA NA NA 85 NA 0.24 -0.08 -0.03 -0.09
Control72 NA NA NA NA 86 NA 0.06 -0.07 -0.07 -0.07
Control73 NA NA NA NA 88 NA 0.10 -0.07 -0.10 -0.06
Control74 NA NA NA NA 89 NA 0.01 -0.08 -0.07 -0.07
Control75 NA NA NA NA 90 NA 0.20 -0.08 -0.05 -0.05
167 
Control76 NA NA NA NA 92 NA 0.22 -0.08 -0.06 -0.10
Control77 NA NA NA NA 94 NA 0.02 -0.08 -0.03 -0.08
Control78 NA NA NA NA 95 NA 0.01 -0.09 -0.05 -0.06
Control79 NA NA NA NA 96 NA 0.08 -0.08 -0.05 -0.09
Control80 NA NA NA NA 97 NA 0.00 -0.08 -0.05 -0.09
Control81 NA NA NA NA 111 NA 0.01 -0.08 -0.04 -0.10
Control82 NA NA NA NA 112 NA 0.02 -0.08 -0.03 -0.08
Control83 NA NA NA NA 114 NA 0.10 -0.07 -0.05 -0.07
Control84 NA NA NA NA 117 NA 0.02 -0.09 -0.05 -0.07
Control85 NA NA NA NA 119 NA 0.27 -0.08 -0.06 -0.09
Control86 NA NA NA NA 121 NA 0.02 -0.07 -0.06 -0.10
Control87 NA NA NA NA 122 NA 0.01 -0.08 -0.05 -0.04
Control88 NA NA NA NA 123 NA 0.00 -0.07 -0.04 -0.06
Control89 NA NA NA NA 126 NA 0.01 -0.07 -0.05 -0.11
Control90 NA NA NA NA 127 NA 0.02 -0.06 -0.07 -0.06
Control91 NA NA NA NA 129 NA 0.00 -0.07 -0.03 -0.06
Control92 NA NA NA NA 131 NA 0.07 -0.06 -0.07 -0.08
Control93 NA NA NA NA 133 NA 0.08 -0.07 -0.06 -0.11
Control94 NA NA NA NA 134 NA 0.00 -0.08 -0.06 -0.08
Table 7.3: Clinical details and test results of constitutional mismatch repair deficiency and control samples. 36 DNA samples from 32 genetically-confirmed 
CMMRD patients were sourced from a number of referring physicians. 94 anonymised control DNA samples, extracted from peripheral blood leukocytes, were 
acquired from patients consulted for non-cancer related conditions at the Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria. All 
control patients had consented for use of residual DNA samples in assay development. Assay Score for each sample was calculated as described in Chapter 5. 
Higher score indicates increased MSI and therefore increased likelihood of CMMRD. gMSI ratios for three markers (A, D2S123; B, D17S250; C D17S791) were 
calculated with the Peak Heights software (Ingham et al, 2013). Marker ratios presented here are the observed ratio minus the marker-specific threshold; positive 
values represent ratios above the threshold. If two or more of the gMSI markers are above the threshold the sample is classified as CMMRD. Thresholds were 
calculated as per Ingham et al (2013), using the same 40 controls as were used for the control distributions for score calculation. 
ND: Not Disclosed. NA: Not Applicable. 
Patients from three families (F1), (F2), (F3) are indicated in Patient ID. * Patient 8 was aplastic when blood samples were collected, or just recovered from aplasia. 
† Patients homozygous for hypomorphic PMS2 mutation. 
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7.3. Appendix C: Frameshift Peptides analysed for Serum Reactivity 
FSP Amino Acid Sequence 
ACVR2(-1) VVHKKRGLFDYKDDDDK 
ACVR2(-2) VHKKEACFKRLLAETCWNGNALDYKDDDDK 
AIM2(-1) KAKKKHREVKRTNSSQLVDYKDDDDK 
AIM2(-2) IKAKKNIEKDYKDDDDK 
ASTE1(-1) NSKKKGRRNRIPAVLRTEGEPLHTPSVGMRETTGLGCDYKDDDDK 
ASTE1(-2) NSKKKAEETEYQLFDYKDDDDK 
BANP(-1) FFPFFCSVGADYKDDDDK 
C14orf106(-1) RVEKKNCSIPTYVKKRKTTNHSSQMTVHDYKDDDDK 
C14orf106(-2) RVEKKIAAYLPMDYKDDDDK 
C1orf34(-2)B RAAWEDKGGGGICGAWDFDWEIDYKDDDDK 
CASP5(-1) NHKKKQLRCWNTWAKMFFMVFLIIWQNTMFDYKDDDDK 
LMAN1(-1) LDKKKRNSRRATPTSKGSLRRKYLRVDYKDDDDK 
LMAN1(-2) ELDKKRGIPEGPPRPPRAACGGNIDYKDDDDK 
MARCKS(-2) TPKKKEALFLQEVFQAERLLLQEEQEGGWRRRDYKDDDDK 
MYH11(-1)A LRGPPHRKLRSDAPGEETRPLSFLLEGLEDVELLKMQMVLDYKDDDDK 
MYH11(-1)B LLKMQMVLRRKRTLETQTSMEPRPVNKQLSTVLHHDYKDDDDK 
MYH11(-1)C QLSTVLHHGKKTKNQNKQTKKTQQQPRTKQNPADCTDYKDDDDK 
MYH11(-2) LRGPPTGNFAVMHQARKRDLFRSFDYKDDDDK 
POLD3(-1) QKEKKGGSEDYKDDDDK 
PTHLH(-1) GLKKKRKTTEEHIICNDYKDDDDK 
Q96PS6(-1) IFFFFKDGVLLSHLGDYKDDDDK 
Q96PS6(-2) PIFFFSKMESYSLTDYKDDDDK 
SLC22A9(-1)A AAQKKNLLCVKCSTCPTYVKGSPSCPLRDLQTLWPILADYKDDDDK 
SLC22A9(-2) AAQKKTFSVDYKDDDDK 
TAF1B(-1) GLKKKTILKKAGIGMCVKVSSIFFINKQKPDYKDDDDK 
TGFBR2(-1) MKEKKSLVRLSSCVPVALMSAMTTSSSQKNITPAILTCCDYKDDDDK 
TMEM60(-2) HNIKKSLVPHCNVTDYKDDDDK 
UPF3A(-1) RCKKKRQINRRKLQRKKDYKDDDDK 
Table 7.4: Synthetic frameshift peptides (FSP) and their amino acid sequence. FSPs are denoted by 
“Gene(deletion length)”. The amino acid sequence is determined by the translation product of the 
gene following deletion in its coding mononucleotide repeat, with the N-terminus to the left and C-
terminus to the right. Amino acids in black represent the 5 amino acids upstream of the frameshift 
mutation, which will be found in the wild type protein. Amino acids in blue represent the novel 
amino acid sequence downstream of the frameshift mutation, generated by the change in reading 
frame. Where the novel sequence is >35 amino acids in length it is split between multiple FSPs, for 
example see MYH11(-1)A, MYH11(-1)B, and MYH11(-1)C. Amino acids in red are the FLAG 
octapeptide that is tagged to the C-terminus of all FSPs and is used as a control for non-specific 
binding. 
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7.4. Appendix D: Marker Loci for the smMIP and Sequencing-based MSI Assay  
Marker Chromosome MNR MNR Start MNR End Variant Variant Position 
BRAF chr7 - - - V600(E) 140453136 
AP0035_SNP1 chr11 A9 127625067 127625075 rs10893736 127625130 
DEPDC2_SNP1 chr8 G8 68926683 68926690 rs4610727 68926700 
GM01_SNP1 chr11 A10 28894429 28894438 rs7951012 28894411 
GM07_SNP1 chr7 A11 93085748 93085758 rs2283006 93085722 
GM09_SNP1 chr20 A8 6836977 6836984 rs6038623 6836952 
GM11_SNP1 chr5 A9 166099891 166099899 rs347435 166099902 
GM11_SNP2 chr5 A9 166099891 166099899 rs72817807 166099948 
GM14_SNP1 chr3 A11 177328818 177328828 rs6804861 177328829 
GM17_SNP1 chr11 A9 95551111 95551119 rs666398 95551136 
GM22_SNP1 chr14 A10 43401010 43401019 rs17113692 43400964 
GM26_SNP1 chr14 A10 49584751 49584760 rs11628435 49584720 
GM29_SNP1 chr3 A10 70905560 70905569 rs2687195 70905581 
IM16_SNP1 chr18 A9 1108767 1108775 rs4392141 1108738 
IM16_SNP2 chr18 A9 1108767 1108775 rs59912715 1108746 
IM16_SNP3 chr18 A9 1108767 1108775 rs73367791 1108784 
IM49_SNP1 chr3 A12 56682066 56682077 rs7642389 56682093 
IM66_SNP1 chr17 G7 48433967 48433973 rs147847688 48433971 
IM66_SNP2 chr17 G7 48433967 48433973 rs141474571 48433973 
IM66_SNP3 chr17 G7 48433967 48433973 rs4794136 48433958 
IM66_SNP4 chr17 G7 48433967 48433973 rs143225448 48433979 
IM66_SNP5 chr17 G7 48433967 48433973 rs140457310 48433950 
KRAS_1 chr12 - - - G12(R/C/S) 25398285 
KRAS_2 chr12 - - - G12(V/A/D) 25398284 
KRAS_3 chr12 - - - G13(C) 25398282 
KRAS_4 chr12 - - - G13(D) 25398281 
LR10_SNP1 chr1 A10 81591388 81591397 rs1768398 81591398 
LR10_SNP2 chr1 A10 81591388 81591397 rs1768397 81591415 
LR11_SNP1 chr2 A11 217217871 217217881 rs13011054 217217857 
LR11_SNP2 chr2 A11 217217871 217217881 rs16855951 217217913 
LR17_SNP1 chr14 A10 55603031 55603040 rs79618905 55603041 
LR17_SNP2 chr14 A10 55603031 55603040 rs77482253 55603042 
LR17_SNP3 chr14 A10 55603031 55603040 rs1009978 55603061 
LR17_SNP4 chr14 A10 55603031 55603040 rs1009977 55603002 
LR20_SNP1 chr1 A8 64029634 64029641 rs217474 64029606 
LR24_SNP1 chr1 A9 153779429 153779437 rs1127091 153779412 
LR36_SNP1 chr4 A12 98999723 98999734 rs17550217 98999699 
LR40_SNP1 chr2 A9 13447470 13447478 rs6432372 13447484 
LR44_SNP1 chr10 A12 99898286 99898297 rs7905384 99898268 
LR44_SNP2 chr10 A12 99898286 99898297 rs7905388 99898281 
LR46_SNP1 chr20 A8 10660085 10660092 rs6040079 10660063 
LR48_SNP1 chr12 A11 77988097 77988107 rs11105832 77988123 
LR49_SNP1 chr15 A7 93619048 93619054 rs12903384 93619037 
LR52_SNP1 chr16 A12 63861441 63861452 rs2434849 63861437 
 
Table 7.5: Marker loci for the smMIP and sequencing-based MSI assay. Loci are specified by 
chromosomal coordinates using reference genome hg 19. Mononucleotide repeats (MNRs) are 
specified by sequence content and the chromosomal coordinate at which the MNR starts and ends. 
Variant can refer to a somatic mutation known to be a driver in colorectal tumorigenesis, or can refer 
to a germline single nucleotide polymorphism.   
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7.5. Appendix E: Sequences of Molecular Inversion Probes, PCR Primers, and Sequencing Primers 
Oligonucleotide Description Oligonucleotide Sequence 
AP0035_2.0001_MIP Molecular inversion probe GCACATTATGTTGTAGTCAAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGTTTATTGGCCATTTGTATATATT 
BRAF_E_0007_MIP Molecular inversion probe CCATCAGTTTGAACAGTTGTCTGGATCCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTCTACTGTTTTCCTTT 
DEPDC2_0039_MIP Molecular inversion probe GTCTTTGACTCACCTGTGTAGTGTCTGCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNATGTTCACACACATGC 
GM01_0004_MIP Molecular inversion probe GGCTGTTACCAACTAAATCTTACCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCCTTTTAGAATGATCAGATT 
GM07_0036_MIP Molecular inversion probe CCAAACCCCATATGTGTGGTTGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTGGGCCCTTTTAGGCATATAG 
GM09_0026_MIP Molecular inversion probe GCATAAGGCTAGGATCATTTCATTCAAGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCACAAAAATCAATGCT 
GM11_0005_MIP Molecular inversion probe GAATACTTAGATACGTAGGTGATACTGAACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCAAAAAAGTACAGTGG 
GM14_0030_MIP Molecular inversion probe CAATGTTTATCCTTTGCTGGAATCAATTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNAATGACTTCCCAGGCT 
GM17_0009_MIP Molecular inversion probe GCAAGGGCCTGCATTGTGGTAAGTTTGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGCTATAAATATCCAGTG 
GM22_0007_MIP Molecular inversion probe CATCTTTCTTTCAAGGTGGTGCTCTTGGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCTATATTCCCCCAAAG 
GM26_D_0002_MIP Molecular inversion probe GTTCTGCTCCCGCTTGCGGATCAAAGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGGATTTAGAATCCAGCTC 
GM29_0020_MIP Molecular inversion probe CTCAGGGCTGAGGAGACTTTTTGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTTTCAGTGTGCCTTCCTGAG 
IM16_0021_MIP Molecular inversion probe TTTTGAAGATGCTTGCATAGCTATCTACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGCTGAGTAATATATGGG 
IM49_0028_MIP Molecular inversion probe GCACGCCTGTAATCCCAAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGGATCGCTTCAGGCCAGGAGTTCAA 
IM66_1.0019_MIP Molecular inversion probe CACGCCAGCCCTCAAGGCCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTCTCCAGACCCACCTTCTTCGCCC 
KRAS_0007_MIP Molecular inversion probe GTGACTATATTAGAACATGTCACACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTCGTCAAGGCACTCTTGCCT 
LR10_0001_MIP Molecular inversion probe CACTGTGAAGCAACACTGCGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGTAGTACTGGTTGAGTCTATTTTT 
LR11_0003_MIP Molecular inversion probe CCTCACATTTTATAAAGACTTTCAACAATCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCATTTCCTGTGCCTTT 
LR17_0011_MIP Molecular inversion probe CTCCAACAGCACCTTTCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTTCACCTTAGTTTGTTGTACTGCCAAA 
LR20_D.0001_MIP Molecular inversion probe GCAACTATTCAATTACAGTATATAGGGGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTATCATGAAATTCTAT 
LR24_0004_MIP Molecular inversion probe GTGGGAAAAATACTTATTCCAGGGAGAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTTTTAAAGGGGAAAGGA 
LR36_0032_MIP Molecular inversion probe AGAGTGCAAAGATAAATGTGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNAGTGGCTGGCACTTGTGGT 
LR40_0017_MIP Molecular inversion probe CAGTTATATATATGAAGAAGCTTGGATACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTCAGTTCAGTTGACTG 
LR44_0006_MIP Molecular inversion probe CACTTTTGTTCCTTGACTGTTTTTTACTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNCTGAGGTAGGCTCATTT 
LR46_0012_MIP Molecular inversion probe GTGAGTCGTCTGTTCTTGTGAATGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNGAGTTCAGTCTTTTCAGGGA 
LR48_0014_MIP Molecular inversion probe GCCCAATTATTTCAACCAGTTTCCACTGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNAGAAGATTCACTCAAA 
LR49_0016_MIP Molecular inversion probe GGAGAAATGTCTGAGGCTGAATTTGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNTGGCTGCCTTTTTAGGAGG 
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LR52_A_0010_MIP Molecular inversion probe GCATGTAGAACTGTTCCTCTAGTAGTCTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNAGGCAATCTTTAAAAC 
MIP_PosCon_MIP Molecular inversion probe GCAGTCTTCTACCTGTGTCTCTTCAGCTTCCCGATCCGACGGTAGTGTNNNNNNATTCACCTCATAGTAGAGCA 
MIP_Ampli_FP MIP universal amplification 
forward primer 
AATGATACGGCGACCACCGAGATCTACACATACGAGATCCGTAATCGGGAAGCTGAAG 
MIP_Ampli_RP MIP universal amplification 
reverse primer 
CAAGCAGAAGACGGCATACGAGATXXXXXXXXACACGCACGATCCGACGGTAGTGT 
AP0035_2.0001_intRP For amplicon validation TGTATGGAAGGAACACAAGAGT 
BRAF_E_0007_intRP For amplicon validation TGTCTGGATCCATTTTGTCATGA 
DEPDC2_1.0039_intFP For amplicon validation GCAAGCTGAAAGATCCTCGG 
DEPDC2_1.0039_intRP For amplicon validation CCGAGGATCTTTCAGCTTGC 
GM01_0004_intRP For amplicon validation TCGGGAAGCTGAAGAATCTGA 
GM07_1.0036_intFP For amplicon validation TGACCAAACCCCATATGTGTG 
GM07_1.0036_intRP For amplicon validation CACATATGGGGTTTGGTCACA 
GM09_1.0026_intRP For amplicon validation CCTGGAATACGGAGCATAAGG 
GM11_2.0005_intRP For amplicon validation TCTGAACCATTCCTTAATTGCCT 
GM14_0022_intRP For amplicon validation AGCTGGGAAGTCATTGAGTCT 
GM14_1.0030_intRP For amplicon validation TGGTCTTTTAGCCTGGGAAGT 
GM17_1.0009_intRP For amplicon validation ACACATGCACTGACTTCTGC 
GM22_0007_intRP For amplicon validation CCAGAGCTTTATAACCAAGAGCA 
GM26_0002_intRP For amplicon validation TTACTAAAGTCCAATCGAGAGCC 
GM29_0020_intRP For amplicon validation CAGGAAGGCACACTGAAACA 
IM16_1.0021_intRP For amplicon validation GGTATGAACACTGCTGATTCCA 
IM49_1.0028_intFP For amplicon validation TCAGGCCAGGAGTTCAAGAA 
IM49_1.0028_intRP For amplicon validation TGTTCTTGAACTCCTGGCCT 
IM66_1.0019_intRP For amplicon validation GAAGAAGGTGGGTCTGGAGA 
KRAS_0007_intRP For amplicon validation GGGAAGCTGAAGAGGCAAGA 
LR10_0001_intRP For amplicon validation ATGTATAACAATTTGGACTTAGCGC 
LR11_2.0003_intRP For amplicon validation TGAAGTTAGGCTCCGTGGTT 
LR17_0011_intRP For amplicon validation GGGGAGCTGAAGTTTGTATGT 
LR20_1.0001_intRP For amplicon validation GGGGCAAAACTAAACATGTAAGT 
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LR24_1.0004_intFP For amplicon validation GGTAACCAAAGCAGGAAAACAT 
LR24_1.0004_intRP For amplicon validation TGGTTACCTTTCCTTTCCCCT 
LR36_1.0032_intFP For amplicon validation TGTGGTGACCCTGAACGTTA 
LR36_1.0032_intRP For amplicon validation TCATTAACGTTCAGGGTCACC 
LR40_0017_intRP For amplicon validation CTGAACTGATGAATGTATAAGCCAC 
LR44_1.0006_intFP For amplicon validation GCCAAGAGTTCAAGACCAGC 
LR44_1.0006_intRP For amplicon validation GTCTCACTTTGTTGCCCAGG 
LR46_0012_intRP For amplicon validation CCTGAAAAGACTGAACTCTGTATCA 
LR48_2.0014_intRP For amplicon validation TGGAAGGAGGGCTAAACTGA 
LR49_1.0016_intRP For amplicon validation CTTTTGTGCCCCTTTCCCAA 
LR52_0010_intRP For amplicon validation GGCTTCTTGTAACCTTTTCTCAAAA 
MIP_bbFP For amplicon validation ACGAGATCTCTAGCAACACG 
MIP_bbRP  For amplicon validation GACCACCGAGATCTACACATAC 
MIP_PosCon_intFP  For amplicon validation TCCTCCAAATGTAGAATCTTCACC 
MIP_PosCon_intRP For amplicon validation ACACAGGTAGAAGACTGCACT 
MIP_Index_Seq_Primer Custom sequencing primer ACACTACCGTCGGATCGTGCGTGT 
MIP_Read1_Seq_Primer Custom sequencing primer CATACGAGATCCGTAATCGGGAAGCTGAAG 
MIP_Read2_Seq_Primer Custom sequencing primer ACACGCACGATCCGACGGTAGTGT 
 
Table 7.6: Oligonucleotide sequences of all probes and primers used in the development of the smMIP and sequencing-based MSI assay. See Chapter 4 for 
details of how each oligonucleotide was used. The MIP universal amplification reverse primer contains a sequence specified as “XXXXXXXX”. This is the sample 
index sequence, and circularised smMIPs from each sample are amplified with a unique sample index sequence to facilitate read de-multiplexing. 
Note: the reverse complement of the sample index sequence specified in the primer is used in the sample sheet for MiSeq loading (see Appendix F). 
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7.6. Appendix F: Example Sample Sheet for MiSeq Loading 
[Header] 
 
IEMFileVersion 4 
Investigator Name Richard Gallon 
Experiment Name 
 
Date 25/01/2017 
Workflow GenerateFASTQ 
Application FASTQ Only 
Assay Nextera XT 
Description 
 
Chemistry Default   
[Reads] 
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151 
 
  
[Settings] 
 
CustomRead1PrimerMix C1 
CustomIndexPrimerMix C2 
CustomRead2PrimerMix C3 
ReverseComplement 0   
[Data] 
 
Sample_ID index 
K562 TGCTAGAG 
HCT116 TGAGAGCT 
PR32516Normal ATAAGCGT 
PR32516Tumour GTCACTCA 
 
Table 7.7: Example sample sheet for MiSeq loading. The sample sheet specifies the workflow to be 
used, the length of reads in forward and reverse orientations, and the use of custom sequencing 
primers. Samples and sample index sequences are specified for read de-multiplexing. This example is 
the sample sheet used for the first sequencing run described in Section 4.4. 
 
 
 
 
 
7.7. Appendix G: PCR Primer Sequences for MSH6 c.3557-1G>C 
Oligonucleotide Oligonucleotide Sequence 
MSH6_7F CCAATATGTGTAGCTCATGATAGC 
MSH6_7R TATTAGTGTTCTCATCCCCGTAG 
 
Table 7.8: Primer sequences for amplification of the MSH6 c.3557-1G>C locus. Used to confirm the 
identity of sample 99 from patient 8, as describe in Section 5.6.   
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7.8. Appendix H: Distribution of Frameshift Peptide versus FLAG-only Control Median 
Fluorescence Intensity 
 
Figure 7.1: Distribution of frameshift peptide (FSP) versus FLAG-only control median fluorescence 
intensity (MFI). Both raw MFI data and ln(MFI) data are shown. As discussed in Section 3.4, log 
transformation reduces heteroscedasticity in the variance between FSP and control MFI. 
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7.9. Appendix I: Read-balancing the Multiplex Pool of Molecular Inversion Probes 
 
Marker Reads Assigned/ Mean Reads 
Read Balanced 
Volume μl 
BRAF 0.80 3.73 
DEPDC2 0.59 5.06 
GM01 1.57 1.91 
GM07 1.20 2.50 
GM09 0.58 5.15 
GM11 0.81 3.71 
GM14 1.65 1.82 
GM17 1.40 2.14 
GM22 3.14 0.96 
GM26 0.64 4.65 
GM29 1.44 2.09 
IM16 1.00 2.99 
IM49 0.24 12.55 
KRAS  0.30 9.87 
LR10 0.62 4.81 
LR11 0.72 4.19 
LR17 1.26 2.37 
LR20 0.34 8.84 
LR24 0.22 13.83 
LR36 1.13 2.66 
LR40 0.71 4.23 
LR44 0.27 11.14 
LR46 2.36 1.27 
LR48 2.22 1.35 
LR49 0.94 3.21 
LR52 1.22 2.46 
   
Mean MIP µl Total MIP µl Total pool µl 
4.60 119.50 460 
 
Table 7.9: Read-balancing the multiplex pool of molecular inversion probes (MIP). For each marker, 
the number of reads assigned across all samples in the training cohort was divided by the mean 
number of reads detected across all markers. This gave a “correction factor”: markers with a 
correction > 1 were over represented in the read data, and markers with a correction factor < 1 were 
under represented in the read data. To balance the number of reads detected for each marker, this 
correction factor was applied to the volume of each MIP added into the multiplex pool, where the 
balanced volume was equal to 3µl divided by the correction factor. The mean volume of 10nM MIPs 
added into the pool was calculated to determine the total pool volume required to dilute each MIP 
100-fold to reach a mean working stock concentration of 0.1nM for each MIP.  
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7.10. Appendix J: Reagent Costs of the smMIP and Sequencing-based MSI Assay 
 
smMIP-MSI assay on Illumina v2 Micro Kit (4 million read capacity)  
Item Cost per item (GBP) No. of samples Cost per sample (GBP)  
MIPs (25 MIPs per reaction) 500 500000 0.00 * 
T4 polynucleotide kinase (2500 Units, 10U/ul) 170 500000 0.00 * 
T4 DNA ligase buffer (6ml) 16 500000 0.00 * 
Ampligase DNA ligase (1000 Units, 5U/ul) 142 200 0.71  
Herculase DNA polymerase 2 (400 reaction kit) 290 225 1.29 † 
Exonuclease I (15,000 Units, 20U/ul) 207 750 0.28  
Exonuclease III (25,000 Units, 100U/ul) 182 250 0.73  
MIP sample indexing reverse primers (60 oligos) 510 192000 0.00 * 
MIP forward primer  8.5 3200 0.00 * 
QIAxcel screening kit (2400 samples) 542 2400 0.23  
AMPure XP DNA cleanup kit (60 ml) 1146 1333 0.86  
Qubit dsDNA HS kit (500 reaction kit) 175 500 0.35  
Custom sequencing primers (3 oligos) 15 3000 0.01  
Illumina v2 Micro Kit (4 million read capacity) 365 60 6.08 ‡ 
Illumina MiSeq machine run (Genomics Core charge) 130 60 2.17  
TOTAL     12.70  
  
Table 7.10: Reagent costs for the smMIP and sequencing-based MSI assay, using a MiSeq v2 Micro Kit and 25 markers. 
* Once smMIPs and primers are purchased the cost per sample is negligible. 
† 0.89ul polymerase used per sample, equivalent to 1.78 kit reactions. 
‡ Using 2000 reads/marker/sample and 25 markers/sample and assuming 0.75 on target reads. 
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smMIP-MSI assay on Illumina v3 Kit (25 million read capacity)  
Item Cost per item (GBP) No. of samples Cost per sample (GBP)  
MIPs (25 MIPs per reaction) 500 500000 0.00 * 
T4 polynucleotide kinase (2500 Units, 10U/ul) 170 500000 0.00 * 
T4 DNA ligase buffer (6ml) 16 500000 0.00 * 
Ampligase DNA ligase (1000 Units, 5U/ul) 142 200 0.71  
Herculase DNA polymerase 2 (400 reaction kit) 290 225 1.29 † 
Exonuclease I (15,000 Units, 20U/ul) 207 750 0.28  
Exonuclease III (25,000 Units, 100U/ul) 182 250 0.73  
MIP sample indexing reverse primers (375 oligos) 3187.5 1200000 0.00 * 
MIP forward primer  8.5 3200 0.00 * 
QIAxcel screening kit (2400 samples) 542 2400 0.23  
AMPure XP DNA cleanup kit (60 ml) 1146 1333 0.86  
Qubit dsDNA HS kit (500 reaction kit) 175 500 0.35  
Custom sequencing primers (3 oligos) 15 18750 0.00  
Illumina v3 Kit (25 million read capacity) 1273 375 3.39 ‡ 
Illumina MiSeq machine run (Genomics Core charge) 130 375 0.35  
TOTAL 
  
8.19  
  
Table 7.11: Reagent costs for the smMIP and sequencing-based MSI assay, using a MiSeq v3 Kit and 25 markers. 
* Once smMIPs and primers are purchased the cost per sample is negligible. 
† 0.89ul polymerase used per sample, equivalent to 1.78 kit reactions. 
‡ Using 2000 reads/marker/sample and 25 markers/sample and assuming 0.75 on target reads. 
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smMIP-MSI assay on Illumina v2 Micro Kit (4 million read capacity)  
Item Cost per item (GBP) No. of samples Cost per sample (GBP)  
MIPs (10 MIPs per reaction) 200 500000 0.00 * 
T4 polynucleotide kinase (2500 Units, 10U/ul) 170 500000 0.00 * 
T4 DNA ligase buffer (6ml) 16 500000 0.00 * 
Ampligase DNA ligase (1000 Units, 5U/ul) 142 200 0.71  
Herculase DNA polymerase 2 (400 reaction kit) 290 225 1.29 † 
Exonuclease I (15,000 Units, 20U/ul) 207 750 0.28  
Exonuclease III (25,000 Units, 100U/ul) 182 250 0.73  
MIP sample indexing reverse primers (60 oligos) 510 192000 0.00 * 
MIP forward primer  8.5 3200 0.00 * 
QIAxcel screening kit (2400 samples) 542 2400 0.23  
AMPure XP DNA cleanup kit (60 ml) 1146 1333 0.86  
Qubit dsDNA HS kit (500 reaction kit) 175 500 0.35  
Custom sequencing primers (3 oligos) 15 3000 0.01  
Illumina v2 Micro Kit (4 million read capacity) 365 150 2.43 ‡ 
Illumina MiSeq machine run (Genomics Core charge) 130 150 0.87  
TOTAL 
  
7.75  
  
Table 7.12: Reagent costs for the smMIP and sequencing-based MSI assay, using a MiSeq v2 Micro Kit and 10 markers. 
* Once smMIPs and primers are purchased the cost per sample is negligible. 
† 0.89ul polymerase used per sample, equivalent to 1.78 kit reactions. 
‡ Using 2000 reads/marker/sample and 10 markers/sample and assuming 0.75 on target reads. 
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smMIP-MSI assay on Illumina v3 Kit (25 million read capacity)  
Item Cost per item (GBP) No. of samples Cost per sample (GBP)  
MIPs (10 MIPs per reaction) 200 500000 0.00 * 
T4 polynucleotide kinase (2500 Units, 10U/ul) 170 500000 0.00 * 
T4 DNA ligase buffer (6ml) 16 500000 0.00 * 
Ampligase DNA ligase (1000 Units, 5U/ul) 142 200 0.71  
Herculase DNA polymerase 2 (400 reaction kit) 290 225 1.29 † 
Exonuclease I (15,000 Units, 20U/ul) 207 750 0.28  
Exonuclease III (25,000 Units, 100U/ul) 182 250 0.73  
MIP sample indexing reverse primers (375 oligos) 3187.5 1200000 0.00 * 
MIP forward primer  8.5 3200 0.00 * 
QIAxcel screening kit (2400 samples) 542 2400 0.23  
AMPure XP DNA cleanup kit (60 ml) 1146 1333 0.86  
Qubit dsDNA HS kit (500 reaction kit) 175 500 0.35  
Custom sequencing primers (3 oligos) 15 18750 0.00  
Illumina v3 Kit (25 million read capacity) 1273 937 1.36 ‡ 
Illumina MiSeq machine run (Genomics Core charge) 130 937 0.14  
TOTAL 
  
5.94  
  
Table 7.13: Reagent costs for the smMIP and sequencing-based MSI assay, using a MiSeq v3 Kit and 10 markers. 
* Once smMIPs and primers are purchased the cost per sample is negligible. 
† 0.89ul polymerase used per sample, equivalent to 1.78 kit reactions. 
‡ Using 2000 reads/marker/sample and 10 markers/sample and assuming 0.75 on target reads. 
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7.11. Appendix K: Modelling the Proportion of smSequences with WT Microsatellite Length 
by the Beta Distribution 
 
Figure 7.2: Comparison of Beta (black line) and empirical (red line) distributions. 40 non-CMMRD 
control samples were sequenced using the smMIP and sequencing-based MSI assay, and the 
proportion of smSequences containing WT reads (prWT) determined for each marker. The 
distribution of prWT in a control population was modelled by a Beta distribution for each marker 
(Section 5.5), which is compared here to the empirical distribution. 
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Figure 7.2: Comparison of Beta (black line) and empirical (red line) distributions of microsatellite 
length variants in controls. 40 non-CMMRD control samples were sequenced using the smMIP and 
sequencing-based MSI assay, and the proportion of smSequences containing WT reads (prWT) 
determined for each marker. The distribution of prWT in a control population was modelled by a 
Beta distribution for each marker (Section 5.5), which is compared here to the empirical distribution. 
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7.12. Appendix L: Three molecular pathways model colorectal carcinogenesis in Lynch 
syndrome. Ahadova, Gallon et al, 2018. 
As part of the work described in Section 2.7.1 and Chapter 3, I had a one month placement 
at the Department of Applied Tumour Biology, Heidelberg University Hospital, Heidelberg, 
Germany. During this time, I worked with collaborators (Dr Aysel Ahadova and Dr Matthias 
Kloor) to study a cohort of adenomas collected from Lynch syndrome gene carriers 
participating in the CAPP2 clinical trial (Burn et al, 2011). In summary, 21 dysplastic 
adenomas were analysed by IHC for loss of MMR protein according to the germline affected 
MMR gene. Of these, 19 (90.5%) were MMRd, and we found 4 samples where it appeared 
that MMR deficiency had occurred in normal colorectal mucosa and progressed to an MMRd 
dysplastic adenoma. This was clearest in the sample shown in Figure 1.7. In addition, I 
performed statistical analyses comparing the observed frequency of mutations in MMRd and 
MMRp CRCs with mutational signatures (Alexandrov et al, 2013). I am joint first author for 
the respective publication (Ahadova et al, 2018). However I felt that this work was too 
distinct from the other studies presented in this thesis, and hence it has not been included. 
The manuscript is appended to this section; as a distinct publication it does not follow the 
same scheme of page numbering. 
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Three molecular pathways model colorectal carcinogenesis in
Lynch syndrome
Aysel Ahadova 1,2,3†, Richard Gallon4†, Johannes Gebert1,2,3, Alexej Ballhausen1,2,3, Volker Endris5, Martina Kirchner5,
Albrecht Stenzinger5, John Burn4, Magnus von Knebel Doeberitz 1,2,3, Hendrik Bl€aker6 and Matthias Kloor1,2,3
1Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg Im Neuenheimer Feld 224, 69120 Heidelberg, Germany
2 Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
3Molecular Medicine Partnership Unit (MMPU), University Hospital Heidelberg, Heidelberg, Germany
4 Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, United Kingdom
5Department of General Pathology, Institute of Pathology, University Hospital Heidelberg Im Neuenheimer Feld 224, Heidelberg 69120, Germany
6Department of General Pathology, University Hospital Charite, Chariteplatz 1, Berlin 10117, Germany
Lynch syndrome is caused by germline mutations of DNA mismatch repair (MMR) genes. MMR deficiency has long been
regarded as a secondary event in the pathogenesis of Lynch syndrome colorectal cancers. Recently, this concept has been
challenged by the discovery of MMR-deficient crypt foci in the normal mucosa. We aimed to reconstruct colorectal carcinogen-
esis in Lynch syndrome by collecting molecular and histology evidence from Lynch syndrome adenomas and carcinomas. We
determined the frequency of MMR deficiency in adenomas from Lynch syndrome mutation carriers by immunohistochemistry
and by systematic literature analysis. To trace back the pathways of pathogenesis, histological growth patterns and muta-
tional signatures were analyzed in Lynch syndrome colorectal cancers. Literature and immunohistochemistry analysis demon-
strated MMR deficiency in 491 (76.7%) out of 640 adenomas (95% CI: 73.3% to 79.8%) from Lynch syndrome mutation
carriers. Histologically normal MMR-deficient crypts were found directly adjacent to dysplastic adenoma tissue, proving their
role as tumor precursors in Lynch syndrome. Accordingly, mutation signature analysis in Lynch colorectal cancers revealed
that KRAS and APC mutations commonly occur after the onset of MMR deficiency. Tumors lacking evidence of polypous growth
frequently presented with CTNNB1 and TP53 mutations. Our findings demonstrate that Lynch syndrome colorectal cancers can
develop through three pathways, with MMR deficiency commonly representing an early and possibly initiating event. This
underlines that targeting MMR-deficient cells by chemoprevention or vaccines against MMR deficiency-induced frameshift pep-
tide neoantigens holds promise for tumor prevention in Lynch syndrome.
Lynch syndrome and familial adenomatous polyposis (FAP)
are two major inherited tumor syndromes predisposing to
colorectal cancer.1 FAP is inherited through a germline
mutation in the APC gene, which, upon a second somatic
hit, results in the formation of hundreds to thousands of ade-
nomatous polyps (polyposis) in the colonic mucosa of muta-
tion carriers.2 The multiple clinically detectable lesions
illustrate that APC germline mutations lead to a strong
increase of the adenoma initiation rate in the colorectum.2,3
In contrast to FAP, polyposis is absent in Lynch syn-
drome, the most common hereditary colorectal cancer syn-
drome in adults, which is caused by germline mutations of
DNA mismatch repair (MMR) genes.4,5 Although some stud-
ies found an increased adenoma incidence in Lynch syn-
drome mutation carriers, adenomatous polyps in Lynch
syndrome were only slightly more prevalent than in the unaf-
fected population.6,7 This observation has suggested that
Lynch syndrome-causing MMR gene germline mutations do
not increase the adenoma initiation rate, but rather accelerate
the progression of preformed adenomas, which have devel-
oped independently from MMR deficiency, into invasive can-
cer.6,8 Therefore, Lynch syndrome was long regarded as a
prime example of an inherited tumor predisposition that
does not act through enhanced tumor initiation.6,8 MMR
deficiency, accordingly, has commonly been believed to be a
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secondary event, and somatic mutations of MMR genes were
thought to occur after the formation of polyps that had been
caused by APC mutations or other events occurring indepen-
dently from MMR deficiency.
Various observations of Lynch syndrome pathogenesis
have been interpreted as supportive of this concept: these
include the existence of polyps with retained or partial
expression of MMR proteins9 found in some Lynch syn-
drome patients.10–12 Moreover, correlation of MMR defi-
ciency with the higher grade and bigger size of the adenomas
seemed to further corroborate the role of MMR deficiency as
a “noninitiating” event in Lynch syndrome-associated colo-
rectal carcinomas.7,9,11,13–15
In recent years, however, the classical view of Lynch syn-
drome as an “accelerating” disease has been challenged, most
importantly by the discovery of MMR-deficient crypt foci
(MMR-DCF), colonic crypts presenting with a normal histo-
logical appearance but already lacking the expression of
MMR proteins.10,16 Although it has not been clear whether
these MMR-DCF had the potential of being true cancer pre-
cursors, it demonstrated that MMR deficiency can strike in
phenotypically normal cells and it in fact does so very fre-
quently during the life of Lynch syndrome mutation car-
riers.16 This observation opened up the possibility that
MMR-deficient colorectal cancers in Lynch syndrome, at least
to a certain proportion, may also develop from such MMR-
DCF. This concept has also been supported by several obser-
vations in path_MMR gene variant carriers: The majority of
adenomas show complete and homogeneous lack of MMR
protein expression in all dysplastic cells,17 50% of MMR-
deficient adenomas smaller than 5 mm have high grade dys-
plasia,14 and some MMR-DCF have aberrant histology,18
pointing to their potential role as cancer precursors. Very
recently, molecular studies on Lynch syndrome-associated
colorectal cancers have provided further support for MMR
deficiency as an event commonly preceding adenoma
formation.19
These conflicting observations could be explained by the
existence of multiple, common pathways of colorectal tumor-
igenesis in Lynch syndrome whereby MMR deficiency can
either precede or follow adenoma formation. Furthermore, an
entirely different pathway of carcinogenesis has been
described that may bypass the formation of polyps and lead
to the formation of invasive cancers from MMR-DCF
through a nonpolypous progression pathway.20 The existence
of MMR-deficient and nonpolypous lesions destined for
either rapid polypous growth or direct tissue invasion would
have wide ranging clinical implications, as such lesions would
escape colonoscopic detection and polypectomy,20 the recom-
mended surveillance and prevention method in Lynch syn-
drome patients. Indeed, whilst colonic surveillance and
polypectomy of Lynch syndrome patients reduces colorectal
cancer-associated mortality,21 the high frequency of interval
cancers in patients under regular colonoscopic surveillance
with polypectomy suggests that a significant proportion of
colorectal lesions are undetectable by colonoscopy and subse-
quently manifest as cancer within surveillance intervals.22
This illustrates that the sequence of mutational events in
Lynch syndrome carcinogenesis, which still represents a
highly controversial topic, is of crucial relevance to the opti-
mal clinical management of these patients.
In addition to the single putative pathway in which MMR
deficiency is a secondary, accelerating event, we hypothesized
that two more common pathways can contribute to Lynch
colorectal pathogenesis. These pathways are both initiated by
nonpolypous and MMR-deficient precursor lesions that can
either develop into polypous adenocarcinoma or invade
directly into the colorectal wall. Therefore, we aimed to
reconstruct the sequence of somatic mutational events in
Lynch syndrome carcinogenesis from two perspectives. First,
we performed a systematic literature review to determine the
proportion of MMR-deficient adenomas in Lynch syndrome
mutation carriers, complemented by the analysis of our own
collection of adenoma samples. Second, we evaluated next-
generation sequencing data of Lynch syndrome-associated
colorectal cancers to detect mutational signatures reflecting
the sequence of mutational events23 and to identify finger-
prints indicative of polypous or nonpolypous growth.
Materials and Methods
Patients and tumor specimens
Formalin-fixed paraffin-embedded tissue sections of 21 dys-
plastic adenomas from 15 Lynch syndrome mutation carriers
participating in the CAPP2 trial (colorectal adenoma/carci-
noma prevention programme 2, path_MLH1 variant carriers,
n5 10; path_MSH2 variant carriers, n5 5) were retrieved
and available for the analysis of MMR protein expression.
The collection of tumors has been described in a previous
study reporting the prevalence of polyps in Lynch syndrome
mutation carriers.24
What’s new?
Whether mutations in mismatch repair (MMR) genes play an initiating or a secondary role in colorectal carcinogenesis in Lynch
syndrome is unclear. To better understand the pathogenic process, the authors of this study developed a Lynch syndrome
model delineating three molecular pathways of colorectal cancer formation. Some colorectal cancers were found to grow from
MMR-proficient adenomas after secondary inactivation of the MMR system. However, most colorectal cancers developed from
MMR-deficient precursor lesions, either via an adenomatous phase or as nonpolypous lesions. The findings underline the
importance of prevention measures targeting MMR-deficient cells in the clinical management of Lynch syndrome.
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Formalin-fixed, paraffin-embedded archival tissue blocks
from 21 carcinomas from Lynch syndrome mutation carriers
(path_MLH1, n5 9, path_MSH2, n5 8, path_MSH6, n5 3,
path_PMS2, n5 1) were obtained from the Department of
Applied Tumor Biology, Institute of Pathology, University
Hospital Heidelberg. All patients provided their informed
and written consent in frame of the German HNPCC Con-
sortium, which was approved by the Institutional Ethics
Committee.
Literature survey
The systematic literature search of studies listed in NCBI
Pubmed by May 15, 2017 was performed using the following
keywords: {mismatch repair deficiency} OR {mismatch repair
protein expression} OR {mismatch repair gene} OR {micro-
satellite instability} OR {microsatellite unstable} OR {MMR
deficiency} OR {MMR gene} OR {MMR loss} OR {MMR pro-
tein expression} OR {MSI} OR {MSI-H}) AND ({adenoma}
OR {adenomatous} OR {colorectal adenoma} OR {colorectal
polyp} OR {dysplasia} OR {dysplastic lesions} OR {polyp} OR
{precancerous} OR {precursor}) AND ({hereditary non-
polyposis colorectal cancer syndrome} OR {HNPCC} OR
{Lynch} OR {Lynch patients} OR {Lynch syndrome} OR
{mutation carriers}. All studies written in English and analyz-
ing MMR deficiency in (1) adenomas (2) from Lynch syn-
drome patients (3) using immunohistochemical staining of
MMR proteins and/or PCR fragment length analysis of
mononucleotide microsatellite markers were collected and
used for integrated data analysis. Adenomas were included as
“Lynch syndrome adenomas” if the described patients ful-
filled the following criteria: proven path_MMR gene variant
carrier OR history of a tumor showing loss of MMR protein
expression plus proven path_MMR gene variant carrier
among first- or second-degree relatives. Only adenomas clas-
sified as “dysplastic” were included in the calculation of the
proportion of MMR-deficient lesions. The lesions were con-
sidered as MMR-deficient if they presented with MMR pro-
tein expression loss, instability of >30% of tested markers or
both. Studies analyzing <20 lesions from Lynch syndrome
patients were excluded. Collection of articles and extraction
of data was performed by one author (AA) and verified by a
second author (MK).
Immunohistochemistry (IHC)
For detection of MMR protein expression, paraffin blocks
were cut into 3-mm-thick sections. Deparaffinization and tis-
sue staining were performed according to standard protocols
published previously.25 The following primary antibodies
were used: anti-MLH1 (clone G168-15, dilution 1:300, BD
Pharmingen, Heidelberg, Germany) or anti-MSH2 (clone
FE11, dilution 1:100, Calbiochem, Darmstadt, Germany),
depending on the germline mutation status of the respective
patient. Staining was visualized using the Vectastain elite
ABC detection system (Vector, Burlingame, Calif., USA) and
using 3,30-Diaminobenzidine (DAB) (Dako) as chromogen.
Hematoxylin was used for blue counterstaining of cell nuclei.
Cells with nuclear staining signals in MMR protein staining
were assessed as MMR-proficient.
Mutational analysis of TCGA and DFCI databases
TCGA26 and DFCI27 databases were used to determine
somatic mutation patterns of commonly mutated colon can-
cer genes APC and KRAS in microsatellite-unstable (MSI)
cancer samples (www.cbioportal.org, status: January 31,
2017)).28,29 Mutational and clinical data (including MSI typ-
ing and CIMP/MLH1 methylation status) were downloaded
and used for stratification of MSI-H, MSI-L and MSS can-
cers. For the present study, MSI-L cancers were grouped
together with MSS cancers and comprised together the
“MSS” group, whereas “MSI-H” cancers are further referred
to as “MSI” throughout the manuscript. MSI cancers with a
negative CIMP/MLH1 methylation status were classified as
“MSI Lynch” and evaluated together with our own cohort of
21 tumors from Lynch syndrome patients, from which APC
and KRAS mutation data were obtained through next genera-
tion panel sequencing. MSI cancers with positive CIMP/
MLH1 methylation status were classified as “MSI sporadic”
and evaluated separately. Samples without mutational data or
without clinical data containing results of MSI typing were
excluded.
The order of mutational events in MSI Lynch colorectal
cancers was explored using the relative frequency of muta-
tions in APC and KRAS and the association of these muta-
tions with MMR deficiency, including insertion and deletion
mutations at homopolymers and substitutions. Substitutions
were typed according to the flanking nucleotide bases as well
as the base transition or transversion, according to the
scheme used by Alexandrov et al.23 The substitution proba-
bilities of mutational signature 6 (COSMIC)23 were used to
define expected frequencies of different substitutions in
MMR-deficient colorectal cancer. To estimate the proportion
of Lynch syndrome colorectal cancers in which MMR defi-
ciency preceded APC mutation, APC mutations were classi-
fied as “MMR deficiency-related” if they were single
nucleotide insertions or deletions affecting homopolymer
sequences (mononucleotide repeats) or if they were C>T
mutations occurring in a CpG sequence context, following a
simplified approach based on mutational signatures.23 Other
mutations were classified as “MMR deficiency-unrelated.”
Library preparation and semiconductor sequencing
Targeted next generation sequencing of 21 Lynch syndrome-
associated colorectal cancers was performed on IonTorrent
PGM and Proton sequencers using a custom 180 amplicon
panel (CRC panel) encompassing mutation HotSpot regions
in 30 genes30 (Supporting Information, Table 2).
Briefly, amplicon library preparation was performed with
the Ion AmpliSeq Library Kit v2.0 using approximately 10 ng
of DNA. The DNA was mixed with the primer pool, contain-
ing all primers for generating the 180 amplicons and the
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AmpliSeq HiFi Master Mix and transferred to a PCR cycler
(BioRad, Munich, Germany). After the end of the PCR reac-
tion, primer end sequences were partially digested using
FuPa reagent, followed by the ligation of barcoded sequenc-
ing adapters (Ion Xpress Barcode Adapters, Life Technolo-
gies). The final library was purified using AMPure XP
magnetic beads (Beckman Coulter, Krefeld, Germany) and
quantified using qPCR (Ion Library Quantitation Kit,
Thermo Fisher Scientific, Waltham, USA) on a StepOnePlus
qPCR machine (Thermo Fisher Scientific, Waltham, USA).
The individual libraries were diluted to a final concentration
of 100 PM, pooled and processed to library amplification on
an Ion OneTouch2. Unenriched libraries were quality-
controlled using Ion Sphere quality control measurement on
a QuBit instrument. After library enrichment (Ion OneTouch
ES), the library was processed for sequencing using the Ion
Torrent 200 bp HiQ sequencing chemistry and the barcoded
libraries were loaded onto 318 or PI chips.
Variant calling and annotation
Data analysis was performed using the Ion Torrent Suite
Software (version 5.0). After base calling, the reads were
aligned against the human genome (hg19) using the TMAP
algorithm within the Torrent Suite. Variant calling was per-
formed with the variant caller plugin within the Torrent Suite
Software and the IonReporter package using a corresponding
bed-file containing the coordinates of the amplified regions.
Only variants with an allele frequency >5% and minimum
coverage >100 reads were taken into account. Variant anno-
tation was performed using Annovar.31 Annotations included
information about nucleotide and amino acid changes of
RefSeq annotated genes, COSMIC and dbSNP entries as well
as detection of possible splice site mutations. For data inter-
pretation and verification, the aligned reads were visualised
using the IGV browser (Broad Institute).32
Statistical analysis
The calculation of 95% confidence intervals (CI) for the
observed frequencies of MMR deficiency in Lynch syndrome
adenomas was performed using the modified Wald method
and GraphPad Prism software (Version 6.02). Fisher’s exact
test was performed to test for significant differences of muta-
tion frequencies between groups, using GraphPad Prism soft-
ware (Version 6.02). Median regression and Kernel density
estimation of residuals was used in R (Version 3.3.1) to ana-
lyse the relationship between the relative frequencies of
observed substitutions and their relative probabilities in
mutational signature 6.23
Results
MMR deficiency in Lynch syndrome adenomas
To determine the frequency of DNA mismatch repair defi-
ciency in adenomas from Lynch syndrome mutation carriers,
we performed a systematic literature analysis. The initial
search of the NCBI Pubmed database resulted in 545 records.
Five hundred and nine publications that evidently did not
address the research topic of interest were excluded based on
the title. Out of the remaining 36 records, 22 were excluded
because they either did not address the research question or
information on MMR deficiency could not be extracted sys-
tematically for the analyzed samples. An additional 2 studies
were excluded because the number of the analyzed samples
was too low (Fig. 1a). The 12 studies that fulfilled the inclu-
sion criteria reported information about MMR deficiency in
dysplastic adenomas, with the number of samples studied
ranging from 25 to 134. In total, 619 Lynch syndrome-
associated dysplastic adenomas were included in the quanti-
tative data synthesis for the calculation of the mean fre-
quency of MMR deficiency in Lynch syndrome-associated
adenomas. 7 out of 12 published studies used both IHC and
PCR methods to determine MMR deficiency, 4 studies used
only IHC and 1 study used only PCR-based methods (Fig.
1b). In studies that used both methods, lesions were classified
as MMR-deficient if at least one of the methods showed evi-
dence of MMR deficiency. In total, evidence of MMR defi-
ciency was detected in 472 out of 619 adenomas, with a
slightly higher proportion of MMR-deficient lesions in
cohorts analyzed by IHC compared to PCR-based methods
(76.41% vs 69.02%, p5 0.017).
In addition to the published series of dysplastic adenomas,
we performed immunohistochemical staining of MMR pro-
teins in 21 dysplastic adenoma specimens obtained during
the CAPP2 trial (Supporting Information, Table 1, Fig. 2).
No significant difference in the proportion of MMR-deficient
lesions was observed among lesions from patients taking
aspirin and those taking placebo (8 of 10 in the aspirin vs
11/11 in the placebo group, p5 0.214). These adenomas were
then included in the quantitative data synthesis, constituting
a final set of 640 dysplastic adenomas with confirmed MMR
deficiency status. Overall, 491 (76.7%) out of these 640 exam-
ined lesions showed evidence of MMR deficiency (95% CI:
73.3–79.8%) (Fig. 1c Forest Plot).
Information about heterogeneity of MMR protein expres-
sion in Lynch syndrome adenomas, that is, the existence of
MMR-proficient dysplastic crypts, can provide important
information about the sequence of mutation events in the
respective lesion. Among the identified publications, explicit
information about heterogeneity was available for 219 dys-
plastic adenomas that presented with MMR protein
loss.11,12,17 In addition, all 19 MMR-deficient adenomas from
the CAPP2 cohort were analyzed for heterogeneity. Alto-
gether, eight (3.3%) of these 238 adenomas showed MMR-
proficient dysplastic crypts. Single adenomas with a heteroge-
neous MMR protein expression pattern have also been
reported in manuscripts not included in the quantitative data
synthesis.10,33
Whereas onset of MMR deficiency occurring in an already
existing adenoma may manifest as heterogeneity among dys-
plastic crypts, MMR deficiency preceding adenoma formation
may be detectable through the presence of adjacent,
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nondysplastic MMR-DCF.16 In fact, one of the MMR-
deficient adenomas analyzed showed such MMR-deficient
nondysplastic crypts (Fig. 2a), indicating that MMR defi-
ciency in this lesion occurred prior to adenoma formation.
Mutation patterns in Lynch syndrome cancers
Although giving a useful hint regarding the possible sequence
of mutational events, examination of adenomas does not pro-
vide any information about tumor progression to cancer. To
estimate the timing of MMR deficiency in Lynch syndrome
associated colorectal cancers, we analyzed the frequencies of
known driver mutations that are likely related to MMR defi-
ciency to reconstruct the sequence of mutational events in
relation to the onset of MMR deficiency.
The focus of this analysis was on mutations of genes play-
ing a key role in the adenoma-carcinoma model of colorectal
cancer, APC, KRAS and TP53.8,34 The analyzed mutations
included small insertions and deletions and base substitu-
tions. Mutational signature 6 from the COSMIC database,23
which is associated with MMR deficient colorectal cancer,
was used as a reference. We hypothesized that the observed
mutations would be associated with this signature if MMR
deficiency preceded their occurrence. We supplemented the
next generation sequencing data of our collection of Lynch
syndrome colorectal cancers (n5 21) with data available in
the TCGA and DFCI databases, from which mutation data of
a total of 752 colorectal cancers samples (“MSI Lynch,”
n5 26) could be included, resulting in a series of 47 colorec-
tal cancers classified as “MSI Lynch” (Supporting Informa-
tion, Fig. 1).
For TP53, which is known to be rarely mutated in Lynch
syndrome colorectal cancers,35 the number of mutation
events in Lynch syndrome cancers was too low for a reliable
analysis. Therefore we first examined mutations of the KRAS
gene, which are considered a late event commonly occurring
after the initiation of carcinogenesis36 and therefore likely to
occur after the onset of MMR deficiency. Oncogenic KRAS
mutations most commonly affect codons 12 and 13 leading
to loss of GTPase activity and in turn constitutive activation
of the KRAS protein.37 In total, 8 different types of substitu-
tion (determined by the base substitution and the context
of flanking nucleotides) were identified in the analyzed
Figure 1. Systematic literature analysis of MSI frequency in Lynch syndrome adenomas. (a) Flow diagram illustrating the numbers of studies
screened, assessed for eligibility, and included in the review according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) recommendations. From an initial set of 545 records screened, 12 studies were eligible and included in the quantitative
synthesis. (b) Tabellary view of the included studies. (c) Forest plot of the results. Together with our own data, MMR deficiency/MSI was
detected in 491 (76.7%) out of 640 adenomas from Lynch syndrome mutation carriers. [Color figure can be viewed at wileyonlinelibrary.com]
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colorectal cancers (Fig. 3a). The relative frequencies of point
mutation types in the KRAS gene observed in MSI Lynch
colorectal cancers were linearly related to their relative proba-
bilities in mutational signature 6 using quantile regression
(b5 0.752, p5 0.033). However, KRAS mutations in MSS
colorectal cancers were not linearly related to their relative
probabilities in signature 6 (b5 0.325, p5 0.674). These find-
ings suggest that KRAS gene mutations in Lynch syndrome
cancers commonly occur after the onset of MMR deficiency
(Fig. 3a).
In contrast to the codon restriction of KRAS mutations,
mutations of the APC tumor suppressor gene are more wide-
spread over the entire gene sequence. Small insertion/deletion
mutations at homopolymers and substitutions were observed
in both, MSI Lynch and MSS colorectal cancers, but in differ-
ent proportions. Single base pair insertion/deletions at homo-
polymers are strongly associated with MMR deficiency and
mutational signature 6, and accounted for 16.7% of APC
mutations in Lynch syndrome colorectal cancers, but only
5.0% of APC mutations in MSS colorectal cancers (Fisher’s
exact test, p5 0.012). As for KRAS, the relative frequency of
APC substitutions were linearly related to their relative prob-
abilities from mutational signature 6 in MSI Lynch colorectal
cancers (b5 1.16, p< 0.001) but not in MSS colorectal can-
cers (b5 0.494, p5 0.336, Fig. 3b).
As a rough approximation of the proportion of tumors
that acquire MMR deficiency before APC mutation, the
observed mutations were grouped into MMR deficiency-
related and MMR deficiency-unrelated. Among Lynch syn-
drome cancers (n5 47), 27 (75%) out of the total 36 APC
mutation events were considered as MMR deficiency-related,
being C>T mutations at CpG sites (n5 21) or single nucle-
otide insertion/deletions at homopolymer sequences (n5 6),
whereas this was the case only in 209 (35%) out of 603 APC
mutations in MSS cancers (Table 1). Using the proportion of
such mutations in MSS cancers as a background, we pre-
dicted the proportion of APC mutations occurring after the
onset of MMR deficiency in hereditary MSI cancers to be
61% (95% CI: 33% to 80%) (Fig. 3c), which is consistent with
the proportion of adenomas with MMR deficiency.
Figure 2. Immunohistochemical MMR protein staining of Lynch syndrome adenomas. Adenomas from the CAPP2 trial were stained for the
MMR protein corresponding to the reported germline mutation (a: MSH2; b, C: MLH1). Loss of MMR protein expression is seen in dysplastic
adenoma crypts (arrows, a–c). Interestingly, nondysplastic crypts demonstrating loss of MMR protein expression were detected in direct
vicinity of one adenomatous lesion (arrowhead, a). MMR proficiency is indicated by brown nuclear staining, MMR deficient cells have blue
nuclei (hematoxylin counterstaining).M
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Nonpolypous cancers in Lynch syndrome: the third
pathway
Previously, we have provided evidence that some Lynch
syndrome-associated colorectal cancers develop through an
adenoma-independent, nonpolypous pathway of progression.
Such nonpolypous colorectal cancers were previously shown
to frequently harbor CTNNB1 mutations as activators of Wnt
signaling.20 We now performed next generation sequencing
to obtain a broader mutational pattern of such proposed
nonpolypous Lynch syndrome colorectal cancers, identified
by the absence of tumor-adjacent adenoma formations, and
compared the mutation profile to cancers with evident ade-
noma history. As previously published,20 CTNNB1 mutations
predominantly occurred in cancers lacking evidence of an
adenomatous precursor stage (5 out of 10 cancers, Fig. 4),
but they were also found in one out of five cancers that
developed in an adenoma. Significant differences between
polypous and nonpolypous cancers with regard to mutations
in colorectal cancer genes were only found for TP53 muta-
tions (p5 0.044, Fig. 4), which were restricted to cancers
lacking evidence of polypous growth. The number of
observed CTNNB1 mutations was too low to determine the
Figure 3. Mutation signature of MMR deficiency in KRAS and APC mutations. (a) KRAS mutation patterns differed significantly between MSI
and MSS colorectal cancers, with a clear predominance of G13D and G12D mutations in MSI cancers, in line with mutation signatures of
MMR deficiency.23 (b) Quantile regression between the relative frequencies of APC substitutions and their probabilities according to the
COSMIC mutation signature of MMR-deficient colorectal cancer (signature 6). A significant relationship was observed for MSI Lynch cancers
(open circles represent types of substitution, b51.16, p<0.001), whereas no such relationship was detected for MSS cancers (crosses
represent types of substitutions, b50.494, p50.336). (c) Estimation of the proportion of APC mutations occurring after MMR-deficiency
based on a simplified approach using mutational signatures: MMR-deficiency-related APC mutations were detected in 27 out of 36 (75%)
APC-mutant Lynch syndrome colorectal cancers. Assuming that only MMR-deficiency related mutations would be observed if all cancers had
MMR deficiency preceding APC mutation and accounting for a background of 35% such mutations also occurring in MSS cancers, this num-
ber corresponds to 61% (95% CI: 33–80%) of MSI Lynch cancers having MMR loss precede APC mutation.
Table 1. Type and number of mutations in the APC gene of APC-mutant cancers
Group
Number of
cancers
analyzed
Number of
mutations
Number of
C> T mut.
Number of
C> T mut. at CpG
Number of ins/
del mut. at MS
Number of
other mut.
Mutations with
MMR deficiency
Si:nature (%)
MSI Lynch 47 36 24 21 6 6 75
MSI sporadic 93 34 15 10 8 11 53
Mss 633 603 271 179 30 302 35
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timing of MMR deficiency. Two tumors lacking both, APC
and CTNNB1 mutations harbored frameshift mutations of
homopolymers in the RNF43 gene (not shown), an alterna-
tive activator of Wnt signaling.
Discussion
This study was initiated to comprehensively address the ques-
tion of distinct pathogenesis pathways in Lynch syndrome on
different levels, by analyzing colorectal lesions of different
progression stages using literature data, molecular profiling
and cancer genome databases.
First, we examined the overall frequency of MMR-
proficient lesions among adenomas in Lynch syndrome muta-
tion carriers by a systematic literature review, providing the
largest dataset available so far. Literature data together with
MMR deficiency data obtained in our own cohort revealed
that MMR-proficient adenomas represent less than a quarter
of all adenomas in Lynch syndrome (23.3%), indicating that
the majority of Lynch syndrome adenomas are MMR-
deficient. Naturally, most of the adenomas included in the lit-
erature analysis were from path_MLH1 and path_MSH2 car-
riers, and future analyses will have to show whether the
proportion of MMR-deficient adenomas may be different in
path_MSH6 and path_PMS2 carriers.
Overall, adenomas analyzed by IHC had a slightly, but
significantly higher frequency of MMR deficiency than those
analyzed by PCR. This is in contrast to the situation in
MMR-deficient colorectal cancers, in which PCR-based meth-
ods have been shown to have a higher sensitivity.38 This dis-
crepancy likely reflects the fact that loss of protein expression
occurs synchronously with the onset of MMR deficiency,
whereas microsatellite instability gradually increases with the
progression of MMR-deficient lesions, hence being less pro-
nounced in adenomas compared to clinically diagnosed can-
cers.39 In the present analysis, we therefore used IHC to
detect MMR deficiency assuming it to have higher sensitivity
than PCR-based techniques and to explore the spatial hetero-
geneity of MMR protein expression.
The vast majority of analyzed adenomas presented with a
complete loss of the respective MMR protein, whereas adeno-
mas presenting with heterogeneous MMR protein expression
patterns in dysplastic crypts were absent in our own cohort,
and reported only very rarely in the literature (3.3%). This
observation can either be explained by MMR-deficient
Figure 4. Mutation status of key colorectal genes in Lynch syndrome cancers. Colorectal cancers were grouped according to the evidence of
polypous growth (no, black; yes, grey; not assessable, white). (a) Patient-wise color-coded mutation data (red, stop mutation; orange,
frameshift insertion/deletion mutation; purple, in-frame deletion; green, amino acid exchange activating oncogene; blue, amino acid
exchange inactivating tumor suppressor gene). (b) Comparison of mutation frequencies between Lynch syndrome-associated colorectal can-
cers with and without evidence of polypous growth. A significantly higher mutation frequency was observed in nonpolypous than polypous
cancers for TP53 (*p50.044).
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dysplastic cells very rapidly overgrowing MMR-proficient
dysplastic cells, or alternatively by MMR deficiency preceding
dysplasia formation. Compatible with the latter possibility,
we detected nondysplastic MMR-deficient crypts directly
adjacent to one dysplastic MMR-deficient adenoma from our
own cohort, proving that MMR deficiency can be an initiat-
ing event in adenoma formation and that MMR-DCF are
bona fide tumor precursors in Lynch syndrome.
To obtain a better estimate of the proportion of MSI colo-
rectal cancer initiated by MMR deficiency, that is, MMR-
DCF, and those originating from MMR-proficient adenomas,
we reconstructed the sequence of events by determining
whether APC and KRAS mutations in manifest cancers
showed fingerprints of pre-existing MMR deficiency. It has
recently been published that APC mutations in Lynch
syndrome-associated colorectal cancers are more frequently
insertion/deletion mutations at repetitive sequences than in
microsatellite-stable colorectal cancers,19 which agrees with
our observations in this study. We extended the mutation
signature analysis to include substitutions and showed that
the relative frequencies of the observed APC substitutions
were different in MSI Lynch and MSS colorectal cancers.
Furthermore, the relative frequencies of each substitution in
MSI Lynch colorectal cancers were similar to what would be
expected if caused by MMR-deficiency, based on the proba-
bilities determined by mutational signature 6, while this was
not the case for MSS colorectal cancers,23 adding further evi-
dence that MMR deficiency frequently precedes APC muta-
tion in Lynch syndrome-associated colorectal carcinogenesis.
By classifying C>T transitions at CpG sites and insertion/
deletion mutations at repetitive sequences as “MMR
deficiency-related,” we predict that approximately 61% of
APC mutations in Lynch syndrome-associated cancers occur
after the onset of MMR deficiency. This observation is com-
patible with the hypothesis that the majority of adenomas
ultimately developing into colorectal cancer in Lynch syn-
drome are initiated by MMR deficiency, in agreement with
the high rate of MMR deficiency in adenomas, the existence
of MMR-DCF and our unique finding of a MMR-deficient
adenoma outgrowing from a MMR-DCF. Accounting for the
fact that part of Lynch syndrome adenomas, instead of APC
mutations, harbor MMR deficiency-induced RNF43 muta-
tions as activators of Wnt/beta-catenin signaling, the percent-
age of adenomas initiated by MMR deficiency may even be
higher than predicted from APC mutation signatures
alone.19,40 Similarly the analysis of KRAS mutation patterns
in MSI Lynch colorectal cancers revealed an association with
the MMR-deficiency related mutational signature 6; as for
APC, our data suggests a sequence of events in which MMR
deficiency commonly precedes activating KRAS mutations. In
addition, MMR deficiency being the cause of subsequent
driver mutations is a likely explanation for the predominance
of G13D mutations in MMR-deficient colorectal cancers as
previously reported,41 in spite of its potentially lower onco-
genic effect compared to codon 12 mutations.42 Our data
also demonstrate the applicability of mutational signature
analysis for tracking sporadic MSI cancer development. Also
in these tumors, an elevated proportion of MMR deficiency-
related APC mutations was observed. However, these results
need to be integrated in carcinogenesis models that account
for the different mutational events and precursor lesions,
such as sessile serrated adenomas.43
Our approach has limitations. First, we did an overall
analysis of APC and KRAS mutations occurring in all tumors
together, not dissecting individual tumors for the occurrence
of multiple mutations. Second, due to lack of information
about path_MMR gene variant status in tumors from DFCI/
TCGA databases, 26 tumors were assigned into the “MSI
Lynch” group due to negative MLH1 promoter methylation/
CIMP status. This approach may lead to the inclusion of a
small number of actually sporadic tumors, as two somatic
mutations affecting both alleles of one MMR gene can lead
to MMR deficiency in 20% of CIMP-negative MSI
tumors.44 We also assume a linear carcinogenesis model, not
referring to the possibility of independent pathways of trans-
formation developing in parts of the same tumor or precan-
cerous lesion. Moreover, we cannot formally exclude the
possibility that the increased proportion of MMR deficiency-
related mutations observed in Lynch syndrome-associated
cancers merely reflects an increased number of passenger
mutations accumulating after transformation and the onset of
MMR deficiency. However, the functional impact of the
observed mutations and the fact that no increased load of
randomly distributed, functionally irrelevant mutations was
observed in oncogenes such as KRAS argues against the pas-
senger mutation assumption and supports the validity of our
conclusions.
Recent prospective studies on CRC incidence in Lynch
syndrome patients under colonoscopic surveillance show that
colorectal cancers occurred despite regular colonoscopy with
polypectomy.22,45 Based on this observation, Møller et al.22
raised the question whether CRC in Lynch syndrome neces-
sarily has to always emerge from a macroscopically visible
lesion. Using panel sequencing,46,47 we examined the possibil-
ity that there is a distinct pathway reflected by a distinct
molecular profile of the manifest cancers, which may support
the concept that part of Lynch syndrome colorectal cancers
may emerge from nonpolypous, that is, “invisible” precursor
lesions.20
Interestingly, a subset of MSI Lynch tumors presented
with mutations of the TP53 gene, which are otherwise rare in
MSI cancers.35 All TP53-mutant tumors presented with a
nonpolypous histology, suggesting that TP53 mutations,
alongside CTNNB1 mutations,20 may represent drivers of
nonpolypous cancer formation in Lynch syndrome. On a
mechanistic level, this observation is very well compatible
with recent evidence that mutant gain-of-function variants of
TP53 are associated with the formation of flat lesions and an
inflammatory phenotype favoring invasive growth in murine
models.48 Clinically, our data support the existence of a
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distinct group of Lynch syndrome colorectal cancers that
may manifest as interval cancers because they are not detect-
able even by high quality colonoscopy.22,45 Due to the limited
number of tumors analyzed by panel sequencing, confirma-
tion in independent tumor collections is strongly encouraged.
The contribution of nonpolypous cancers to the overall
colorectal cancer burden in Lynch syndrome remains to be
determined and most likely will vary between populations. In
this context, it has to be kept in mind that the surveillance
scheme applied in management of Lynch syndrome, which
differs between countries,22,49 will most likely influence the
picture significantly, because, as mentioned above, colonos-
copy will, with a much higher likelihood detect, polypous
adenomas compared to nonpolypous precursor lesions.
Therefore, compared to a population not under regular colo-
noscopy, carcinomas developing through the nonpolypous
tumorigenesis pathway will be much more frequent in popu-
lations participating in, for example, annual colonoscopy
screening programs.
Due to low number of CTNNB1 and TP53 mutations, their
timing with respect to MMR deficiency could not be reliably
determined. However, CTNNB1 mutations are known to be
associated with MSI cancers,50 in particular with hereditary
MSI CRC.20,51 It has also been shown that in colonic tissue
CTNNB1 mutations alone are unable to drive activation of
Wnt signaling.52 Taken together with the high number of
MMR-DCF in the normal colonic mucosa of Lynch syndrome
patients, the scenario in which CTNNB1 strikes in an
already MMR-deficient cell and leads to nonpolypous progres-
sion is much more likely than the reversed order of the events.
However, studies need to be performed to determine the tim-
ing of mutations associated with nonpolypous growth in
Lynch CRC.
In summary, the conflicting models of colorectal Lynch
syndrome pathogenesis—MMR deficiency as a late event3,8,53
versus MMR deficiency as an early event17,19,20—can only be
reconciled by a unifying model that accepts the existence of
distinct pathways of colorectal carcinogenesis in Lynch syn-
drome (Fig. 5). Indeed, our study provides histological and
molecular evidence that Lynch syndrome-associated colorec-
tal cancers do not follow one single pathway, but three path-
ways separated from each other by the type and timing of
key mutation events: colorectal cancers in Lynch syndrome
can in fact grow out from MMR-proficient adenomas after
secondary inactivation of the MMR system (pathway 1).
However, a larger part of cancers appear to develop from
precursor lesions in which MMR deficiency is an early event,
likely to include MMR-DCF, either through an adenomatous
phase (pathway 2) or as nonpolypous lesions with immediate
invasive growth (pathway 3). Future studies will have to
Figure 5. Integrative model of colorectal carcinogenesis in Lynch syndrome (Sankey diagram). Lynch syndrome colorectal cancer develop-
ment follows three distinct routes. A subset of Lynch syndrome colorectal cancers develops through (1) MMR deficiency-independent ade-
noma formation with secondary MMR inactivation. Most commonly, however, tumor formation follows or is initiated by MMR deficiency,
which can either lead to (2) MMR-deficient adenoma formation, or to (3) entirely nonpolypous progression into invasive cancer. The relative
contribution of the three pathways is predicted to vary between populations and will depend on factors such as availability of colonoscopy
screening and screening intervals. For better visibility, pre-malignant lesions that do not develop into cancer are not included in the dia-
gram, because their number greatly exceeds the number of carcinomas. [Color figure can be viewed at wileyonlinelibrary.com]
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assess the relative contribution of each of these pathways to
the colorectal cancer burden in Lynch syndrome, the effec-
tiveness of screening programs to prevent each of these can-
cer types and the impact of the pathogenesis on patients’
outcome and survival.
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